(function(){const t=document.createElement("link").relList;if(t&&t.supports&&t.supports("modulepreload"))return;for(const s of document.querySelectorAll('link[rel="modulepreload"]'))n(s);new MutationObserver(s=>{for(const r of s)if(r.type==="childList")for(const o of r.addedNodes)o.tagName==="LINK"&&o.rel==="modulepreload"&&n(o)}).observe(document,{childList:!0,subtree:!0});function a(s){const r={};return s.integrity&&(r.integrity=s.integrity),s.referrerPolicy&&(r.referrerPolicy=s.referrerPolicy),s.crossOrigin==="use-credentials"?r.credentials="include":s.crossOrigin==="anonymous"?r.credentials="omit":r.credentials="same-origin",r}function n(s){if(s.ep)return;s.ep=!0;const r=a(s);fetch(s.href,r)}})();function lc(e){return e&&e.__esModule&&Object.prototype.hasOwnProperty.call(e,"default")?e.default:e}var cc={exports:{}},ns={},dc={exports:{}},G={};/**
 * @license React
 * react.production.min.js
 *
 * Copyright (c) Facebook, Inc. and its affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var $a=Symbol.for("react.element"),Iu=Symbol.for("react.portal"),Eu=Symbol.for("react.fragment"),Fu=Symbol.for("react.strict_mode"),Ou=Symbol.for("react.profiler"),Bu=Symbol.for("react.provider"),Vu=Symbol.for("react.context"),qu=Symbol.for("react.forward_ref"),Uu=Symbol.for("react.suspense"),Gu=Symbol.for("react.memo"),Hu=Symbol.for("react.lazy"),Ko=Symbol.iterator;function zu(e){return e===null||typeof e!="object"?null:(e=Ko&&e[Ko]||e["@@iterator"],typeof e=="function"?e:null)}var uc={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},mc=Object.assign,pc={};function ta(e,t,a){this.props=e,this.context=t,this.refs=pc,this.updater=a||uc}ta.prototype.isReactComponent={};ta.prototype.setState=function(e,t){if(typeof e!="object"&&typeof e!="function"&&e!=null)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")};ta.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")};function fc(){}fc.prototype=ta.prototype;function Kr(e,t,a){this.props=e,this.context=t,this.refs=pc,this.updater=a||uc}var Qr=Kr.prototype=new fc;Qr.constructor=Kr;mc(Qr,ta.prototype);Qr.isPureReactComponent=!0;var Qo=Array.isArray,hc=Object.prototype.hasOwnProperty,Yr={current:null},gc={key:!0,ref:!0,__self:!0,__source:!0};function yc(e,t,a){var n,s={},r=null,o=null;if(t!=null)for(n in t.ref!==void 0&&(o=t.ref),t.key!==void 0&&(r=""+t.key),t)hc.call(t,n)&&!gc.hasOwnProperty(n)&&(s[n]=t[n]);var l=arguments.length-2;if(l===1)s.children=a;else if(1<l){for(var d=Array(l),u=0;u<l;u++)d[u]=arguments[u+2];s.children=d}if(e&&e.defaultProps)for(n in l=e.defaultProps,l)s[n]===void 0&&(s[n]=l[n]);return{$$typeof:$a,type:e,key:r,ref:o,props:s,_owner:Yr.current}}function Wu(e,t){return{$$typeof:$a,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}function Xr(e){return typeof e=="object"&&e!==null&&e.$$typeof===$a}function _u(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,function(a){return t[a]})}var Yo=/\/+/g;function Ss(e,t){return typeof e=="object"&&e!==null&&e.key!=null?_u(""+e.key):t.toString(36)}function bn(e,t,a,n,s){var r=typeof e;(r==="undefined"||r==="boolean")&&(e=null);var o=!1;if(e===null)o=!0;else switch(r){case"string":case"number":o=!0;break;case"object":switch(e.$$typeof){case $a:case Iu:o=!0}}if(o)return o=e,s=s(o),e=n===""?"."+Ss(o,0):n,Qo(s)?(a="",e!=null&&(a=e.replace(Yo,"$&/")+"/"),bn(s,t,a,"",function(u){return u})):s!=null&&(Xr(s)&&(s=Wu(s,a+(!s.key||o&&o.key===s.key?"":(""+s.key).replace(Yo,"$&/")+"/")+e)),t.push(s)),1;if(o=0,n=n===""?".":n+":",Qo(e))for(var l=0;l<e.length;l++){r=e[l];var d=n+Ss(r,l);o+=bn(r,t,a,d,s)}else if(d=zu(e),typeof d=="function")for(e=d.call(e),l=0;!(r=e.next()).done;)r=r.value,d=n+Ss(r,l++),o+=bn(r,t,a,d,s);else if(r==="object")throw t=String(e),Error("Objects are not valid as a React child (found: "+(t==="[object Object]"?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return o}function tn(e,t,a){if(e==null)return e;var n=[],s=0;return bn(e,n,"","",function(r){return t.call(a,r,s++)}),n}function $u(e){if(e._status===-1){var t=e._result;t=t(),t.then(function(a){(e._status===0||e._status===-1)&&(e._status=1,e._result=a)},function(a){(e._status===0||e._status===-1)&&(e._status=2,e._result=a)}),e._status===-1&&(e._status=0,e._result=t)}if(e._status===1)return e._result.default;throw e._result}var Oe={current:null},Cn={transition:null},Ku={ReactCurrentDispatcher:Oe,ReactCurrentBatchConfig:Cn,ReactCurrentOwner:Yr};function vc(){throw Error("act(...) is not supported in production builds of React.")}G.Children={map:tn,forEach:function(e,t,a){tn(e,function(){t.apply(this,arguments)},a)},count:function(e){var t=0;return tn(e,function(){t++}),t},toArray:function(e){return tn(e,function(t){return t})||[]},only:function(e){if(!Xr(e))throw Error("React.Children.only expected to receive a single React element child.");return e}};G.Component=ta;G.Fragment=Eu;G.Profiler=Ou;G.PureComponent=Kr;G.StrictMode=Fu;G.Suspense=Uu;G.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=Ku;G.act=vc;G.cloneElement=function(e,t,a){if(e==null)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var n=mc({},e.props),s=e.key,r=e.ref,o=e._owner;if(t!=null){if(t.ref!==void 0&&(r=t.ref,o=Yr.current),t.key!==void 0&&(s=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(d in t)hc.call(t,d)&&!gc.hasOwnProperty(d)&&(n[d]=t[d]===void 0&&l!==void 0?l[d]:t[d])}var d=arguments.length-2;if(d===1)n.children=a;else if(1<d){l=Array(d);for(var u=0;u<d;u++)l[u]=arguments[u+2];n.children=l}return{$$typeof:$a,type:e.type,key:s,ref:r,props:n,_owner:o}};G.createContext=function(e){return e={$$typeof:Vu,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null},e.Provider={$$typeof:Bu,_context:e},e.Consumer=e};G.createElement=yc;G.createFactory=function(e){var t=yc.bind(null,e);return t.type=e,t};G.createRef=function(){return{current:null}};G.forwardRef=function(e){return{$$typeof:qu,render:e}};G.isValidElement=Xr;G.lazy=function(e){return{$$typeof:Hu,_payload:{_status:-1,_result:e},_init:$u}};G.memo=function(e,t){return{$$typeof:Gu,type:e,compare:t===void 0?null:t}};G.startTransition=function(e){var t=Cn.transition;Cn.transition={};try{e()}finally{Cn.transition=t}};G.unstable_act=vc;G.useCallback=function(e,t){return Oe.current.useCallback(e,t)};G.useContext=function(e){return Oe.current.useContext(e)};G.useDebugValue=function(){};G.useDeferredValue=function(e){return Oe.current.useDeferredValue(e)};G.useEffect=function(e,t){return Oe.current.useEffect(e,t)};G.useId=function(){return Oe.current.useId()};G.useImperativeHandle=function(e,t,a){return Oe.current.useImperativeHandle(e,t,a)};G.useInsertionEffect=function(e,t){return Oe.current.useInsertionEffect(e,t)};G.useLayoutEffect=function(e,t){return Oe.current.useLayoutEffect(e,t)};G.useMemo=function(e,t){return Oe.current.useMemo(e,t)};G.useReducer=function(e,t,a){return Oe.current.useReducer(e,t,a)};G.useRef=function(e){return Oe.current.useRef(e)};G.useState=function(e){return Oe.current.useState(e)};G.useSyncExternalStore=function(e,t,a){return Oe.current.useSyncExternalStore(e,t,a)};G.useTransition=function(){return Oe.current.useTransition()};G.version="18.3.1";dc.exports=G;var A=dc.exports;const Qu=lc(A);/**
 * @license React
 * react-jsx-runtime.production.min.js
 *
 * Copyright (c) Facebook, Inc. and its affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Yu=A,Xu=Symbol.for("react.element"),Ju=Symbol.for("react.fragment"),Zu=Object.prototype.hasOwnProperty,em=Yu.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,tm={key:!0,ref:!0,__self:!0,__source:!0};function xc(e,t,a){var n,s={},r=null,o=null;a!==void 0&&(r=""+a),t.key!==void 0&&(r=""+t.key),t.ref!==void 0&&(o=t.ref);for(n in t)Zu.call(t,n)&&!tm.hasOwnProperty(n)&&(s[n]=t[n]);if(e&&e.defaultProps)for(n in t=e.defaultProps,t)s[n]===void 0&&(s[n]=t[n]);return{$$typeof:Xu,type:e,key:r,ref:o,props:s,_owner:em.current}}ns.Fragment=Ju;ns.jsx=xc;ns.jsxs=xc;cc.exports=ns;var i=cc.exports,er={},bc={exports:{}},Ye={},Cc={exports:{}},wc={};/**
 * @license React
 * scheduler.production.min.js
 *
 * Copyright (c) Facebook, Inc. and its affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */(function(e){function t(f,k){var D=f.length;f.push(k);e:for(;0<D;){var L=D-1>>>1,O=f[L];if(0<s(O,k))f[L]=k,f[D]=O,D=L;else break e}}function a(f){return f.length===0?null:f[0]}function n(f){if(f.length===0)return null;var k=f[0],D=f.pop();if(D!==k){f[0]=D;e:for(var L=0,O=f.length,V=O>>>1;L<V;){var U=2*(L+1)-1,ee=f[U],ae=U+1,he=f[ae];if(0>s(ee,D))ae<O&&0>s(he,ee)?(f[L]=he,f[ae]=D,L=ae):(f[L]=ee,f[U]=D,L=U);else if(ae<O&&0>s(he,D))f[L]=he,f[ae]=D,L=ae;else break e}}return k}function s(f,k){var D=f.sortIndex-k.sortIndex;return D!==0?D:f.id-k.id}if(typeof performance=="object"&&typeof performance.now=="function"){var r=performance;e.unstable_now=function(){return r.now()}}else{var o=Date,l=o.now();e.unstable_now=function(){return o.now()-l}}var d=[],u=[],g=1,p=null,y=3,x=!1,w=!1,b=!1,j=typeof setTimeout=="function"?setTimeout:null,m=typeof clearTimeout=="function"?clearTimeout:null,c=typeof setImmediate<"u"?setImmediate:null;typeof navigator<"u"&&navigator.scheduling!==void 0&&navigator.scheduling.isInputPending!==void 0&&navigator.scheduling.isInputPending.bind(navigator.scheduling);function h(f){for(var k=a(u);k!==null;){if(k.callback===null)n(u);else if(k.startTime<=f)n(u),k.sortIndex=k.expirationTime,t(d,k);else break;k=a(u)}}function C(f){if(b=!1,h(f),!w)if(a(d)!==null)w=!0,We(P);else{var k=a(u);k!==null&&fe(C,k.startTime-f)}}function P(f,k){w=!1,b&&(b=!1,m(N),N=-1),x=!0;var D=y;try{for(h(k),p=a(d);p!==null&&(!(p.expirationTime>k)||f&&!q());){var L=p.callback;if(typeof L=="function"){p.callback=null,y=p.priorityLevel;var O=L(p.expirationTime<=k);k=e.unstable_now(),typeof O=="function"?p.callback=O:p===a(d)&&n(d),h(k)}else n(d);p=a(d)}if(p!==null)var V=!0;else{var U=a(u);U!==null&&fe(C,U.startTime-k),V=!1}return V}finally{p=null,y=D,x=!1}}var R=!1,v=null,N=-1,F=5,I=-1;function q(){return!(e.unstable_now()-I<F)}function be(){if(v!==null){var f=e.unstable_now();I=f;var k=!0;try{k=v(!0,f)}finally{k?re():(R=!1,v=null)}}else R=!1}var re;if(typeof c=="function")re=function(){c(be)};else if(typeof MessageChannel<"u"){var Ce=new MessageChannel,Me=Ce.port2;Ce.port1.onmessage=be,re=function(){Me.postMessage(null)}}else re=function(){j(be,0)};function We(f){v=f,R||(R=!0,re())}function fe(f,k){N=j(function(){f(e.unstable_now())},k)}e.unstable_IdlePriority=5,e.unstable_ImmediatePriority=1,e.unstable_LowPriority=4,e.unstable_NormalPriority=3,e.unstable_Profiling=null,e.unstable_UserBlockingPriority=2,e.unstable_cancelCallback=function(f){f.callback=null},e.unstable_continueExecution=function(){w||x||(w=!0,We(P))},e.unstable_forceFrameRate=function(f){0>f||125<f?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):F=0<f?Math.floor(1e3/f):5},e.unstable_getCurrentPriorityLevel=function(){return y},e.unstable_getFirstCallbackNode=function(){return a(d)},e.unstable_next=function(f){switch(y){case 1:case 2:case 3:var k=3;break;default:k=y}var D=y;y=k;try{return f()}finally{y=D}},e.unstable_pauseExecution=function(){},e.unstable_requestPaint=function(){},e.unstable_runWithPriority=function(f,k){switch(f){case 1:case 2:case 3:case 4:case 5:break;default:f=3}var D=y;y=f;try{return k()}finally{y=D}},e.unstable_scheduleCallback=function(f,k,D){var L=e.unstable_now();switch(typeof D=="object"&&D!==null?(D=D.delay,D=typeof D=="number"&&0<D?L+D:L):D=L,f){case 1:var O=-1;break;case 2:O=250;break;case 5:O=1073741823;break;case 4:O=1e4;break;default:O=5e3}return O=D+O,f={id:g++,callback:k,priorityLevel:f,startTime:D,expirationTime:O,sortIndex:-1},D>L?(f.sortIndex=D,t(u,f),a(d)===null&&f===a(u)&&(b?(m(N),N=-1):b=!0,fe(C,D-L))):(f.sortIndex=O,t(d,f),w||x||(w=!0,We(P))),f},e.unstable_shouldYield=q,e.unstable_wrapCallback=function(f){var k=y;return function(){var D=y;y=k;try{return f.apply(this,arguments)}finally{y=D}}}})(wc);Cc.exports=wc;var im=Cc.exports;/**
 * @license React
 * react-dom.production.min.js
 *
 * Copyright (c) Facebook, Inc. and its affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var am=A,Qe=im;function M(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,a=1;a<arguments.length;a++)t+="&args[]="+encodeURIComponent(arguments[a]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var Nc=new Set,ka={};function yi(e,t){Wi(e,t),Wi(e+"Capture",t)}function Wi(e,t){for(ka[e]=t,e=0;e<t.length;e++)Nc.add(t[e])}var jt=!(typeof window>"u"||typeof window.document>"u"||typeof window.document.createElement>"u"),tr=Object.prototype.hasOwnProperty,nm=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,Xo={},Jo={};function sm(e){return tr.call(Jo,e)?!0:tr.call(Xo,e)?!1:nm.test(e)?Jo[e]=!0:(Xo[e]=!0,!1)}function rm(e,t,a,n){if(a!==null&&a.type===0)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return n?!1:a!==null?!a.acceptsBooleans:(e=e.toLowerCase().slice(0,5),e!=="data-"&&e!=="aria-");default:return!1}}function om(e,t,a,n){if(t===null||typeof t>"u"||rm(e,t,a,n))return!0;if(n)return!1;if(a!==null)switch(a.type){case 3:return!t;case 4:return t===!1;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}function Be(e,t,a,n,s,r,o){this.acceptsBooleans=t===2||t===3||t===4,this.attributeName=n,this.attributeNamespace=s,this.mustUseProperty=a,this.propertyName=e,this.type=t,this.sanitizeURL=r,this.removeEmptyString=o}var Pe={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach(function(e){Pe[e]=new Be(e,0,!1,e,null,!1,!1)});[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach(function(e){var t=e[0];Pe[t]=new Be(t,1,!1,e[1],null,!1,!1)});["contentEditable","draggable","spellCheck","value"].forEach(function(e){Pe[e]=new Be(e,2,!1,e.toLowerCase(),null,!1,!1)});["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach(function(e){Pe[e]=new Be(e,2,!1,e,null,!1,!1)});"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach(function(e){Pe[e]=new Be(e,3,!1,e.toLowerCase(),null,!1,!1)});["checked","multiple","muted","selected"].forEach(function(e){Pe[e]=new Be(e,3,!0,e,null,!1,!1)});["capture","download"].forEach(function(e){Pe[e]=new Be(e,4,!1,e,null,!1,!1)});["cols","rows","size","span"].forEach(function(e){Pe[e]=new Be(e,6,!1,e,null,!1,!1)});["rowSpan","start"].forEach(function(e){Pe[e]=new Be(e,5,!1,e.toLowerCase(),null,!1,!1)});var Jr=/[\-:]([a-z])/g;function Zr(e){return e[1].toUpperCase()}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach(function(e){var t=e.replace(Jr,Zr);Pe[t]=new Be(t,1,!1,e,null,!1,!1)});"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach(function(e){var t=e.replace(Jr,Zr);Pe[t]=new Be(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)});["xml:base","xml:lang","xml:space"].forEach(function(e){var t=e.replace(Jr,Zr);Pe[t]=new Be(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)});["tabIndex","crossOrigin"].forEach(function(e){Pe[e]=new Be(e,1,!1,e.toLowerCase(),null,!1,!1)});Pe.xlinkHref=new Be("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1);["src","href","action","formAction"].forEach(function(e){Pe[e]=new Be(e,1,!1,e.toLowerCase(),null,!0,!0)});function eo(e,t,a,n){var s=Pe.hasOwnProperty(t)?Pe[t]:null;(s!==null?s.type!==0:n||!(2<t.length)||t[0]!=="o"&&t[0]!=="O"||t[1]!=="n"&&t[1]!=="N")&&(om(t,a,s,n)&&(a=null),n||s===null?sm(t)&&(a===null?e.removeAttribute(t):e.setAttribute(t,""+a)):s.mustUseProperty?e[s.propertyName]=a===null?s.type===3?!1:"":a:(t=s.attributeName,n=s.attributeNamespace,a===null?e.removeAttribute(t):(s=s.type,a=s===3||s===4&&a===!0?"":""+a,n?e.setAttributeNS(n,t,a):e.setAttribute(t,a))))}var It=am.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,an=Symbol.for("react.element"),Di=Symbol.for("react.portal"),Pi=Symbol.for("react.fragment"),to=Symbol.for("react.strict_mode"),ir=Symbol.for("react.profiler"),Ac=Symbol.for("react.provider"),Sc=Symbol.for("react.context"),io=Symbol.for("react.forward_ref"),ar=Symbol.for("react.suspense"),nr=Symbol.for("react.suspense_list"),ao=Symbol.for("react.memo"),Ot=Symbol.for("react.lazy"),Tc=Symbol.for("react.offscreen"),Zo=Symbol.iterator;function oa(e){return e===null||typeof e!="object"?null:(e=Zo&&e[Zo]||e["@@iterator"],typeof e=="function"?e:null)}var de=Object.assign,Ts;function ha(e){if(Ts===void 0)try{throw Error()}catch(a){var t=a.stack.trim().match(/\n( *(at )?)/);Ts=t&&t[1]||""}return`
`+Ts+e}var Ds=!1;function Ps(e,t){if(!e||Ds)return"";Ds=!0;var a=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),typeof Reflect=="object"&&Reflect.construct){try{Reflect.construct(t,[])}catch(u){var n=u}Reflect.construct(e,[],t)}else{try{t.call()}catch(u){n=u}e.call(t.prototype)}else{try{throw Error()}catch(u){n=u}e()}}catch(u){if(u&&n&&typeof u.stack=="string"){for(var s=u.stack.split(`
`),r=n.stack.split(`
`),o=s.length-1,l=r.length-1;1<=o&&0<=l&&s[o]!==r[l];)l--;for(;1<=o&&0<=l;o--,l--)if(s[o]!==r[l]){if(o!==1||l!==1)do if(o--,l--,0>l||s[o]!==r[l]){var d=`
`+s[o].replace(" at new "," at ");return e.displayName&&d.includes("<anonymous>")&&(d=d.replace("<anonymous>",e.displayName)),d}while(1<=o&&0<=l);break}}}finally{Ds=!1,Error.prepareStackTrace=a}return(e=e?e.displayName||e.name:"")?ha(e):""}function lm(e){switch(e.tag){case 5:return ha(e.type);case 16:return ha("Lazy");case 13:return ha("Suspense");case 19:return ha("SuspenseList");case 0:case 2:case 15:return e=Ps(e.type,!1),e;case 11:return e=Ps(e.type.render,!1),e;case 1:return e=Ps(e.type,!0),e;default:return""}}function sr(e){if(e==null)return null;if(typeof e=="function")return e.displayName||e.name||null;if(typeof e=="string")return e;switch(e){case Pi:return"Fragment";case Di:return"Portal";case ir:return"Profiler";case to:return"StrictMode";case ar:return"Suspense";case nr:return"SuspenseList"}if(typeof e=="object")switch(e.$$typeof){case Sc:return(e.displayName||"Context")+".Consumer";case Ac:return(e._context.displayName||"Context")+".Provider";case io:var t=e.render;return e=e.displayName,e||(e=t.displayName||t.name||"",e=e!==""?"ForwardRef("+e+")":"ForwardRef"),e;case ao:return t=e.displayName||null,t!==null?t:sr(e.type)||"Memo";case Ot:t=e._payload,e=e._init;try{return sr(e(t))}catch{}}return null}function cm(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=t.render,e=e.displayName||e.name||"",t.displayName||(e!==""?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return sr(t);case 8:return t===to?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if(typeof t=="function")return t.displayName||t.name||null;if(typeof t=="string")return t}return null}function Xt(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":return e;case"object":return e;default:return""}}function Dc(e){var t=e.type;return(e=e.nodeName)&&e.toLowerCase()==="input"&&(t==="checkbox"||t==="radio")}function dm(e){var t=Dc(e)?"checked":"value",a=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),n=""+e[t];if(!e.hasOwnProperty(t)&&typeof a<"u"&&typeof a.get=="function"&&typeof a.set=="function"){var s=a.get,r=a.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return s.call(this)},set:function(o){n=""+o,r.call(this,o)}}),Object.defineProperty(e,t,{enumerable:a.enumerable}),{getValue:function(){return n},setValue:function(o){n=""+o},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}function nn(e){e._valueTracker||(e._valueTracker=dm(e))}function Pc(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var a=t.getValue(),n="";return e&&(n=Dc(e)?e.checked?"true":"false":e.value),e=n,e!==a?(t.setValue(e),!0):!1}function Ln(e){if(e=e||(typeof document<"u"?document:void 0),typeof e>"u")return null;try{return e.activeElement||e.body}catch{return e.body}}function rr(e,t){var a=t.checked;return de({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:a??e._wrapperState.initialChecked})}function el(e,t){var a=t.defaultValue==null?"":t.defaultValue,n=t.checked!=null?t.checked:t.defaultChecked;a=Xt(t.value!=null?t.value:a),e._wrapperState={initialChecked:n,initialValue:a,controlled:t.type==="checkbox"||t.type==="radio"?t.checked!=null:t.value!=null}}function kc(e,t){t=t.checked,t!=null&&eo(e,"checked",t,!1)}function or(e,t){kc(e,t);var a=Xt(t.value),n=t.type;if(a!=null)n==="number"?(a===0&&e.value===""||e.value!=a)&&(e.value=""+a):e.value!==""+a&&(e.value=""+a);else if(n==="submit"||n==="reset"){e.removeAttribute("value");return}t.hasOwnProperty("value")?lr(e,t.type,a):t.hasOwnProperty("defaultValue")&&lr(e,t.type,Xt(t.defaultValue)),t.checked==null&&t.defaultChecked!=null&&(e.defaultChecked=!!t.defaultChecked)}function tl(e,t,a){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var n=t.type;if(!(n!=="submit"&&n!=="reset"||t.value!==void 0&&t.value!==null))return;t=""+e._wrapperState.initialValue,a||t===e.value||(e.value=t),e.defaultValue=t}a=e.name,a!==""&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,a!==""&&(e.name=a)}function lr(e,t,a){(t!=="number"||Ln(e.ownerDocument)!==e)&&(a==null?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+a&&(e.defaultValue=""+a))}var ga=Array.isArray;function Vi(e,t,a,n){if(e=e.options,t){t={};for(var s=0;s<a.length;s++)t["$"+a[s]]=!0;for(a=0;a<e.length;a++)s=t.hasOwnProperty("$"+e[a].value),e[a].selected!==s&&(e[a].selected=s),s&&n&&(e[a].defaultSelected=!0)}else{for(a=""+Xt(a),t=null,s=0;s<e.length;s++){if(e[s].value===a){e[s].selected=!0,n&&(e[s].defaultSelected=!0);return}t!==null||e[s].disabled||(t=e[s])}t!==null&&(t.selected=!0)}}function cr(e,t){if(t.dangerouslySetInnerHTML!=null)throw Error(M(91));return de({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function il(e,t){var a=t.value;if(a==null){if(a=t.children,t=t.defaultValue,a!=null){if(t!=null)throw Error(M(92));if(ga(a)){if(1<a.length)throw Error(M(93));a=a[0]}t=a}t==null&&(t=""),a=t}e._wrapperState={initialValue:Xt(a)}}function jc(e,t){var a=Xt(t.value),n=Xt(t.defaultValue);a!=null&&(a=""+a,a!==e.value&&(e.value=a),t.defaultValue==null&&e.defaultValue!==a&&(e.defaultValue=a)),n!=null&&(e.defaultValue=""+n)}function al(e){var t=e.textContent;t===e._wrapperState.initialValue&&t!==""&&t!==null&&(e.value=t)}function Rc(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function dr(e,t){return e==null||e==="http://www.w3.org/1999/xhtml"?Rc(t):e==="http://www.w3.org/2000/svg"&&t==="foreignObject"?"http://www.w3.org/1999/xhtml":e}var sn,Lc=function(e){return typeof MSApp<"u"&&MSApp.execUnsafeLocalFunction?function(t,a,n,s){MSApp.execUnsafeLocalFunction(function(){return e(t,a,n,s)})}:e}(function(e,t){if(e.namespaceURI!=="http://www.w3.org/2000/svg"||"innerHTML"in e)e.innerHTML=t;else{for(sn=sn||document.createElement("div"),sn.innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=sn.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}});function ja(e,t){if(t){var a=e.firstChild;if(a&&a===e.lastChild&&a.nodeType===3){a.nodeValue=t;return}}e.textContent=t}var xa={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},um=["Webkit","ms","Moz","O"];Object.keys(xa).forEach(function(e){um.forEach(function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),xa[t]=xa[e]})});function Mc(e,t,a){return t==null||typeof t=="boolean"||t===""?"":a||typeof t!="number"||t===0||xa.hasOwnProperty(e)&&xa[e]?(""+t).trim():t+"px"}function Ic(e,t){e=e.style;for(var a in t)if(t.hasOwnProperty(a)){var n=a.indexOf("--")===0,s=Mc(a,t[a],n);a==="float"&&(a="cssFloat"),n?e.setProperty(a,s):e[a]=s}}var mm=de({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function ur(e,t){if(t){if(mm[e]&&(t.children!=null||t.dangerouslySetInnerHTML!=null))throw Error(M(137,e));if(t.dangerouslySetInnerHTML!=null){if(t.children!=null)throw Error(M(60));if(typeof t.dangerouslySetInnerHTML!="object"||!("__html"in t.dangerouslySetInnerHTML))throw Error(M(61))}if(t.style!=null&&typeof t.style!="object")throw Error(M(62))}}function mr(e,t){if(e.indexOf("-")===-1)return typeof t.is=="string";switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var pr=null;function no(e){return e=e.target||e.srcElement||window,e.correspondingUseElement&&(e=e.correspondingUseElement),e.nodeType===3?e.parentNode:e}var fr=null,qi=null,Ui=null;function nl(e){if(e=Ya(e)){if(typeof fr!="function")throw Error(M(280));var t=e.stateNode;t&&(t=cs(t),fr(e.stateNode,e.type,t))}}function Ec(e){qi?Ui?Ui.push(e):Ui=[e]:qi=e}function Fc(){if(qi){var e=qi,t=Ui;if(Ui=qi=null,nl(e),t)for(e=0;e<t.length;e++)nl(t[e])}}function Oc(e,t){return e(t)}function Bc(){}var ks=!1;function Vc(e,t,a){if(ks)return e(t,a);ks=!0;try{return Oc(e,t,a)}finally{ks=!1,(qi!==null||Ui!==null)&&(Bc(),Fc())}}function Ra(e,t){var a=e.stateNode;if(a===null)return null;var n=cs(a);if(n===null)return null;a=n[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(n=!n.disabled)||(e=e.type,n=!(e==="button"||e==="input"||e==="select"||e==="textarea")),e=!n;break e;default:e=!1}if(e)return null;if(a&&typeof a!="function")throw Error(M(231,t,typeof a));return a}var hr=!1;if(jt)try{var la={};Object.defineProperty(la,"passive",{get:function(){hr=!0}}),window.addEventListener("test",la,la),window.removeEventListener("test",la,la)}catch{hr=!1}function pm(e,t,a,n,s,r,o,l,d){var u=Array.prototype.slice.call(arguments,3);try{t.apply(a,u)}catch(g){this.onError(g)}}var ba=!1,Mn=null,In=!1,gr=null,fm={onError:function(e){ba=!0,Mn=e}};function hm(e,t,a,n,s,r,o,l,d){ba=!1,Mn=null,pm.apply(fm,arguments)}function gm(e,t,a,n,s,r,o,l,d){if(hm.apply(this,arguments),ba){if(ba){var u=Mn;ba=!1,Mn=null}else throw Error(M(198));In||(In=!0,gr=u)}}function vi(e){var t=e,a=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do t=e,t.flags&4098&&(a=t.return),e=t.return;while(e)}return t.tag===3?a:null}function qc(e){if(e.tag===13){var t=e.memoizedState;if(t===null&&(e=e.alternate,e!==null&&(t=e.memoizedState)),t!==null)return t.dehydrated}return null}function sl(e){if(vi(e)!==e)throw Error(M(188))}function ym(e){var t=e.alternate;if(!t){if(t=vi(e),t===null)throw Error(M(188));return t!==e?null:e}for(var a=e,n=t;;){var s=a.return;if(s===null)break;var r=s.alternate;if(r===null){if(n=s.return,n!==null){a=n;continue}break}if(s.child===r.child){for(r=s.child;r;){if(r===a)return sl(s),e;if(r===n)return sl(s),t;r=r.sibling}throw Error(M(188))}if(a.return!==n.return)a=s,n=r;else{for(var o=!1,l=s.child;l;){if(l===a){o=!0,a=s,n=r;break}if(l===n){o=!0,n=s,a=r;break}l=l.sibling}if(!o){for(l=r.child;l;){if(l===a){o=!0,a=r,n=s;break}if(l===n){o=!0,n=r,a=s;break}l=l.sibling}if(!o)throw Error(M(189))}}if(a.alternate!==n)throw Error(M(190))}if(a.tag!==3)throw Error(M(188));return a.stateNode.current===a?e:t}function Uc(e){return e=ym(e),e!==null?Gc(e):null}function Gc(e){if(e.tag===5||e.tag===6)return e;for(e=e.child;e!==null;){var t=Gc(e);if(t!==null)return t;e=e.sibling}return null}var Hc=Qe.unstable_scheduleCallback,rl=Qe.unstable_cancelCallback,vm=Qe.unstable_shouldYield,xm=Qe.unstable_requestPaint,pe=Qe.unstable_now,bm=Qe.unstable_getCurrentPriorityLevel,so=Qe.unstable_ImmediatePriority,zc=Qe.unstable_UserBlockingPriority,En=Qe.unstable_NormalPriority,Cm=Qe.unstable_LowPriority,Wc=Qe.unstable_IdlePriority,ss=null,Ct=null;function wm(e){if(Ct&&typeof Ct.onCommitFiberRoot=="function")try{Ct.onCommitFiberRoot(ss,e,void 0,(e.current.flags&128)===128)}catch{}}var mt=Math.clz32?Math.clz32:Sm,Nm=Math.log,Am=Math.LN2;function Sm(e){return e>>>=0,e===0?32:31-(Nm(e)/Am|0)|0}var rn=64,on=4194304;function ya(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return e&4194240;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return e&130023424;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function Fn(e,t){var a=e.pendingLanes;if(a===0)return 0;var n=0,s=e.suspendedLanes,r=e.pingedLanes,o=a&268435455;if(o!==0){var l=o&~s;l!==0?n=ya(l):(r&=o,r!==0&&(n=ya(r)))}else o=a&~s,o!==0?n=ya(o):r!==0&&(n=ya(r));if(n===0)return 0;if(t!==0&&t!==n&&!(t&s)&&(s=n&-n,r=t&-t,s>=r||s===16&&(r&4194240)!==0))return t;if(n&4&&(n|=a&16),t=e.entangledLanes,t!==0)for(e=e.entanglements,t&=n;0<t;)a=31-mt(t),s=1<<a,n|=e[a],t&=~s;return n}function Tm(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return-1;case 134217728:case 268435456:case 536870912:case 1073741824:return-1;default:return-1}}function Dm(e,t){for(var a=e.suspendedLanes,n=e.pingedLanes,s=e.expirationTimes,r=e.pendingLanes;0<r;){var o=31-mt(r),l=1<<o,d=s[o];d===-1?(!(l&a)||l&n)&&(s[o]=Tm(l,t)):d<=t&&(e.expiredLanes|=l),r&=~l}}function yr(e){return e=e.pendingLanes&-1073741825,e!==0?e:e&1073741824?1073741824:0}function _c(){var e=rn;return rn<<=1,!(rn&4194240)&&(rn=64),e}function js(e){for(var t=[],a=0;31>a;a++)t.push(e);return t}function Ka(e,t,a){e.pendingLanes|=t,t!==536870912&&(e.suspendedLanes=0,e.pingedLanes=0),e=e.eventTimes,t=31-mt(t),e[t]=a}function Pm(e,t){var a=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var n=e.eventTimes;for(e=e.expirationTimes;0<a;){var s=31-mt(a),r=1<<s;t[s]=0,n[s]=-1,e[s]=-1,a&=~r}}function ro(e,t){var a=e.entangledLanes|=t;for(e=e.entanglements;a;){var n=31-mt(a),s=1<<n;s&t|e[n]&t&&(e[n]|=t),a&=~s}}var Z=0;function $c(e){return e&=-e,1<e?4<e?e&268435455?16:536870912:4:1}var Kc,oo,Qc,Yc,Xc,vr=!1,ln=[],Ht=null,zt=null,Wt=null,La=new Map,Ma=new Map,Vt=[],km="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function ol(e,t){switch(e){case"focusin":case"focusout":Ht=null;break;case"dragenter":case"dragleave":zt=null;break;case"mouseover":case"mouseout":Wt=null;break;case"pointerover":case"pointerout":La.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Ma.delete(t.pointerId)}}function ca(e,t,a,n,s,r){return e===null||e.nativeEvent!==r?(e={blockedOn:t,domEventName:a,eventSystemFlags:n,nativeEvent:r,targetContainers:[s]},t!==null&&(t=Ya(t),t!==null&&oo(t)),e):(e.eventSystemFlags|=n,t=e.targetContainers,s!==null&&t.indexOf(s)===-1&&t.push(s),e)}function jm(e,t,a,n,s){switch(t){case"focusin":return Ht=ca(Ht,e,t,a,n,s),!0;case"dragenter":return zt=ca(zt,e,t,a,n,s),!0;case"mouseover":return Wt=ca(Wt,e,t,a,n,s),!0;case"pointerover":var r=s.pointerId;return La.set(r,ca(La.get(r)||null,e,t,a,n,s)),!0;case"gotpointercapture":return r=s.pointerId,Ma.set(r,ca(Ma.get(r)||null,e,t,a,n,s)),!0}return!1}function Jc(e){var t=ri(e.target);if(t!==null){var a=vi(t);if(a!==null){if(t=a.tag,t===13){if(t=qc(a),t!==null){e.blockedOn=t,Xc(e.priority,function(){Qc(a)});return}}else if(t===3&&a.stateNode.current.memoizedState.isDehydrated){e.blockedOn=a.tag===3?a.stateNode.containerInfo:null;return}}}e.blockedOn=null}function wn(e){if(e.blockedOn!==null)return!1;for(var t=e.targetContainers;0<t.length;){var a=xr(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(a===null){a=e.nativeEvent;var n=new a.constructor(a.type,a);pr=n,a.target.dispatchEvent(n),pr=null}else return t=Ya(a),t!==null&&oo(t),e.blockedOn=a,!1;t.shift()}return!0}function ll(e,t,a){wn(e)&&a.delete(t)}function Rm(){vr=!1,Ht!==null&&wn(Ht)&&(Ht=null),zt!==null&&wn(zt)&&(zt=null),Wt!==null&&wn(Wt)&&(Wt=null),La.forEach(ll),Ma.forEach(ll)}function da(e,t){e.blockedOn===t&&(e.blockedOn=null,vr||(vr=!0,Qe.unstable_scheduleCallback(Qe.unstable_NormalPriority,Rm)))}function Ia(e){function t(s){return da(s,e)}if(0<ln.length){da(ln[0],e);for(var a=1;a<ln.length;a++){var n=ln[a];n.blockedOn===e&&(n.blockedOn=null)}}for(Ht!==null&&da(Ht,e),zt!==null&&da(zt,e),Wt!==null&&da(Wt,e),La.forEach(t),Ma.forEach(t),a=0;a<Vt.length;a++)n=Vt[a],n.blockedOn===e&&(n.blockedOn=null);for(;0<Vt.length&&(a=Vt[0],a.blockedOn===null);)Jc(a),a.blockedOn===null&&Vt.shift()}var Gi=It.ReactCurrentBatchConfig,On=!0;function Lm(e,t,a,n){var s=Z,r=Gi.transition;Gi.transition=null;try{Z=1,lo(e,t,a,n)}finally{Z=s,Gi.transition=r}}function Mm(e,t,a,n){var s=Z,r=Gi.transition;Gi.transition=null;try{Z=4,lo(e,t,a,n)}finally{Z=s,Gi.transition=r}}function lo(e,t,a,n){if(On){var s=xr(e,t,a,n);if(s===null)qs(e,t,n,Bn,a),ol(e,n);else if(jm(s,e,t,a,n))n.stopPropagation();else if(ol(e,n),t&4&&-1<km.indexOf(e)){for(;s!==null;){var r=Ya(s);if(r!==null&&Kc(r),r=xr(e,t,a,n),r===null&&qs(e,t,n,Bn,a),r===s)break;s=r}s!==null&&n.stopPropagation()}else qs(e,t,n,null,a)}}var Bn=null;function xr(e,t,a,n){if(Bn=null,e=no(n),e=ri(e),e!==null)if(t=vi(e),t===null)e=null;else if(a=t.tag,a===13){if(e=qc(t),e!==null)return e;e=null}else if(a===3){if(t.stateNode.current.memoizedState.isDehydrated)return t.tag===3?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Bn=e,null}function Zc(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(bm()){case so:return 1;case zc:return 4;case En:case Cm:return 16;case Wc:return 536870912;default:return 16}default:return 16}}var Ut=null,co=null,Nn=null;function ed(){if(Nn)return Nn;var e,t=co,a=t.length,n,s="value"in Ut?Ut.value:Ut.textContent,r=s.length;for(e=0;e<a&&t[e]===s[e];e++);var o=a-e;for(n=1;n<=o&&t[a-n]===s[r-n];n++);return Nn=s.slice(e,1<n?1-n:void 0)}function An(e){var t=e.keyCode;return"charCode"in e?(e=e.charCode,e===0&&t===13&&(e=13)):e=t,e===10&&(e=13),32<=e||e===13?e:0}function cn(){return!0}function cl(){return!1}function Xe(e){function t(a,n,s,r,o){this._reactName=a,this._targetInst=s,this.type=n,this.nativeEvent=r,this.target=o,this.currentTarget=null;for(var l in e)e.hasOwnProperty(l)&&(a=e[l],this[l]=a?a(r):r[l]);return this.isDefaultPrevented=(r.defaultPrevented!=null?r.defaultPrevented:r.returnValue===!1)?cn:cl,this.isPropagationStopped=cl,this}return de(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var a=this.nativeEvent;a&&(a.preventDefault?a.preventDefault():typeof a.returnValue!="unknown"&&(a.returnValue=!1),this.isDefaultPrevented=cn)},stopPropagation:function(){var a=this.nativeEvent;a&&(a.stopPropagation?a.stopPropagation():typeof a.cancelBubble!="unknown"&&(a.cancelBubble=!0),this.isPropagationStopped=cn)},persist:function(){},isPersistent:cn}),t}var ia={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},uo=Xe(ia),Qa=de({},ia,{view:0,detail:0}),Im=Xe(Qa),Rs,Ls,ua,rs=de({},Qa,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:mo,button:0,buttons:0,relatedTarget:function(e){return e.relatedTarget===void 0?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ua&&(ua&&e.type==="mousemove"?(Rs=e.screenX-ua.screenX,Ls=e.screenY-ua.screenY):Ls=Rs=0,ua=e),Rs)},movementY:function(e){return"movementY"in e?e.movementY:Ls}}),dl=Xe(rs),Em=de({},rs,{dataTransfer:0}),Fm=Xe(Em),Om=de({},Qa,{relatedTarget:0}),Ms=Xe(Om),Bm=de({},ia,{animationName:0,elapsedTime:0,pseudoElement:0}),Vm=Xe(Bm),qm=de({},ia,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),Um=Xe(qm),Gm=de({},ia,{data:0}),ul=Xe(Gm),Hm={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},zm={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Wm={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function _m(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):(e=Wm[e])?!!t[e]:!1}function mo(){return _m}var $m=de({},Qa,{key:function(e){if(e.key){var t=Hm[e.key]||e.key;if(t!=="Unidentified")return t}return e.type==="keypress"?(e=An(e),e===13?"Enter":String.fromCharCode(e)):e.type==="keydown"||e.type==="keyup"?zm[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:mo,charCode:function(e){return e.type==="keypress"?An(e):0},keyCode:function(e){return e.type==="keydown"||e.type==="keyup"?e.keyCode:0},which:function(e){return e.type==="keypress"?An(e):e.type==="keydown"||e.type==="keyup"?e.keyCode:0}}),Km=Xe($m),Qm=de({},rs,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0}),ml=Xe(Qm),Ym=de({},Qa,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:mo}),Xm=Xe(Ym),Jm=de({},ia,{propertyName:0,elapsedTime:0,pseudoElement:0}),Zm=Xe(Jm),ep=de({},rs,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),tp=Xe(ep),ip=[9,13,27,32],po=jt&&"CompositionEvent"in window,Ca=null;jt&&"documentMode"in document&&(Ca=document.documentMode);var ap=jt&&"TextEvent"in window&&!Ca,td=jt&&(!po||Ca&&8<Ca&&11>=Ca),pl=" ",fl=!1;function id(e,t){switch(e){case"keyup":return ip.indexOf(t.keyCode)!==-1;case"keydown":return t.keyCode!==229;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function ad(e){return e=e.detail,typeof e=="object"&&"data"in e?e.data:null}var ki=!1;function np(e,t){switch(e){case"compositionend":return ad(t);case"keypress":return t.which!==32?null:(fl=!0,pl);case"textInput":return e=t.data,e===pl&&fl?null:e;default:return null}}function sp(e,t){if(ki)return e==="compositionend"||!po&&id(e,t)?(e=ed(),Nn=co=Ut=null,ki=!1,e):null;switch(e){case"paste":return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return td&&t.locale!=="ko"?null:t.data;default:return null}}var rp={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function hl(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t==="input"?!!rp[e.type]:t==="textarea"}function nd(e,t,a,n){Ec(n),t=Vn(t,"onChange"),0<t.length&&(a=new uo("onChange","change",null,a,n),e.push({event:a,listeners:t}))}var wa=null,Ea=null;function op(e){hd(e,0)}function os(e){var t=Li(e);if(Pc(t))return e}function lp(e,t){if(e==="change")return t}var sd=!1;if(jt){var Is;if(jt){var Es="oninput"in document;if(!Es){var gl=document.createElement("div");gl.setAttribute("oninput","return;"),Es=typeof gl.oninput=="function"}Is=Es}else Is=!1;sd=Is&&(!document.documentMode||9<document.documentMode)}function yl(){wa&&(wa.detachEvent("onpropertychange",rd),Ea=wa=null)}function rd(e){if(e.propertyName==="value"&&os(Ea)){var t=[];nd(t,Ea,e,no(e)),Vc(op,t)}}function cp(e,t,a){e==="focusin"?(yl(),wa=t,Ea=a,wa.attachEvent("onpropertychange",rd)):e==="focusout"&&yl()}function dp(e){if(e==="selectionchange"||e==="keyup"||e==="keydown")return os(Ea)}function up(e,t){if(e==="click")return os(t)}function mp(e,t){if(e==="input"||e==="change")return os(t)}function pp(e,t){return e===t&&(e!==0||1/e===1/t)||e!==e&&t!==t}var ft=typeof Object.is=="function"?Object.is:pp;function Fa(e,t){if(ft(e,t))return!0;if(typeof e!="object"||e===null||typeof t!="object"||t===null)return!1;var a=Object.keys(e),n=Object.keys(t);if(a.length!==n.length)return!1;for(n=0;n<a.length;n++){var s=a[n];if(!tr.call(t,s)||!ft(e[s],t[s]))return!1}return!0}function vl(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function xl(e,t){var a=vl(e);e=0;for(var n;a;){if(a.nodeType===3){if(n=e+a.textContent.length,e<=t&&n>=t)return{node:a,offset:t-e};e=n}e:{for(;a;){if(a.nextSibling){a=a.nextSibling;break e}a=a.parentNode}a=void 0}a=vl(a)}}function od(e,t){return e&&t?e===t?!0:e&&e.nodeType===3?!1:t&&t.nodeType===3?od(e,t.parentNode):"contains"in e?e.contains(t):e.compareDocumentPosition?!!(e.compareDocumentPosition(t)&16):!1:!1}function ld(){for(var e=window,t=Ln();t instanceof e.HTMLIFrameElement;){try{var a=typeof t.contentWindow.location.href=="string"}catch{a=!1}if(a)e=t.contentWindow;else break;t=Ln(e.document)}return t}function fo(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&(t==="input"&&(e.type==="text"||e.type==="search"||e.type==="tel"||e.type==="url"||e.type==="password")||t==="textarea"||e.contentEditable==="true")}function fp(e){var t=ld(),a=e.focusedElem,n=e.selectionRange;if(t!==a&&a&&a.ownerDocument&&od(a.ownerDocument.documentElement,a)){if(n!==null&&fo(a)){if(t=n.start,e=n.end,e===void 0&&(e=t),"selectionStart"in a)a.selectionStart=t,a.selectionEnd=Math.min(e,a.value.length);else if(e=(t=a.ownerDocument||document)&&t.defaultView||window,e.getSelection){e=e.getSelection();var s=a.textContent.length,r=Math.min(n.start,s);n=n.end===void 0?r:Math.min(n.end,s),!e.extend&&r>n&&(s=n,n=r,r=s),s=xl(a,r);var o=xl(a,n);s&&o&&(e.rangeCount!==1||e.anchorNode!==s.node||e.anchorOffset!==s.offset||e.focusNode!==o.node||e.focusOffset!==o.offset)&&(t=t.createRange(),t.setStart(s.node,s.offset),e.removeAllRanges(),r>n?(e.addRange(t),e.extend(o.node,o.offset)):(t.setEnd(o.node,o.offset),e.addRange(t)))}}for(t=[],e=a;e=e.parentNode;)e.nodeType===1&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for(typeof a.focus=="function"&&a.focus(),a=0;a<t.length;a++)e=t[a],e.element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hp=jt&&"documentMode"in document&&11>=document.documentMode,ji=null,br=null,Na=null,Cr=!1;function bl(e,t,a){var n=a.window===a?a.document:a.nodeType===9?a:a.ownerDocument;Cr||ji==null||ji!==Ln(n)||(n=ji,"selectionStart"in n&&fo(n)?n={start:n.selectionStart,end:n.selectionEnd}:(n=(n.ownerDocument&&n.ownerDocument.defaultView||window).getSelection(),n={anchorNode:n.anchorNode,anchorOffset:n.anchorOffset,focusNode:n.focusNode,focusOffset:n.focusOffset}),Na&&Fa(Na,n)||(Na=n,n=Vn(br,"onSelect"),0<n.length&&(t=new uo("onSelect","select",null,t,a),e.push({event:t,listeners:n}),t.target=ji)))}function dn(e,t){var a={};return a[e.toLowerCase()]=t.toLowerCase(),a["Webkit"+e]="webkit"+t,a["Moz"+e]="moz"+t,a}var Ri={animationend:dn("Animation","AnimationEnd"),animationiteration:dn("Animation","AnimationIteration"),animationstart:dn("Animation","AnimationStart"),transitionend:dn("Transition","TransitionEnd")},Fs={},cd={};jt&&(cd=document.createElement("div").style,"AnimationEvent"in window||(delete Ri.animationend.animation,delete Ri.animationiteration.animation,delete Ri.animationstart.animation),"TransitionEvent"in window||delete Ri.transitionend.transition);function ls(e){if(Fs[e])return Fs[e];if(!Ri[e])return e;var t=Ri[e],a;for(a in t)if(t.hasOwnProperty(a)&&a in cd)return Fs[e]=t[a];return e}var dd=ls("animationend"),ud=ls("animationiteration"),md=ls("animationstart"),pd=ls("transitionend"),fd=new Map,Cl="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Zt(e,t){fd.set(e,t),yi(t,[e])}for(var Os=0;Os<Cl.length;Os++){var Bs=Cl[Os],gp=Bs.toLowerCase(),yp=Bs[0].toUpperCase()+Bs.slice(1);Zt(gp,"on"+yp)}Zt(dd,"onAnimationEnd");Zt(ud,"onAnimationIteration");Zt(md,"onAnimationStart");Zt("dblclick","onDoubleClick");Zt("focusin","onFocus");Zt("focusout","onBlur");Zt(pd,"onTransitionEnd");Wi("onMouseEnter",["mouseout","mouseover"]);Wi("onMouseLeave",["mouseout","mouseover"]);Wi("onPointerEnter",["pointerout","pointerover"]);Wi("onPointerLeave",["pointerout","pointerover"]);yi("onChange","change click focusin focusout input keydown keyup selectionchange".split(" "));yi("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" "));yi("onBeforeInput",["compositionend","keypress","textInput","paste"]);yi("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" "));yi("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" "));yi("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var va="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),vp=new Set("cancel close invalid load scroll toggle".split(" ").concat(va));function wl(e,t,a){var n=e.type||"unknown-event";e.currentTarget=a,gm(n,t,void 0,e),e.currentTarget=null}function hd(e,t){t=(t&4)!==0;for(var a=0;a<e.length;a++){var n=e[a],s=n.event;n=n.listeners;e:{var r=void 0;if(t)for(var o=n.length-1;0<=o;o--){var l=n[o],d=l.instance,u=l.currentTarget;if(l=l.listener,d!==r&&s.isPropagationStopped())break e;wl(s,l,u),r=d}else for(o=0;o<n.length;o++){if(l=n[o],d=l.instance,u=l.currentTarget,l=l.listener,d!==r&&s.isPropagationStopped())break e;wl(s,l,u),r=d}}}if(In)throw e=gr,In=!1,gr=null,e}function ne(e,t){var a=t[Tr];a===void 0&&(a=t[Tr]=new Set);var n=e+"__bubble";a.has(n)||(gd(t,e,2,!1),a.add(n))}function Vs(e,t,a){var n=0;t&&(n|=4),gd(a,e,n,t)}var un="_reactListening"+Math.random().toString(36).slice(2);function Oa(e){if(!e[un]){e[un]=!0,Nc.forEach(function(a){a!=="selectionchange"&&(vp.has(a)||Vs(a,!1,e),Vs(a,!0,e))});var t=e.nodeType===9?e:e.ownerDocument;t===null||t[un]||(t[un]=!0,Vs("selectionchange",!1,t))}}function gd(e,t,a,n){switch(Zc(t)){case 1:var s=Lm;break;case 4:s=Mm;break;default:s=lo}a=s.bind(null,t,a,e),s=void 0,!hr||t!=="touchstart"&&t!=="touchmove"&&t!=="wheel"||(s=!0),n?s!==void 0?e.addEventListener(t,a,{capture:!0,passive:s}):e.addEventListener(t,a,!0):s!==void 0?e.addEventListener(t,a,{passive:s}):e.addEventListener(t,a,!1)}function qs(e,t,a,n,s){var r=n;if(!(t&1)&&!(t&2)&&n!==null)e:for(;;){if(n===null)return;var o=n.tag;if(o===3||o===4){var l=n.stateNode.containerInfo;if(l===s||l.nodeType===8&&l.parentNode===s)break;if(o===4)for(o=n.return;o!==null;){var d=o.tag;if((d===3||d===4)&&(d=o.stateNode.containerInfo,d===s||d.nodeType===8&&d.parentNode===s))return;o=o.return}for(;l!==null;){if(o=ri(l),o===null)return;if(d=o.tag,d===5||d===6){n=r=o;continue e}l=l.parentNode}}n=n.return}Vc(function(){var u=r,g=no(a),p=[];e:{var y=fd.get(e);if(y!==void 0){var x=uo,w=e;switch(e){case"keypress":if(An(a)===0)break e;case"keydown":case"keyup":x=Km;break;case"focusin":w="focus",x=Ms;break;case"focusout":w="blur",x=Ms;break;case"beforeblur":case"afterblur":x=Ms;break;case"click":if(a.button===2)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":x=dl;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":x=Fm;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":x=Xm;break;case dd:case ud:case md:x=Vm;break;case pd:x=Zm;break;case"scroll":x=Im;break;case"wheel":x=tp;break;case"copy":case"cut":case"paste":x=Um;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":x=ml}var b=(t&4)!==0,j=!b&&e==="scroll",m=b?y!==null?y+"Capture":null:y;b=[];for(var c=u,h;c!==null;){h=c;var C=h.stateNode;if(h.tag===5&&C!==null&&(h=C,m!==null&&(C=Ra(c,m),C!=null&&b.push(Ba(c,C,h)))),j)break;c=c.return}0<b.length&&(y=new x(y,w,null,a,g),p.push({event:y,listeners:b}))}}if(!(t&7)){e:{if(y=e==="mouseover"||e==="pointerover",x=e==="mouseout"||e==="pointerout",y&&a!==pr&&(w=a.relatedTarget||a.fromElement)&&(ri(w)||w[Rt]))break e;if((x||y)&&(y=g.window===g?g:(y=g.ownerDocument)?y.defaultView||y.parentWindow:window,x?(w=a.relatedTarget||a.toElement,x=u,w=w?ri(w):null,w!==null&&(j=vi(w),w!==j||w.tag!==5&&w.tag!==6)&&(w=null)):(x=null,w=u),x!==w)){if(b=dl,C="onMouseLeave",m="onMouseEnter",c="mouse",(e==="pointerout"||e==="pointerover")&&(b=ml,C="onPointerLeave",m="onPointerEnter",c="pointer"),j=x==null?y:Li(x),h=w==null?y:Li(w),y=new b(C,c+"leave",x,a,g),y.target=j,y.relatedTarget=h,C=null,ri(g)===u&&(b=new b(m,c+"enter",w,a,g),b.target=h,b.relatedTarget=j,C=b),j=C,x&&w)t:{for(b=x,m=w,c=0,h=b;h;h=Ti(h))c++;for(h=0,C=m;C;C=Ti(C))h++;for(;0<c-h;)b=Ti(b),c--;for(;0<h-c;)m=Ti(m),h--;for(;c--;){if(b===m||m!==null&&b===m.alternate)break t;b=Ti(b),m=Ti(m)}b=null}else b=null;x!==null&&Nl(p,y,x,b,!1),w!==null&&j!==null&&Nl(p,j,w,b,!0)}}e:{if(y=u?Li(u):window,x=y.nodeName&&y.nodeName.toLowerCase(),x==="select"||x==="input"&&y.type==="file")var P=lp;else if(hl(y))if(sd)P=mp;else{P=dp;var R=cp}else(x=y.nodeName)&&x.toLowerCase()==="input"&&(y.type==="checkbox"||y.type==="radio")&&(P=up);if(P&&(P=P(e,u))){nd(p,P,a,g);break e}R&&R(e,y,u),e==="focusout"&&(R=y._wrapperState)&&R.controlled&&y.type==="number"&&lr(y,"number",y.value)}switch(R=u?Li(u):window,e){case"focusin":(hl(R)||R.contentEditable==="true")&&(ji=R,br=u,Na=null);break;case"focusout":Na=br=ji=null;break;case"mousedown":Cr=!0;break;case"contextmenu":case"mouseup":case"dragend":Cr=!1,bl(p,a,g);break;case"selectionchange":if(hp)break;case"keydown":case"keyup":bl(p,a,g)}var v;if(po)e:{switch(e){case"compositionstart":var N="onCompositionStart";break e;case"compositionend":N="onCompositionEnd";break e;case"compositionupdate":N="onCompositionUpdate";break e}N=void 0}else ki?id(e,a)&&(N="onCompositionEnd"):e==="keydown"&&a.keyCode===229&&(N="onCompositionStart");N&&(td&&a.locale!=="ko"&&(ki||N!=="onCompositionStart"?N==="onCompositionEnd"&&ki&&(v=ed()):(Ut=g,co="value"in Ut?Ut.value:Ut.textContent,ki=!0)),R=Vn(u,N),0<R.length&&(N=new ul(N,e,null,a,g),p.push({event:N,listeners:R}),v?N.data=v:(v=ad(a),v!==null&&(N.data=v)))),(v=ap?np(e,a):sp(e,a))&&(u=Vn(u,"onBeforeInput"),0<u.length&&(g=new ul("onBeforeInput","beforeinput",null,a,g),p.push({event:g,listeners:u}),g.data=v))}hd(p,t)})}function Ba(e,t,a){return{instance:e,listener:t,currentTarget:a}}function Vn(e,t){for(var a=t+"Capture",n=[];e!==null;){var s=e,r=s.stateNode;s.tag===5&&r!==null&&(s=r,r=Ra(e,a),r!=null&&n.unshift(Ba(e,r,s)),r=Ra(e,t),r!=null&&n.push(Ba(e,r,s))),e=e.return}return n}function Ti(e){if(e===null)return null;do e=e.return;while(e&&e.tag!==5);return e||null}function Nl(e,t,a,n,s){for(var r=t._reactName,o=[];a!==null&&a!==n;){var l=a,d=l.alternate,u=l.stateNode;if(d!==null&&d===n)break;l.tag===5&&u!==null&&(l=u,s?(d=Ra(a,r),d!=null&&o.unshift(Ba(a,d,l))):s||(d=Ra(a,r),d!=null&&o.push(Ba(a,d,l)))),a=a.return}o.length!==0&&e.push({event:t,listeners:o})}var xp=/\r\n?/g,bp=/\u0000|\uFFFD/g;function Al(e){return(typeof e=="string"?e:""+e).replace(xp,`
`).replace(bp,"")}function mn(e,t,a){if(t=Al(t),Al(e)!==t&&a)throw Error(M(425))}function qn(){}var wr=null,Nr=null;function Ar(e,t){return e==="textarea"||e==="noscript"||typeof t.children=="string"||typeof t.children=="number"||typeof t.dangerouslySetInnerHTML=="object"&&t.dangerouslySetInnerHTML!==null&&t.dangerouslySetInnerHTML.__html!=null}var Sr=typeof setTimeout=="function"?setTimeout:void 0,Cp=typeof clearTimeout=="function"?clearTimeout:void 0,Sl=typeof Promise=="function"?Promise:void 0,wp=typeof queueMicrotask=="function"?queueMicrotask:typeof Sl<"u"?function(e){return Sl.resolve(null).then(e).catch(Np)}:Sr;function Np(e){setTimeout(function(){throw e})}function Us(e,t){var a=t,n=0;do{var s=a.nextSibling;if(e.removeChild(a),s&&s.nodeType===8)if(a=s.data,a==="/$"){if(n===0){e.removeChild(s),Ia(t);return}n--}else a!=="$"&&a!=="$?"&&a!=="$!"||n++;a=s}while(a);Ia(t)}function _t(e){for(;e!=null;e=e.nextSibling){var t=e.nodeType;if(t===1||t===3)break;if(t===8){if(t=e.data,t==="$"||t==="$!"||t==="$?")break;if(t==="/$")return null}}return e}function Tl(e){e=e.previousSibling;for(var t=0;e;){if(e.nodeType===8){var a=e.data;if(a==="$"||a==="$!"||a==="$?"){if(t===0)return e;t--}else a==="/$"&&t++}e=e.previousSibling}return null}var aa=Math.random().toString(36).slice(2),xt="__reactFiber$"+aa,Va="__reactProps$"+aa,Rt="__reactContainer$"+aa,Tr="__reactEvents$"+aa,Ap="__reactListeners$"+aa,Sp="__reactHandles$"+aa;function ri(e){var t=e[xt];if(t)return t;for(var a=e.parentNode;a;){if(t=a[Rt]||a[xt]){if(a=t.alternate,t.child!==null||a!==null&&a.child!==null)for(e=Tl(e);e!==null;){if(a=e[xt])return a;e=Tl(e)}return t}e=a,a=e.parentNode}return null}function Ya(e){return e=e[xt]||e[Rt],!e||e.tag!==5&&e.tag!==6&&e.tag!==13&&e.tag!==3?null:e}function Li(e){if(e.tag===5||e.tag===6)return e.stateNode;throw Error(M(33))}function cs(e){return e[Va]||null}var Dr=[],Mi=-1;function ei(e){return{current:e}}function se(e){0>Mi||(e.current=Dr[Mi],Dr[Mi]=null,Mi--)}function ie(e,t){Mi++,Dr[Mi]=e.current,e.current=t}var Jt={},Le=ei(Jt),Ge=ei(!1),mi=Jt;function _i(e,t){var a=e.type.contextTypes;if(!a)return Jt;var n=e.stateNode;if(n&&n.__reactInternalMemoizedUnmaskedChildContext===t)return n.__reactInternalMemoizedMaskedChildContext;var s={},r;for(r in a)s[r]=t[r];return n&&(e=e.stateNode,e.__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=s),s}function He(e){return e=e.childContextTypes,e!=null}function Un(){se(Ge),se(Le)}function Dl(e,t,a){if(Le.current!==Jt)throw Error(M(168));ie(Le,t),ie(Ge,a)}function yd(e,t,a){var n=e.stateNode;if(t=t.childContextTypes,typeof n.getChildContext!="function")return a;n=n.getChildContext();for(var s in n)if(!(s in t))throw Error(M(108,cm(e)||"Unknown",s));return de({},a,n)}function Gn(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||Jt,mi=Le.current,ie(Le,e),ie(Ge,Ge.current),!0}function Pl(e,t,a){var n=e.stateNode;if(!n)throw Error(M(169));a?(e=yd(e,t,mi),n.__reactInternalMemoizedMergedChildContext=e,se(Ge),se(Le),ie(Le,e)):se(Ge),ie(Ge,a)}var St=null,ds=!1,Gs=!1;function vd(e){St===null?St=[e]:St.push(e)}function Tp(e){ds=!0,vd(e)}function ti(){if(!Gs&&St!==null){Gs=!0;var e=0,t=Z;try{var a=St;for(Z=1;e<a.length;e++){var n=a[e];do n=n(!0);while(n!==null)}St=null,ds=!1}catch(s){throw St!==null&&(St=St.slice(e+1)),Hc(so,ti),s}finally{Z=t,Gs=!1}}return null}var Ii=[],Ei=0,Hn=null,zn=0,Je=[],Ze=0,pi=null,Tt=1,Dt="";function ni(e,t){Ii[Ei++]=zn,Ii[Ei++]=Hn,Hn=e,zn=t}function xd(e,t,a){Je[Ze++]=Tt,Je[Ze++]=Dt,Je[Ze++]=pi,pi=e;var n=Tt;e=Dt;var s=32-mt(n)-1;n&=~(1<<s),a+=1;var r=32-mt(t)+s;if(30<r){var o=s-s%5;r=(n&(1<<o)-1).toString(32),n>>=o,s-=o,Tt=1<<32-mt(t)+s|a<<s|n,Dt=r+e}else Tt=1<<r|a<<s|n,Dt=e}function ho(e){e.return!==null&&(ni(e,1),xd(e,1,0))}function go(e){for(;e===Hn;)Hn=Ii[--Ei],Ii[Ei]=null,zn=Ii[--Ei],Ii[Ei]=null;for(;e===pi;)pi=Je[--Ze],Je[Ze]=null,Dt=Je[--Ze],Je[Ze]=null,Tt=Je[--Ze],Je[Ze]=null}var Ke=null,$e=null,oe=!1,ut=null;function bd(e,t){var a=et(5,null,null,0);a.elementType="DELETED",a.stateNode=t,a.return=e,t=e.deletions,t===null?(e.deletions=[a],e.flags|=16):t.push(a)}function kl(e,t){switch(e.tag){case 5:var a=e.type;return t=t.nodeType!==1||a.toLowerCase()!==t.nodeName.toLowerCase()?null:t,t!==null?(e.stateNode=t,Ke=e,$e=_t(t.firstChild),!0):!1;case 6:return t=e.pendingProps===""||t.nodeType!==3?null:t,t!==null?(e.stateNode=t,Ke=e,$e=null,!0):!1;case 13:return t=t.nodeType!==8?null:t,t!==null?(a=pi!==null?{id:Tt,overflow:Dt}:null,e.memoizedState={dehydrated:t,treeContext:a,retryLane:1073741824},a=et(18,null,null,0),a.stateNode=t,a.return=e,e.child=a,Ke=e,$e=null,!0):!1;default:return!1}}function Pr(e){return(e.mode&1)!==0&&(e.flags&128)===0}function kr(e){if(oe){var t=$e;if(t){var a=t;if(!kl(e,t)){if(Pr(e))throw Error(M(418));t=_t(a.nextSibling);var n=Ke;t&&kl(e,t)?bd(n,a):(e.flags=e.flags&-4097|2,oe=!1,Ke=e)}}else{if(Pr(e))throw Error(M(418));e.flags=e.flags&-4097|2,oe=!1,Ke=e}}}function jl(e){for(e=e.return;e!==null&&e.tag!==5&&e.tag!==3&&e.tag!==13;)e=e.return;Ke=e}function pn(e){if(e!==Ke)return!1;if(!oe)return jl(e),oe=!0,!1;var t;if((t=e.tag!==3)&&!(t=e.tag!==5)&&(t=e.type,t=t!=="head"&&t!=="body"&&!Ar(e.type,e.memoizedProps)),t&&(t=$e)){if(Pr(e))throw Cd(),Error(M(418));for(;t;)bd(e,t),t=_t(t.nextSibling)}if(jl(e),e.tag===13){if(e=e.memoizedState,e=e!==null?e.dehydrated:null,!e)throw Error(M(317));e:{for(e=e.nextSibling,t=0;e;){if(e.nodeType===8){var a=e.data;if(a==="/$"){if(t===0){$e=_t(e.nextSibling);break e}t--}else a!=="$"&&a!=="$!"&&a!=="$?"||t++}e=e.nextSibling}$e=null}}else $e=Ke?_t(e.stateNode.nextSibling):null;return!0}function Cd(){for(var e=$e;e;)e=_t(e.nextSibling)}function $i(){$e=Ke=null,oe=!1}function yo(e){ut===null?ut=[e]:ut.push(e)}var Dp=It.ReactCurrentBatchConfig;function ma(e,t,a){if(e=a.ref,e!==null&&typeof e!="function"&&typeof e!="object"){if(a._owner){if(a=a._owner,a){if(a.tag!==1)throw Error(M(309));var n=a.stateNode}if(!n)throw Error(M(147,e));var s=n,r=""+e;return t!==null&&t.ref!==null&&typeof t.ref=="function"&&t.ref._stringRef===r?t.ref:(t=function(o){var l=s.refs;o===null?delete l[r]:l[r]=o},t._stringRef=r,t)}if(typeof e!="string")throw Error(M(284));if(!a._owner)throw Error(M(290,e))}return e}function fn(e,t){throw e=Object.prototype.toString.call(t),Error(M(31,e==="[object Object]"?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function Rl(e){var t=e._init;return t(e._payload)}function wd(e){function t(m,c){if(e){var h=m.deletions;h===null?(m.deletions=[c],m.flags|=16):h.push(c)}}function a(m,c){if(!e)return null;for(;c!==null;)t(m,c),c=c.sibling;return null}function n(m,c){for(m=new Map;c!==null;)c.key!==null?m.set(c.key,c):m.set(c.index,c),c=c.sibling;return m}function s(m,c){return m=Yt(m,c),m.index=0,m.sibling=null,m}function r(m,c,h){return m.index=h,e?(h=m.alternate,h!==null?(h=h.index,h<c?(m.flags|=2,c):h):(m.flags|=2,c)):(m.flags|=1048576,c)}function o(m){return e&&m.alternate===null&&(m.flags|=2),m}function l(m,c,h,C){return c===null||c.tag!==6?(c=Qs(h,m.mode,C),c.return=m,c):(c=s(c,h),c.return=m,c)}function d(m,c,h,C){var P=h.type;return P===Pi?g(m,c,h.props.children,C,h.key):c!==null&&(c.elementType===P||typeof P=="object"&&P!==null&&P.$$typeof===Ot&&Rl(P)===c.type)?(C=s(c,h.props),C.ref=ma(m,c,h),C.return=m,C):(C=Rn(h.type,h.key,h.props,null,m.mode,C),C.ref=ma(m,c,h),C.return=m,C)}function u(m,c,h,C){return c===null||c.tag!==4||c.stateNode.containerInfo!==h.containerInfo||c.stateNode.implementation!==h.implementation?(c=Ys(h,m.mode,C),c.return=m,c):(c=s(c,h.children||[]),c.return=m,c)}function g(m,c,h,C,P){return c===null||c.tag!==7?(c=ui(h,m.mode,C,P),c.return=m,c):(c=s(c,h),c.return=m,c)}function p(m,c,h){if(typeof c=="string"&&c!==""||typeof c=="number")return c=Qs(""+c,m.mode,h),c.return=m,c;if(typeof c=="object"&&c!==null){switch(c.$$typeof){case an:return h=Rn(c.type,c.key,c.props,null,m.mode,h),h.ref=ma(m,null,c),h.return=m,h;case Di:return c=Ys(c,m.mode,h),c.return=m,c;case Ot:var C=c._init;return p(m,C(c._payload),h)}if(ga(c)||oa(c))return c=ui(c,m.mode,h,null),c.return=m,c;fn(m,c)}return null}function y(m,c,h,C){var P=c!==null?c.key:null;if(typeof h=="string"&&h!==""||typeof h=="number")return P!==null?null:l(m,c,""+h,C);if(typeof h=="object"&&h!==null){switch(h.$$typeof){case an:return h.key===P?d(m,c,h,C):null;case Di:return h.key===P?u(m,c,h,C):null;case Ot:return P=h._init,y(m,c,P(h._payload),C)}if(ga(h)||oa(h))return P!==null?null:g(m,c,h,C,null);fn(m,h)}return null}function x(m,c,h,C,P){if(typeof C=="string"&&C!==""||typeof C=="number")return m=m.get(h)||null,l(c,m,""+C,P);if(typeof C=="object"&&C!==null){switch(C.$$typeof){case an:return m=m.get(C.key===null?h:C.key)||null,d(c,m,C,P);case Di:return m=m.get(C.key===null?h:C.key)||null,u(c,m,C,P);case Ot:var R=C._init;return x(m,c,h,R(C._payload),P)}if(ga(C)||oa(C))return m=m.get(h)||null,g(c,m,C,P,null);fn(c,C)}return null}function w(m,c,h,C){for(var P=null,R=null,v=c,N=c=0,F=null;v!==null&&N<h.length;N++){v.index>N?(F=v,v=null):F=v.sibling;var I=y(m,v,h[N],C);if(I===null){v===null&&(v=F);break}e&&v&&I.alternate===null&&t(m,v),c=r(I,c,N),R===null?P=I:R.sibling=I,R=I,v=F}if(N===h.length)return a(m,v),oe&&ni(m,N),P;if(v===null){for(;N<h.length;N++)v=p(m,h[N],C),v!==null&&(c=r(v,c,N),R===null?P=v:R.sibling=v,R=v);return oe&&ni(m,N),P}for(v=n(m,v);N<h.length;N++)F=x(v,m,N,h[N],C),F!==null&&(e&&F.alternate!==null&&v.delete(F.key===null?N:F.key),c=r(F,c,N),R===null?P=F:R.sibling=F,R=F);return e&&v.forEach(function(q){return t(m,q)}),oe&&ni(m,N),P}function b(m,c,h,C){var P=oa(h);if(typeof P!="function")throw Error(M(150));if(h=P.call(h),h==null)throw Error(M(151));for(var R=P=null,v=c,N=c=0,F=null,I=h.next();v!==null&&!I.done;N++,I=h.next()){v.index>N?(F=v,v=null):F=v.sibling;var q=y(m,v,I.value,C);if(q===null){v===null&&(v=F);break}e&&v&&q.alternate===null&&t(m,v),c=r(q,c,N),R===null?P=q:R.sibling=q,R=q,v=F}if(I.done)return a(m,v),oe&&ni(m,N),P;if(v===null){for(;!I.done;N++,I=h.next())I=p(m,I.value,C),I!==null&&(c=r(I,c,N),R===null?P=I:R.sibling=I,R=I);return oe&&ni(m,N),P}for(v=n(m,v);!I.done;N++,I=h.next())I=x(v,m,N,I.value,C),I!==null&&(e&&I.alternate!==null&&v.delete(I.key===null?N:I.key),c=r(I,c,N),R===null?P=I:R.sibling=I,R=I);return e&&v.forEach(function(be){return t(m,be)}),oe&&ni(m,N),P}function j(m,c,h,C){if(typeof h=="object"&&h!==null&&h.type===Pi&&h.key===null&&(h=h.props.children),typeof h=="object"&&h!==null){switch(h.$$typeof){case an:e:{for(var P=h.key,R=c;R!==null;){if(R.key===P){if(P=h.type,P===Pi){if(R.tag===7){a(m,R.sibling),c=s(R,h.props.children),c.return=m,m=c;break e}}else if(R.elementType===P||typeof P=="object"&&P!==null&&P.$$typeof===Ot&&Rl(P)===R.type){a(m,R.sibling),c=s(R,h.props),c.ref=ma(m,R,h),c.return=m,m=c;break e}a(m,R);break}else t(m,R);R=R.sibling}h.type===Pi?(c=ui(h.props.children,m.mode,C,h.key),c.return=m,m=c):(C=Rn(h.type,h.key,h.props,null,m.mode,C),C.ref=ma(m,c,h),C.return=m,m=C)}return o(m);case Di:e:{for(R=h.key;c!==null;){if(c.key===R)if(c.tag===4&&c.stateNode.containerInfo===h.containerInfo&&c.stateNode.implementation===h.implementation){a(m,c.sibling),c=s(c,h.children||[]),c.return=m,m=c;break e}else{a(m,c);break}else t(m,c);c=c.sibling}c=Ys(h,m.mode,C),c.return=m,m=c}return o(m);case Ot:return R=h._init,j(m,c,R(h._payload),C)}if(ga(h))return w(m,c,h,C);if(oa(h))return b(m,c,h,C);fn(m,h)}return typeof h=="string"&&h!==""||typeof h=="number"?(h=""+h,c!==null&&c.tag===6?(a(m,c.sibling),c=s(c,h),c.return=m,m=c):(a(m,c),c=Qs(h,m.mode,C),c.return=m,m=c),o(m)):a(m,c)}return j}var Ki=wd(!0),Nd=wd(!1),Wn=ei(null),_n=null,Fi=null,vo=null;function xo(){vo=Fi=_n=null}function bo(e){var t=Wn.current;se(Wn),e._currentValue=t}function jr(e,t,a){for(;e!==null;){var n=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,n!==null&&(n.childLanes|=t)):n!==null&&(n.childLanes&t)!==t&&(n.childLanes|=t),e===a)break;e=e.return}}function Hi(e,t){_n=e,vo=Fi=null,e=e.dependencies,e!==null&&e.firstContext!==null&&(e.lanes&t&&(Ue=!0),e.firstContext=null)}function it(e){var t=e._currentValue;if(vo!==e)if(e={context:e,memoizedValue:t,next:null},Fi===null){if(_n===null)throw Error(M(308));Fi=e,_n.dependencies={lanes:0,firstContext:e}}else Fi=Fi.next=e;return t}var oi=null;function Co(e){oi===null?oi=[e]:oi.push(e)}function Ad(e,t,a,n){var s=t.interleaved;return s===null?(a.next=a,Co(t)):(a.next=s.next,s.next=a),t.interleaved=a,Lt(e,n)}function Lt(e,t){e.lanes|=t;var a=e.alternate;for(a!==null&&(a.lanes|=t),a=e,e=e.return;e!==null;)e.childLanes|=t,a=e.alternate,a!==null&&(a.childLanes|=t),a=e,e=e.return;return a.tag===3?a.stateNode:null}var Bt=!1;function wo(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Sd(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Pt(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function $t(e,t,a){var n=e.updateQueue;if(n===null)return null;if(n=n.shared,W&2){var s=n.pending;return s===null?t.next=t:(t.next=s.next,s.next=t),n.pending=t,Lt(e,a)}return s=n.interleaved,s===null?(t.next=t,Co(n)):(t.next=s.next,s.next=t),n.interleaved=t,Lt(e,a)}function Sn(e,t,a){if(t=t.updateQueue,t!==null&&(t=t.shared,(a&4194240)!==0)){var n=t.lanes;n&=e.pendingLanes,a|=n,t.lanes=a,ro(e,a)}}function Ll(e,t){var a=e.updateQueue,n=e.alternate;if(n!==null&&(n=n.updateQueue,a===n)){var s=null,r=null;if(a=a.firstBaseUpdate,a!==null){do{var o={eventTime:a.eventTime,lane:a.lane,tag:a.tag,payload:a.payload,callback:a.callback,next:null};r===null?s=r=o:r=r.next=o,a=a.next}while(a!==null);r===null?s=r=t:r=r.next=t}else s=r=t;a={baseState:n.baseState,firstBaseUpdate:s,lastBaseUpdate:r,shared:n.shared,effects:n.effects},e.updateQueue=a;return}e=a.lastBaseUpdate,e===null?a.firstBaseUpdate=t:e.next=t,a.lastBaseUpdate=t}function $n(e,t,a,n){var s=e.updateQueue;Bt=!1;var r=s.firstBaseUpdate,o=s.lastBaseUpdate,l=s.shared.pending;if(l!==null){s.shared.pending=null;var d=l,u=d.next;d.next=null,o===null?r=u:o.next=u,o=d;var g=e.alternate;g!==null&&(g=g.updateQueue,l=g.lastBaseUpdate,l!==o&&(l===null?g.firstBaseUpdate=u:l.next=u,g.lastBaseUpdate=d))}if(r!==null){var p=s.baseState;o=0,g=u=d=null,l=r;do{var y=l.lane,x=l.eventTime;if((n&y)===y){g!==null&&(g=g.next={eventTime:x,lane:0,tag:l.tag,payload:l.payload,callback:l.callback,next:null});e:{var w=e,b=l;switch(y=t,x=a,b.tag){case 1:if(w=b.payload,typeof w=="function"){p=w.call(x,p,y);break e}p=w;break e;case 3:w.flags=w.flags&-65537|128;case 0:if(w=b.payload,y=typeof w=="function"?w.call(x,p,y):w,y==null)break e;p=de({},p,y);break e;case 2:Bt=!0}}l.callback!==null&&l.lane!==0&&(e.flags|=64,y=s.effects,y===null?s.effects=[l]:y.push(l))}else x={eventTime:x,lane:y,tag:l.tag,payload:l.payload,callback:l.callback,next:null},g===null?(u=g=x,d=p):g=g.next=x,o|=y;if(l=l.next,l===null){if(l=s.shared.pending,l===null)break;y=l,l=y.next,y.next=null,s.lastBaseUpdate=y,s.shared.pending=null}}while(!0);if(g===null&&(d=p),s.baseState=d,s.firstBaseUpdate=u,s.lastBaseUpdate=g,t=s.shared.interleaved,t!==null){s=t;do o|=s.lane,s=s.next;while(s!==t)}else r===null&&(s.shared.lanes=0);hi|=o,e.lanes=o,e.memoizedState=p}}function Ml(e,t,a){if(e=t.effects,t.effects=null,e!==null)for(t=0;t<e.length;t++){var n=e[t],s=n.callback;if(s!==null){if(n.callback=null,n=a,typeof s!="function")throw Error(M(191,s));s.call(n)}}}var Xa={},wt=ei(Xa),qa=ei(Xa),Ua=ei(Xa);function li(e){if(e===Xa)throw Error(M(174));return e}function No(e,t){switch(ie(Ua,t),ie(qa,e),ie(wt,Xa),e=t.nodeType,e){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:dr(null,"");break;default:e=e===8?t.parentNode:t,t=e.namespaceURI||null,e=e.tagName,t=dr(t,e)}se(wt),ie(wt,t)}function Qi(){se(wt),se(qa),se(Ua)}function Td(e){li(Ua.current);var t=li(wt.current),a=dr(t,e.type);t!==a&&(ie(qa,e),ie(wt,a))}function Ao(e){qa.current===e&&(se(wt),se(qa))}var le=ei(0);function Kn(e){for(var t=e;t!==null;){if(t.tag===13){var a=t.memoizedState;if(a!==null&&(a=a.dehydrated,a===null||a.data==="$?"||a.data==="$!"))return t}else if(t.tag===19&&t.memoizedProps.revealOrder!==void 0){if(t.flags&128)return t}else if(t.child!==null){t.child.return=t,t=t.child;continue}if(t===e)break;for(;t.sibling===null;){if(t.return===null||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var Hs=[];function So(){for(var e=0;e<Hs.length;e++)Hs[e]._workInProgressVersionPrimary=null;Hs.length=0}var Tn=It.ReactCurrentDispatcher,zs=It.ReactCurrentBatchConfig,fi=0,ce=null,ve=null,we=null,Qn=!1,Aa=!1,Ga=0,Pp=0;function ke(){throw Error(M(321))}function To(e,t){if(t===null)return!1;for(var a=0;a<t.length&&a<e.length;a++)if(!ft(e[a],t[a]))return!1;return!0}function Do(e,t,a,n,s,r){if(fi=r,ce=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,Tn.current=e===null||e.memoizedState===null?Lp:Mp,e=a(n,s),Aa){r=0;do{if(Aa=!1,Ga=0,25<=r)throw Error(M(301));r+=1,we=ve=null,t.updateQueue=null,Tn.current=Ip,e=a(n,s)}while(Aa)}if(Tn.current=Yn,t=ve!==null&&ve.next!==null,fi=0,we=ve=ce=null,Qn=!1,t)throw Error(M(300));return e}function Po(){var e=Ga!==0;return Ga=0,e}function vt(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return we===null?ce.memoizedState=we=e:we=we.next=e,we}function at(){if(ve===null){var e=ce.alternate;e=e!==null?e.memoizedState:null}else e=ve.next;var t=we===null?ce.memoizedState:we.next;if(t!==null)we=t,ve=e;else{if(e===null)throw Error(M(310));ve=e,e={memoizedState:ve.memoizedState,baseState:ve.baseState,baseQueue:ve.baseQueue,queue:ve.queue,next:null},we===null?ce.memoizedState=we=e:we=we.next=e}return we}function Ha(e,t){return typeof t=="function"?t(e):t}function Ws(e){var t=at(),a=t.queue;if(a===null)throw Error(M(311));a.lastRenderedReducer=e;var n=ve,s=n.baseQueue,r=a.pending;if(r!==null){if(s!==null){var o=s.next;s.next=r.next,r.next=o}n.baseQueue=s=r,a.pending=null}if(s!==null){r=s.next,n=n.baseState;var l=o=null,d=null,u=r;do{var g=u.lane;if((fi&g)===g)d!==null&&(d=d.next={lane:0,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null}),n=u.hasEagerState?u.eagerState:e(n,u.action);else{var p={lane:g,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null};d===null?(l=d=p,o=n):d=d.next=p,ce.lanes|=g,hi|=g}u=u.next}while(u!==null&&u!==r);d===null?o=n:d.next=l,ft(n,t.memoizedState)||(Ue=!0),t.memoizedState=n,t.baseState=o,t.baseQueue=d,a.lastRenderedState=n}if(e=a.interleaved,e!==null){s=e;do r=s.lane,ce.lanes|=r,hi|=r,s=s.next;while(s!==e)}else s===null&&(a.lanes=0);return[t.memoizedState,a.dispatch]}function _s(e){var t=at(),a=t.queue;if(a===null)throw Error(M(311));a.lastRenderedReducer=e;var n=a.dispatch,s=a.pending,r=t.memoizedState;if(s!==null){a.pending=null;var o=s=s.next;do r=e(r,o.action),o=o.next;while(o!==s);ft(r,t.memoizedState)||(Ue=!0),t.memoizedState=r,t.baseQueue===null&&(t.baseState=r),a.lastRenderedState=r}return[r,n]}function Dd(){}function Pd(e,t){var a=ce,n=at(),s=t(),r=!ft(n.memoizedState,s);if(r&&(n.memoizedState=s,Ue=!0),n=n.queue,ko(Rd.bind(null,a,n,e),[e]),n.getSnapshot!==t||r||we!==null&&we.memoizedState.tag&1){if(a.flags|=2048,za(9,jd.bind(null,a,n,s,t),void 0,null),Ne===null)throw Error(M(349));fi&30||kd(a,t,s)}return s}function kd(e,t,a){e.flags|=16384,e={getSnapshot:t,value:a},t=ce.updateQueue,t===null?(t={lastEffect:null,stores:null},ce.updateQueue=t,t.stores=[e]):(a=t.stores,a===null?t.stores=[e]:a.push(e))}function jd(e,t,a,n){t.value=a,t.getSnapshot=n,Ld(t)&&Md(e)}function Rd(e,t,a){return a(function(){Ld(t)&&Md(e)})}function Ld(e){var t=e.getSnapshot;e=e.value;try{var a=t();return!ft(e,a)}catch{return!0}}function Md(e){var t=Lt(e,1);t!==null&&pt(t,e,1,-1)}function Il(e){var t=vt();return typeof e=="function"&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Ha,lastRenderedState:e},t.queue=e,e=e.dispatch=Rp.bind(null,ce,e),[t.memoizedState,e]}function za(e,t,a,n){return e={tag:e,create:t,destroy:a,deps:n,next:null},t=ce.updateQueue,t===null?(t={lastEffect:null,stores:null},ce.updateQueue=t,t.lastEffect=e.next=e):(a=t.lastEffect,a===null?t.lastEffect=e.next=e:(n=a.next,a.next=e,e.next=n,t.lastEffect=e)),e}function Id(){return at().memoizedState}function Dn(e,t,a,n){var s=vt();ce.flags|=e,s.memoizedState=za(1|t,a,void 0,n===void 0?null:n)}function us(e,t,a,n){var s=at();n=n===void 0?null:n;var r=void 0;if(ve!==null){var o=ve.memoizedState;if(r=o.destroy,n!==null&&To(n,o.deps)){s.memoizedState=za(t,a,r,n);return}}ce.flags|=e,s.memoizedState=za(1|t,a,r,n)}function El(e,t){return Dn(8390656,8,e,t)}function ko(e,t){return us(2048,8,e,t)}function Ed(e,t){return us(4,2,e,t)}function Fd(e,t){return us(4,4,e,t)}function Od(e,t){if(typeof t=="function")return e=e(),t(e),function(){t(null)};if(t!=null)return e=e(),t.current=e,function(){t.current=null}}function Bd(e,t,a){return a=a!=null?a.concat([e]):null,us(4,4,Od.bind(null,t,e),a)}function jo(){}function Vd(e,t){var a=at();t=t===void 0?null:t;var n=a.memoizedState;return n!==null&&t!==null&&To(t,n[1])?n[0]:(a.memoizedState=[e,t],e)}function qd(e,t){var a=at();t=t===void 0?null:t;var n=a.memoizedState;return n!==null&&t!==null&&To(t,n[1])?n[0]:(e=e(),a.memoizedState=[e,t],e)}function Ud(e,t,a){return fi&21?(ft(a,t)||(a=_c(),ce.lanes|=a,hi|=a,e.baseState=!0),t):(e.baseState&&(e.baseState=!1,Ue=!0),e.memoizedState=a)}function kp(e,t){var a=Z;Z=a!==0&&4>a?a:4,e(!0);var n=zs.transition;zs.transition={};try{e(!1),t()}finally{Z=a,zs.transition=n}}function Gd(){return at().memoizedState}function jp(e,t,a){var n=Qt(e);if(a={lane:n,action:a,hasEagerState:!1,eagerState:null,next:null},Hd(e))zd(t,a);else if(a=Ad(e,t,a,n),a!==null){var s=Fe();pt(a,e,n,s),Wd(a,t,n)}}function Rp(e,t,a){var n=Qt(e),s={lane:n,action:a,hasEagerState:!1,eagerState:null,next:null};if(Hd(e))zd(t,s);else{var r=e.alternate;if(e.lanes===0&&(r===null||r.lanes===0)&&(r=t.lastRenderedReducer,r!==null))try{var o=t.lastRenderedState,l=r(o,a);if(s.hasEagerState=!0,s.eagerState=l,ft(l,o)){var d=t.interleaved;d===null?(s.next=s,Co(t)):(s.next=d.next,d.next=s),t.interleaved=s;return}}catch{}finally{}a=Ad(e,t,s,n),a!==null&&(s=Fe(),pt(a,e,n,s),Wd(a,t,n))}}function Hd(e){var t=e.alternate;return e===ce||t!==null&&t===ce}function zd(e,t){Aa=Qn=!0;var a=e.pending;a===null?t.next=t:(t.next=a.next,a.next=t),e.pending=t}function Wd(e,t,a){if(a&4194240){var n=t.lanes;n&=e.pendingLanes,a|=n,t.lanes=a,ro(e,a)}}var Yn={readContext:it,useCallback:ke,useContext:ke,useEffect:ke,useImperativeHandle:ke,useInsertionEffect:ke,useLayoutEffect:ke,useMemo:ke,useReducer:ke,useRef:ke,useState:ke,useDebugValue:ke,useDeferredValue:ke,useTransition:ke,useMutableSource:ke,useSyncExternalStore:ke,useId:ke,unstable_isNewReconciler:!1},Lp={readContext:it,useCallback:function(e,t){return vt().memoizedState=[e,t===void 0?null:t],e},useContext:it,useEffect:El,useImperativeHandle:function(e,t,a){return a=a!=null?a.concat([e]):null,Dn(4194308,4,Od.bind(null,t,e),a)},useLayoutEffect:function(e,t){return Dn(4194308,4,e,t)},useInsertionEffect:function(e,t){return Dn(4,2,e,t)},useMemo:function(e,t){var a=vt();return t=t===void 0?null:t,e=e(),a.memoizedState=[e,t],e},useReducer:function(e,t,a){var n=vt();return t=a!==void 0?a(t):t,n.memoizedState=n.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},n.queue=e,e=e.dispatch=jp.bind(null,ce,e),[n.memoizedState,e]},useRef:function(e){var t=vt();return e={current:e},t.memoizedState=e},useState:Il,useDebugValue:jo,useDeferredValue:function(e){return vt().memoizedState=e},useTransition:function(){var e=Il(!1),t=e[0];return e=kp.bind(null,e[1]),vt().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,a){var n=ce,s=vt();if(oe){if(a===void 0)throw Error(M(407));a=a()}else{if(a=t(),Ne===null)throw Error(M(349));fi&30||kd(n,t,a)}s.memoizedState=a;var r={value:a,getSnapshot:t};return s.queue=r,El(Rd.bind(null,n,r,e),[e]),n.flags|=2048,za(9,jd.bind(null,n,r,a,t),void 0,null),a},useId:function(){var e=vt(),t=Ne.identifierPrefix;if(oe){var a=Dt,n=Tt;a=(n&~(1<<32-mt(n)-1)).toString(32)+a,t=":"+t+"R"+a,a=Ga++,0<a&&(t+="H"+a.toString(32)),t+=":"}else a=Pp++,t=":"+t+"r"+a.toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},Mp={readContext:it,useCallback:Vd,useContext:it,useEffect:ko,useImperativeHandle:Bd,useInsertionEffect:Ed,useLayoutEffect:Fd,useMemo:qd,useReducer:Ws,useRef:Id,useState:function(){return Ws(Ha)},useDebugValue:jo,useDeferredValue:function(e){var t=at();return Ud(t,ve.memoizedState,e)},useTransition:function(){var e=Ws(Ha)[0],t=at().memoizedState;return[e,t]},useMutableSource:Dd,useSyncExternalStore:Pd,useId:Gd,unstable_isNewReconciler:!1},Ip={readContext:it,useCallback:Vd,useContext:it,useEffect:ko,useImperativeHandle:Bd,useInsertionEffect:Ed,useLayoutEffect:Fd,useMemo:qd,useReducer:_s,useRef:Id,useState:function(){return _s(Ha)},useDebugValue:jo,useDeferredValue:function(e){var t=at();return ve===null?t.memoizedState=e:Ud(t,ve.memoizedState,e)},useTransition:function(){var e=_s(Ha)[0],t=at().memoizedState;return[e,t]},useMutableSource:Dd,useSyncExternalStore:Pd,useId:Gd,unstable_isNewReconciler:!1};function ct(e,t){if(e&&e.defaultProps){t=de({},t),e=e.defaultProps;for(var a in e)t[a]===void 0&&(t[a]=e[a]);return t}return t}function Rr(e,t,a,n){t=e.memoizedState,a=a(n,t),a=a==null?t:de({},t,a),e.memoizedState=a,e.lanes===0&&(e.updateQueue.baseState=a)}var ms={isMounted:function(e){return(e=e._reactInternals)?vi(e)===e:!1},enqueueSetState:function(e,t,a){e=e._reactInternals;var n=Fe(),s=Qt(e),r=Pt(n,s);r.payload=t,a!=null&&(r.callback=a),t=$t(e,r,s),t!==null&&(pt(t,e,s,n),Sn(t,e,s))},enqueueReplaceState:function(e,t,a){e=e._reactInternals;var n=Fe(),s=Qt(e),r=Pt(n,s);r.tag=1,r.payload=t,a!=null&&(r.callback=a),t=$t(e,r,s),t!==null&&(pt(t,e,s,n),Sn(t,e,s))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var a=Fe(),n=Qt(e),s=Pt(a,n);s.tag=2,t!=null&&(s.callback=t),t=$t(e,s,n),t!==null&&(pt(t,e,n,a),Sn(t,e,n))}};function Fl(e,t,a,n,s,r,o){return e=e.stateNode,typeof e.shouldComponentUpdate=="function"?e.shouldComponentUpdate(n,r,o):t.prototype&&t.prototype.isPureReactComponent?!Fa(a,n)||!Fa(s,r):!0}function _d(e,t,a){var n=!1,s=Jt,r=t.contextType;return typeof r=="object"&&r!==null?r=it(r):(s=He(t)?mi:Le.current,n=t.contextTypes,r=(n=n!=null)?_i(e,s):Jt),t=new t(a,r),e.memoizedState=t.state!==null&&t.state!==void 0?t.state:null,t.updater=ms,e.stateNode=t,t._reactInternals=e,n&&(e=e.stateNode,e.__reactInternalMemoizedUnmaskedChildContext=s,e.__reactInternalMemoizedMaskedChildContext=r),t}function Ol(e,t,a,n){e=t.state,typeof t.componentWillReceiveProps=="function"&&t.componentWillReceiveProps(a,n),typeof t.UNSAFE_componentWillReceiveProps=="function"&&t.UNSAFE_componentWillReceiveProps(a,n),t.state!==e&&ms.enqueueReplaceState(t,t.state,null)}function Lr(e,t,a,n){var s=e.stateNode;s.props=a,s.state=e.memoizedState,s.refs={},wo(e);var r=t.contextType;typeof r=="object"&&r!==null?s.context=it(r):(r=He(t)?mi:Le.current,s.context=_i(e,r)),s.state=e.memoizedState,r=t.getDerivedStateFromProps,typeof r=="function"&&(Rr(e,t,r,a),s.state=e.memoizedState),typeof t.getDerivedStateFromProps=="function"||typeof s.getSnapshotBeforeUpdate=="function"||typeof s.UNSAFE_componentWillMount!="function"&&typeof s.componentWillMount!="function"||(t=s.state,typeof s.componentWillMount=="function"&&s.componentWillMount(),typeof s.UNSAFE_componentWillMount=="function"&&s.UNSAFE_componentWillMount(),t!==s.state&&ms.enqueueReplaceState(s,s.state,null),$n(e,a,s,n),s.state=e.memoizedState),typeof s.componentDidMount=="function"&&(e.flags|=4194308)}function Yi(e,t){try{var a="",n=t;do a+=lm(n),n=n.return;while(n);var s=a}catch(r){s=`
Error generating stack: `+r.message+`
`+r.stack}return{value:e,source:t,stack:s,digest:null}}function $s(e,t,a){return{value:e,source:null,stack:a??null,digest:t??null}}function Mr(e,t){try{console.error(t.value)}catch(a){setTimeout(function(){throw a})}}var Ep=typeof WeakMap=="function"?WeakMap:Map;function $d(e,t,a){a=Pt(-1,a),a.tag=3,a.payload={element:null};var n=t.value;return a.callback=function(){Jn||(Jn=!0,Hr=n),Mr(e,t)},a}function Kd(e,t,a){a=Pt(-1,a),a.tag=3;var n=e.type.getDerivedStateFromError;if(typeof n=="function"){var s=t.value;a.payload=function(){return n(s)},a.callback=function(){Mr(e,t)}}var r=e.stateNode;return r!==null&&typeof r.componentDidCatch=="function"&&(a.callback=function(){Mr(e,t),typeof n!="function"&&(Kt===null?Kt=new Set([this]):Kt.add(this));var o=t.stack;this.componentDidCatch(t.value,{componentStack:o!==null?o:""})}),a}function Bl(e,t,a){var n=e.pingCache;if(n===null){n=e.pingCache=new Ep;var s=new Set;n.set(t,s)}else s=n.get(t),s===void 0&&(s=new Set,n.set(t,s));s.has(a)||(s.add(a),e=Qp.bind(null,e,t,a),t.then(e,e))}function Vl(e){do{var t;if((t=e.tag===13)&&(t=e.memoizedState,t=t!==null?t.dehydrated!==null:!0),t)return e;e=e.return}while(e!==null);return null}function ql(e,t,a,n,s){return e.mode&1?(e.flags|=65536,e.lanes=s,e):(e===t?e.flags|=65536:(e.flags|=128,a.flags|=131072,a.flags&=-52805,a.tag===1&&(a.alternate===null?a.tag=17:(t=Pt(-1,1),t.tag=2,$t(a,t,1))),a.lanes|=1),e)}var Fp=It.ReactCurrentOwner,Ue=!1;function Ee(e,t,a,n){t.child=e===null?Nd(t,null,a,n):Ki(t,e.child,a,n)}function Ul(e,t,a,n,s){a=a.render;var r=t.ref;return Hi(t,s),n=Do(e,t,a,n,r,s),a=Po(),e!==null&&!Ue?(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~s,Mt(e,t,s)):(oe&&a&&ho(t),t.flags|=1,Ee(e,t,n,s),t.child)}function Gl(e,t,a,n,s){if(e===null){var r=a.type;return typeof r=="function"&&!Bo(r)&&r.defaultProps===void 0&&a.compare===null&&a.defaultProps===void 0?(t.tag=15,t.type=r,Qd(e,t,r,n,s)):(e=Rn(a.type,null,n,t,t.mode,s),e.ref=t.ref,e.return=t,t.child=e)}if(r=e.child,!(e.lanes&s)){var o=r.memoizedProps;if(a=a.compare,a=a!==null?a:Fa,a(o,n)&&e.ref===t.ref)return Mt(e,t,s)}return t.flags|=1,e=Yt(r,n),e.ref=t.ref,e.return=t,t.child=e}function Qd(e,t,a,n,s){if(e!==null){var r=e.memoizedProps;if(Fa(r,n)&&e.ref===t.ref)if(Ue=!1,t.pendingProps=n=r,(e.lanes&s)!==0)e.flags&131072&&(Ue=!0);else return t.lanes=e.lanes,Mt(e,t,s)}return Ir(e,t,a,n,s)}function Yd(e,t,a){var n=t.pendingProps,s=n.children,r=e!==null?e.memoizedState:null;if(n.mode==="hidden")if(!(t.mode&1))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},ie(Bi,_e),_e|=a;else{if(!(a&1073741824))return e=r!==null?r.baseLanes|a:a,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,ie(Bi,_e),_e|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},n=r!==null?r.baseLanes:a,ie(Bi,_e),_e|=n}else r!==null?(n=r.baseLanes|a,t.memoizedState=null):n=a,ie(Bi,_e),_e|=n;return Ee(e,t,s,a),t.child}function Xd(e,t){var a=t.ref;(e===null&&a!==null||e!==null&&e.ref!==a)&&(t.flags|=512,t.flags|=2097152)}function Ir(e,t,a,n,s){var r=He(a)?mi:Le.current;return r=_i(t,r),Hi(t,s),a=Do(e,t,a,n,r,s),n=Po(),e!==null&&!Ue?(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~s,Mt(e,t,s)):(oe&&n&&ho(t),t.flags|=1,Ee(e,t,a,s),t.child)}function Hl(e,t,a,n,s){if(He(a)){var r=!0;Gn(t)}else r=!1;if(Hi(t,s),t.stateNode===null)Pn(e,t),_d(t,a,n),Lr(t,a,n,s),n=!0;else if(e===null){var o=t.stateNode,l=t.memoizedProps;o.props=l;var d=o.context,u=a.contextType;typeof u=="object"&&u!==null?u=it(u):(u=He(a)?mi:Le.current,u=_i(t,u));var g=a.getDerivedStateFromProps,p=typeof g=="function"||typeof o.getSnapshotBeforeUpdate=="function";p||typeof o.UNSAFE_componentWillReceiveProps!="function"&&typeof o.componentWillReceiveProps!="function"||(l!==n||d!==u)&&Ol(t,o,n,u),Bt=!1;var y=t.memoizedState;o.state=y,$n(t,n,o,s),d=t.memoizedState,l!==n||y!==d||Ge.current||Bt?(typeof g=="function"&&(Rr(t,a,g,n),d=t.memoizedState),(l=Bt||Fl(t,a,l,n,y,d,u))?(p||typeof o.UNSAFE_componentWillMount!="function"&&typeof o.componentWillMount!="function"||(typeof o.componentWillMount=="function"&&o.componentWillMount(),typeof o.UNSAFE_componentWillMount=="function"&&o.UNSAFE_componentWillMount()),typeof o.componentDidMount=="function"&&(t.flags|=4194308)):(typeof o.componentDidMount=="function"&&(t.flags|=4194308),t.memoizedProps=n,t.memoizedState=d),o.props=n,o.state=d,o.context=u,n=l):(typeof o.componentDidMount=="function"&&(t.flags|=4194308),n=!1)}else{o=t.stateNode,Sd(e,t),l=t.memoizedProps,u=t.type===t.elementType?l:ct(t.type,l),o.props=u,p=t.pendingProps,y=o.context,d=a.contextType,typeof d=="object"&&d!==null?d=it(d):(d=He(a)?mi:Le.current,d=_i(t,d));var x=a.getDerivedStateFromProps;(g=typeof x=="function"||typeof o.getSnapshotBeforeUpdate=="function")||typeof o.UNSAFE_componentWillReceiveProps!="function"&&typeof o.componentWillReceiveProps!="function"||(l!==p||y!==d)&&Ol(t,o,n,d),Bt=!1,y=t.memoizedState,o.state=y,$n(t,n,o,s);var w=t.memoizedState;l!==p||y!==w||Ge.current||Bt?(typeof x=="function"&&(Rr(t,a,x,n),w=t.memoizedState),(u=Bt||Fl(t,a,u,n,y,w,d)||!1)?(g||typeof o.UNSAFE_componentWillUpdate!="function"&&typeof o.componentWillUpdate!="function"||(typeof o.componentWillUpdate=="function"&&o.componentWillUpdate(n,w,d),typeof o.UNSAFE_componentWillUpdate=="function"&&o.UNSAFE_componentWillUpdate(n,w,d)),typeof o.componentDidUpdate=="function"&&(t.flags|=4),typeof o.getSnapshotBeforeUpdate=="function"&&(t.flags|=1024)):(typeof o.componentDidUpdate!="function"||l===e.memoizedProps&&y===e.memoizedState||(t.flags|=4),typeof o.getSnapshotBeforeUpdate!="function"||l===e.memoizedProps&&y===e.memoizedState||(t.flags|=1024),t.memoizedProps=n,t.memoizedState=w),o.props=n,o.state=w,o.context=d,n=u):(typeof o.componentDidUpdate!="function"||l===e.memoizedProps&&y===e.memoizedState||(t.flags|=4),typeof o.getSnapshotBeforeUpdate!="function"||l===e.memoizedProps&&y===e.memoizedState||(t.flags|=1024),n=!1)}return Er(e,t,a,n,r,s)}function Er(e,t,a,n,s,r){Xd(e,t);var o=(t.flags&128)!==0;if(!n&&!o)return s&&Pl(t,a,!1),Mt(e,t,r);n=t.stateNode,Fp.current=t;var l=o&&typeof a.getDerivedStateFromError!="function"?null:n.render();return t.flags|=1,e!==null&&o?(t.child=Ki(t,e.child,null,r),t.child=Ki(t,null,l,r)):Ee(e,t,l,r),t.memoizedState=n.state,s&&Pl(t,a,!0),t.child}function Jd(e){var t=e.stateNode;t.pendingContext?Dl(e,t.pendingContext,t.pendingContext!==t.context):t.context&&Dl(e,t.context,!1),No(e,t.containerInfo)}function zl(e,t,a,n,s){return $i(),yo(s),t.flags|=256,Ee(e,t,a,n),t.child}var Fr={dehydrated:null,treeContext:null,retryLane:0};function Or(e){return{baseLanes:e,cachePool:null,transitions:null}}function Zd(e,t,a){var n=t.pendingProps,s=le.current,r=!1,o=(t.flags&128)!==0,l;if((l=o)||(l=e!==null&&e.memoizedState===null?!1:(s&2)!==0),l?(r=!0,t.flags&=-129):(e===null||e.memoizedState!==null)&&(s|=1),ie(le,s&1),e===null)return kr(t),e=t.memoizedState,e!==null&&(e=e.dehydrated,e!==null)?(t.mode&1?e.data==="$!"?t.lanes=8:t.lanes=1073741824:t.lanes=1,null):(o=n.children,e=n.fallback,r?(n=t.mode,r=t.child,o={mode:"hidden",children:o},!(n&1)&&r!==null?(r.childLanes=0,r.pendingProps=o):r=hs(o,n,0,null),e=ui(e,n,a,null),r.return=t,e.return=t,r.sibling=e,t.child=r,t.child.memoizedState=Or(a),t.memoizedState=Fr,e):Ro(t,o));if(s=e.memoizedState,s!==null&&(l=s.dehydrated,l!==null))return Op(e,t,o,n,l,s,a);if(r){r=n.fallback,o=t.mode,s=e.child,l=s.sibling;var d={mode:"hidden",children:n.children};return!(o&1)&&t.child!==s?(n=t.child,n.childLanes=0,n.pendingProps=d,t.deletions=null):(n=Yt(s,d),n.subtreeFlags=s.subtreeFlags&14680064),l!==null?r=Yt(l,r):(r=ui(r,o,a,null),r.flags|=2),r.return=t,n.return=t,n.sibling=r,t.child=n,n=r,r=t.child,o=e.child.memoizedState,o=o===null?Or(a):{baseLanes:o.baseLanes|a,cachePool:null,transitions:o.transitions},r.memoizedState=o,r.childLanes=e.childLanes&~a,t.memoizedState=Fr,n}return r=e.child,e=r.sibling,n=Yt(r,{mode:"visible",children:n.children}),!(t.mode&1)&&(n.lanes=a),n.return=t,n.sibling=null,e!==null&&(a=t.deletions,a===null?(t.deletions=[e],t.flags|=16):a.push(e)),t.child=n,t.memoizedState=null,n}function Ro(e,t){return t=hs({mode:"visible",children:t},e.mode,0,null),t.return=e,e.child=t}function hn(e,t,a,n){return n!==null&&yo(n),Ki(t,e.child,null,a),e=Ro(t,t.pendingProps.children),e.flags|=2,t.memoizedState=null,e}function Op(e,t,a,n,s,r,o){if(a)return t.flags&256?(t.flags&=-257,n=$s(Error(M(422))),hn(e,t,o,n)):t.memoizedState!==null?(t.child=e.child,t.flags|=128,null):(r=n.fallback,s=t.mode,n=hs({mode:"visible",children:n.children},s,0,null),r=ui(r,s,o,null),r.flags|=2,n.return=t,r.return=t,n.sibling=r,t.child=n,t.mode&1&&Ki(t,e.child,null,o),t.child.memoizedState=Or(o),t.memoizedState=Fr,r);if(!(t.mode&1))return hn(e,t,o,null);if(s.data==="$!"){if(n=s.nextSibling&&s.nextSibling.dataset,n)var l=n.dgst;return n=l,r=Error(M(419)),n=$s(r,n,void 0),hn(e,t,o,n)}if(l=(o&e.childLanes)!==0,Ue||l){if(n=Ne,n!==null){switch(o&-o){case 4:s=2;break;case 16:s=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:s=32;break;case 536870912:s=268435456;break;default:s=0}s=s&(n.suspendedLanes|o)?0:s,s!==0&&s!==r.retryLane&&(r.retryLane=s,Lt(e,s),pt(n,e,s,-1))}return Oo(),n=$s(Error(M(421))),hn(e,t,o,n)}return s.data==="$?"?(t.flags|=128,t.child=e.child,t=Yp.bind(null,e),s._reactRetry=t,null):(e=r.treeContext,$e=_t(s.nextSibling),Ke=t,oe=!0,ut=null,e!==null&&(Je[Ze++]=Tt,Je[Ze++]=Dt,Je[Ze++]=pi,Tt=e.id,Dt=e.overflow,pi=t),t=Ro(t,n.children),t.flags|=4096,t)}function Wl(e,t,a){e.lanes|=t;var n=e.alternate;n!==null&&(n.lanes|=t),jr(e.return,t,a)}function Ks(e,t,a,n,s){var r=e.memoizedState;r===null?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:n,tail:a,tailMode:s}:(r.isBackwards=t,r.rendering=null,r.renderingStartTime=0,r.last=n,r.tail=a,r.tailMode=s)}function eu(e,t,a){var n=t.pendingProps,s=n.revealOrder,r=n.tail;if(Ee(e,t,n.children,a),n=le.current,n&2)n=n&1|2,t.flags|=128;else{if(e!==null&&e.flags&128)e:for(e=t.child;e!==null;){if(e.tag===13)e.memoizedState!==null&&Wl(e,a,t);else if(e.tag===19)Wl(e,a,t);else if(e.child!==null){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;e.sibling===null;){if(e.return===null||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}n&=1}if(ie(le,n),!(t.mode&1))t.memoizedState=null;else switch(s){case"forwards":for(a=t.child,s=null;a!==null;)e=a.alternate,e!==null&&Kn(e)===null&&(s=a),a=a.sibling;a=s,a===null?(s=t.child,t.child=null):(s=a.sibling,a.sibling=null),Ks(t,!1,s,a,r);break;case"backwards":for(a=null,s=t.child,t.child=null;s!==null;){if(e=s.alternate,e!==null&&Kn(e)===null){t.child=s;break}e=s.sibling,s.sibling=a,a=s,s=e}Ks(t,!0,a,null,r);break;case"together":Ks(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Pn(e,t){!(t.mode&1)&&e!==null&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Mt(e,t,a){if(e!==null&&(t.dependencies=e.dependencies),hi|=t.lanes,!(a&t.childLanes))return null;if(e!==null&&t.child!==e.child)throw Error(M(153));if(t.child!==null){for(e=t.child,a=Yt(e,e.pendingProps),t.child=a,a.return=t;e.sibling!==null;)e=e.sibling,a=a.sibling=Yt(e,e.pendingProps),a.return=t;a.sibling=null}return t.child}function Bp(e,t,a){switch(t.tag){case 3:Jd(t),$i();break;case 5:Td(t);break;case 1:He(t.type)&&Gn(t);break;case 4:No(t,t.stateNode.containerInfo);break;case 10:var n=t.type._context,s=t.memoizedProps.value;ie(Wn,n._currentValue),n._currentValue=s;break;case 13:if(n=t.memoizedState,n!==null)return n.dehydrated!==null?(ie(le,le.current&1),t.flags|=128,null):a&t.child.childLanes?Zd(e,t,a):(ie(le,le.current&1),e=Mt(e,t,a),e!==null?e.sibling:null);ie(le,le.current&1);break;case 19:if(n=(a&t.childLanes)!==0,e.flags&128){if(n)return eu(e,t,a);t.flags|=128}if(s=t.memoizedState,s!==null&&(s.rendering=null,s.tail=null,s.lastEffect=null),ie(le,le.current),n)break;return null;case 22:case 23:return t.lanes=0,Yd(e,t,a)}return Mt(e,t,a)}var tu,Br,iu,au;tu=function(e,t){for(var a=t.child;a!==null;){if(a.tag===5||a.tag===6)e.appendChild(a.stateNode);else if(a.tag!==4&&a.child!==null){a.child.return=a,a=a.child;continue}if(a===t)break;for(;a.sibling===null;){if(a.return===null||a.return===t)return;a=a.return}a.sibling.return=a.return,a=a.sibling}};Br=function(){};iu=function(e,t,a,n){var s=e.memoizedProps;if(s!==n){e=t.stateNode,li(wt.current);var r=null;switch(a){case"input":s=rr(e,s),n=rr(e,n),r=[];break;case"select":s=de({},s,{value:void 0}),n=de({},n,{value:void 0}),r=[];break;case"textarea":s=cr(e,s),n=cr(e,n),r=[];break;default:typeof s.onClick!="function"&&typeof n.onClick=="function"&&(e.onclick=qn)}ur(a,n);var o;a=null;for(u in s)if(!n.hasOwnProperty(u)&&s.hasOwnProperty(u)&&s[u]!=null)if(u==="style"){var l=s[u];for(o in l)l.hasOwnProperty(o)&&(a||(a={}),a[o]="")}else u!=="dangerouslySetInnerHTML"&&u!=="children"&&u!=="suppressContentEditableWarning"&&u!=="suppressHydrationWarning"&&u!=="autoFocus"&&(ka.hasOwnProperty(u)?r||(r=[]):(r=r||[]).push(u,null));for(u in n){var d=n[u];if(l=s!=null?s[u]:void 0,n.hasOwnProperty(u)&&d!==l&&(d!=null||l!=null))if(u==="style")if(l){for(o in l)!l.hasOwnProperty(o)||d&&d.hasOwnProperty(o)||(a||(a={}),a[o]="");for(o in d)d.hasOwnProperty(o)&&l[o]!==d[o]&&(a||(a={}),a[o]=d[o])}else a||(r||(r=[]),r.push(u,a)),a=d;else u==="dangerouslySetInnerHTML"?(d=d?d.__html:void 0,l=l?l.__html:void 0,d!=null&&l!==d&&(r=r||[]).push(u,d)):u==="children"?typeof d!="string"&&typeof d!="number"||(r=r||[]).push(u,""+d):u!=="suppressContentEditableWarning"&&u!=="suppressHydrationWarning"&&(ka.hasOwnProperty(u)?(d!=null&&u==="onScroll"&&ne("scroll",e),r||l===d||(r=[])):(r=r||[]).push(u,d))}a&&(r=r||[]).push("style",a);var u=r;(t.updateQueue=u)&&(t.flags|=4)}};au=function(e,t,a,n){a!==n&&(t.flags|=4)};function pa(e,t){if(!oe)switch(e.tailMode){case"hidden":t=e.tail;for(var a=null;t!==null;)t.alternate!==null&&(a=t),t=t.sibling;a===null?e.tail=null:a.sibling=null;break;case"collapsed":a=e.tail;for(var n=null;a!==null;)a.alternate!==null&&(n=a),a=a.sibling;n===null?t||e.tail===null?e.tail=null:e.tail.sibling=null:n.sibling=null}}function je(e){var t=e.alternate!==null&&e.alternate.child===e.child,a=0,n=0;if(t)for(var s=e.child;s!==null;)a|=s.lanes|s.childLanes,n|=s.subtreeFlags&14680064,n|=s.flags&14680064,s.return=e,s=s.sibling;else for(s=e.child;s!==null;)a|=s.lanes|s.childLanes,n|=s.subtreeFlags,n|=s.flags,s.return=e,s=s.sibling;return e.subtreeFlags|=n,e.childLanes=a,t}function Vp(e,t,a){var n=t.pendingProps;switch(go(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return je(t),null;case 1:return He(t.type)&&Un(),je(t),null;case 3:return n=t.stateNode,Qi(),se(Ge),se(Le),So(),n.pendingContext&&(n.context=n.pendingContext,n.pendingContext=null),(e===null||e.child===null)&&(pn(t)?t.flags|=4:e===null||e.memoizedState.isDehydrated&&!(t.flags&256)||(t.flags|=1024,ut!==null&&(_r(ut),ut=null))),Br(e,t),je(t),null;case 5:Ao(t);var s=li(Ua.current);if(a=t.type,e!==null&&t.stateNode!=null)iu(e,t,a,n,s),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!n){if(t.stateNode===null)throw Error(M(166));return je(t),null}if(e=li(wt.current),pn(t)){n=t.stateNode,a=t.type;var r=t.memoizedProps;switch(n[xt]=t,n[Va]=r,e=(t.mode&1)!==0,a){case"dialog":ne("cancel",n),ne("close",n);break;case"iframe":case"object":case"embed":ne("load",n);break;case"video":case"audio":for(s=0;s<va.length;s++)ne(va[s],n);break;case"source":ne("error",n);break;case"img":case"image":case"link":ne("error",n),ne("load",n);break;case"details":ne("toggle",n);break;case"input":el(n,r),ne("invalid",n);break;case"select":n._wrapperState={wasMultiple:!!r.multiple},ne("invalid",n);break;case"textarea":il(n,r),ne("invalid",n)}ur(a,r),s=null;for(var o in r)if(r.hasOwnProperty(o)){var l=r[o];o==="children"?typeof l=="string"?n.textContent!==l&&(r.suppressHydrationWarning!==!0&&mn(n.textContent,l,e),s=["children",l]):typeof l=="number"&&n.textContent!==""+l&&(r.suppressHydrationWarning!==!0&&mn(n.textContent,l,e),s=["children",""+l]):ka.hasOwnProperty(o)&&l!=null&&o==="onScroll"&&ne("scroll",n)}switch(a){case"input":nn(n),tl(n,r,!0);break;case"textarea":nn(n),al(n);break;case"select":case"option":break;default:typeof r.onClick=="function"&&(n.onclick=qn)}n=s,t.updateQueue=n,n!==null&&(t.flags|=4)}else{o=s.nodeType===9?s:s.ownerDocument,e==="http://www.w3.org/1999/xhtml"&&(e=Rc(a)),e==="http://www.w3.org/1999/xhtml"?a==="script"?(e=o.createElement("div"),e.innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):typeof n.is=="string"?e=o.createElement(a,{is:n.is}):(e=o.createElement(a),a==="select"&&(o=e,n.multiple?o.multiple=!0:n.size&&(o.size=n.size))):e=o.createElementNS(e,a),e[xt]=t,e[Va]=n,tu(e,t,!1,!1),t.stateNode=e;e:{switch(o=mr(a,n),a){case"dialog":ne("cancel",e),ne("close",e),s=n;break;case"iframe":case"object":case"embed":ne("load",e),s=n;break;case"video":case"audio":for(s=0;s<va.length;s++)ne(va[s],e);s=n;break;case"source":ne("error",e),s=n;break;case"img":case"image":case"link":ne("error",e),ne("load",e),s=n;break;case"details":ne("toggle",e),s=n;break;case"input":el(e,n),s=rr(e,n),ne("invalid",e);break;case"option":s=n;break;case"select":e._wrapperState={wasMultiple:!!n.multiple},s=de({},n,{value:void 0}),ne("invalid",e);break;case"textarea":il(e,n),s=cr(e,n),ne("invalid",e);break;default:s=n}ur(a,s),l=s;for(r in l)if(l.hasOwnProperty(r)){var d=l[r];r==="style"?Ic(e,d):r==="dangerouslySetInnerHTML"?(d=d?d.__html:void 0,d!=null&&Lc(e,d)):r==="children"?typeof d=="string"?(a!=="textarea"||d!=="")&&ja(e,d):typeof d=="number"&&ja(e,""+d):r!=="suppressContentEditableWarning"&&r!=="suppressHydrationWarning"&&r!=="autoFocus"&&(ka.hasOwnProperty(r)?d!=null&&r==="onScroll"&&ne("scroll",e):d!=null&&eo(e,r,d,o))}switch(a){case"input":nn(e),tl(e,n,!1);break;case"textarea":nn(e),al(e);break;case"option":n.value!=null&&e.setAttribute("value",""+Xt(n.value));break;case"select":e.multiple=!!n.multiple,r=n.value,r!=null?Vi(e,!!n.multiple,r,!1):n.defaultValue!=null&&Vi(e,!!n.multiple,n.defaultValue,!0);break;default:typeof s.onClick=="function"&&(e.onclick=qn)}switch(a){case"button":case"input":case"select":case"textarea":n=!!n.autoFocus;break e;case"img":n=!0;break e;default:n=!1}}n&&(t.flags|=4)}t.ref!==null&&(t.flags|=512,t.flags|=2097152)}return je(t),null;case 6:if(e&&t.stateNode!=null)au(e,t,e.memoizedProps,n);else{if(typeof n!="string"&&t.stateNode===null)throw Error(M(166));if(a=li(Ua.current),li(wt.current),pn(t)){if(n=t.stateNode,a=t.memoizedProps,n[xt]=t,(r=n.nodeValue!==a)&&(e=Ke,e!==null))switch(e.tag){case 3:mn(n.nodeValue,a,(e.mode&1)!==0);break;case 5:e.memoizedProps.suppressHydrationWarning!==!0&&mn(n.nodeValue,a,(e.mode&1)!==0)}r&&(t.flags|=4)}else n=(a.nodeType===9?a:a.ownerDocument).createTextNode(n),n[xt]=t,t.stateNode=n}return je(t),null;case 13:if(se(le),n=t.memoizedState,e===null||e.memoizedState!==null&&e.memoizedState.dehydrated!==null){if(oe&&$e!==null&&t.mode&1&&!(t.flags&128))Cd(),$i(),t.flags|=98560,r=!1;else if(r=pn(t),n!==null&&n.dehydrated!==null){if(e===null){if(!r)throw Error(M(318));if(r=t.memoizedState,r=r!==null?r.dehydrated:null,!r)throw Error(M(317));r[xt]=t}else $i(),!(t.flags&128)&&(t.memoizedState=null),t.flags|=4;je(t),r=!1}else ut!==null&&(_r(ut),ut=null),r=!0;if(!r)return t.flags&65536?t:null}return t.flags&128?(t.lanes=a,t):(n=n!==null,n!==(e!==null&&e.memoizedState!==null)&&n&&(t.child.flags|=8192,t.mode&1&&(e===null||le.current&1?xe===0&&(xe=3):Oo())),t.updateQueue!==null&&(t.flags|=4),je(t),null);case 4:return Qi(),Br(e,t),e===null&&Oa(t.stateNode.containerInfo),je(t),null;case 10:return bo(t.type._context),je(t),null;case 17:return He(t.type)&&Un(),je(t),null;case 19:if(se(le),r=t.memoizedState,r===null)return je(t),null;if(n=(t.flags&128)!==0,o=r.rendering,o===null)if(n)pa(r,!1);else{if(xe!==0||e!==null&&e.flags&128)for(e=t.child;e!==null;){if(o=Kn(e),o!==null){for(t.flags|=128,pa(r,!1),n=o.updateQueue,n!==null&&(t.updateQueue=n,t.flags|=4),t.subtreeFlags=0,n=a,a=t.child;a!==null;)r=a,e=n,r.flags&=14680066,o=r.alternate,o===null?(r.childLanes=0,r.lanes=e,r.child=null,r.subtreeFlags=0,r.memoizedProps=null,r.memoizedState=null,r.updateQueue=null,r.dependencies=null,r.stateNode=null):(r.childLanes=o.childLanes,r.lanes=o.lanes,r.child=o.child,r.subtreeFlags=0,r.deletions=null,r.memoizedProps=o.memoizedProps,r.memoizedState=o.memoizedState,r.updateQueue=o.updateQueue,r.type=o.type,e=o.dependencies,r.dependencies=e===null?null:{lanes:e.lanes,firstContext:e.firstContext}),a=a.sibling;return ie(le,le.current&1|2),t.child}e=e.sibling}r.tail!==null&&pe()>Xi&&(t.flags|=128,n=!0,pa(r,!1),t.lanes=4194304)}else{if(!n)if(e=Kn(o),e!==null){if(t.flags|=128,n=!0,a=e.updateQueue,a!==null&&(t.updateQueue=a,t.flags|=4),pa(r,!0),r.tail===null&&r.tailMode==="hidden"&&!o.alternate&&!oe)return je(t),null}else 2*pe()-r.renderingStartTime>Xi&&a!==1073741824&&(t.flags|=128,n=!0,pa(r,!1),t.lanes=4194304);r.isBackwards?(o.sibling=t.child,t.child=o):(a=r.last,a!==null?a.sibling=o:t.child=o,r.last=o)}return r.tail!==null?(t=r.tail,r.rendering=t,r.tail=t.sibling,r.renderingStartTime=pe(),t.sibling=null,a=le.current,ie(le,n?a&1|2:a&1),t):(je(t),null);case 22:case 23:return Fo(),n=t.memoizedState!==null,e!==null&&e.memoizedState!==null!==n&&(t.flags|=8192),n&&t.mode&1?_e&1073741824&&(je(t),t.subtreeFlags&6&&(t.flags|=8192)):je(t),null;case 24:return null;case 25:return null}throw Error(M(156,t.tag))}function qp(e,t){switch(go(t),t.tag){case 1:return He(t.type)&&Un(),e=t.flags,e&65536?(t.flags=e&-65537|128,t):null;case 3:return Qi(),se(Ge),se(Le),So(),e=t.flags,e&65536&&!(e&128)?(t.flags=e&-65537|128,t):null;case 5:return Ao(t),null;case 13:if(se(le),e=t.memoizedState,e!==null&&e.dehydrated!==null){if(t.alternate===null)throw Error(M(340));$i()}return e=t.flags,e&65536?(t.flags=e&-65537|128,t):null;case 19:return se(le),null;case 4:return Qi(),null;case 10:return bo(t.type._context),null;case 22:case 23:return Fo(),null;case 24:return null;default:return null}}var gn=!1,Re=!1,Up=typeof WeakSet=="function"?WeakSet:Set,E=null;function Oi(e,t){var a=e.ref;if(a!==null)if(typeof a=="function")try{a(null)}catch(n){ue(e,t,n)}else a.current=null}function Vr(e,t,a){try{a()}catch(n){ue(e,t,n)}}var _l=!1;function Gp(e,t){if(wr=On,e=ld(),fo(e)){if("selectionStart"in e)var a={start:e.selectionStart,end:e.selectionEnd};else e:{a=(a=e.ownerDocument)&&a.defaultView||window;var n=a.getSelection&&a.getSelection();if(n&&n.rangeCount!==0){a=n.anchorNode;var s=n.anchorOffset,r=n.focusNode;n=n.focusOffset;try{a.nodeType,r.nodeType}catch{a=null;break e}var o=0,l=-1,d=-1,u=0,g=0,p=e,y=null;t:for(;;){for(var x;p!==a||s!==0&&p.nodeType!==3||(l=o+s),p!==r||n!==0&&p.nodeType!==3||(d=o+n),p.nodeType===3&&(o+=p.nodeValue.length),(x=p.firstChild)!==null;)y=p,p=x;for(;;){if(p===e)break t;if(y===a&&++u===s&&(l=o),y===r&&++g===n&&(d=o),(x=p.nextSibling)!==null)break;p=y,y=p.parentNode}p=x}a=l===-1||d===-1?null:{start:l,end:d}}else a=null}a=a||{start:0,end:0}}else a=null;for(Nr={focusedElem:e,selectionRange:a},On=!1,E=t;E!==null;)if(t=E,e=t.child,(t.subtreeFlags&1028)!==0&&e!==null)e.return=t,E=e;else for(;E!==null;){t=E;try{var w=t.alternate;if(t.flags&1024)switch(t.tag){case 0:case 11:case 15:break;case 1:if(w!==null){var b=w.memoizedProps,j=w.memoizedState,m=t.stateNode,c=m.getSnapshotBeforeUpdate(t.elementType===t.type?b:ct(t.type,b),j);m.__reactInternalSnapshotBeforeUpdate=c}break;case 3:var h=t.stateNode.containerInfo;h.nodeType===1?h.textContent="":h.nodeType===9&&h.documentElement&&h.removeChild(h.documentElement);break;case 5:case 6:case 4:case 17:break;default:throw Error(M(163))}}catch(C){ue(t,t.return,C)}if(e=t.sibling,e!==null){e.return=t.return,E=e;break}E=t.return}return w=_l,_l=!1,w}function Sa(e,t,a){var n=t.updateQueue;if(n=n!==null?n.lastEffect:null,n!==null){var s=n=n.next;do{if((s.tag&e)===e){var r=s.destroy;s.destroy=void 0,r!==void 0&&Vr(t,a,r)}s=s.next}while(s!==n)}}function ps(e,t){if(t=t.updateQueue,t=t!==null?t.lastEffect:null,t!==null){var a=t=t.next;do{if((a.tag&e)===e){var n=a.create;a.destroy=n()}a=a.next}while(a!==t)}}function qr(e){var t=e.ref;if(t!==null){var a=e.stateNode;switch(e.tag){case 5:e=a;break;default:e=a}typeof t=="function"?t(e):t.current=e}}function nu(e){var t=e.alternate;t!==null&&(e.alternate=null,nu(t)),e.child=null,e.deletions=null,e.sibling=null,e.tag===5&&(t=e.stateNode,t!==null&&(delete t[xt],delete t[Va],delete t[Tr],delete t[Ap],delete t[Sp])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function su(e){return e.tag===5||e.tag===3||e.tag===4}function $l(e){e:for(;;){for(;e.sibling===null;){if(e.return===null||su(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;e.tag!==5&&e.tag!==6&&e.tag!==18;){if(e.flags&2||e.child===null||e.tag===4)continue e;e.child.return=e,e=e.child}if(!(e.flags&2))return e.stateNode}}function Ur(e,t,a){var n=e.tag;if(n===5||n===6)e=e.stateNode,t?a.nodeType===8?a.parentNode.insertBefore(e,t):a.insertBefore(e,t):(a.nodeType===8?(t=a.parentNode,t.insertBefore(e,a)):(t=a,t.appendChild(e)),a=a._reactRootContainer,a!=null||t.onclick!==null||(t.onclick=qn));else if(n!==4&&(e=e.child,e!==null))for(Ur(e,t,a),e=e.sibling;e!==null;)Ur(e,t,a),e=e.sibling}function Gr(e,t,a){var n=e.tag;if(n===5||n===6)e=e.stateNode,t?a.insertBefore(e,t):a.appendChild(e);else if(n!==4&&(e=e.child,e!==null))for(Gr(e,t,a),e=e.sibling;e!==null;)Gr(e,t,a),e=e.sibling}var Te=null,dt=!1;function Ft(e,t,a){for(a=a.child;a!==null;)ru(e,t,a),a=a.sibling}function ru(e,t,a){if(Ct&&typeof Ct.onCommitFiberUnmount=="function")try{Ct.onCommitFiberUnmount(ss,a)}catch{}switch(a.tag){case 5:Re||Oi(a,t);case 6:var n=Te,s=dt;Te=null,Ft(e,t,a),Te=n,dt=s,Te!==null&&(dt?(e=Te,a=a.stateNode,e.nodeType===8?e.parentNode.removeChild(a):e.removeChild(a)):Te.removeChild(a.stateNode));break;case 18:Te!==null&&(dt?(e=Te,a=a.stateNode,e.nodeType===8?Us(e.parentNode,a):e.nodeType===1&&Us(e,a),Ia(e)):Us(Te,a.stateNode));break;case 4:n=Te,s=dt,Te=a.stateNode.containerInfo,dt=!0,Ft(e,t,a),Te=n,dt=s;break;case 0:case 11:case 14:case 15:if(!Re&&(n=a.updateQueue,n!==null&&(n=n.lastEffect,n!==null))){s=n=n.next;do{var r=s,o=r.destroy;r=r.tag,o!==void 0&&(r&2||r&4)&&Vr(a,t,o),s=s.next}while(s!==n)}Ft(e,t,a);break;case 1:if(!Re&&(Oi(a,t),n=a.stateNode,typeof n.componentWillUnmount=="function"))try{n.props=a.memoizedProps,n.state=a.memoizedState,n.componentWillUnmount()}catch(l){ue(a,t,l)}Ft(e,t,a);break;case 21:Ft(e,t,a);break;case 22:a.mode&1?(Re=(n=Re)||a.memoizedState!==null,Ft(e,t,a),Re=n):Ft(e,t,a);break;default:Ft(e,t,a)}}function Kl(e){var t=e.updateQueue;if(t!==null){e.updateQueue=null;var a=e.stateNode;a===null&&(a=e.stateNode=new Up),t.forEach(function(n){var s=Xp.bind(null,e,n);a.has(n)||(a.add(n),n.then(s,s))})}}function ot(e,t){var a=t.deletions;if(a!==null)for(var n=0;n<a.length;n++){var s=a[n];try{var r=e,o=t,l=o;e:for(;l!==null;){switch(l.tag){case 5:Te=l.stateNode,dt=!1;break e;case 3:Te=l.stateNode.containerInfo,dt=!0;break e;case 4:Te=l.stateNode.containerInfo,dt=!0;break e}l=l.return}if(Te===null)throw Error(M(160));ru(r,o,s),Te=null,dt=!1;var d=s.alternate;d!==null&&(d.return=null),s.return=null}catch(u){ue(s,t,u)}}if(t.subtreeFlags&12854)for(t=t.child;t!==null;)ou(t,e),t=t.sibling}function ou(e,t){var a=e.alternate,n=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(ot(t,e),yt(e),n&4){try{Sa(3,e,e.return),ps(3,e)}catch(b){ue(e,e.return,b)}try{Sa(5,e,e.return)}catch(b){ue(e,e.return,b)}}break;case 1:ot(t,e),yt(e),n&512&&a!==null&&Oi(a,a.return);break;case 5:if(ot(t,e),yt(e),n&512&&a!==null&&Oi(a,a.return),e.flags&32){var s=e.stateNode;try{ja(s,"")}catch(b){ue(e,e.return,b)}}if(n&4&&(s=e.stateNode,s!=null)){var r=e.memoizedProps,o=a!==null?a.memoizedProps:r,l=e.type,d=e.updateQueue;if(e.updateQueue=null,d!==null)try{l==="input"&&r.type==="radio"&&r.name!=null&&kc(s,r),mr(l,o);var u=mr(l,r);for(o=0;o<d.length;o+=2){var g=d[o],p=d[o+1];g==="style"?Ic(s,p):g==="dangerouslySetInnerHTML"?Lc(s,p):g==="children"?ja(s,p):eo(s,g,p,u)}switch(l){case"input":or(s,r);break;case"textarea":jc(s,r);break;case"select":var y=s._wrapperState.wasMultiple;s._wrapperState.wasMultiple=!!r.multiple;var x=r.value;x!=null?Vi(s,!!r.multiple,x,!1):y!==!!r.multiple&&(r.defaultValue!=null?Vi(s,!!r.multiple,r.defaultValue,!0):Vi(s,!!r.multiple,r.multiple?[]:"",!1))}s[Va]=r}catch(b){ue(e,e.return,b)}}break;case 6:if(ot(t,e),yt(e),n&4){if(e.stateNode===null)throw Error(M(162));s=e.stateNode,r=e.memoizedProps;try{s.nodeValue=r}catch(b){ue(e,e.return,b)}}break;case 3:if(ot(t,e),yt(e),n&4&&a!==null&&a.memoizedState.isDehydrated)try{Ia(t.containerInfo)}catch(b){ue(e,e.return,b)}break;case 4:ot(t,e),yt(e);break;case 13:ot(t,e),yt(e),s=e.child,s.flags&8192&&(r=s.memoizedState!==null,s.stateNode.isHidden=r,!r||s.alternate!==null&&s.alternate.memoizedState!==null||(Io=pe())),n&4&&Kl(e);break;case 22:if(g=a!==null&&a.memoizedState!==null,e.mode&1?(Re=(u=Re)||g,ot(t,e),Re=u):ot(t,e),yt(e),n&8192){if(u=e.memoizedState!==null,(e.stateNode.isHidden=u)&&!g&&e.mode&1)for(E=e,g=e.child;g!==null;){for(p=E=g;E!==null;){switch(y=E,x=y.child,y.tag){case 0:case 11:case 14:case 15:Sa(4,y,y.return);break;case 1:Oi(y,y.return);var w=y.stateNode;if(typeof w.componentWillUnmount=="function"){n=y,a=y.return;try{t=n,w.props=t.memoizedProps,w.state=t.memoizedState,w.componentWillUnmount()}catch(b){ue(n,a,b)}}break;case 5:Oi(y,y.return);break;case 22:if(y.memoizedState!==null){Yl(p);continue}}x!==null?(x.return=y,E=x):Yl(p)}g=g.sibling}e:for(g=null,p=e;;){if(p.tag===5){if(g===null){g=p;try{s=p.stateNode,u?(r=s.style,typeof r.setProperty=="function"?r.setProperty("display","none","important"):r.display="none"):(l=p.stateNode,d=p.memoizedProps.style,o=d!=null&&d.hasOwnProperty("display")?d.display:null,l.style.display=Mc("display",o))}catch(b){ue(e,e.return,b)}}}else if(p.tag===6){if(g===null)try{p.stateNode.nodeValue=u?"":p.memoizedProps}catch(b){ue(e,e.return,b)}}else if((p.tag!==22&&p.tag!==23||p.memoizedState===null||p===e)&&p.child!==null){p.child.return=p,p=p.child;continue}if(p===e)break e;for(;p.sibling===null;){if(p.return===null||p.return===e)break e;g===p&&(g=null),p=p.return}g===p&&(g=null),p.sibling.return=p.return,p=p.sibling}}break;case 19:ot(t,e),yt(e),n&4&&Kl(e);break;case 21:break;default:ot(t,e),yt(e)}}function yt(e){var t=e.flags;if(t&2){try{e:{for(var a=e.return;a!==null;){if(su(a)){var n=a;break e}a=a.return}throw Error(M(160))}switch(n.tag){case 5:var s=n.stateNode;n.flags&32&&(ja(s,""),n.flags&=-33);var r=$l(e);Gr(e,r,s);break;case 3:case 4:var o=n.stateNode.containerInfo,l=$l(e);Ur(e,l,o);break;default:throw Error(M(161))}}catch(d){ue(e,e.return,d)}e.flags&=-3}t&4096&&(e.flags&=-4097)}function Hp(e,t,a){E=e,lu(e)}function lu(e,t,a){for(var n=(e.mode&1)!==0;E!==null;){var s=E,r=s.child;if(s.tag===22&&n){var o=s.memoizedState!==null||gn;if(!o){var l=s.alternate,d=l!==null&&l.memoizedState!==null||Re;l=gn;var u=Re;if(gn=o,(Re=d)&&!u)for(E=s;E!==null;)o=E,d=o.child,o.tag===22&&o.memoizedState!==null?Xl(s):d!==null?(d.return=o,E=d):Xl(s);for(;r!==null;)E=r,lu(r),r=r.sibling;E=s,gn=l,Re=u}Ql(e)}else s.subtreeFlags&8772&&r!==null?(r.return=s,E=r):Ql(e)}}function Ql(e){for(;E!==null;){var t=E;if(t.flags&8772){var a=t.alternate;try{if(t.flags&8772)switch(t.tag){case 0:case 11:case 15:Re||ps(5,t);break;case 1:var n=t.stateNode;if(t.flags&4&&!Re)if(a===null)n.componentDidMount();else{var s=t.elementType===t.type?a.memoizedProps:ct(t.type,a.memoizedProps);n.componentDidUpdate(s,a.memoizedState,n.__reactInternalSnapshotBeforeUpdate)}var r=t.updateQueue;r!==null&&Ml(t,r,n);break;case 3:var o=t.updateQueue;if(o!==null){if(a=null,t.child!==null)switch(t.child.tag){case 5:a=t.child.stateNode;break;case 1:a=t.child.stateNode}Ml(t,o,a)}break;case 5:var l=t.stateNode;if(a===null&&t.flags&4){a=l;var d=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":d.autoFocus&&a.focus();break;case"img":d.src&&(a.src=d.src)}}break;case 6:break;case 4:break;case 12:break;case 13:if(t.memoizedState===null){var u=t.alternate;if(u!==null){var g=u.memoizedState;if(g!==null){var p=g.dehydrated;p!==null&&Ia(p)}}}break;case 19:case 17:case 21:case 22:case 23:case 25:break;default:throw Error(M(163))}Re||t.flags&512&&qr(t)}catch(y){ue(t,t.return,y)}}if(t===e){E=null;break}if(a=t.sibling,a!==null){a.return=t.return,E=a;break}E=t.return}}function Yl(e){for(;E!==null;){var t=E;if(t===e){E=null;break}var a=t.sibling;if(a!==null){a.return=t.return,E=a;break}E=t.return}}function Xl(e){for(;E!==null;){var t=E;try{switch(t.tag){case 0:case 11:case 15:var a=t.return;try{ps(4,t)}catch(d){ue(t,a,d)}break;case 1:var n=t.stateNode;if(typeof n.componentDidMount=="function"){var s=t.return;try{n.componentDidMount()}catch(d){ue(t,s,d)}}var r=t.return;try{qr(t)}catch(d){ue(t,r,d)}break;case 5:var o=t.return;try{qr(t)}catch(d){ue(t,o,d)}}}catch(d){ue(t,t.return,d)}if(t===e){E=null;break}var l=t.sibling;if(l!==null){l.return=t.return,E=l;break}E=t.return}}var zp=Math.ceil,Xn=It.ReactCurrentDispatcher,Lo=It.ReactCurrentOwner,tt=It.ReactCurrentBatchConfig,W=0,Ne=null,ge=null,De=0,_e=0,Bi=ei(0),xe=0,Wa=null,hi=0,fs=0,Mo=0,Ta=null,qe=null,Io=0,Xi=1/0,At=null,Jn=!1,Hr=null,Kt=null,yn=!1,Gt=null,Zn=0,Da=0,zr=null,kn=-1,jn=0;function Fe(){return W&6?pe():kn!==-1?kn:kn=pe()}function Qt(e){return e.mode&1?W&2&&De!==0?De&-De:Dp.transition!==null?(jn===0&&(jn=_c()),jn):(e=Z,e!==0||(e=window.event,e=e===void 0?16:Zc(e.type)),e):1}function pt(e,t,a,n){if(50<Da)throw Da=0,zr=null,Error(M(185));Ka(e,a,n),(!(W&2)||e!==Ne)&&(e===Ne&&(!(W&2)&&(fs|=a),xe===4&&qt(e,De)),ze(e,n),a===1&&W===0&&!(t.mode&1)&&(Xi=pe()+500,ds&&ti()))}function ze(e,t){var a=e.callbackNode;Dm(e,t);var n=Fn(e,e===Ne?De:0);if(n===0)a!==null&&rl(a),e.callbackNode=null,e.callbackPriority=0;else if(t=n&-n,e.callbackPriority!==t){if(a!=null&&rl(a),t===1)e.tag===0?Tp(Jl.bind(null,e)):vd(Jl.bind(null,e)),wp(function(){!(W&6)&&ti()}),a=null;else{switch($c(n)){case 1:a=so;break;case 4:a=zc;break;case 16:a=En;break;case 536870912:a=Wc;break;default:a=En}a=gu(a,cu.bind(null,e))}e.callbackPriority=t,e.callbackNode=a}}function cu(e,t){if(kn=-1,jn=0,W&6)throw Error(M(327));var a=e.callbackNode;if(zi()&&e.callbackNode!==a)return null;var n=Fn(e,e===Ne?De:0);if(n===0)return null;if(n&30||n&e.expiredLanes||t)t=es(e,n);else{t=n;var s=W;W|=2;var r=uu();(Ne!==e||De!==t)&&(At=null,Xi=pe()+500,di(e,t));do try{$p();break}catch(l){du(e,l)}while(!0);xo(),Xn.current=r,W=s,ge!==null?t=0:(Ne=null,De=0,t=xe)}if(t!==0){if(t===2&&(s=yr(e),s!==0&&(n=s,t=Wr(e,s))),t===1)throw a=Wa,di(e,0),qt(e,n),ze(e,pe()),a;if(t===6)qt(e,n);else{if(s=e.current.alternate,!(n&30)&&!Wp(s)&&(t=es(e,n),t===2&&(r=yr(e),r!==0&&(n=r,t=Wr(e,r))),t===1))throw a=Wa,di(e,0),qt(e,n),ze(e,pe()),a;switch(e.finishedWork=s,e.finishedLanes=n,t){case 0:case 1:throw Error(M(345));case 2:si(e,qe,At);break;case 3:if(qt(e,n),(n&130023424)===n&&(t=Io+500-pe(),10<t)){if(Fn(e,0)!==0)break;if(s=e.suspendedLanes,(s&n)!==n){Fe(),e.pingedLanes|=e.suspendedLanes&s;break}e.timeoutHandle=Sr(si.bind(null,e,qe,At),t);break}si(e,qe,At);break;case 4:if(qt(e,n),(n&4194240)===n)break;for(t=e.eventTimes,s=-1;0<n;){var o=31-mt(n);r=1<<o,o=t[o],o>s&&(s=o),n&=~r}if(n=s,n=pe()-n,n=(120>n?120:480>n?480:1080>n?1080:1920>n?1920:3e3>n?3e3:4320>n?4320:1960*zp(n/1960))-n,10<n){e.timeoutHandle=Sr(si.bind(null,e,qe,At),n);break}si(e,qe,At);break;case 5:si(e,qe,At);break;default:throw Error(M(329))}}}return ze(e,pe()),e.callbackNode===a?cu.bind(null,e):null}function Wr(e,t){var a=Ta;return e.current.memoizedState.isDehydrated&&(di(e,t).flags|=256),e=es(e,t),e!==2&&(t=qe,qe=a,t!==null&&_r(t)),e}function _r(e){qe===null?qe=e:qe.push.apply(qe,e)}function Wp(e){for(var t=e;;){if(t.flags&16384){var a=t.updateQueue;if(a!==null&&(a=a.stores,a!==null))for(var n=0;n<a.length;n++){var s=a[n],r=s.getSnapshot;s=s.value;try{if(!ft(r(),s))return!1}catch{return!1}}}if(a=t.child,t.subtreeFlags&16384&&a!==null)a.return=t,t=a;else{if(t===e)break;for(;t.sibling===null;){if(t.return===null||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}function qt(e,t){for(t&=~Mo,t&=~fs,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var a=31-mt(t),n=1<<a;e[a]=-1,t&=~n}}function Jl(e){if(W&6)throw Error(M(327));zi();var t=Fn(e,0);if(!(t&1))return ze(e,pe()),null;var a=es(e,t);if(e.tag!==0&&a===2){var n=yr(e);n!==0&&(t=n,a=Wr(e,n))}if(a===1)throw a=Wa,di(e,0),qt(e,t),ze(e,pe()),a;if(a===6)throw Error(M(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,si(e,qe,At),ze(e,pe()),null}function Eo(e,t){var a=W;W|=1;try{return e(t)}finally{W=a,W===0&&(Xi=pe()+500,ds&&ti())}}function gi(e){Gt!==null&&Gt.tag===0&&!(W&6)&&zi();var t=W;W|=1;var a=tt.transition,n=Z;try{if(tt.transition=null,Z=1,e)return e()}finally{Z=n,tt.transition=a,W=t,!(W&6)&&ti()}}function Fo(){_e=Bi.current,se(Bi)}function di(e,t){e.finishedWork=null,e.finishedLanes=0;var a=e.timeoutHandle;if(a!==-1&&(e.timeoutHandle=-1,Cp(a)),ge!==null)for(a=ge.return;a!==null;){var n=a;switch(go(n),n.tag){case 1:n=n.type.childContextTypes,n!=null&&Un();break;case 3:Qi(),se(Ge),se(Le),So();break;case 5:Ao(n);break;case 4:Qi();break;case 13:se(le);break;case 19:se(le);break;case 10:bo(n.type._context);break;case 22:case 23:Fo()}a=a.return}if(Ne=e,ge=e=Yt(e.current,null),De=_e=t,xe=0,Wa=null,Mo=fs=hi=0,qe=Ta=null,oi!==null){for(t=0;t<oi.length;t++)if(a=oi[t],n=a.interleaved,n!==null){a.interleaved=null;var s=n.next,r=a.pending;if(r!==null){var o=r.next;r.next=s,n.next=o}a.pending=n}oi=null}return e}function du(e,t){do{var a=ge;try{if(xo(),Tn.current=Yn,Qn){for(var n=ce.memoizedState;n!==null;){var s=n.queue;s!==null&&(s.pending=null),n=n.next}Qn=!1}if(fi=0,we=ve=ce=null,Aa=!1,Ga=0,Lo.current=null,a===null||a.return===null){xe=1,Wa=t,ge=null;break}e:{var r=e,o=a.return,l=a,d=t;if(t=De,l.flags|=32768,d!==null&&typeof d=="object"&&typeof d.then=="function"){var u=d,g=l,p=g.tag;if(!(g.mode&1)&&(p===0||p===11||p===15)){var y=g.alternate;y?(g.updateQueue=y.updateQueue,g.memoizedState=y.memoizedState,g.lanes=y.lanes):(g.updateQueue=null,g.memoizedState=null)}var x=Vl(o);if(x!==null){x.flags&=-257,ql(x,o,l,r,t),x.mode&1&&Bl(r,u,t),t=x,d=u;var w=t.updateQueue;if(w===null){var b=new Set;b.add(d),t.updateQueue=b}else w.add(d);break e}else{if(!(t&1)){Bl(r,u,t),Oo();break e}d=Error(M(426))}}else if(oe&&l.mode&1){var j=Vl(o);if(j!==null){!(j.flags&65536)&&(j.flags|=256),ql(j,o,l,r,t),yo(Yi(d,l));break e}}r=d=Yi(d,l),xe!==4&&(xe=2),Ta===null?Ta=[r]:Ta.push(r),r=o;do{switch(r.tag){case 3:r.flags|=65536,t&=-t,r.lanes|=t;var m=$d(r,d,t);Ll(r,m);break e;case 1:l=d;var c=r.type,h=r.stateNode;if(!(r.flags&128)&&(typeof c.getDerivedStateFromError=="function"||h!==null&&typeof h.componentDidCatch=="function"&&(Kt===null||!Kt.has(h)))){r.flags|=65536,t&=-t,r.lanes|=t;var C=Kd(r,l,t);Ll(r,C);break e}}r=r.return}while(r!==null)}pu(a)}catch(P){t=P,ge===a&&a!==null&&(ge=a=a.return);continue}break}while(!0)}function uu(){var e=Xn.current;return Xn.current=Yn,e===null?Yn:e}function Oo(){(xe===0||xe===3||xe===2)&&(xe=4),Ne===null||!(hi&268435455)&&!(fs&268435455)||qt(Ne,De)}function es(e,t){var a=W;W|=2;var n=uu();(Ne!==e||De!==t)&&(At=null,di(e,t));do try{_p();break}catch(s){du(e,s)}while(!0);if(xo(),W=a,Xn.current=n,ge!==null)throw Error(M(261));return Ne=null,De=0,xe}function _p(){for(;ge!==null;)mu(ge)}function $p(){for(;ge!==null&&!vm();)mu(ge)}function mu(e){var t=hu(e.alternate,e,_e);e.memoizedProps=e.pendingProps,t===null?pu(e):ge=t,Lo.current=null}function pu(e){var t=e;do{var a=t.alternate;if(e=t.return,t.flags&32768){if(a=qp(a,t),a!==null){a.flags&=32767,ge=a;return}if(e!==null)e.flags|=32768,e.subtreeFlags=0,e.deletions=null;else{xe=6,ge=null;return}}else if(a=Vp(a,t,_e),a!==null){ge=a;return}if(t=t.sibling,t!==null){ge=t;return}ge=t=e}while(t!==null);xe===0&&(xe=5)}function si(e,t,a){var n=Z,s=tt.transition;try{tt.transition=null,Z=1,Kp(e,t,a,n)}finally{tt.transition=s,Z=n}return null}function Kp(e,t,a,n){do zi();while(Gt!==null);if(W&6)throw Error(M(327));a=e.finishedWork;var s=e.finishedLanes;if(a===null)return null;if(e.finishedWork=null,e.finishedLanes=0,a===e.current)throw Error(M(177));e.callbackNode=null,e.callbackPriority=0;var r=a.lanes|a.childLanes;if(Pm(e,r),e===Ne&&(ge=Ne=null,De=0),!(a.subtreeFlags&2064)&&!(a.flags&2064)||yn||(yn=!0,gu(En,function(){return zi(),null})),r=(a.flags&15990)!==0,a.subtreeFlags&15990||r){r=tt.transition,tt.transition=null;var o=Z;Z=1;var l=W;W|=4,Lo.current=null,Gp(e,a),ou(a,e),fp(Nr),On=!!wr,Nr=wr=null,e.current=a,Hp(a),xm(),W=l,Z=o,tt.transition=r}else e.current=a;if(yn&&(yn=!1,Gt=e,Zn=s),r=e.pendingLanes,r===0&&(Kt=null),wm(a.stateNode),ze(e,pe()),t!==null)for(n=e.onRecoverableError,a=0;a<t.length;a++)s=t[a],n(s.value,{componentStack:s.stack,digest:s.digest});if(Jn)throw Jn=!1,e=Hr,Hr=null,e;return Zn&1&&e.tag!==0&&zi(),r=e.pendingLanes,r&1?e===zr?Da++:(Da=0,zr=e):Da=0,ti(),null}function zi(){if(Gt!==null){var e=$c(Zn),t=tt.transition,a=Z;try{if(tt.transition=null,Z=16>e?16:e,Gt===null)var n=!1;else{if(e=Gt,Gt=null,Zn=0,W&6)throw Error(M(331));var s=W;for(W|=4,E=e.current;E!==null;){var r=E,o=r.child;if(E.flags&16){var l=r.deletions;if(l!==null){for(var d=0;d<l.length;d++){var u=l[d];for(E=u;E!==null;){var g=E;switch(g.tag){case 0:case 11:case 15:Sa(8,g,r)}var p=g.child;if(p!==null)p.return=g,E=p;else for(;E!==null;){g=E;var y=g.sibling,x=g.return;if(nu(g),g===u){E=null;break}if(y!==null){y.return=x,E=y;break}E=x}}}var w=r.alternate;if(w!==null){var b=w.child;if(b!==null){w.child=null;do{var j=b.sibling;b.sibling=null,b=j}while(b!==null)}}E=r}}if(r.subtreeFlags&2064&&o!==null)o.return=r,E=o;else e:for(;E!==null;){if(r=E,r.flags&2048)switch(r.tag){case 0:case 11:case 15:Sa(9,r,r.return)}var m=r.sibling;if(m!==null){m.return=r.return,E=m;break e}E=r.return}}var c=e.current;for(E=c;E!==null;){o=E;var h=o.child;if(o.subtreeFlags&2064&&h!==null)h.return=o,E=h;else e:for(o=c;E!==null;){if(l=E,l.flags&2048)try{switch(l.tag){case 0:case 11:case 15:ps(9,l)}}catch(P){ue(l,l.return,P)}if(l===o){E=null;break e}var C=l.sibling;if(C!==null){C.return=l.return,E=C;break e}E=l.return}}if(W=s,ti(),Ct&&typeof Ct.onPostCommitFiberRoot=="function")try{Ct.onPostCommitFiberRoot(ss,e)}catch{}n=!0}return n}finally{Z=a,tt.transition=t}}return!1}function Zl(e,t,a){t=Yi(a,t),t=$d(e,t,1),e=$t(e,t,1),t=Fe(),e!==null&&(Ka(e,1,t),ze(e,t))}function ue(e,t,a){if(e.tag===3)Zl(e,e,a);else for(;t!==null;){if(t.tag===3){Zl(t,e,a);break}else if(t.tag===1){var n=t.stateNode;if(typeof t.type.getDerivedStateFromError=="function"||typeof n.componentDidCatch=="function"&&(Kt===null||!Kt.has(n))){e=Yi(a,e),e=Kd(t,e,1),t=$t(t,e,1),e=Fe(),t!==null&&(Ka(t,1,e),ze(t,e));break}}t=t.return}}function Qp(e,t,a){var n=e.pingCache;n!==null&&n.delete(t),t=Fe(),e.pingedLanes|=e.suspendedLanes&a,Ne===e&&(De&a)===a&&(xe===4||xe===3&&(De&130023424)===De&&500>pe()-Io?di(e,0):Mo|=a),ze(e,t)}function fu(e,t){t===0&&(e.mode&1?(t=on,on<<=1,!(on&130023424)&&(on=4194304)):t=1);var a=Fe();e=Lt(e,t),e!==null&&(Ka(e,t,a),ze(e,a))}function Yp(e){var t=e.memoizedState,a=0;t!==null&&(a=t.retryLane),fu(e,a)}function Xp(e,t){var a=0;switch(e.tag){case 13:var n=e.stateNode,s=e.memoizedState;s!==null&&(a=s.retryLane);break;case 19:n=e.stateNode;break;default:throw Error(M(314))}n!==null&&n.delete(t),fu(e,a)}var hu;hu=function(e,t,a){if(e!==null)if(e.memoizedProps!==t.pendingProps||Ge.current)Ue=!0;else{if(!(e.lanes&a)&&!(t.flags&128))return Ue=!1,Bp(e,t,a);Ue=!!(e.flags&131072)}else Ue=!1,oe&&t.flags&1048576&&xd(t,zn,t.index);switch(t.lanes=0,t.tag){case 2:var n=t.type;Pn(e,t),e=t.pendingProps;var s=_i(t,Le.current);Hi(t,a),s=Do(null,t,n,e,s,a);var r=Po();return t.flags|=1,typeof s=="object"&&s!==null&&typeof s.render=="function"&&s.$$typeof===void 0?(t.tag=1,t.memoizedState=null,t.updateQueue=null,He(n)?(r=!0,Gn(t)):r=!1,t.memoizedState=s.state!==null&&s.state!==void 0?s.state:null,wo(t),s.updater=ms,t.stateNode=s,s._reactInternals=t,Lr(t,n,e,a),t=Er(null,t,n,!0,r,a)):(t.tag=0,oe&&r&&ho(t),Ee(null,t,s,a),t=t.child),t;case 16:n=t.elementType;e:{switch(Pn(e,t),e=t.pendingProps,s=n._init,n=s(n._payload),t.type=n,s=t.tag=Zp(n),e=ct(n,e),s){case 0:t=Ir(null,t,n,e,a);break e;case 1:t=Hl(null,t,n,e,a);break e;case 11:t=Ul(null,t,n,e,a);break e;case 14:t=Gl(null,t,n,ct(n.type,e),a);break e}throw Error(M(306,n,""))}return t;case 0:return n=t.type,s=t.pendingProps,s=t.elementType===n?s:ct(n,s),Ir(e,t,n,s,a);case 1:return n=t.type,s=t.pendingProps,s=t.elementType===n?s:ct(n,s),Hl(e,t,n,s,a);case 3:e:{if(Jd(t),e===null)throw Error(M(387));n=t.pendingProps,r=t.memoizedState,s=r.element,Sd(e,t),$n(t,n,null,a);var o=t.memoizedState;if(n=o.element,r.isDehydrated)if(r={element:n,isDehydrated:!1,cache:o.cache,pendingSuspenseBoundaries:o.pendingSuspenseBoundaries,transitions:o.transitions},t.updateQueue.baseState=r,t.memoizedState=r,t.flags&256){s=Yi(Error(M(423)),t),t=zl(e,t,n,a,s);break e}else if(n!==s){s=Yi(Error(M(424)),t),t=zl(e,t,n,a,s);break e}else for($e=_t(t.stateNode.containerInfo.firstChild),Ke=t,oe=!0,ut=null,a=Nd(t,null,n,a),t.child=a;a;)a.flags=a.flags&-3|4096,a=a.sibling;else{if($i(),n===s){t=Mt(e,t,a);break e}Ee(e,t,n,a)}t=t.child}return t;case 5:return Td(t),e===null&&kr(t),n=t.type,s=t.pendingProps,r=e!==null?e.memoizedProps:null,o=s.children,Ar(n,s)?o=null:r!==null&&Ar(n,r)&&(t.flags|=32),Xd(e,t),Ee(e,t,o,a),t.child;case 6:return e===null&&kr(t),null;case 13:return Zd(e,t,a);case 4:return No(t,t.stateNode.containerInfo),n=t.pendingProps,e===null?t.child=Ki(t,null,n,a):Ee(e,t,n,a),t.child;case 11:return n=t.type,s=t.pendingProps,s=t.elementType===n?s:ct(n,s),Ul(e,t,n,s,a);case 7:return Ee(e,t,t.pendingProps,a),t.child;case 8:return Ee(e,t,t.pendingProps.children,a),t.child;case 12:return Ee(e,t,t.pendingProps.children,a),t.child;case 10:e:{if(n=t.type._context,s=t.pendingProps,r=t.memoizedProps,o=s.value,ie(Wn,n._currentValue),n._currentValue=o,r!==null)if(ft(r.value,o)){if(r.children===s.children&&!Ge.current){t=Mt(e,t,a);break e}}else for(r=t.child,r!==null&&(r.return=t);r!==null;){var l=r.dependencies;if(l!==null){o=r.child;for(var d=l.firstContext;d!==null;){if(d.context===n){if(r.tag===1){d=Pt(-1,a&-a),d.tag=2;var u=r.updateQueue;if(u!==null){u=u.shared;var g=u.pending;g===null?d.next=d:(d.next=g.next,g.next=d),u.pending=d}}r.lanes|=a,d=r.alternate,d!==null&&(d.lanes|=a),jr(r.return,a,t),l.lanes|=a;break}d=d.next}}else if(r.tag===10)o=r.type===t.type?null:r.child;else if(r.tag===18){if(o=r.return,o===null)throw Error(M(341));o.lanes|=a,l=o.alternate,l!==null&&(l.lanes|=a),jr(o,a,t),o=r.sibling}else o=r.child;if(o!==null)o.return=r;else for(o=r;o!==null;){if(o===t){o=null;break}if(r=o.sibling,r!==null){r.return=o.return,o=r;break}o=o.return}r=o}Ee(e,t,s.children,a),t=t.child}return t;case 9:return s=t.type,n=t.pendingProps.children,Hi(t,a),s=it(s),n=n(s),t.flags|=1,Ee(e,t,n,a),t.child;case 14:return n=t.type,s=ct(n,t.pendingProps),s=ct(n.type,s),Gl(e,t,n,s,a);case 15:return Qd(e,t,t.type,t.pendingProps,a);case 17:return n=t.type,s=t.pendingProps,s=t.elementType===n?s:ct(n,s),Pn(e,t),t.tag=1,He(n)?(e=!0,Gn(t)):e=!1,Hi(t,a),_d(t,n,s),Lr(t,n,s,a),Er(null,t,n,!0,e,a);case 19:return eu(e,t,a);case 22:return Yd(e,t,a)}throw Error(M(156,t.tag))};function gu(e,t){return Hc(e,t)}function Jp(e,t,a,n){this.tag=e,this.key=a,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=n,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function et(e,t,a,n){return new Jp(e,t,a,n)}function Bo(e){return e=e.prototype,!(!e||!e.isReactComponent)}function Zp(e){if(typeof e=="function")return Bo(e)?1:0;if(e!=null){if(e=e.$$typeof,e===io)return 11;if(e===ao)return 14}return 2}function Yt(e,t){var a=e.alternate;return a===null?(a=et(e.tag,t,e.key,e.mode),a.elementType=e.elementType,a.type=e.type,a.stateNode=e.stateNode,a.alternate=e,e.alternate=a):(a.pendingProps=t,a.type=e.type,a.flags=0,a.subtreeFlags=0,a.deletions=null),a.flags=e.flags&14680064,a.childLanes=e.childLanes,a.lanes=e.lanes,a.child=e.child,a.memoizedProps=e.memoizedProps,a.memoizedState=e.memoizedState,a.updateQueue=e.updateQueue,t=e.dependencies,a.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext},a.sibling=e.sibling,a.index=e.index,a.ref=e.ref,a}function Rn(e,t,a,n,s,r){var o=2;if(n=e,typeof e=="function")Bo(e)&&(o=1);else if(typeof e=="string")o=5;else e:switch(e){case Pi:return ui(a.children,s,r,t);case to:o=8,s|=8;break;case ir:return e=et(12,a,t,s|2),e.elementType=ir,e.lanes=r,e;case ar:return e=et(13,a,t,s),e.elementType=ar,e.lanes=r,e;case nr:return e=et(19,a,t,s),e.elementType=nr,e.lanes=r,e;case Tc:return hs(a,s,r,t);default:if(typeof e=="object"&&e!==null)switch(e.$$typeof){case Ac:o=10;break e;case Sc:o=9;break e;case io:o=11;break e;case ao:o=14;break e;case Ot:o=16,n=null;break e}throw Error(M(130,e==null?e:typeof e,""))}return t=et(o,a,t,s),t.elementType=e,t.type=n,t.lanes=r,t}function ui(e,t,a,n){return e=et(7,e,n,t),e.lanes=a,e}function hs(e,t,a,n){return e=et(22,e,n,t),e.elementType=Tc,e.lanes=a,e.stateNode={isHidden:!1},e}function Qs(e,t,a){return e=et(6,e,null,t),e.lanes=a,e}function Ys(e,t,a){return t=et(4,e.children!==null?e.children:[],e.key,t),t.lanes=a,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function ef(e,t,a,n,s){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=js(0),this.expirationTimes=js(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=js(0),this.identifierPrefix=n,this.onRecoverableError=s,this.mutableSourceEagerHydrationData=null}function Vo(e,t,a,n,s,r,o,l,d){return e=new ef(e,t,a,l,d),t===1?(t=1,r===!0&&(t|=8)):t=0,r=et(3,null,null,t),e.current=r,r.stateNode=e,r.memoizedState={element:n,isDehydrated:a,cache:null,transitions:null,pendingSuspenseBoundaries:null},wo(r),e}function tf(e,t,a){var n=3<arguments.length&&arguments[3]!==void 0?arguments[3]:null;return{$$typeof:Di,key:n==null?null:""+n,children:e,containerInfo:t,implementation:a}}function yu(e){if(!e)return Jt;e=e._reactInternals;e:{if(vi(e)!==e||e.tag!==1)throw Error(M(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(He(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(t!==null);throw Error(M(171))}if(e.tag===1){var a=e.type;if(He(a))return yd(e,a,t)}return t}function vu(e,t,a,n,s,r,o,l,d){return e=Vo(a,n,!0,e,s,r,o,l,d),e.context=yu(null),a=e.current,n=Fe(),s=Qt(a),r=Pt(n,s),r.callback=t??null,$t(a,r,s),e.current.lanes=s,Ka(e,s,n),ze(e,n),e}function gs(e,t,a,n){var s=t.current,r=Fe(),o=Qt(s);return a=yu(a),t.context===null?t.context=a:t.pendingContext=a,t=Pt(r,o),t.payload={element:e},n=n===void 0?null:n,n!==null&&(t.callback=n),e=$t(s,t,o),e!==null&&(pt(e,s,o,r),Sn(e,s,o)),o}function ts(e){if(e=e.current,!e.child)return null;switch(e.child.tag){case 5:return e.child.stateNode;default:return e.child.stateNode}}function ec(e,t){if(e=e.memoizedState,e!==null&&e.dehydrated!==null){var a=e.retryLane;e.retryLane=a!==0&&a<t?a:t}}function qo(e,t){ec(e,t),(e=e.alternate)&&ec(e,t)}function af(){return null}var xu=typeof reportError=="function"?reportError:function(e){console.error(e)};function Uo(e){this._internalRoot=e}ys.prototype.render=Uo.prototype.render=function(e){var t=this._internalRoot;if(t===null)throw Error(M(409));gs(e,t,null,null)};ys.prototype.unmount=Uo.prototype.unmount=function(){var e=this._internalRoot;if(e!==null){this._internalRoot=null;var t=e.containerInfo;gi(function(){gs(null,e,null,null)}),t[Rt]=null}};function ys(e){this._internalRoot=e}ys.prototype.unstable_scheduleHydration=function(e){if(e){var t=Yc();e={blockedOn:null,target:e,priority:t};for(var a=0;a<Vt.length&&t!==0&&t<Vt[a].priority;a++);Vt.splice(a,0,e),a===0&&Jc(e)}};function Go(e){return!(!e||e.nodeType!==1&&e.nodeType!==9&&e.nodeType!==11)}function vs(e){return!(!e||e.nodeType!==1&&e.nodeType!==9&&e.nodeType!==11&&(e.nodeType!==8||e.nodeValue!==" react-mount-point-unstable "))}function tc(){}function nf(e,t,a,n,s){if(s){if(typeof n=="function"){var r=n;n=function(){var u=ts(o);r.call(u)}}var o=vu(t,n,e,0,null,!1,!1,"",tc);return e._reactRootContainer=o,e[Rt]=o.current,Oa(e.nodeType===8?e.parentNode:e),gi(),o}for(;s=e.lastChild;)e.removeChild(s);if(typeof n=="function"){var l=n;n=function(){var u=ts(d);l.call(u)}}var d=Vo(e,0,!1,null,null,!1,!1,"",tc);return e._reactRootContainer=d,e[Rt]=d.current,Oa(e.nodeType===8?e.parentNode:e),gi(function(){gs(t,d,a,n)}),d}function xs(e,t,a,n,s){var r=a._reactRootContainer;if(r){var o=r;if(typeof s=="function"){var l=s;s=function(){var d=ts(o);l.call(d)}}gs(t,o,e,s)}else o=nf(a,t,e,s,n);return ts(o)}Kc=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var a=ya(t.pendingLanes);a!==0&&(ro(t,a|1),ze(t,pe()),!(W&6)&&(Xi=pe()+500,ti()))}break;case 13:gi(function(){var n=Lt(e,1);if(n!==null){var s=Fe();pt(n,e,1,s)}}),qo(e,1)}};oo=function(e){if(e.tag===13){var t=Lt(e,134217728);if(t!==null){var a=Fe();pt(t,e,134217728,a)}qo(e,134217728)}};Qc=function(e){if(e.tag===13){var t=Qt(e),a=Lt(e,t);if(a!==null){var n=Fe();pt(a,e,t,n)}qo(e,t)}};Yc=function(){return Z};Xc=function(e,t){var a=Z;try{return Z=e,t()}finally{Z=a}};fr=function(e,t,a){switch(t){case"input":if(or(e,a),t=a.name,a.type==="radio"&&t!=null){for(a=e;a.parentNode;)a=a.parentNode;for(a=a.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<a.length;t++){var n=a[t];if(n!==e&&n.form===e.form){var s=cs(n);if(!s)throw Error(M(90));Pc(n),or(n,s)}}}break;case"textarea":jc(e,a);break;case"select":t=a.value,t!=null&&Vi(e,!!a.multiple,t,!1)}};Oc=Eo;Bc=gi;var sf={usingClientEntryPoint:!1,Events:[Ya,Li,cs,Ec,Fc,Eo]},fa={findFiberByHostInstance:ri,bundleType:0,version:"18.3.1",rendererPackageName:"react-dom"},rf={bundleType:fa.bundleType,version:fa.version,rendererPackageName:fa.rendererPackageName,rendererConfig:fa.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:It.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return e=Uc(e),e===null?null:e.stateNode},findFiberByHostInstance:fa.findFiberByHostInstance||af,findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.3.1-next-f1338f8080-20240426"};if(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__<"u"){var vn=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!vn.isDisabled&&vn.supportsFiber)try{ss=vn.inject(rf),Ct=vn}catch{}}Ye.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=sf;Ye.createPortal=function(e,t){var a=2<arguments.length&&arguments[2]!==void 0?arguments[2]:null;if(!Go(t))throw Error(M(200));return tf(e,t,null,a)};Ye.createRoot=function(e,t){if(!Go(e))throw Error(M(299));var a=!1,n="",s=xu;return t!=null&&(t.unstable_strictMode===!0&&(a=!0),t.identifierPrefix!==void 0&&(n=t.identifierPrefix),t.onRecoverableError!==void 0&&(s=t.onRecoverableError)),t=Vo(e,1,!1,null,null,a,!1,n,s),e[Rt]=t.current,Oa(e.nodeType===8?e.parentNode:e),new Uo(t)};Ye.findDOMNode=function(e){if(e==null)return null;if(e.nodeType===1)return e;var t=e._reactInternals;if(t===void 0)throw typeof e.render=="function"?Error(M(188)):(e=Object.keys(e).join(","),Error(M(268,e)));return e=Uc(t),e=e===null?null:e.stateNode,e};Ye.flushSync=function(e){return gi(e)};Ye.hydrate=function(e,t,a){if(!vs(t))throw Error(M(200));return xs(null,e,t,!0,a)};Ye.hydrateRoot=function(e,t,a){if(!Go(e))throw Error(M(405));var n=a!=null&&a.hydratedSources||null,s=!1,r="",o=xu;if(a!=null&&(a.unstable_strictMode===!0&&(s=!0),a.identifierPrefix!==void 0&&(r=a.identifierPrefix),a.onRecoverableError!==void 0&&(o=a.onRecoverableError)),t=vu(t,null,e,1,a??null,s,!1,r,o),e[Rt]=t.current,Oa(e),n)for(e=0;e<n.length;e++)a=n[e],s=a._getVersion,s=s(a._source),t.mutableSourceEagerHydrationData==null?t.mutableSourceEagerHydrationData=[a,s]:t.mutableSourceEagerHydrationData.push(a,s);return new ys(t)};Ye.render=function(e,t,a){if(!vs(t))throw Error(M(200));return xs(null,e,t,!1,a)};Ye.unmountComponentAtNode=function(e){if(!vs(e))throw Error(M(40));return e._reactRootContainer?(gi(function(){xs(null,null,e,!1,function(){e._reactRootContainer=null,e[Rt]=null})}),!0):!1};Ye.unstable_batchedUpdates=Eo;Ye.unstable_renderSubtreeIntoContainer=function(e,t,a,n){if(!vs(a))throw Error(M(200));if(e==null||e._reactInternals===void 0)throw Error(M(38));return xs(e,t,a,!1,n)};Ye.version="18.3.1-next-f1338f8080-20240426";function bu(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(bu)}catch(e){console.error(e)}}bu(),bc.exports=Ye;var Cu=bc.exports;const wu=lc(Cu);var ic=Cu;er.createRoot=ic.createRoot,er.hydrateRoot=ic.hydrateRoot;var ac={},of="@vercel/analytics",lf="1.6.1",cf=()=>{window.va||(window.va=function(...t){(window.vaq=window.vaq||[]).push(t)})};function Nu(){return typeof window<"u"}function Au(){try{const e="production"}catch{}return"production"}function df(e="auto"){if(e==="auto"){window.vam=Au();return}window.vam=e}function uf(){return(Nu()?window.vam:Au())||"production"}function $r(){return uf()==="development"}function mf(e){return e.scriptSrc?e.scriptSrc:$r()?"https://va.vercel-scripts.com/v1/script.debug.js":e.basePath?`${e.basePath}/insights/script.js`:"/_vercel/insights/script.js"}function pf(e={debug:!0}){var t;if(!Nu())return;df(e.mode),cf(),e.beforeSend&&((t=window.va)==null||t.call(window,"beforeSend",e.beforeSend));const a=mf(e);if(document.head.querySelector(`script[src*="${a}"]`))return;const n=document.createElement("script");n.src=a,n.defer=!0,n.dataset.sdkn=of+(e.framework?`/${e.framework}`:""),n.dataset.sdkv=lf,e.disableAutoTrack&&(n.dataset.disableAutoTrack="1"),e.endpoint?n.dataset.endpoint=e.endpoint:e.basePath&&(n.dataset.endpoint=`${e.basePath}/insights`),e.dsn&&(n.dataset.dsn=e.dsn),n.onerror=()=>{const s=$r()?"Please check if any ad blockers are enabled and try again.":"Be sure to enable Web Analytics for your project and deploy again. See https://vercel.com/docs/analytics/quickstart for more information.";console.log(`[Vercel Web Analytics] Failed to load script from ${a}. ${s}`)},$r()&&e.debug===!1&&(n.dataset.debug="false"),document.head.appendChild(n)}function ff({route:e,path:t}){var a;(a=window.va)==null||a.call(window,"pageview",{route:e,path:t})}function hf(){if(!(typeof process>"u"||typeof ac>"u"))return ac.REACT_APP_VERCEL_OBSERVABILITY_BASEPATH}function gf(e){return A.useEffect(()=>{var t;e.beforeSend&&((t=window.va)==null||t.call(window,"beforeSend",e.beforeSend))},[e.beforeSend]),A.useEffect(()=>{pf({framework:e.framework||"react",basePath:e.basePath??hf(),...e.route!==void 0&&{disableAutoTrack:!0},...e})},[]),A.useEffect(()=>{e.route&&e.path&&ff({route:e.route,path:e.path})},[e.route,e.path]),null}function Su(){return typeof window<"u"}function yf(){try{const e="production"}catch{}return"production"}function Tu(){return(Su()?window.vam:yf())||"production"}function nc(){return Tu()==="production"}function vf(){return Tu()==="development"}function xf(e,{[e]:t,...a}){return a}function bf(e,t){if(!e)return;let a=e;const n=[];for(const[s,r]of Object.entries(e))typeof r=="object"&&r!==null&&(t.strip?a=xf(s,a):n.push(s));if(n.length>0&&!t.strip)throw Error(`The following properties are not valid: ${n.join(", ")}. Only strings, numbers, booleans, and null are allowed.`);return a}function Ji(e,t,a){var n,s;if(!Su()){const r="[Vercel Web Analytics] Please import `track` from `@vercel/analytics/server` when using this function in a server environment";if(nc())console.warn(r);else throw new Error(r);return}if(!t){(n=window.va)==null||n.call(window,"event",{name:e,options:a});return}try{const r=bf(t,{strip:nc()});(s=window.va)==null||s.call(window,"event",{name:e,data:r,options:a})}catch(r){r instanceof Error&&vf()&&console.error(r)}}const Pa=[{date:"Dec 14, 2025",type:"updated",testId:null,testName:"Data Accuracy Corrections",vendor:null,category:"Multiple",description:'Corrected overstated claims and regulatory status: Cologuard - removed "ONLY" self-collection claim, moved USPSTF to guidelines field; TSO Comprehensive - narrowed CDx claims to FDA-labeled scope (NTRK/RET at launch); TSO 500 - clarified RUO in US; Oncomine Comprehensive Assay Plus - changed to RUO pending CE-IVD verification; GeneseeqPrime - corrected clearance date to Aug 2025; Epi proColon - updated reimbursement to "coverage variable/limited"; clonoSEQ - added US/EU distribution model notes.',contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 14, 2025",type:"updated",testId:null,testName:"CDx Category Reclassification",vendor:null,category:"Multiple",description:"Reclassified 6 therapy-selection companion diagnostics from TRM/MRD to TDS: cobas EGFR v2, cobas KRAS, therascreen EGFR, OncoBEAM RAS CRC, PGDx elio plasma focus (from TRM), and LeukoStrat CDx FLT3 (from MRD). These tests are primarily CDx for therapy selection, not treatment response monitoring or MRD detection. Category placement now reflects FDA-labeled intended use.",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 14, 2025",type:"feature",testId:null,testName:"IVD Kit Support",vendor:null,category:"All",description:"Added Product Type taxonomy distinguishing Self-Collection kits (patient collects at home), Laboratory IVD Kits (distributed reagents for CLIA labs), and Central Lab Services (send-out tests). New filter enables users to find tests by distribution model. Added 16 IVD kit entries: ECD - Cologuard, Epi proColon; MRD - clonoSEQ Assay, LymphoTrack Dx IGH Assay, BD OneFlow B-ALL MRD Kit; TDS - TruSight Oncology Comprehensive, GeneseeqPrime, PGDx elio tissue complete, Oncomine Comprehensive Assay Plus, TSO 500, cobas EGFR Mutation Test v2, cobas KRAS Mutation Test, therascreen EGFR RGQ PCR Kit, OncoBEAM RAS CRC Kit, PGDx elio plasma focus Dx, LeukoStrat CDx FLT3 Mutation Assay.",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 14, 2025",type:"added",testId:"ecd-kit-1",testName:"Cologuard",vendor:"Exact Sciences",category:"ECD",description:"Added FDA PMA-approved self-collection CRC screening kit. Only at-home collection cancer screening test. Stool DNA + FIT, 92% CRC sensitivity, 87% specificity. USPSTF Grade A recommendation.",contributor:null,affiliation:"OpenOnco",citation:"https://www.cologuard.com/"},{date:"Dec 14, 2025",type:"added",testId:"mrd-kit-1",testName:"clonoSEQ Assay",vendor:"Adaptive Biotechnologies",category:"MRD",description:"Added FDA-cleared IVD kit for MRD detection in hematologic malignancies. First and only FDA-cleared MRD IVD. Available as reagent kit for MiSeqDx labs.",contributor:null,affiliation:"OpenOnco",citation:"https://www.clonoseq.com/"},{date:"Dec 14, 2025",type:"added",testId:"tds-kit-1",testName:"TruSight Oncology Comprehensive",vendor:"Illumina",category:"TDS",description:"Added first FDA-approved distributable CGP IVD kit with pan-cancer CDx claims. 517 genes, enables in-house comprehensive genomic profiling.",contributor:null,affiliation:"OpenOnco",citation:"https://www.illumina.com/products/by-type/ivd-products/trusight-oncology-comprehensive.html"},{date:"Dec 14, 2025",type:"added",testId:"tds-kit-6",testName:"cobas EGFR Mutation Test v2",vendor:"Roche",category:"TDS",description:"Added FDA-approved EGFR liquid biopsy CDx kit. First liquid biopsy test FDA-approved (2016). Gold standard for EGFR TKI therapy selection.",contributor:null,affiliation:"OpenOnco",citation:"https://diagnostics.roche.com/global/en/products/tests/cobas-egfr-mutation-test-v2-ins.html"},{date:"Dec 13, 2025",type:"updated",testId:"trm-12",testName:"Reveal TRM",vendor:"Guardant Health",category:"TRM",description:"Corrected tumor fraction methodology for Reveal TRM and Reveal MRD: epiTF (epigenetic Tumor Fraction) calculated from 19,000+ differentially methylated loci, mutation-agnostic. Removed duplicate Guardant360 Response entry (trm-10).",contributor:"Brandon Guida",affiliation:"Guardant Health (vendor)",citation:null},{date:"Dec 13, 2025",type:"added",testId:"tds-18",testName:"IsoPSA",vendor:"Cleveland Diagnostics",category:"TDS",description:"Added FDA PMA-approved protein structure-based prostate cancer diagnostic. IsoClear platform analyzes PSA structural variants (not concentration) to aid biopsy decisions. 90.2% sensitivity, runs on standard analyzers (COBAS, Siemens, Abbott). In NCCN and AUA/SUO guidelines, Medicare covered.",contributor:"Sameer Rohatgi",affiliation:"Cleveland Diagnostics",citation:"https://www.businesswire.com/news/home/20251201324198/en/FDA-Approves-IsoPSA----Cleveland-Diagnostics-Novel-Blood-Based-Prostate-Cancer-Test"},{date:"Dec 13, 2025",type:"updated",testId:"mrd-23",testName:"LymphoVista",vendor:"LIQOMICS",category:"MRD",description:"Corrected turnaround times per vendor: Initial TAT and Follow-up TAT both 10 days (previously listed as 2-4 weeks).",contributor:"Jens Winter",affiliation:"LIQOMICS (vendor)",citation:null},{date:"Dec 12, 2025",type:"updated",testId:"tds-16",testName:"Northstar Select",vendor:"BillionToOne",category:"TDS",description:"Updated reimbursement status: Medicare coverage via MolDx (Palmetto GBA LCD L38043) effective February 14, 2025.",contributor:"David Huland",affiliation:"BillionToOne (vendor)",citation:"https://www.billiontoone.com/news-media/billiontoone-announces-medicare-coverage-for-northstar-select"},{date:"Dec 12, 2025",type:"updated",testId:"trm-1",testName:"Guardant360 Response (DISCONTINUED)",vendor:"Guardant Health",category:"TRM",description:"PRODUCT DISCONTINUED: Sun-setted per vendor. Guardant has consolidated monitoring portfolio to Reveal MRD (early-stage) and Reveal TRM (advanced/metastatic). Guardant360 Response is no longer commercially available.",contributor:"Brandon Guida PhD",affiliation:"Guardant Health (vendor)",citation:null},{date:"Dec 12, 2025",type:"added",testId:"trm-12",testName:"Reveal TRM",vendor:"Guardant Health",category:"TRM",description:"Added new methylation-based therapy response monitoring test for advanced/metastatic solid tumors. Uses Guardant Infinity platform with epigenetic tumor fraction (epiTF) quantification from 19,000+ differentially methylated locimutation-agnostic. Precision down to ~0.01% TF, not confounded by CNAs or CHIP. Validated in >50,000 cfDNA samples across 20+ cancer types (AACR 2025).",contributor:"Brandon Guida PhD",affiliation:"Guardant Health (vendor)",citation:null},{date:"Dec 12, 2025",type:"updated",testId:"mrd-6",testName:"Reveal MRD",vendor:"Guardant Health",category:"MRD",description:'Renamed from "Reveal" to "Reveal MRD" per vendor product consolidation. Expanded cancer types to include breast and non-small cell lung cancer (previously CRC only). Early-stage cancer focus for MRD detection/recurrence monitoring after curative-intent therapy.',contributor:"Brandon Guida PhD",affiliation:"Guardant Health (vendor)",citation:null},{date:"Dec 13, 2025",type:"feature",testId:null,testName:"Site Update",vendor:null,category:null,description:"Added shareable comparison links (copy link button in comparison modal). Fixed print-to-PDF bug that repeated Page 1 on all pages.",contributor:"Jeff Hull",affiliation:"BillionToOne (via LinkedIn)",citation:null},{date:"Dec 13, 2025",type:"updated",testId:"mrd-15",testName:"Foresight CLARITY Lymphoma",vendor:"Natera",category:"MRD",description:"Updated per vendor: Matched Normal = Yes; LOD95 = 0.7 ppm (previously listed as LOD). Added analytical validation publication citation.",contributor:"John Truesdell",affiliation:"Natera/Foresight (vendor)",citation:"https://pubmed.ncbi.nlm.nih.gov/40353795/"},{date:"Dec 12, 2025",type:"updated",testId:"mrd-2",testName:"NeXT Personal Dx",vendor:"Personalis",category:"MRD",description:"Updated turnaround times per vendor: initial TAT now 21 days (was 35), follow-up TAT now 10 days (was 12). Confirmed blood volume (20 mL, two Streck tubes) and variants tracked (~1,800).",contributor:"Dan Norton",affiliation:"Personalis (vendor)",citation:null},{date:"Dec 11, 2025",type:"updated",testId:"mrd-19",testName:"clonoSEQ",vendor:"Adaptive Biotechnologies",category:"MRD",description:"Clarified sample requirements: baseline Clonality (ID) test accepts fresh or archived samples from bone marrow aspirate, peripheral blood, or soft tissue (e.g., plasmacytoma, lymph node biopsy). Subsequent Tracking (MRD) tests use standard fresh bone marrow or blood.",contributor:"Christine Hanley",affiliation:"Adaptive Biotechnologies (vendor)",citation:null},{date:"Dec 11, 2025",type:"added",testId:"tds-17",testName:"Guardant360 Liquid",vendor:"Guardant Health",category:"TDS",description:"Added comprehensive 744-gene liquid biopsy LDT (distinct from 74-gene FDA-approved CDx). Features: genomic + epigenomic (promoter methylation) insights, CHIP filtering, virus detection (EBV/HPV), tumor fraction quantification. Runs on Guardant Infinity platform with 10x more genes and 10x higher sensitivity than previous version.",contributor:"Brandon (Scott) Guida PhD",affiliation:"Guardant Health (vendor)",citation:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf"},{date:"Dec 11, 2025",type:"updated",testId:"multiple",testName:"Clinical Settings Tags",vendor:"Multiple",category:"MRD",description:"Added clinicalSettings field to all MRD tests to capture validated clinical contexts: Neoadjuvant (monitoring during pre-surgery therapy), Post-Surgery (landmark ~4 weeks after resection), Post-Adjuvant (after chemotherapy), and Surveillance (longitudinal recurrence monitoring). Added filter by clinical setting. Based on vendor feedback from Personalis (Dan Norton) on clinical context-specific performance data.",contributor:"Dan Norton",affiliation:"Personalis",citation:null},{date:"Dec 12, 2025",type:"added",testId:"mrd-23",testName:"LymphoVista",vendor:"LIQOMICS",category:"MRD",description:"Added European lymphoma-focused ctDNA MRD test covering B-cell lymphomas (DLBCL, FL, MCL, Burkitt, CNS) and Hodgkin lymphoma via LymphoVista HL variant. Duplex sequencing with LoD 6.6910. Clinical validation: 92.1% PPV in r/r DLBCL post-CAR-T/chemo (EHA 2024); HR 6.9 for PFS in Hodgkin (ASH 2024, HD21 trial).",contributor:"Jens Winter",affiliation:"LIQOMICS (vendor)",citation:"https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping"},{date:"Dec 11, 2025",type:"added",testId:"mrd-22",testName:"CancerDetect",vendor:"IMBdx",category:"MRD",description:"Added Korean tumor-informed MRD test using large-scale mutation tracking (up to 300 variants). 0.001% LOD. Innovative Medical Technology designation.",contributor:"Sunghoon Heo",affiliation:"IMBdx (vendor)",citation:"https://www.nature.com/articles/s41416-023-02300-3"},{date:"Dec 11, 2025",type:"added",testId:"mrd-21",testName:"Latitude",vendor:"Natera",category:"MRD",description:"Added tissue-free (tumor-nave) methylation-based MRD test for CRC. No tumor tissue required. Validated in CIRCULATE-JAPAN GALAXY Study.",contributor:"Sunghoon Heo",affiliation:"IMBdx",citation:"https://www.natera.com/oncology/latitude-tissue-free-mrd/"},{date:"Dec 11, 2025",type:"added",testId:"mrd-20",testName:"Signatera Genome",vendor:"Natera",category:"MRD",description:"Added WGS-informed version of Signatera with 64 variants tracked and 1 ppm LOD (~100x more sensitive than standard Signatera).",contributor:"Sunghoon Heo",affiliation:"IMBdx",citation:"https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/"},{date:"Dec 11, 2025",type:"updated",testId:"mrd-9",testName:"Labcorp Plasma Detect",vendor:"Labcorp",category:"MRD",description:"Fixed duplicate entry: merged mrd-17 into mrd-9. Updated with expanded cancer types (lung, bladder in validation), improved LOD (10 ppm), lead time data, and newer clinical trial citations.",contributor:"Sunghoon Heo",affiliation:"IMBdx",citation:null},{date:"Dec 10, 2025",type:"updated",testId:"tds-15",testName:"NEO PanTracer Tissue",vendor:"NeoGenomics",category:"TDS",description:'Renamed from "Neo Comprehensive" to "NEO PanTracer Tissue" to reflect NeoGenomics product rebrand.',contributor:"Heather Robinson",affiliation:"Illumina",citation:"https://www.neogenomics.com/providers/test/NTG-HCSX-02AX/neo-comprehensive-solid-tumor/"},{date:"Dec 10, 2025",type:"updated",testId:"mrd-19",testName:"clonoSEQ",vendor:"Adaptive Biotechnologies",category:"MRD",description:"Vendor update: TAT changed to 7 days (serial monitoring) from 14 days (baseline); updated Target Population to list specific indications (ALL, CLL, DLBCL, MCL, MM); clarified tumor tissue requirement for hematologic assay.",contributor:"Christine Hanley",affiliation:"Adaptive Biotechnologies",citation:null},{date:"Dec 10, 2025",type:"updated",testId:"multiple",testName:"Medicare ADLT Data",vendor:"Multiple",category:"All",description:"Added Medicare CLFS reimbursement rates and ADLT status to 8 tests: Signatera ($3,500), Guardant360 CDx ($5,000), FoundationOne CDx ($3,500), FoundationOne Liquid CDx ($3,500), Shield ($1,495), NavDx ($1,800), Tempus xT CDx ($4,500), clonoSEQ ($2,007). Added PLA vs CPT code type distinction.",contributor:null,affiliation:"OpenOnco",citation:"https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/files"},{date:"Dec 10, 2025",type:"added",testId:"mrd-19",testName:"clonoSEQ",vendor:"Adaptive Biotechnologies",category:"MRD",description:"Added clonoSEQ - first and only FDA-cleared MRD test for hematologic malignancies (MM, B-ALL, CLL). Uses NGS immunosequencing of B/T-cell receptor genes with 10 sensitivity. Medicare coverage for MM, ALL, CLL, DLBCL, MCL.",contributor:"Christine Hanley",affiliation:"Adaptive Biotechnologies",citation:"https://www.clonoseq.com/"},{date:"Dec 10, 2025",type:"updated",testId:"tds-1",testName:"FoundationOne CDx",vendor:"Foundation Medicine",category:"TDS",description:"Added international availability info - available in 100+ countries via Roche global network (EU lab in Penzberg, Germany; MHLW approved in Japan)",contributor:null,affiliation:"OpenOnco",citation:"https://www.roche.com/media/releases/med-cor-2021-10-25"},{date:"Dec 10, 2025",type:"updated",testId:"tds-2",testName:"FoundationOne Liquid CDx",vendor:"Foundation Medicine",category:"TDS",description:"Added international availability info - available in 100+ countries via Roche global network",contributor:null,affiliation:"OpenOnco",citation:"https://www.roche.com/media/releases/med-cor-2021-10-25"},{date:"Dec 10, 2025",type:"updated",testId:"tds-3",testName:"FoundationOne Heme",vendor:"Foundation Medicine",category:"TDS",description:"Added international availability info - available via Roche global network",contributor:null,affiliation:"OpenOnco",citation:"https://www.roche.com/media/releases/med-cor-2021-10-25"},{date:"Dec 10, 2025",type:"updated",testId:"mrd-9",testName:"FoundationOne Tracker (MRD)",vendor:"Foundation Medicine",category:"MRD",description:"Added international availability info for investigational/early access program",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 10, 2025",type:"updated",testId:"mrd-11",testName:"Foundation TI-WGS MRD (RUO)",vendor:"Foundation Medicine",category:"MRD",description:"Added international availability info for RUO via FlexOMx Lab",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 10, 2025",type:"updated",testId:"trm-6",testName:"FoundationOne Tracker (TRM)",vendor:"Foundation Medicine",category:"TRM",description:"Added international availability info - available via Roche affiliates",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 10, 2025",type:"updated",testId:"trm-7",testName:"FoundationOne Monitor",vendor:"Foundation Medicine",category:"TRM",description:"Added international availability info - available via Roche affiliates",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 9, 2025",type:"added",testId:"tds-16",testName:"Northstar Select",vendor:"BillionToOne",category:"TDS",description:"Initial database entry - liquid biopsy CGP with 0.15% VAF LOD",contributor:"Rob Manor",affiliation:"BillionToOne",citation:"https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00038-4/fulltext"},{date:"Dec 9, 2025",type:"updated",testId:"trm-8",testName:"Northstar Response",vendor:"BillionToOne",category:"TRM",description:"Updated methylated loci count from >500 to >2200 (v2 panel expansion)",contributor:"Rob Manor",affiliation:"BillionToOne",citation:"https://www.northstaronc.com/northstar-response"},{date:"Dec 10, 2025",type:"removed",testId:"trm-9",testName:"MSK-ACCESS powered with SOPHiA DDM",vendor:"SOPHiA GENETICS",category:"TRM",description:"Removed - RUO kitted product not directly orderable by physicians. Vendor confirmed test does not meet inclusion criteria.",contributor:"Julien Pontis",affiliation:"SOPHiA GENETICS",citation:null},{date:"Dec 8, 2025",type:"added",testId:"mrd-16",testName:"Invitae PCM",vendor:"Labcorp (Invitae)",category:"MRD",description:"Initial database entry",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 8, 2025",type:"added",testId:"tds-15",testName:"Neo Comprehensive",vendor:"NeoGenomics",category:"TDS",description:"Initial database entry",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 7, 2025",type:"added",testId:"ecd-13",testName:"Signal-C",vendor:"Universal DX",category:"ECD",description:"Initial database entry",contributor:null,affiliation:"OpenOnco",citation:null},{date:"Dec 7, 2025",type:"added",testId:"mrd-15",testName:"Foresight CLARITY Lymphoma",vendor:"Natera",category:"MRD",description:"Initial database entry",contributor:"John Truesdell",affiliation:"Foresight Diagnostics",citation:null},{date:"Dec 5, 2025",type:"added",testId:"ecd-11",testName:"EPISEEK",vendor:"Precision Epigenomics",category:"ECD",description:"Initial database entry",contributor:"Richard Bernert",affiliation:"Precision Epigenomics",citation:null}],z=[{id:"mrd-1",sampleCategory:"Blood/Plasma",name:"Haystack MRD",vendor:"Quest Diagnostics",approach:"Tumor-informed",method:"Whole-genomederived personalized panel; ~50 variants tracked; low error suppression",cancerTypes:["Multi-solid"],indicationsNotes:"Tumor-informed MRD assay for multiple common and rare solid tumors; Quest/Resolution MRD platform, FDA Breakthrough Device designation.",sensitivity:95,sensitivityCitations:"https://haystackmrd.com/",sensitivityNotes:"Headline 95% sensitivity is analytical; clinical sensitivity by stage not yet published from large prospective cohorts.",sensitivityStagesReported:"Analytical validation (stages not specified)",stageIISensitivity:null,stageIISensitivityNotes:"FDA Breakthrough Device designation specifically for Stage II CRC (Aug 2025); stage-specific clinical sensitivity data expected from ongoing trials.",stageIIISensitivity:null,stageIIISensitivityNotes:"Stage III-specific data not yet published; NCT07125729 head-to-head vs Signatera includes Stage IIIV CRC.",landmarkSensitivityCitations:"https://haystackmrd.com/faq/",longitudinalSensitivityCitations:"https://haystackmrd.com/",lod:"6 ppm",lod95:"6 ppm (0.0006% tumor fraction)",lodCitations:"https://haystackmrd.com/",lodNotes:"LoD95 (95% limit of detection) is ~6 ppm (0.0006% tumor fraction). This represents the ctDNA level at which 95% of replicates are detected as positive in analytical validation studies.",requiresTumorTissue:"Yes",requiresMatchedNormal:"Yes",variantsTracked:"50",variantsTrackedNotes:"Up to ~50 tumor-specific variants selected from tumor and matched-normal whole-exome sequencing; variants filtered to avoid CHIP-associated regions.",initialTat:30,initialTatNotes:"Baseline tumor+normal whole-exome profiling and panel design typically ~4 weeks (~30 days) from sample receipt.",followUpTat:7,followUpTatNotes:"Post-baseline MRD blood draws generally reported within about 57 days (Quest/Haystack FAQs; Quest Q&A sometimes quotes 710 days).",bloodVolume:30,bloodVolumeNotes:"Quest test directory for Haystack MRD monitoring lists three 10 mL cfDNA tubes (30 mL total) as standard collection; minimum acceptable volume ~24 mL.",tat:30,tatNotes:"Overall paradigm: ~4 weeks for initial panel build, ~1 week for subsequent MRD timepoints.",fdaStatus:"CLIA LDT (Quest Diagnostics); FDA Breakthrough Device designation for stage II colorectal cancer (Aug 2025).",reimbursement:"Coverage emerging (~70% of tests reimbursed); Medicare pilot for CRC plus growing commercial coverage.",reimbursementNote:"As of mid-2025, Quest reports ~70% of Haystack MRD tests are reimbursed across payers. Medicare pilot coverage in place for CRC, with active engagement with CMS for broader LCD. Commercial payer coverage growing; patient access programs available.",cptCodes:"0561U",clinicalAvailability:"Clinical LDT  shipping",clinicalTrials:"NCT07125729 (150; resectable stage IIIV CRC; Haystack vs Signatera head-to-head); NCT06979661 (25; MRD-PORT trial; post-op stage IIIII NSCLC; Haystack MRD-guided RT); NCT05798663/AFT-57 (158; unresectable stage III NSCLC; atezolizumab  tiragolumab CRT; Haystack MRD used for correlative MRD analyses)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT07125729 | https://clinicaltrials.gov/study/NCT06979661 | https://clinicaltrials.gov/study/NCT05798663",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"Validated for post-surgical MRD assessment and longitudinal surveillance. Clinical trials focus on post-operative and surveillance settings in CRC and NSCLC.",totalParticipants:333,numPublications:17},{id:"mrd-2",sampleCategory:"Blood/Plasma",name:"NeXT Personal Dx",vendor:"Personalis",approach:"Tumor-informed",method:"Tumor-informed, whole-genome-based MRD assay: WGS of tumor and matched normal identifies up to ~1,800 patient-specific variants, which are tracked at high depth in plasma to detect ctDNA down to ~13 parts per million (ppm).",cancerTypes:["Breast","Colorectal","NSCLC"],indicationsNotes:"Personalis NeXT Personal Dx tumor-informed MRD assay. Medicare-covered for early-stage breast cancer recurrence monitoring; clinical data also reported in colorectal cancer and NSCLC.",sensitivity:null,sensitivityCitations:"https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",sensitivityNotes:"Reported as 100% sensitivity in validation cohort (n=493); insufficient data for population-level estimates. Value set to null to avoid misleading comparisons.",sensitivityStagesReported:"Not separately reported (small validation cohort)",stageIISensitivity:null,stageIISensitivityNotes:"Stage-specific sensitivity not reported; validation cohort too small for stage breakdown.",stageIIISensitivity:null,stageIIISensitivityNotes:"Stage-specific sensitivity not reported.",specificity:null,specificityCitations:"https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",specificityNotes:"Reported as 100% specificity in validation cohort (n=493); insufficient data for population-level estimates. Value set to null to avoid misleading comparisons.",longitudinalSensitivity:null,longitudinalSensitivityCitations:"https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",longitudinalSensitivityNotes:"Reported as 100% in validation cohort; value set to null pending larger studies.",longitudinalSpecificity:null,longitudinalSpecificityCitations:"https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",longitudinalSpecificityNotes:"Reported as 100% in validation cohort; value set to null pending larger studies.",lod:"1.67 ppm",lod95:"3.45 ppm",lodCitations:"Northcott et al. Oncotarget 2024; Personalis NeXT Personal Dx analytical validation brochure.",lodNotes:"Detection threshold is 1.67 ppm; LOD95 (95% confidence) is 3.45 ppm. The gap between these values means serial testing can catch lower-level disease.",leadTimeVsImaging:450,leadTimeVsImagingCitations:"Garcia-Murillas et al. Ann Oncol 2025; TRACERx NSCLC data.",leadTimeVsImagingNotes:"450 days (15 months) is the median lead time from the Garcia-Murillas et al. Ann Oncol 2025 early-stage breast cancer cohort (range 0.9-61.5 months). This is the median from this specific study, not a universal NeXT median across all indications. NSCLC TRACERx data showed ~6 months.",vendorRequestedChanges:"2025-12-03: Personalis requested lead time update to 15 months (450 days) based on Ann Oncol 2025 breast cancer paper (Garcia-Murillas et al.). Verified against source and updated.",requiresTumorTissue:"Yes",requiresMatchedNormal:"Yes",variantsTracked:"1800",variantsTrackedNotes:"Personalized panels track on the order of 1,800 tumor-specific variants per patient based on tumor/normal whole-genome sequencing, with additional investigational content in some implementations.",initialTat:21,initialTatNotes:"Initial report turnaround is 21 days per vendor (Dan Norton, Personalis, Dec 2025).",followUpTat:10,followUpTatNotes:"Follow-up monitoring draws reported within 10 days per vendor (Dan Norton, Personalis, Dec 2025).",bloodVolume:20,bloodVolumeNotes:"Monitoring commonly uses two 10 mL Streck cfDNA tubes (20 mL total); baseline also requires FFPE tumor tissue and matched-normal blood.",tat:21,tatNotes:"Initial report: 21 days; follow-up monitoring: 10 days (vendor-confirmed Dec 2025).",fdaStatus:"CLIA LDT (early access / clinical offering)",reimbursement:"Medicare coverage for stage II-III breast cancer MRD surveillance; additional solid tumor coverage via Tempus xM collaboration expanding.",cptCodes:"MolDX with DEX Z-code",clinicalAvailability:"Clinical LDT  shipping (initial market availability)",exampleTestReport:"https://www.personalis.com/wp-content/uploads/2024/07/NeXT-Personal-Dx-Clinical-Report-Template-DOC-002568B.pdf",clinicalTrials:"NCT06230185 (422); VICTORI study interim cohort (~71)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT06230185",clinicalSettings:["Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Validated for post-surgical MRD, post-adjuvant assessment, and longitudinal surveillance. Medicare coverage specifically for breast cancer recurrence monitoring/surveillance setting.",totalParticipants:493,numPublications:4,numPublicationsPlus:!0},{id:"mrd-3",sampleCategory:"Blood/Plasma",name:"Oncodetect",vendor:"Exact Sciences",approach:"Tumor-informed",method:"Tumor-informed hybrid-capture ctDNA assay: tumor plus matched-normal sequencing to select up to ~200 somatic variants per patient, followed by targeted hybrid-capture NGS with CHIP-aware filtering.",cancerTypes:["Multi-solid"],indicationsNotes:"Exact Sciences Oncodetect tumor-informed circulating tumor DNA (ctDNA) MRD test, marketed for use across solid tumors; designed for post-surgical and surveillance use cases.",sensitivity:91,sensitivityCitations:"https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",sensitivityNotes:"In CRC, results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively.",sensitivityStagesReported:"Stage IIIII combined (CRC)",stageIISensitivity:null,stageIISensitivityNotes:"Stage II-specific CRC sensitivity not separately reported in Alpha-CORRECT publications; combined with Stage III. Stage-specific breakdowns would be informative for treatment decisions.",stageIIISensitivity:null,stageIIISensitivityNotes:"Alpha-CORRECT cohort primarily Stage III CRC; stage-specific breakdown not published.",stageDataExpected:!0,specificity:94,specificityCitations:"https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",specificityNotes:"In CRC (Alpha-CORRECT study), Oncodetect demonstrated specificities of 80% at the post-surgical timepoint and 94% during surveillance monitoring.",ppv:50,ppvNotes:"CRC postsurgical 3y PPV 50% (Alpha-/Beta-CORRECT).",npv:96,npvNotes:"CRC postsurgical 3y NPV 96%.",landmarkSensitivity:78,landmarkSensitivityNotes:"CRC postsurgical sensitivity.",landmarkSpecificity:80,longitudinalSensitivity:91,longitudinalSensitivityCitations:"https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",longitudinalSensitivityNotes:"CRC surveillance sensitivity.",longitudinalSpecificity:94,longitudinalSpecificityCitations:"https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",longitudinalSpecificityNotes:"CRC surveillance specificity.",lod:null,lod95:"15 ppm",lodNotes:"LoD95 of 15 ppm per Exact Sciences analytical validation whitepaper. Detection threshold not separately disclosed.",lodCitations:"Exact Sciences Oncodetect LoD whitepaper; ASCO data presentations.",leadTimeVsImaging:317,leadTimeVsImagingNotes:"Median lead time ~10.4 months (~317 days) from first MRD-positive Oncodetect result to radiologic recurrence in the -CORRECT stage III CRC cohort. This is the median from this specific study, not a universal value across all indications.",leadTimeVsImagingCitations:"Exact Sciences -CORRECT press release; J Surg Oncol/JCO presentations.",requiresTumorTissue:"Yes",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"White paper: WES tumor + matched-normal buffy coat.",variantsTracked:"200",variantsTrackedNotes:"Panel tracks up to 200 tumor-specific variants per patient (median ~170) with roadmap to higher-plex designs.",initialTat:28,initialTatNotes:"Provider-facing materials describe baseline tissue+normal discovery and panel creation in roughly 4 weeks.",followUpTat:10,followUpTatNotes:"Monitoring blood draws typically result within about 10 days after sample receipt.",bloodVolumeNotes:"3 LBgard cfDNA tubes required for blood draw; tissue required at baseline",tat:28,tatNotes:"Approximate baseline TAT ~4 weeks; subsequent MRD timepoints ~10 days.",fdaStatus:"CLIA LDT",reimbursement:"Medicare (CRC only)",reimbursementNote:"Medicare MolDX coverage for colorectal cancer MRD only (announced July 2025). Not covered for other cancer types. Broader payer adoption evolving.",cptCodes:"PLA pending",cptCodesNotes:"Payer policies vary.",clinicalAvailability:"Clinical LDT  shipping",independentValidation:"Yes",independentValidationNotes:"Prospective Alpha-/Beta-CORRECT CRC cohorts.",exampleTestReport:"https://www.exactsciences.com/-/media/project/headless/one-exact-web/documents/products-services/oncodetect/providers/sample-report-stage-iii-escalation.pdf?rev=10365d7a28c8467eb25d253943ce8fe9",clinicalTrials:"NCT06398743 (416); -CORRECT observational study (124)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT06398743",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"Validated for post-surgical MRD assessment (78% sensitivity) and longitudinal surveillance (91% sensitivity) in CRC per Alpha-CORRECT study.",totalParticipants:540,numPublications:1,numPublicationsPlus:!0},{id:"mrd-4",sampleCategory:"Blood/Plasma",name:"Pathlight",vendor:"SAGA Diagnostics",approach:"Tumor-informed",method:"Tumor-informed MRD platform using whole-genome profiling to identify structural variants (SVs) and other truncal events, which are then tracked using sensitive digital PCR and/or NGS in serial plasma samples.",cancerTypes:["Breast","Multi-solid"],indicationsNotes:"SAGA Diagnostics Pathlight tumor-informed MRD assay. Medicare coverage announced for breast cancer across all subtypes (HR+/HER2-, HER2+, and triple-negative); platform positioned as multi-cancer MRD.",sensitivity:null,sensitivityCitations:"https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",sensitivityNotes:"Reported as 100% sensitivity in small validation cohort (n=100, TRACER study) per Medicare coverage decision. Value set to null pending larger validation studies.",specificity:null,specificityCitations:"https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",specificityNotes:"Reported as 100% specificity in small validation cohort (n=100, TRACER study) per Medicare coverage decision. Value set to null pending larger validation studies.",landmarkSensitivity:null,landmarkSpecificity:null,longitudinalSensitivity:null,longitudinalSensitivityCitations:"https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",longitudinalSensitivityNotes:"Reported as 100% in small breast cohort (n=100); value set to null pending larger validation.",longitudinalSpecificity:null,longitudinalSpecificityCitations:"https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",longitudinalSpecificityNotes:"Reported as 100% in small breast cohort (n=100); value set to null pending larger validation.",lod:null,lod95:"~5 ppm",lodNotes:"SAGA materials describe an LoD95 on the order of 5 ppm in analytical studies of SV-based assays. Detection threshold not separately disclosed.",leadTimeVsImaging:411,leadTimeVsImagingCitations:"https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",leadTimeVsImagingNotes:"Early-stage breast cancer cohort data highlight median lead time 13.7 months (~411 days) between MRD positivity and clinical/radiologic recurrence.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Tumor-informed (WGS of tumor); structural variants tracked by dPCR.",requiresMatchedNormal:"Yes",tat:28,tatNotes:"Initial tumor profiling and personalized assay build typically reported in ~34 weeks; subsequent blood tests often return in ~35 days in published experience.",fdaStatus:"CLIA LDT (US) with international laboratory service offerings.",reimbursement:"Medicare coverage for early-stage breast cancer; additional coverage emerging.",reimbursementNote:"CMS coverage established for Pathlight MRD in early-stage breast cancer across all subtypes (2025); other indications and payers evolving.",cptCodes:"No dedicated PLA as of 2025; payer-specific coding applies.",cptCodesNotes:"Contact vendor for current billing guidance.",clinicalAvailability:"Clinical LDT  shipping (select geographies)",clinicalTrials:"TRACER study (cTdna evaluation in eaRly breAst canCER); 100 patients with stage IIII breast cancer of all subtypes; Clinical Cancer Research, Jan 2025",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"TRACER study validated longitudinal MRD surveillance in early-stage breast cancer with lead time ~13.7 months vs imaging.",totalParticipants:100,numPublications:8,numPublicationsPlus:!0},{id:"mrd-5",sampleCategory:"Blood/Plasma",name:"RaDaR ST",vendor:"NeoGenomics",approach:"Tumor-informed",method:"Tumor-informed MRD assay on the InVision/ RaDaR platform: tumor and matched-normal sequencing identify up to 48 variants, which are tracked by deep NGS with error suppression.",cancerTypes:["Breast","Head & Neck","Multi-solid"],indicationsNotes:"NeoGenomics RaDaR ST tumor-informed MRD assay with Medicare coverage for HR+/HER2- breast cancer (including late recurrence >5 years) and HPV-negative head and neck cancer; supportive data across multiple solid tumors.",sensitivity:95.7,sensitivityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC10870111/",sensitivityNotes:"RaDaR ST demonstrated 97% concordance and maintained equivalent sensitivity with RaDaR 1.0. In breast, 95.7% sensitivity and 91.0% specificity.",specificity:91,specificityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC10870111/",specificityNotes:"RaDaR ST demonstrated 97% concordance with RaDaR 1.0. In breast cancer validation, specificity was 91.0%.",lod:"~10 ppm",lodCitations:"https://ir.neogenomics.com/news-events/press-releases/detail/310/neogenomics-to-present-radar-st-bridging-study-at-islb-2025-demonstrating-reliable-mrd-detection-across-solid-tumors",lodNotes:"Analytical validation for the RaDaR assay supports reliable detection around 10 ppm with 7090% sensitivity at that level in contrived samples.",requiresTumorTissue:"Yes",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Buffy coat matched normal used for germline filtering in studies.",variantsTracked:"48",variantsTrackedNotes:"Tracks up to 48 patient-specific variants.",initialTat:35,initialTatNotes:"NeoGenomics materials typically describe baseline discovery and panel build in ~5 weeks.",followUpTat:7,followUpTatNotes:"Serial MRD monitoring blood draws generally reported within ~7 days after receipt.",tat:35,tatNotes:"Approximate TAT ~5 weeks baseline, ~1 week longitudinally.",fdaStatus:"CLIA LDT",reimbursement:"Medicare coverage for selected indications; MolDX framework applied.",reimbursementNote:"LCDs describe coverage in specific solid tumors (e.g., breast and HPV-negative head & neck cancer) with broader multi-tumor positioning in trials.",commercialPayers:["Blue Shield of California"],commercialPayersCitations:"https://www.decibio.com/",commercialPayersNotes:"Blue Shield of California covers RaDaR for MRD testing. Coverage continues to expand as clinical evidence builds.",cptCodes:"PLA under consideration.",cptCodesNotes:"Contact vendor for current billing guidance.",clinicalAvailability:"Clinical LDT  shipping",clinicalTrials:"ISLB 2025 bridging study, 'Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types'; 166 patients across 15 solid tumor types; 97% concordance with RaDaR 1.0",clinicalSettings:["Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Validated for post-surgical MRD, post-adjuvant, and surveillance monitoring. Medicare coverage for HR+/HER2- breast cancer (including late recurrence >5 years) and HPV-negative head and neck cancer.",totalParticipants:166,numPublications:10,numPublicationsPlus:!0},{id:"mrd-6",sampleCategory:"Blood/Plasma",name:"Reveal MRD",vendor:"Guardant Health",approach:"Tumor-nave",method:"Tumor-nave, blood-only ctDNA MRD test using epigenetic tumor fraction (epiTF) detection on Guardant Infinity platform. Analyzes over 19,000 differentially methylated loci for mutation-agnostic ctDNA detection. Detects residual disease and recurrence without requiring tumor tissue.",cancerTypes:["Colorectal","Breast","Non-small cell lung cancer (NSCLC)"],indicationsNotes:"Guardant Reveal MRD tumor-nave ctDNA test for early-stage cancer MRD detection and recurrence monitoring after curative-intent treatment. Medicare coverage for CRC; breast and NSCLC coverage expanding.",sensitivity:81,sensitivityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC11443202/",sensitivityNotes:"COSMOS 2024 longitudinal sensitivity for stage II+ CRC is ~81%. Earlier landmark/Reinert 2021 data showed 55-63% sensitivity. Headline value reflects current COSMOS longitudinal performance.",sensitivityStagesReported:"Stage IIIV combined",stageIISensitivity:null,stageIISensitivityNotes:"Stage II-specific sensitivity not separately reported; combined with stages IIIIV in headline figures. Stage-specific data would help clinicians counsel Stage II patients.",stageIIISensitivity:null,stageIIISensitivityNotes:"Stage III-specific sensitivity not separately reported.",stageDataExpected:!0,specificity:98,specificityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC11443202/",specificityNotes:"COSMOS 2024 longitudinal specificity is 98% for CRC. Earlier landmark data showed 100% specificity but with serial/longitudinal testing, 91-98% is more representative.",landmarkSensitivity:63,landmarkSensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/33926918/",landmarkSensitivityNotes:"CRC landmark sensitivity (stage IIIII).",landmarkSpecificity:98,landmarkSpecificityCitations:"https://pubmed.ncbi.nlm.nih.gov/33926918/",landmarkSpecificityNotes:"CRC landmark specificity (stage IIIII); updated from 100% to align with longitudinal data.",longitudinalSensitivity:81,longitudinalSensitivityCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",longitudinalSpecificity:98,longitudinalSpecificityCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",lodNotes:"Guardant has not published a single universal LoD value for Reveal; internal data suggest detection of very low VAF ctDNA (well below 0.1%), but performance is study- and context-dependent, so no single number is encoded here.",leadTimeVsImaging:159,leadTimeVsImagingCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",leadTimeVsImagingNotes:"CRC median 4.77 months from MRD+ to recurrence.",requiresTumorTissue:null,requiresTumorTissueNotes:"Plasma-only (tissue-free) MRD assay; tumor tissue is not required for panel design.",requiresMatchedNormal:null,requiresMatchedNormalNotes:"Does not require a matched-normal blood sample.",initialTat:7,initialTatCitations:"https://www.guardanthealth.com/solutions/guardant-reveal/",initialTatNotes:"Vendor-reported 7-day median TAT.",followUpTat:7,followUpTatCitations:"https://www.guardanthealth.com/solutions/guardant-reveal/",followUpTatNotes:"Vendor-reported 7-day median TAT.",bloodVolume:20,bloodVolumeCitations:"https://www.guardanthealth.com/solutions/guardant-reveal/",bloodVolumeNotes:"Commonly collected as two 10 mL Streck cfDNA tubes (20 mL).",tat:7,tatCitations:"https://www.guardanthealth.com/solutions/guardant-reveal/",tatNotes:"Guardant reports a typical ~7-day turnaround from sample receipt for Reveal.",fdaStatus:"CLIA LDT; not FDA cleared/approved as of 2025.",reimbursement:"Medicare (CRC only)",reimbursementNote:"Medicare MolDX coverage for colorectal cancer MRD only - post-surgical and surveillance settings after curative-intent treatment. Not covered for other cancer types. Commercial coverage expanding via select BCBS plans.",commercialPayers:["BCBS Louisiana","Geisinger Health Plan"],commercialPayersCitations:"https://www.businesswire.com/news/home/20230720806084/en/Guardant-Health-receives-first-commercial-payor-coverage-for-Guardant-Reveal%E2%84%A2-test-from-Blue-Cross-and-Blue-Shield-of-Louisiana/",commercialPayersNotes:"Blue Cross Blue Shield of Louisiana became first commercial payer to cover Guardant Reveal in July 2023. Geisinger Health Plan added coverage later in 2023. Additional BCBS plans (including BCBS Massachusetts) appear to have medical policies; verify with specific plan.",cptCodes:"0569U (Guardant Reveal PLA code from mid-2025).",cptCodesNotes:"Guardant Reveal PLA (2025).",availableRegions:["US"],clinicalAvailability:"Clinical LDT  shipping",exampleTestReport:"https://learn.colontown.org/wp-content/uploads/2022/01/Reveal-Sample-Report_postsurgery-positive-2-v2.pdf",clinicalTrials:"NCCTG N0147 adjuvant FOLFOX trial (>2000; Guardant Reveal ctDNA analysis)",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"Validated for post-surgical landmark assessment (63% sensitivity) and longitudinal surveillance (81% sensitivity) in CRC. Medicare coverage for both post-surgical and surveillance settings.",totalParticipants:2e3,numPublications:10,numPublicationsPlus:!0},{id:"mrd-7",sampleCategory:"Blood/Plasma",name:"Signatera",vendor:"Natera",approach:"Tumor-informed",method:"Tumor-informed, multiplex PCRNGS ctDNA assay: tumor and matched-normal WES identify personal SNVs, and a 16-variant (or higher in newer versions) customized panel is tracked in serial plasma at high depth.",cancerTypes:["Colorectal","Breast","Bladder","NSCLC","Ovarian/Fallopian/Primary peritoneal","Pan-solid ICI"],indicationsNotes:"Natera Signatera tumor-informed MRD assay with Medicare coverage for multiple solid-tumor indications: CRC (stage IIIV & oligometastatic, adjuvant & recurrence), breast cancer (neoadjuvant and stage IIb+ adjuvant & recurrence), bladder cancer (MIBC), NSCLC (stage IIII surveillance), and ovarian/fallopian/primary peritoneal cancer (adjuvant & recurrence), plus pan-solid tumor immune-checkpoint inhibitor (ICI) response monitoring.",sensitivity:94,sensitivityCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",sensitivityNotes:"Recurrence Surveillance: CRC: 88-93% sens., 98% spec. Breast: 88-89% sens., 95-99% spec. Lung: 80-99% sens., 96-99% spec. Bladder: 99% sens., 98% spec. Ovarian: 99% sens.",sensitivityStagesReported:"Stage IIIV combined (varies by cancer type)",stageIISensitivity:null,stageIISensitivityNotes:"CRC Stage II landmark ~65-73% in CIRCULATE-Japan; longitudinal higher. Stage II not separately reported for other cancer types. Stage-specific breakdowns would help inform treatment decisions.",stageIIISensitivity:null,stageIIISensitivityNotes:"Stage III typically shows higher sensitivity than Stage II due to higher tumor burden; specific values combined with other stages in most publications.",stageDataExpected:!0,specificity:98,specificityCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",specificityNotes:"Specificity ranges by cancer type: CRC 98%, Breast 95-99%, Lung 96-99%, Bladder 98%. Headline value of 98% reflects typical performance across indications.",ppv:98,ppvCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",ppvNotes:"Overall PPV >98% (vendor, multi-tumor).",npv:96,npvCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",npvNotes:"NSCLC distant/extracranial single timepoint NPV.",landmarkSensitivity:75,landmarkSensitivityCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",landmarkSensitivityNotes:"NSCLC distant/extracranial single timepoint sensitivity.",longitudinalSensitivity:94,longitudinalSensitivityCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",longitudinalSensitivityNotes:"NSCLC distant/extracranial longitudinal sensitivity.",longitudinalSpecificity:98,longitudinalSpecificityCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",longitudinalSpecificityNotes:"Longitudinal specificity across cancer types ranges 96-99%; 98% represents typical performance.",lod:"~0.01% VAF",lodCitations:"https://www.natera.com/oncology/signatera-mrd-test/",lodNotes:"Natera reports analytical sensitivity to ~0.01% tumor fraction with high specificity using integrated digital error suppression.",leadTimeVsImaging:300,leadTimeVsImagingCitations:"https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",leadTimeVsImagingNotes:"Ovarian ~10 months; NSCLC >7 months earlier than imaging.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Tumor-informed; needs primary tumor tissue.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Matched normal blood required.",variantsTracked:"16",variantsTrackedNotes:"Original commercial design tracks 16 somatic variants per patient; some research/Genome configurations track more (e.g., 64) but 16 remains the standard clinical panel.",variantsTrackedCitations:"https://www.natera.com/oncology/signatera-mrd-test/",initialTat:28,initialTatNotes:"Baseline tumor/normal sequencing and panel design typically require ~34 weeks.",initialTatCitations:"https://www.natera.com/oncology/signatera-mrd-test/",followUpTat:9,followUpTatNotes:"Longitudinal MRD blood draws generally reported within ~710 days.",followUpTatCitations:"https://www.natera.com/oncology/signatera-mrd-test/",bloodVolume:20,bloodVolumeNotes:"Commonly two Streck cfDNA tubes (~10 mL each) for monitoring; tissue + matched normal required at baseline",bloodVolumeCitations:"https://www.natera.com/oncology/signatera-mrd-test/",tat:28,tatNotes:"Overall paradigm: ~4 weeks for initial build, ~11.5 weeks for follow-up tests.",fdaStatus:"CLIA LDT; not FDA-cleared/approved as of late 2025 (clinical validation via numerous peer-reviewed studies).",reimbursement:"Medicare (CRC, Breast, Bladder, NSCLC, Ovarian, ICI)",reimbursementNote:"Medicare MolDX coverage for: CRC (stage II-IV, oligometastatic), breast cancer (neoadjuvant, stage IIb+ adjuvant/recurrence), bladder (MIBC), NSCLC (stage I-III surveillance), ovarian/fallopian/peritoneal, and pan-solid ICI response monitoring. ADLT pricing. Coverage varies by indication - verify specific cancer type with payer.",commercialPayers:["UnitedHealthcare","Cigna","Anthem BCBS","BCBS Louisiana","Blue Shield of California"],commercialPayersCitations:"https://www.natera.com/oncology/billing/",commercialPayersNotes:"Natera is in-network with most major health plans including Cigna, UnitedHealthcare, and Blue Shield of California. BCBS Louisiana provides explicit coverage. Note: Aetna lists Signatera codes as in-network but current policies show non-covered; verify with plan.",cptCodes:"0340U (ADLT)",cptCodesNotes:"Signatera PLA (ADLT pricing).",codeType:"PLA",medicareRate:3500,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,availableRegions:["US","EU","UK","International"],clinicalAvailability:"Clinical LDT  shipping",independentValidation:"Yes",independentValidationNotes:"Multiple peer-reviewed and prospective studies across tumors.",exampleTestReport:"https://www.natera.com/resource-library/signatera/signatera-patient-test-sample-report/",clinicalTrials:"BESPOKE CRC (NCT04264702); multicentre prospective observational study of ~2,000 stage IIV colorectal cancer patients at up to 200 U.S. sites (MRD and surveillance cohorts)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT04264702",clinicalSettings:["Neoadjuvant","Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Most broadly validated across clinical settings. Neoadjuvant: breast cancer (I-SPY2 trial, Medicare covered). Post-surgery: landmark ~4 weeks (75% NSCLC sens). Post-adjuvant: after chemo completion. Surveillance: longitudinal monitoring (94% NSCLC sens). Medicare covers all settings for CRC, breast, bladder, NSCLC, ovarian.",totalParticipants:2e3,numPublications:100,numPublicationsPlus:!0},{id:"mrd-8",sampleCategory:"Blood/Plasma",name:"Tempus xM MRD",vendor:"Tempus",approach:"Tumor-nave",method:"Tumor-nave MRD assay that combines variant-based ctDNA detection with methylation/fragmentomics signals in a dual-workflow, blood-only design; current clinical positioning focuses on colorectal cancer.",cancerTypes:["Colorectal"],indicationsNotes:"Tempus xM tumor-nave MRD assay currently marketed for colorectal cancer, with coverage and data focused on CRC; separate Tempus xM (NeXT Personal Dx) tumor-informed offering for solid tumors, including breast.",landmarkSensitivity:61.1,landmarkSensitivityNotes:"CRC landmark sensitivity from GALAXY (CIRCULATE-Japan) subset analysis of 80 resected stage II-III colorectal cancer patients.",landmarkSensitivityCitations:"Tempus BusinessWire press release May 2024; GALAXY/CIRCULATE-Japan CRC cohort data.",landmarkSpecificity:94,landmarkSpecificityNotes:"CRC landmark specificity from GALAXY (CIRCULATE-Japan) subset analysis.",landmarkSpecificityCitations:"Tempus BusinessWire press release May 2024; GALAXY/CIRCULATE-Japan CRC cohort data.",longitudinalSensitivity:83.3,longitudinalSensitivityCitations:"https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",longitudinalSpecificity:89.5,longitudinalSpecificityCitations:"https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",lodNotes:"Tempus has published performance at very low ctDNA levels in colorectal cancer trials (e.g., CIRCULATE-Japan) but does not advertise a single, assay-wide LoD figure; numeric field left blank.",requiresTumorTissue:null,requiresMatchedNormal:null,initialTatNotes:"Tempus positions xM as having a relatively rapid turnaround because tumor tissue is not required; detailed baseline TAT figures are not consistently disclosed, so no single value is encoded.",followUpTatNotes:"Public materials emphasize rapid repeat testing from blood-only workflows; specific day counts vary by context and are not standardized in a single published metric.",bloodVolume:17,bloodVolumeCitations:"https://www.tempus.com/wp-content/uploads/2024/01/Tempus-LS_xM-RUO-Overview.pdf",bloodVolumeNotes:"RUO specimen overview describes two 8.5 mL Streck cfDNA tubes (~17 mL total) per timepoint.",tatNotes:"Overall TAT is marketed as faster than tumor-informed assays due to avoiding tissue sequencing, but a precise canonical value is not available.",fdaStatus:"CLIA LDT (for clinical xM portfolio) with RUO offering for biopharma; not FDA cleared/approved as of 2025.",reimbursement:"Coverage emerging; verify payer-specific policies.",reimbursementNote:"xM MRD is newer than some competitors; commercial and Medicare coverage are evolving and may currently be more limited than for Signatera or Guardant Reveal.",cptCodes:"Contact vendor for current billing guidance.",clinicalAvailability:"Clinical LDT  shipping for colorectal cancer; RUO version also available via Tempus Life Sciences.",clinicalTrials:"GALAXY (CIRCULATE-Japan) subset analysis; 80 resected stage IIIII colorectal cancer patients randomly selected and enriched for recurrence; Tempus xM tumor-nave MRD assay with methylation + variant classifiers",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"Validated for post-surgical landmark (61% sens, 94% spec) and longitudinal surveillance (83% sens, 90% spec) in CRC via GALAXY/CIRCULATE-Japan.",totalParticipants:80,numPublications:3,numPublicationsPlus:!0},{id:"mrd-9",sampleCategory:"Blood/Plasma",name:"Labcorp Plasma Detect",vendor:"Labcorp",approach:"Tumor-informed",method:"Tumor-informed whole-genome sequencing (WGS) ctDNA MRD assay: WGS of tumor tissue, buffy coat (germline) and plasma at a landmark time point is used with a proprietary machine-learning pipeline to identify thousands of high-confidence, patient-specific somatic variants (median ~5000 SNVs), which are then tracked longitudinally in cell-free DNA without bespoke panel design.",cancerTypes:["Colon cancer (Stage III)","Lung cancer (in validation)","Bladder cancer (in validation)","Multi-solid (expanding)"],indicationsNotes:"Labcorp Plasma Detect WGS-based MRD assay. Clinically validated for post-surgery and post-adjuvant MRD assessment in stage III colon cancer (PROVENC3); clinical use launched April 2025 via Early Experience Program. Expanding to additional solid tumors including lung and bladder cancer.",specificity:99.4,specificityCitations:"https://oncology.labcorp.com/biopharma-partners/plasma-detect",specificityNotes:"Analytical specificity ~99.4% for ctDNA-negative reference specimens in internal validation; clinical specificity for recurrence is still being characterized (PROVENC3 and related studies).",lod:"10 ppm",lod95:"10 ppm (0.001%)",lodCitations:"https://oncology.labcorp.com/biopharma-partners/plasma-detect; Labcorp Plasma Detect product page.",lodNotes:"LOD95 of 0.001% (10 ppm). WGS approach tracks thousands of tumor-specific variants (vs 18-50 for WES-based approaches), enabling improved sensitivity at low ctDNA levels.",leadTimeVsImaging:null,leadTimeVsImagingCitations:"Labcorp press releases Nov 2025.",leadTimeVsImagingNotes:"Detects disease progression up to 18 months earlier than standard clinical measures (median 2.3 months lead time in chemotherapy monitoring study).",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires FFPE tumor tissue at the landmark time point for WGS to define the tumor-informed MRD signature plus buffy coat for germline/CHIP filtering.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Uses buffy coat (PBMC) germline DNA to filter germline and nontumor-specific variants; germline input is required for assay design.",variantsTracked:"5000",variantsTrackedCitations:"https://oncology.labcorp.com/biopharma-partners/plasma-detect",variantsTrackedNotes:"Median of ~5000 high-confidence tumor-specific single nucleotide variants (SNVs) per patient in the MRD signature, tracked longitudinally. No bespoke panel manufacturing required.",initialTat:14,initialTatCitations:"https://oncology.labcorp.com/biopharma-partners/plasma-detect",initialTatNotes:"Landmark ctDNA MRD result available in as few as 14 days from sample receipt. Standardized WGS workflow eliminates custom reagent delays.",followUpTat:7,followUpTatCitations:"https://oncology.labcorp.com/biopharma-partners/plasma-detect",followUpTatNotes:"Longitudinal surveillance time points reported in as few as 7 days from sample receipt.",bloodVolume:20,bloodVolumeCitations:"https://oncology.labcorp.com/biopharma-partners/plasma-detect",bloodVolumeNotes:"Two 10 mL Streck blood collection tubes (BCT) for plasma and buffy coat at the landmark time point; plasma-only draws (Streck tubes) for longitudinal monitoring.",tat:14,tatNotes:"Landmark (initial) MRD result in as few as 14 days and longitudinal MRD results in as few as 7 days from sample receipt (Plasma Detect assay specifications).",fdaStatus:"CLIA LDT",fdaStatusCitations:"Labcorp press release April 2025.",reimbursement:"Coverage emerging",reimbursementNote:"Clinical use launched April 2025 for stage III colon cancer via Early Experience Program. Reimbursement pathways in development. No public Medicare LCD or dedicated PLA code as of 2025.",cptCodesNotes:"No public PLA/CPT code specific to Labcorp Plasma Detect as of 2025; contact Labcorp for current billing guidance.",clinicalAvailability:"Clinical LDT  Early Experience Program (stage III colon cancer); Research Use for other indications",independentValidation:"Yes",independentValidationNotes:"Clinically validated in the PROVENC3 stage III colon cancer cohort (AACR 2024) and related ASCO/ESMO presentations assessing post-surgery and post-adjuvant ctDNA status and recurrence risk.",clinicalTrials:"PROVENC3 (colon cancer validation with NKI); MEDOCC-CrEATE (stage II colon ACT); 10+ additional clinical studies in US and internationally",clinicalTrialsCitations:"Labcorp press releases; Nature Medicine 2025; Clinical Cancer Research 2025.",clinicalSettings:["Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Validated in PROVENC3 for post-surgical and post-adjuvant ctDNA assessment in stage III colon cancer. Longitudinal surveillance also validated.",totalParticipants:236,totalParticipantsNotes:"236 patients in PROVENC3; currently evaluated in 10+ clinical studies across multiple cancer types.",numPublications:2,numPublicationsCitations:"Nature Medicine 2025 (mesothelioma); Clinical Cancer Research 2025 (head and neck).",isClinicalLDT:!0,regulatoryStatusNotes:"Developed under PGDx quality management system and design control. Clinical use for stage III colon cancer; research use for other solid tumors. Expanding indications expected."},{id:"mrd-10",sampleCategory:"Blood/Plasma",name:"FoundationOne Tracker (MRD)",vendor:"Foundation Medicine / Natera",approach:"Tumor-informed",method:"Personalized ctDNA assay derived from FoundationOne CDx tumor sequencing; uses 2-16 patient-specific somatic variants to detect and quantify mean tumor molecules per mL (MTM/mL) in serial plasma samples via multiplex PCR workflow.",cancerTypes:["Multi-solid tumors"],indicationsNotes:"Tissue-informed ctDNA MRD assay for early- and late-stage solid tumors. Uses archival or new tumor tissue profiled by FoundationOne CDx to build a patient-specific panel, then quantifies MTM/mL in serial plasma samples for MRD detection and surveillance after curative-intent therapy. Note: The TRM application has separate clinical availability with Medicare coverage; the MRD application remains investigational.",sensitivity:null,sensitivityCitations:"Zollinger DR et al. PLoS One 2024;19:e0302129; IMpower131 trial data (Kasi PM et al. Clin Cancer Res 2023).",sensitivityNotes:"Analytical validation reports >97.3% sensitivity at 5 MTM/mL when at least two tumor variants are monitored; clinical MRD sensitivity is indication- and timepoint-specific.",specificity:null,specificityCitations:"Zollinger DR et al. PLoS One 2024;19:e0302129.",specificityNotes:"Sample-level analytical specificity was 99.6% in contrived and clinical samples; not encoded as a single global clinical specificity across all indications.",lod:null,lodCitations:"Zollinger DR et al. PLoS One 2024;19:e0302129.",lodNotes:"Performance is reported in units of MTM/mL rather than a single tumor-fraction percentage; analytical sensitivity 5 MTM/mL with 2 variants monitored.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires prior or concurrent tumor CGP by FoundationOne CDx to identify 2-16 patient-specific somatic variants for personalized panel design.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Germline and CHIP filtering performed computationally without mandatory matched-normal sequencing.",initialTat:null,initialTatNotes:"Analytical-workflow TAT is roughly 7-10 days from sample receipt and variant design to result; initial result requires completed FoundationOne CDx.",followUpTat:null,followUpTatNotes:"Serial MRD timepoints reuse the established patient-specific panel with similar turnaround.",bloodVolume:null,bloodVolumeNotes:"Foundation does not publish a fixed blood volume; typical mPCR ctDNA workflows use two Streck tubes (~20 mL whole blood).",fdaStatus:"FDA Breakthrough Device designation (Feb 2022) for MRD detection in early-stage solid tumors; investigational/early access assay  NOT yet FDA cleared.",fdaStatusCitations:"Foundation Medicine press release, February 3, 2022.",reimbursement:"Not applicable",reimbursementNote:"MRD applications are investigational; not routinely billed to payers. Note: TRM use has separate Medicare coverage (see TRM category).",cptCodesNotes:"None for MRD investigational use.",availableRegions:["US","EU","International"],availableRegionsNotes:"Investigational use available via Foundation Medicine and Roche global network for biopharma collaborations.",clinicalAvailability:"Investigational / early access program via Foundation Medicine for MRD applications; biopharma and academic collaborations globally.",clinicalTrials:"Used in translational and interventional cohorts for MRD (e.g., early bladder cancer post-cystectomy, stage II/III CRC) correlating ctDNA dynamics with outcomes.",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"Investigational MRD application validated in post-surgical and surveillance settings across multiple solid tumors. FDA Breakthrough Device designation for MRD detection.",totalParticipants:null,numPublications:3,numPublicationsPlus:!0,isRUO:!1,isInvestigational:!0,isClinicalLDT:!0,regulatoryStatusNotes:"Holds FDA Breakthrough Device designation for MRD but is not yet FDA cleared. The underlying assay platform is a clinical LDT (same technology as FoundationOne Tracker TRM which has Medicare coverage), but MRD-specific applications remain investigational."},{id:"mrd-11",sampleCategory:"Blood/Plasma",name:"Foundation TI-WGS MRD (RUO)",vendor:"Foundation Medicine",approach:"Tumor-informed",method:"Tissue-informed whole-genome sequencing MRD assay; WGS of tumor tissue and longitudinal plasma combined with a proprietary bioinformatics algorithm to detect and quantify ctDNA tumor fraction by monitoring hundreds to thousands of tumor-specific variants.",cancerTypes:["Multi-solid tumors"],indicationsNotes:"Sensitive MRD assay offered for research use in early- and late-stage solid tumors. Available through Foundation's FlexOMx Lab for drug-development studies requiring deep ctDNA detection (e.g., early-stage or low-shedding cancers).",sensitivity:null,sensitivityCitations:"Foundation Medicine press release, September 23, 2025; https://www.foundationmedicine.com/monitoring-portfolio",sensitivityNotes:"Feasibility data indicate high sensitivity at low tumor fractions; cross-indication sensitivity values are study-specific.",specificity:null,specificityCitations:"Foundation Medicine Monitoring Portfolio technical specifications.",specificityNotes:"Described as demonstrating high specificity in feasibility data; values are study- and tumor-specific.",lod:"10 ppm (0.001%)",lodCitations:"https://www.foundationmedicine.com/monitoring-portfolio",lodNotes:"Reported to detect ctDNA tumor fraction down to 10 ppm in both early- and late-stage cancer.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires WGS of tumor tissue to build the patient-specific genomic signature; typically uses the same FFPE block as FoundationOne CDx.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Product highlights emphasize that matched-normal samples are NOT required for CHIP/germline filtering.",initialTat:null,initialTatNotes:"TAT depends on WGS depth and study design; not publicly specified for this RUO assay.",followUpTat:null,followUpTatNotes:"Follow-up draws reuse the existing tumor-informed signature; timelines negotiated at study level.",bloodVolume:null,bloodVolumeNotes:"Standard ctDNA plasma volumes; explicit whole-blood volume not specified publicly.",fdaStatus:"Research Use Only (RUO)  CLIA-certified, CAP-accredited FlexOMx Lab; NOT FDA cleared.",fdaStatusCitations:"Foundation Medicine press release, September 23, 2025.",reimbursement:"Not applicable",reimbursementNote:"RUO only; costs are sponsor-funded in research/clinical-development collaborations.",cptCodesNotes:"None (RUO research assay).",availableRegions:["US","EU","International"],availableRegionsNotes:"RUO available globally via Foundation's FlexOMx Lab for biopharma and academic partnerships.",clinicalAvailability:"Available globally to biopharma and academic partners as a central-lab RUO MRD solution via Foundation's FlexOMx Lab. Launched September 2025.",clinicalTrials:"Positioned for MRD assessment and ctDNA kinetics in oncology drug-development studies, particularly early-stage or low-shed settings.",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"RUO platform for research use in post-surgical MRD assessment and longitudinal surveillance, particularly in early-stage or low-shedding tumors.",totalParticipants:null,numPublications:0,numPublicationsPlus:!1,isRUO:!0,isInvestigational:!1,isClinicalLDT:!1,regulatoryStatusNotes:"Research Use Only assay launched September 2025 through FlexOMx Lab; offered for retrospective clinical trials and research studies, not for diagnostic use."},{id:"mrd-12",sampleCategory:"Blood/Plasma",name:"Veracyte MRD (C2i Genomics platform)",vendor:"Veracyte (C2i Genomics)",approach:"Tumor-informed",method:"Whole-genome sequencing (WGS) of tumor tissue and germline DNA combined with AI-driven pattern recognition to create patient-specific ctDNA signatures; subsequent blood samples are analyzed via WGS and AI to detect residual cancer.",cancerTypes:["Muscle-invasive bladder cancer (first indication)","Multi-solid (planned expansion)"],indicationsNotes:"WGS-based MRD testing platform acquired by Veracyte from C2i Genomics in February 2024. First clinical test planned for muscle-invasive bladder cancer (MIBC) with launch expected H1 2026.",sensitivity:91,sensitivityCitations:"European Urology publication (Nordentoft I et al.); EAU25 presentation (Abstract A0162); GenomeWeb May 2025.",sensitivityNotes:"Prior publication showed 91% sensitivity at 92% specificity in urothelial carcinoma. TOMBOLA trial data presented at EAU25 demonstrated higher accuracy than ddPCR.",specificity:88,specificityCitations:"EAU25 presentation, TOMBOLA trial (Abstract A0162).",specificityNotes:"TOMBOLA trial showed 88% specificity at 6-month milestone vs 62% for ddPCR; detected recurrence 93 days earlier than imaging.",lod:null,lodCitations:"Veracyte investor communications.",lodNotes:"WGS-based approach; specific LoD threshold not publicly disclosed.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires WGS of tumor tissue and germline DNA to establish patient-specific signature.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"WGS of germline (non-tumor) DNA is part of the workflow to distinguish somatic from germline variants.",initialTat:14,initialTatNotes:"Sample to result in approximately 2 weeks per acquisition announcement.",followUpTat:14,followUpTatNotes:"Follow-up samples analyzed via WGS with similar turnaround.",bloodVolume:4,bloodVolumeCitations:"GEN Edge January 2024; C2i acquisition announcement.",bloodVolumeNotes:"Requires less than one tube of blood (as little as 3-4 mL blood or 1-2 mL plasma).",fdaStatus:"Pre-commercial research platform; NOT FDA cleared. First clinical test (MIBC) expected H1 2026.",fdaStatusCitations:"Veracyte Q1 2025 earnings; GenomeWeb May 2025; EAU25 presentation.",reimbursement:"Not applicable",reimbursementNote:"Pre-commercial; Veracyte plans to leverage established urology channel for MIBC indication.",cptCodesNotes:"None (pre-commercial).",clinicalAvailability:"Pre-commercial research platform. Clinical launch planned H1 2026 for muscle-invasive bladder cancer.",clinicalTrials:"TOMBOLA trial (NCT04138628)  multicenter interventional in MIBC (100 patients); UMBRELLA trial (enrolled Q1 2025) for pancreatic cancer, sarcoma, CRC, NSCLC.",clinicalTrialsCitations:"Veracyte Q1 2025 earnings; EAU25 presentation.",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"TOMBOLA trial validates post-surgical and surveillance MRD in muscle-invasive bladder cancer. Detected recurrence 93 days earlier than imaging.",totalParticipants:100,numPublications:2,numPublicationsPlus:!0,isRUO:!0,isInvestigational:!0,isClinicalLDT:!1,regulatoryStatusNotes:"Pre-commercial investigational WGS-based MRD platform acquired by Veracyte (Feb 2024, $70M + $25M milestones). TOMBOLA trial supports validation. First clinical test for MIBC expected H1 2026."},{id:"mrd-13",sampleCategory:"Blood/Plasma",name:"Guardant LUNAR (RUO platform)",vendor:"Guardant Health",approach:"Tumor-nave",method:"Plasma-only ctDNA assay integrating genomic alterations (SNVs, indels) with epigenomic cancer signatures (aberrant DNA methylation) to detect MRD without requiring tumor tissue sequencing. Originally called LUNAR-1.",cancerTypes:["Colorectal cancer (primary validation)","Multi-solid (research)"],indicationsNotes:"Research platform that evolved into the clinical Guardant Reveal LDT. Designed to detect MRD without prior knowledge of patient's tumor mutations by combining genomic and methylation signatures.",sensitivity:56,sensitivityCitations:"Parikh AR et al. Clin Cancer Res 2021;27:5586-5594.",sensitivityNotes:"In CRC cohort (n=84 evaluable): landmark sensitivity 56% (1 month post-therapy), longitudinal sensitivity 69%. Integrating epigenomic analysis enhanced sensitivity by 25-36%.",specificity:100,specificityCitations:"Parikh AR et al. Clin Cancer Res 2021;27:5586-5594.",specificityNotes:"Landmark specificity ~100% with 100% PPV (all 15 patients with detectable ctDNA recurred); longitudinal specificity ~91%.",lod:null,lodCitations:"Parikh AR et al. Clin Cancer Res 2021.",lodNotes:"Performance expressed via recurrence sensitivity/specificity; detects genomic alterations down to 0.01% allele frequency.",requiresTumorTissue:"No",requiresTumorTissueNotes:"Explicitly designed as plasma-only assay, not requiring sequencing of tumor tissue  a key differentiator from tissue-informed approaches.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Plasma-only assay uses integrated genomic and epigenomic signatures without matched-normal sequencing; filters CHIP variants computationally.",initialTat:null,initialTatNotes:"Research platform TAT was study-specific; clinical derivative (Guardant Reveal) reports ~10-14 day TAT.",followUpTat:null,followUpTatNotes:"Follow-up draws processed via same plasma-only workflow.",bloodVolume:4,bloodVolumeCitations:"Parikh AR et al. Clin Cancer Res 2021.",bloodVolumeNotes:"CRC MRD study used median 4 mL plasma (range 1-4 mL).",fdaStatus:"Research-use-only MRD platform; clinical implementation transitioned to Guardant Reveal LDT.",fdaStatusCitations:"Parikh AR et al. Clin Cancer Res 2021; Guardant Health website.",reimbursement:"Not applicable",reimbursementNote:"RUO platform; costs study-funded. Clinical product Guardant Reveal has separate reimbursement pathway.",cptCodesNotes:"None (research platform; Guardant Reveal is the clinical LDT).",clinicalAvailability:"Available to academic and biopharma partners as research platform. Guardant Reveal is the clinical LDT derived from this technology.",clinicalTrials:"CRC MRD study at Massachusetts General (Parikh et al. 2021, n=103); COSMOS study; PEGASUS trial; COBRA trial.",clinicalTrialsCitations:"Parikh AR et al. Clin Cancer Res 2021;27:5586-5594.",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"RUO platform validated for post-therapy landmark (56% sens at 1 month) and longitudinal surveillance (69% sens) in CRC.",totalParticipants:103,numPublications:5,numPublicationsPlus:!0,isRUO:!0,isInvestigational:!1,isClinicalLDT:!1,regulatoryStatusNotes:"Research/development platform (originally LUNAR-1); the patient-facing MRD offering is Guardant Reveal (tracked separately as CLIA LDT). Demonstrated feasibility of tumor-uninformed plasma-only MRD detection."},{id:"mrd-14",sampleCategory:"Blood/Plasma",name:"NavDx",vendor:"Naveris",approach:"Tumor-nave",method:"Proprietary quantitative digital droplet PCR assay detecting tumor tissue modified viral (TTMV)-HPV DNA fragments in plasma; detects HPV genotypes 16, 18, 31, 33, and 35; reports TTMV Score (normalized TTMV-HPV DNA fragments/mL plasma).",cancerTypes:["HPV+ oropharyngeal (head & neck) cancer","Anal squamous cell carcinoma (ASCC)","HPV-driven gynecologic cancers (via NavDx+Gyn)"],indicationsNotes:"First and only clinically validated circulating TTMV-HPV DNA blood test. Detects MRD and recurrence in HPV-driven cancers before clinical or radiographic evidence. Used across the care continuum: pre-treatment baseline, treatment response assessment, post-treatment MRD surveillance, and recurrence detection.",leadTimeVsImaging:120,leadTimeVsImagingCitations:"Chera BS et al. J Clin Oncol 2020;38:1050-1058; NavDx surveillance data.",leadTimeVsImagingNotes:"Median ~4 months (~120 days) lead time vs imaging for recurrence detection in HPV-driven oropharyngeal cancer surveillance cohorts.",sensitivity:90.4,sensitivityCitations:"Ferrandino RN et al. JAMA Otolaryngol Head Neck Surg 2023; Hanna GJ et al. Clin Cancer Res 2023; Diagnostics 2023;13:725.",sensitivityNotes:"Clinical sensitivity 90.4% for recurrent HPV-associated OPSCC; 91.5% for pre-treatment diagnosis; 79.2-89% for surveillance depending on timepoint. For ASCC, multi-center study showed high accuracy.",specificity:98.6,specificityCitations:"Ferrandino RN et al. JAMA Otolaryngol Head Neck Surg 2023; Hanna GJ et al. Clin Cancer Res 2023.",specificityNotes:"Clinical specificity 98.6% for OPSCC; 97-100% in surveillance cohorts. Reliably distinguishes TTMV-HPV DNA from non-cancerous HPV DNA sources.",ppv:98,ppvNotes:"Per-test PPV of 98% for ASCC; 97.9% for OPSCC. 95% PPV for cancer recurrence when patients had at least one positive test result.",npv:95,npvNotes:"Per-test NPV of 95% for ASCC; 95.7-98% for OPSCC surveillance. 98% of patients whose TTMV Score remained negative had no recurrence.",lod:null,lodCitations:"Diagnostics 2023;13:725 (analytical validation).",lodNotes:"Analytical LOD: 0.56-1.31 copies/L for HPV types 16, 18, 31, 33, 35. LOQ: 1.20-4.11 copies/L. LOB: 0-0.32 copies/L.",requiresTumorTissue:"No",requiresTumorTissueNotes:"Tumor-nave approach; does not require prior tumor sequencing. Detects HPV-derived ctDNA directly without need for patient-specific panel design. For patients without pre-treatment NavDx, primary tumor tissue may be tested to confirm HPV genotype.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"No matched normal required; TTMV-HPV DNA biomarker is tumor-specific by nature.",initialTat:null,initialTatNotes:"Sample stability validated for 7 days post-collection in Streck tubes; specific TAT not publicly disclosed.",followUpTat:null,followUpTatNotes:"Serial monitoring uses same assay with consistent turnaround.",bloodVolume:10,bloodVolumeCitations:"NavDx physician ordering information.",bloodVolumeNotes:"One 10-mL Streck tube of whole blood required.",fdaStatus:"Clinical LDT  CLIA high-complexity test; CAP and NYSDOH accredited; NOT FDA cleared",fdaStatusCitations:"Naveris website; Diagnostics 2023;13:725.",reimbursement:"Medicare",reimbursementNote:"Medicare coverage via Palmetto GBA MolDX: HPV+ oropharyngeal cancer (Nov 2023), anal squamous cell carcinoma (Nov 2025). CMS ADLT designation effective April 2024.",commercialPayers:["Highmark","Blue Shield of California"],commercialPayersCitations:"Naveris press releases Feb 2024, July 2024.",commercialPayersNotes:"Highmark coverage announced Feb 2024; Blue Shield of California coverage effective July 1, 2024.",cptCodes:"0356U",cptCodesNotes:"CPT 0356U for TTMV-HPV DNA testing; ADLT status effective April 1, 2024.",codeType:"PLA",medicareRate:1800,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,clinicalAvailability:"Commercially available in US. Integrated into clinical practice by >1,000 healthcare providers at >400 medical sites. ~100,000 patient-physician encounters.",clinicalTrials:"Phase II MRD+ study at Memorial Sloan Kettering (HB-200 intervention for HPV16+ HNSCC with molecular relapse); multiple validation cohorts.",clinicalTrialsCitations:"Naveris press release April 2024; Chera BS et al. J Clin Oncol 2020;38:1050-1058; Berger BM et al. Clin Cancer Res 2022;28:4292-4301.",clinicalSettings:["Neoadjuvant","Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Used across entire care continuum for HPV+ cancers: pre-treatment baseline, treatment response during neoadjuvant/adjuvant therapy, post-treatment MRD assessment, and long-term surveillance. Median 4-month lead time vs imaging.",totalParticipants:null,totalParticipantsNotes:"Validation across multiple published cohorts totaling >1,000 patients; JAMA study included 163 diagnostic + 290 surveillance patients.",numPublications:35,numPublicationsPlus:!0,isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"First MRD test with Medicare coverage for HPV-driven cancers. Clinical LDT with ADLT designation. Unique tumor-nave approach detecting viral-derived ctDNA rather than somatic mutations. Proven clinical utility in 35+ peer-reviewed publications."},{id:"mrd-15",sampleCategory:"Blood/Plasma",name:"Foresight CLARITY Lymphoma",vendor:"Natera",vendorOriginal:"Foresight Diagnostics",approach:"Tumor-informed",method:"PhasED-Seq (Phased variant Enrichment and Detection Sequencing): 150kb fixed capture panel leveraging somatic hypermutation in B-cell malignancies. Off-the-shelf panel (no custom reagent design) interrogates phased variants in stereotypical genomic regions. Requires concordant detection of 2 phased non-reference variants on same DNA molecule. Background error rate ~1.95E-08.",cancerTypes:["Diffuse large B-cell lymphoma (DLBCL)","Large B-cell lymphoma (LBCL)","Follicular lymphoma","Classic Hodgkin lymphoma","Multiple myeloma"],indicationsNotes:"Sensitive MRD assay for B-cell malignancies leveraging phased variant technology in somatic hypermutation regions. First ctDNA-MRD test included in NCCN Guidelines for B-Cell Lymphomas (Dec 2024). Acquired by Natera December 2025. Solid tumor version (up to 5,000 variants, 0.3 ppm LOD) in development but not yet clinically available.",sensitivity:90.62,sensitivityCitations:"Boehm N et al. Oncotarget 2025;16:329-336; JCO 2025 pooled analysis (n=137).",sensitivityNotes:"Positive percent agreement 90.62% (95% CI 74.98-98.02%) in DLBCL analytical validation. End-of-treatment MRD detection identified 90% of patients who later relapsed vs 45% for PET/CT.",specificity:97.65,specificityCitations:"Boehm N et al. Oncotarget 2025;16:329-336.",specificityNotes:"Negative percent agreement 97.65% (95% CI 87.43-99.94%) in DLBCL validation. False positive rate 0.24%.",lod:"0.7 ppm",lod95:"0.7 ppm",lodCitations:"Boehm N et al. Oncotarget 2025;16:329-336; Truesdell J et al. PubMed 40353795 (analytical validation).",lodNotes:"LOD95 = 0.7 ppm per vendor and analytical validation paper. Solid tumor version (in development) achieves 0.3 ppm.",leadTimeVsImaging:200,leadTimeVsImagingCitations:"Foresight CLARITY product page; Roschewski M et al. ASH 2023.",leadTimeVsImagingNotes:"Detects relapse approximately 200 days earlier than PET/CT imaging in DLBCL. PhasED-Seq correctly identified 90% of patients who later relapsed vs 45% identified by PET/CT.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires tumor-derived material but flexible source: pre-treatment PLASMA (when tumor is shedding) OR tumor tissue. No tissue biopsy required if adequate pre-treatment plasma available.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Requires matched normal sample per vendor confirmation.",variantsTracked:"100s",variantsTrackedNotes:"Fixed 150kb panel interrogates hundreds of phased variants in somatic hypermutation regions. No custom reagent design required (unlike solid tumor WGS approaches).",initialTat:8,initialTatNotes:"8-10 days for new patient baseline. Off-the-shelf panel eliminates custom reagent design delay.",followUpTat:8,followUpTatNotes:"8-10 days for MRD monitoring timepoints. Same turnaround as baseline due to fixed panel approach.",bloodVolume:null,bloodVolumeNotes:"Standard blood draw volume; specific volume not publicly disclosed.",fdaStatus:"CLIA LDT  NOT FDA cleared/approved",fdaStatusCitations:"Foresight website; CAP: 9346637, CLIA: 06D2287941",reimbursement:"Not established",reimbursementNote:"Research/trial use primarily. NCCN guideline inclusion may support future reimbursement pathway. Clinical launch expected 2026 post-Natera integration.",cptCodes:null,clinicalAvailability:"Research/trial use; limited clinical ordering. Central CLIA lab (Boulder, CO). Clinical launch expected 2026.",clinicalTrials:"NCT06500273 (ALPHA3 - MRD+ LBCL patients post-remission); NCT06693830 (SHORTEN-ctDNA - ctDNA-guided chemotherapy de-escalation); multiple biopharma and academic partnerships",clinicalTrialsCitations:"Foresight Diagnostics press releases 2025; ClinicalTrials.gov",totalParticipants:null,totalParticipantsNotes:"Used in 3 prospective MRD-driven clinical trials. JCO pooled analysis included 137 DLBCL patients from 5 prospective studies.",numPublications:40,numPublicationsPlus:!0,numPublicationsCitations:"Foresight website; Natera acquisition announcement noted 15 abstracts at ASH 2025.",clinicalSettings:["Neoadjuvant","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Validated for MRD assessment during/after frontline therapy in DLBCL and surveillance monitoring. First ctDNA-MRD test in NCCN Guidelines for DLBCL. Used to adjudicate PET-positive results at end of therapy.",isRUO:!1,isInvestigational:!0,isClinicalLDT:!0,regulatoryStatusNotes:"CLIA-registered laboratory (CAP: 9346637, CLIA: 06D2287941). First ctDNA-MRD test in NCCN B-Cell Lymphoma guidelines. Acquired by Natera Dec 5, 2025 for $275M upfront + $175M earnouts.",nccnGuidelines:!0,nccnGuidelinesNotes:"NCCN B-Cell Lymphomas V.2.2025 (Dec 2024): ctDNA-MRD testing with assay LOD <1ppm recommended to adjudicate PET-positive results at end of frontline DLBCL therapy.",vendorDataSource:"John Truesdell (Natera/Foresight) Dec 2025; https://pubmed.ncbi.nlm.nih.gov/40353795/",solidTumorVersionNotes:"Foresight CLARITY for solid tumors is in development (not clinically available). Uses WGS baseline with up to 5,000 phased+low-error variants and achieves 0.3 ppm LOD. Requires custom reagent design like other MRD products.",acquisitionDetails:{acquirer:"Natera",date:"2025-12-05",upfrontValueUSD:275e6,earnoutPotentialUSD:175e6}},{id:"mrd-16",sampleCategory:"Blood/Plasma",name:"Invitae PCM",vendor:"Labcorp (Invitae)",approach:"Tumor-informed",method:"Tumor-informed, whole-exome sequencing-based MRD assay: WES of tumor and matched normal identifies 18-50 patient-specific variants, which are tracked at high depth in plasma using Anchored Multiplex PCR (AMP) chemistry with error correction.",cancerTypes:["NSCLC","Breast","Colorectal","Pancreatic","Head and neck","Multi-solid"],indicationsNotes:"Invitae Personalized Cancer Monitoring (PCM) pan-cancer tumor-informed MRD assay, now part of Labcorp following Aug 2024 acquisition. Co-developed with TRACERx consortium. FDA Breakthrough Device designation. Not indicated for hematological malignancies, CNS malignancies, or sarcomas.",sensitivity:76.9,sensitivityCitations:"Garcia-Murillas I et al. Breast Cancer Res 2025; TRACERx lung cancer studies.",sensitivityNotes:"76.9% clinical sensitivity in breast cancer monitoring phase for patients who relapsed. TRACERx NSCLC showed 93% (13/14) prediction of relapse post-resection.",specificity:100,specificityCitations:"Garcia-Murillas I et al. Breast Cancer Res 2025.",specificityNotes:"100% specificity in breast cancer monitoring cohort (n=61). No false positives reported.",lod:"80 ppm",lod95:null,lodCitations:"Invitae PCM analytical validation; GenomeWeb Sept 2023.",lodNotes:"LOD of 0.008% VAF (80 ppm) with 60ng cfDNA input and 18-50 variants at baseline threshold. LOD of 0.05% VAF (500 ppm) with 10ng cfDNA and 18 variants at monitoring threshold.",leadTimeVsImaging:351,leadTimeVsImagingCitations:"Garcia-Murillas I et al. Breast Cancer Res 2025.",leadTimeVsImagingNotes:"Median lead time 11.7 months (351 days) before clinical relapse in breast cancer. TRACERx NSCLC showed median 70 days, up to 136 days in follow-up cohort.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires FFPE tumor tissue plus matched-normal blood for baseline WES panel design.",requiresMatchedNormal:"Yes",variantsTracked:"18-50",variantsTrackedNotes:"Invitae algorithm selects 18-50 tumor-specific variants from WES results. Range allows balance of sensitivity in low vs high mutational burden cancers.",initialTat:21,initialTatNotes:"Approximately 3 weeks for baseline panel design from tumor/normal WES.",followUpTat:10,followUpTatNotes:"Monitoring timepoints typically reported within 10 days.",bloodVolume:20,bloodVolumeNotes:"Standard collection: two 10mL Streck cfDNA tubes (20mL total).",fdaStatus:"CLIA LDT; FDA Breakthrough Device designation",fdaStatusCitations:"Invitae/Labcorp website; FDA BDD program.",reimbursement:"Coverage emerging",reimbursementNote:"Under Novitas MAC jurisdiction (not MolDX/Palmetto). Labcorp pursuing coverage pathways post-acquisition.",cptCodes:null,clinicalAvailability:"Clinical LDT  shipping (Metro Park, NJ laboratory)",clinicalTrials:"TRACERx (NSCLC, ~850 pts); MARIA (pan-tumor); ARTEMIS (pancreatic); multiple breast and GI studies",clinicalTrialsCitations:"Invitae/Labcorp press releases; ClinicalTrials.gov",totalParticipants:1e3,totalParticipantsNotes:"TRACERx alone enrolled ~850 pts; additional studies in breast, pancreatic, colorectal.",numPublications:15,numPublicationsPlus:!0,numPublicationsCitations:"TRACERx consortium publications; Garcia-Murillas et al.",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"TRACERx consortium validated post-surgical MRD assessment (93% recurrence prediction in NSCLC) and longitudinal surveillance (median 11.7 month lead time in breast cancer).",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"CAP-accredited, CLIA-certified laboratory (Metro Park, NJ). Acquired by Labcorp Aug 2024 via Invitae bankruptcy sale ($239M)."},{id:"mrd-18",sampleCategory:"Blood/Plasma",name:"Caris Assure",vendor:"Caris Life Sciences",approach:"Tumor-nave MRD (WES/WTS cfDNA + cfRNA)",method:"AI-enabled whole exome and whole transcriptome sequencing (WES/WTS) from plasma cfDNA/cfRNA and buffy coat WBC DNA/RNA with machine learning MRD model; CHIP subtraction for accuracy",methodCitations:"https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/physicians/physician-tests/caris-assure/",cancerTypes:["All solid tumors"],targetPopulation:"Cancer patients requiring MRD detection and disease monitoring; tumor-nave approach does not require prior tissue profiling",indicationsNotes:"Multi-functional platform validated for MRD detection across solid tumors. Disease-free survival stratification: HR=33.4 (p<0.005) for MRD-positive vs MRD-negative patients. Also supports therapy selection and treatment response monitoring on same platform.",sensitivity:null,sensitivityNotes:"MRD model trained on 3,439 patients and validated on independent set of 86 MRD patients. Tumor-nave approach using AI-derived features from plasma.",sensitivityCitations:"https://www.nature.com/articles/s41598-025-08986-0",specificity:99.6,specificityNotes:"99.6% specificity in MRD/monitoring validation cohorts.",specificityCitations:"https://www.nature.com/articles/s41598-025-08986-0",performanceNotes:"For MRD detection, disease-free survival of patients predicted to have an event (MRD-positive) was significantly shorter than those predicted MRD-negative (HR=33.4, p<0.005). For monitoring, HR=4.39, p=0.008. Uses tumor-nave approach - no prior tissue profiling required.",performanceCitations:"https://www.nature.com/articles/s41598-025-08986-0",fdaStatus:"CLIA LDT",reimbursement:"Coverage Varies",reimbursementNote:"Coverage expanding; contact Caris for current payer coverage.",clinicalAvailability:"Commercially available in US since late 2022",availableRegions:["US"],initialTat:14,initialTatNotes:"Initial MRD assessment typically 10-14 business days.",followUpTat:14,sampleType:"Whole blood",bloodVolume:20,bloodVolumeNotes:"Approximately 20mL whole blood; plasma and buffy coat analyzed separately.",clinicalTrials:"MRD model validated on 86 patients; monitoring validated on 101 patients; 3,439 training samples",totalParticipants:3626,numPublications:5,numPublicationsPlus:!0,numPublicationsCitations:"https://www.nature.com/articles/s41598-025-08986-0",clinicalSettings:["Post-Surgery","Surveillance"],clinicalSettingsNotes:"Validated for post-surgical MRD assessment (HR=33.4 for MRD+ vs MRD-) and longitudinal disease monitoring (HR=4.39). Tumor-nave approach enables testing without prior tissue profiling.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,technologyDifferentiator:"Tumor-nave MRD approach using AI/ML on WES/WTS data - no prior tissue profiling required. Only liquid biopsy sequencing both plasma and buffy coat for CHIP subtraction, improving accuracy over plasma-only assays."},{id:"mrd-19",sampleCategory:"Bone Marrow/Blood",name:"clonoSEQ",vendor:"Adaptive Biotechnologies",approach:"Tumor-informed (Immunosequencing)",method:"NGS-based immunosequencing of B-cell (IGH, IGK, IGL) and T-cell receptor gene rearrangements. Identifies patient-specific clonal DNA sequences ('barcodes') at diagnosis, then tracks these sequences in subsequent samples to quantify MRD with sensitivity to 10 (1 cancer cell per million).",methodCitations:"https://www.clonoseq.com/about-clonoseq/ | https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer",cancerTypes:["Multiple myeloma","B-cell ALL","CLL","DLBCL","Mantle cell lymphoma","Other lymphoid malignancies"],cancerTypesNotes:"FDA-cleared for MM (bone marrow), B-ALL (bone marrow), and CLL (blood or bone marrow). Available as CLIA-validated LDT for DLBCL, MCL, and other lymphoid cancers.",cancerTypesCitations:"https://www.clonoseq.com/technical-summary/",targetPopulation:"Patients with lymphoid malignancies (like Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma) requiring MRD assessment during and after treatment to evaluate prognosis, monitor remission, and detect potential relapse.",indicationsNotes:"First and only FDA-cleared MRD test for hematologic malignancies. Uses NGS immunosequencing to detect residual cancer cells at 100x greater sensitivity than standard flow cytometry. Two-step testing: Clonality (ID) test identifies trackable sequences at diagnosis; Tracking (MRD) tests monitor those sequences in subsequent samples.",sensitivity:null,sensitivityNotes:"Detects MRD at 10 sensitivity (1 cancer cell per 1 million healthy cells) given sufficient sample input (20 g DNA). This is 100x more sensitive than standard flow cytometry (10). Sensitivity is sample-dependent based on DNA input quantity.",sensitivityCitations:"https://www.clonoseq.com/about-clonoseq/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",specificity:null,specificityNotes:"Analytical validation demonstrated high specificity with well-characterized limit of blank (LoB) to minimize false positives from non-malignant clones.",specificityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",lod:"10 (1 in 1 million cells)",lodNotes:"LoD of 1.9 malignant cells at 20 g DNA input. Sensitivity scales with DNA input - higher DNA input enables deeper detection. Maximum sensitivity of 10 achievable with sufficient sample material.",lodCitations:"https://www.clonoseq.com/wp-content/uploads/2021/08/PNL-10027-03_clonoSEQ-Technical-Information.pdf",requiresTumorTissue:"No",requiresTumorTissueNotes:"Does not require solid tumor tissue. Requires high-disease-burden baseline sample (fresh or archived) for initial Clonality (ID) test to identify trackable sequences: Fresh or archived sample from bone marrow aspirate, peripheral blood, or soft tissue. Subsequent clonoSEQ Tracking (MRD) uses standard fresh bone marrow or blood samples.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Does not require separate matched normal sequencing. Clonality criteria (3% of like sequences, 0.2% of total cells, etc.) distinguish malignant from normal B/T-cell populations.",initialTat:14,initialTatNotes:"Initial Clonality (ID) test to identify trackable sequences: ~14 days from sample receipt.",followUpTat:7,followUpTatNotes:"Serial MRD monitoring (Tracking tests): ~7 days from sample receipt. Requires prior valid Clonality result.",bloodVolume:null,bloodVolumeNotes:"Bone marrow: 1 mL aspirate recommended. Blood (CLL): 2 mL whole blood. Sample requirements vary by specimen type.",sampleRequirements:"Bone marrow aspirate (1 mL EDTA), peripheral blood (2 mL EDTA for CLL), or archived FFPE/slides. Fresh specimens preferred; stored specimens accepted with longer TAT.",sampleRequirementsCitations:"https://www.clonoseq.com/ordering-clonoseq/",fdaStatus:"FDA De Novo cleared (Sept 2018 for MM and B-ALL; Aug 2020 expanded for CLL in blood and bone marrow). First FDA-cleared NGS-based MRD test.",fdaApprovalDate:"2018-09-28",fdaStatusCitations:"https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer | https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-receives-expanded-fda-clearance",nccnRecommended:!0,nccnGuidelinesAligned:["Multiple Myeloma","ALL","CLL"],nccnGuidelinesNotes:"NCCN Category 2A recommendation for MRD assessment in MM (at each treatment stage), ALL, and CLL. NGS specifically included as recommended MRD assessment method.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1",reimbursement:"Medicare",reimbursementNote:"National Medicare coverage for MM, B-ALL, CLL, DLBCL, and MCL via MolDX program. Medicare CLFS rate: $2,007 per test (PLA 0364U); episode pricing $8,029 across all covered indications. Positive coverage from major commercial insurers for MM and ALL. 90% of patients pay $0 for testing.",reimbursementCitations:"https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-clinical-lab-fee-schedule",cptCodes:"0364U",codeType:"PLA",medicareRate:2007,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,listPrice:2007,listPriceNotes:"Medicare CLFS rate $2,007 per test as of January 2025. Episode pricing (full testing series) $8,029.",listPriceCitations:"https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-clinical-lab-fee-schedule",clinicalAvailability:"Commercially available in US since 2018. Single-site assay performed at Adaptive Biotechnologies laboratory in Seattle, WA.",clinicalAvailabilityCitations:"https://www.clonoseq.com/ordering-clonoseq/",availableRegions:["US","EU","International"],availableRegionsNotes:"US: FDA-cleared IVD via Seattle lab. EU: CE-marked, available via Roche and regional partners. International availability via MedGenome (India) and other distributors.",clinicalTrials:"Validated in major phase III trials including ALCYONE (706 pts, transplant-ineligible NDMM), POLLUX (569 pts, R/R MM), MASTER (daratumumab-KRd MRD-guided discontinuation), DETERMINATION (RVd  ASCT), multiple ALL and CLL studies. Used in 25 of 28 NCCN cancer centers.",clinicalTrialsCitations:"https://ous.clonoseq.com/for-clinicians/clinical-data/ | https://www.clonoseq.com/multiple-myeloma/",totalParticipants:5e3,totalParticipantsNotes:"Estimated >5,000 patients across published clinical validation studies. ALCYONE alone included 706 patients.",numPublications:100,numPublicationsPlus:!0,numPublicationsNotes:"Extensive peer-reviewed evidence including validation studies in MM, ALL, CLL, lymphomas. Clinical data incorporated into FDA drug approvals and NCCN guidelines.",clinicalSettings:["Neoadjuvant","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Validated across treatment phases for hematologic malignancies: during induction/consolidation therapy, after treatment completion, and long-term surveillance. NCCN recommends MRD assessment at each treatment stage in MM.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!1,regulatoryStatusNotes:"FDA-cleared IVD for MM, B-ALL, CLL. Additionally available as CLIA-validated LDT for DLBCL, MCL, and other lymphoid malignancies. Only FDA-cleared MRD test for hematologic malignancies.",technologyDifferentiator:"Hematologic MRD test using immunosequencing of B/T-cell receptor genes - fundamentally different from solid tumor ctDNA assays. First and only FDA-cleared MRD test. 10 sensitivity (100x more sensitive than flow cytometry). Quantitative results track disease burden over time, not just positive/negative. Blood-based testing available for CLL reduces need for bone marrow biopsies."},{id:"mrd-20",sampleCategory:"Blood/Plasma",name:"Signatera Genome",vendor:"Natera",approach:"Tumor-informed (WGS)",method:"Whole-genome sequencing-informed tumor-informed ctDNA assay using mPCR-NGS. WGS identifies patient-specific variants, then 64 clonal variants are selected and tracked via multiplex PCR with ultra-deep sequencing (up to 350,000x coverage per variant). Same proven mPCR workflow as standard Signatera but with enhanced sensitivity.",methodCitations:"https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",cancerTypes:["Breast cancer","NSCLC","Melanoma","Renal cell carcinoma","Colorectal cancer","Multi-solid tumors"],targetPopulation:"Patients with solid tumors requiring ultrasensitive MRD detection, particularly those where standard Signatera sensitivity may be insufficient or where maximal lead time to recurrence is desired",indicationsNotes:"Genome-scale version of Signatera offering enhanced sensitivity (1 ppm LOD) and increased lead time to recurrence. Uses WGS instead of WES for variant identification, enabling selection of optimal 64 clonal variants for tracking. Same Medicare coverage as standard Signatera for covered indications.",sensitivity:94,sensitivityNotes:"94% longitudinal sensitivity for detecting distant, extracranial recurrence in pan-cancer validation cohort (392 patients, >2,600 plasma samples across breast, NSCLC, melanoma, RCC, and CRC).",sensitivityCitations:"George M, et al. ASCO 2025 poster.",specificity:100,specificityNotes:"100% specificity for distant, extracranial recurrence detection in pan-cancer validation cohort.",specificityCitations:"George M, et al. ASCO 2025 poster.",lod:"1 ppm",lod95:"1 ppm",lodNotes:"Ultra-sensitive detection down to 1 part per million (1 ppm), representing ~100x improvement over standard WES-based Signatera. Achieved through tracking 64 variants (vs 16) with ultra-deep sequencing.",lodCitations:"https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",leadTimeVsImaging:null,leadTimeVsImagingNotes:"Increased lead times to recurrence compared to standard Signatera due to enhanced sensitivity. ctDNA-positive patients had 36x higher risk of relapse than ctDNA-negative patients.",leadTimeVsImagingCitations:"George M, et al. ASCO 2025 poster.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires tumor tissue for whole-genome sequencing to identify patient-specific variants. Same sample requirements as standard Signatera.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Matched normal (blood) required for germline filtering.",variantsTracked:"64",variantsTrackedNotes:"64 highly curated clonal variants selected for optimized balance of ultra-sensitivity and high specificity (vs 16 variants in standard Signatera).",variantsTrackedCitations:"https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",initialTat:28,initialTatNotes:"Initial result in approximately 4 weeks (vs ~2 weeks for standard Signatera) due to WGS requirement.",followUpTat:7,followUpTatNotes:"Subsequent monitoring results in 7-10 days, same as standard Signatera.",bloodVolume:null,bloodVolumeNotes:"Same sample requirements as standard Signatera (two Streck tubes).",fdaStatus:"CLIA LDT",fdaStatusNotes:"Laboratory-developed test. Uses same Medicare coverage pathway as FDA-cleared Signatera for covered indications.",nccnRecommended:!0,nccnGuidelinesAligned:["Colorectal Cancer","Breast Cancer","NSCLC","Bladder Cancer","Ovarian Cancer"],nccnGuidelinesNotes:"Covered under same NCCN recommendations as standard Signatera for MRD-guided care.",reimbursement:"Medicare",reimbursementNote:"Same Medicare coverage as standard Signatera for covered indications: Stage II-IV CRC, Stage IIb+ breast cancer, MIBC, Stage I-III NSCLC surveillance, Stage II-IV ovarian cancer, and ICI response monitoring for any solid tumor.",reimbursementCitations:"https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",cptCodes:"0239U",codeType:"PLA",medicareRate:3500,medicareStatus:"Priced",adltStatus:!0,listPrice:3500,listPriceNotes:"Expected same pricing as standard Signatera ($3,500 Medicare CLFS rate).",clinicalAvailability:"Commercially available via Natera. Can only be ordered for new patients (cannot convert existing Signatera orders).",clinicalAvailabilityCitations:"https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",clinicalTrials:"Pan-cancer validation in 392 patients with breast, NSCLC, melanoma, RCC, and CRC across >2,600 plasma samples (ASCO 2025).",clinicalTrialsCitations:"https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3142",totalParticipants:392,totalParticipantsNotes:"392 patients in initial pan-cancer validation cohort with >2,600 plasma samples analyzed.",numPublications:1,numPublicationsNotes:"Initial clinical data presented at ASCO 2025. Backed by >100 publications for standard Signatera platform.",clinicalSettings:["Neoadjuvant","Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Same clinical settings as standard Signatera with enhanced 1 ppm sensitivity. Validates across neoadjuvant, post-surgical, post-adjuvant, and surveillance settings in breast, NSCLC, melanoma, RCC, CRC.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"CLIA-certified LDT leveraging Natera's established Signatera infrastructure. Uses proven mPCR-NGS workflow with WGS-informed variant selection for enhanced sensitivity.",technologyDifferentiator:"WGS-informed evolution of Signatera tracking 64 variants (vs 16) at 1 ppm LOD (vs ~100 ppm). Ultra-deep sequencing up to 350,000x coverage per variant. Designed for cases requiring maximum sensitivity and lead time. Same trusted mPCR workflow backed by >1M Signatera tests."},{id:"mrd-21",sampleCategory:"Blood/Plasma",name:"Latitude",vendor:"Natera",approach:"Tumor-nave (methylation)",method:"Tissue-free, blood-based MRD test using targeted methylation panel composed of differentially methylated regions (DMRs) specifically designed for colorectal cancer. Does not require tumor tissue - analyzes cfDNA methylation patterns directly from blood.",methodCitations:"https://www.natera.com/oncology/latitude-tissue-free-mrd/",cancerTypes:["Colorectal cancer"],targetPopulation:"CRC patients requiring MRD detection when tumor tissue is unavailable, insufficient, or when faster turnaround is needed",indicationsNotes:"Tissue-free MRD test for colorectal cancer. Ideal for patients where tumor tissue is not available for Signatera. Uses methylation-based approach rather than somatic variant tracking. Currently CRC-only; expansion to other cancers expected.",sensitivity:81,sensitivityNotes:"81% longitudinal sensitivity (84% for colon cancer specifically). 58% single time point sensitivity. Validated in CIRCULATE-JAPAN GALAXY Study.",sensitivityCitations:"https://www.natera.com/oncology/latitude-tissue-free-mrd/ | CIRCULATE-JAPAN GALAXY Study",specificity:97,specificityNotes:"97% sample-level specificity in validation cohort.",specificityCitations:"https://www.natera.com/oncology/latitude-tissue-free-mrd/",lod:null,lodNotes:"LOD not publicly disclosed. Methylation-based approach differs from variant-tracking assays.",leadTimeVsImaging:4.6,leadTimeVsImagingNotes:"4.6 months median lead time before radiographic relapse in validation study.",leadTimeVsImagingCitations:"https://www.natera.com/oncology/latitude-tissue-free-mrd/",requiresTumorTissue:"No",requiresTumorTissueNotes:"Tissue-free assay - does not require tumor tissue. Key differentiator from Signatera.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Methylation-based approach does not require matched normal for variant filtering.",variantsTracked:null,variantsTrackedNotes:"Uses methylation markers (DMRs) rather than somatic variants.",initialTat:null,initialTatNotes:"Fast turnaround time (no tumor sequencing required). Specific TAT not publicly disclosed.",followUpTat:null,followUpTatNotes:"Subsequent monitoring with same fast TAT as initial test.",bloodVolume:null,bloodVolumeNotes:"Standard blood collection; specific volume not publicly disclosed.",fdaStatus:"CLIA LDT",fdaStatusNotes:"Laboratory-developed test. Not FDA cleared.",reimbursement:"Coverage Varies",reimbursementNote:"Reimbursement status for Latitude specifically not yet established. May be covered under existing MRD codes for CRC.",clinicalAvailability:"Commercially available via Natera for colorectal cancer patients",clinicalAvailabilityCitations:"https://www.natera.com/oncology/latitude-tissue-free-mrd/",clinicalTrials:"Validated in CIRCULATE-JAPAN GALAXY Study: 195 CRC patients, 1,300+ plasma samples. Latitude-positive patients had HR=10 for DFS (p<0.001). Latitude-positive patients who did not receive ACT had 100% relapse rate (26/26 PPV).",clinicalTrialsCitations:"https://www.natera.com/oncology/latitude-tissue-free-mrd/",clinicalSettings:["Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Tissue-free CRC MRD validated for post-surgical and post-adjuvant assessment, plus surveillance monitoring. GALAXY study showed HR=10 for recurrence in MRD+ patients.",totalParticipants:195,totalParticipantsNotes:"195 patients in CIRCULATE-JAPAN GALAXY validation study with 1,300+ plasma samples.",numPublications:null,numPublicationsNotes:"Initial validation data from CIRCULATE-JAPAN GALAXY Study. Full publication record building.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"CLIA-certified LDT from Natera. Complements Signatera for cases where tumor tissue is unavailable.",technologyDifferentiator:"Tissue-free MRD for CRC - no tumor tissue required. Uses methylation-based detection rather than somatic variant tracking. Enables MRD testing when tissue is unavailable, insufficient, or degraded. Part of Natera's comprehensive MRD portfolio alongside Signatera and Signatera Genome."},{id:"mrd-22",sampleCategory:"Blood/Plasma",name:"CancerDetect",vendor:"IMBdx",approach:"Tumor-informed (hybrid)",method:"Tumor-informed hybrid approach combining large-scale personalized mutation tracking (up to 300 patient-specific variants from tumor WES) with tumor-agnostic hotspot regions covering 58 clinically actionable mutations across 15 genes. Uses hybridization capture with UMI-based error suppression and ultra-deep sequencing (~100,000x). Proprietary HQS technology for false positive reduction.",methodCitations:"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282 | https://www.nature.com/articles/s41416-023-02300-3",cancerTypes:["Colorectal cancer","Breast cancer","Gastric cancer"],targetPopulation:"Stage II-III solid tumor patients requiring MRD detection post-surgery, particularly CRC, breast, and gastric cancer",indicationsNotes:"Korean-developed tumor-informed MRD test using large-scale mutation profiling strategy. Tracks median 185 variants per patient (up to 300). Designated as 'Innovative Medical Technology' by Korean Ministry of Health and Welfare (similar to FDA Breakthrough Device). Used in nationwide phase III interventional trial (NCT05534087) for MRD-guided treatment escalation.",sensitivity:null,sensitivityNotes:"Clinical sensitivity 61.9% for predicting recurrence within 3 years at postoperative 3-week timepoint. In silico simulation shows increased sensitivity with more monitoring variants.",sensitivityCitations:"https://www.nature.com/articles/s41416-023-02300-3",specificity:99.9,specificityNotes:"99.9% analytical specificity for bespoke (personalized) regions. 95% specificity for hotspot regions. 1.5% false positive rate in cross-panel analysis.",specificityCitations:"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",lod:"0.001%",lod95:"0.001%",lodNotes:"LOD95 of 0.001% (10 ppm) for bespoke regions, 0.1% for hotspot regions. Limit of blank 0.0003% for bespoke regions. Achieved through large-scale mutation tracking combined with ultra-deep sequencing.",lodCitations:"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",leadTimeVsImaging:null,leadTimeVsImagingNotes:"Postoperative MRD positivity strongly associated with recurrence (adjusted HR 8.40, 95% CI 3.49-20.2). Patients with MRD clearance after adjuvant therapy showed significantly better outcomes.",leadTimeVsImagingCitations:"https://www.nature.com/articles/s41416-023-02300-3",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires tumor tissue for whole-exome sequencing to identify patient-specific variants. Fresh frozen tissue preferred.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"PBMC sequencing used to filter germline variants and CHIP mutations from cfDNA results.",variantsTracked:"Up to 300",variantsTrackedNotes:"Median 185 variants tracked per patient (range 116-300). Large-scale mutation profiling strategy shown to improve sensitivity at low ctDNA fractions (<0.01%).",variantsTrackedCitations:"https://www.nature.com/articles/s41416-023-02300-3",initialTat:28,initialTatNotes:"Initial TAT 28 days (4 weeks). Reduced from previous 8-10 weeks in earlier version.",followUpTat:14,followUpTatNotes:"Follow-up monitoring TAT 14 days (2 weeks).",bloodVolume:null,bloodVolumeNotes:"1-10 mL plasma used for cfDNA extraction.",fdaStatus:"Not FDA cleared",fdaStatusNotes:"Korean 'Innovative Medical Technology' designation from Ministry of Health and Welfare (analogous to FDA Breakthrough Device Designation). Not FDA cleared for US market.",nccnRecommended:!1,reimbursement:"Coverage Varies",reimbursementNote:"Korean national health insurance coverage under Innovative Medical Technology pathway. Not available in US market.",clinicalAvailability:"Commercially available in South Korea via IMBdx",clinicalAvailabilityCitations:"https://www.imbdx.com/eng/",availableRegions:["South Korea"],availableRegionsNotes:"Currently available in South Korea. International expansion potential.",clinicalTrials:"Phase III interventional trial (NCT05534087) for MRD-guided treatment escalation in CRC. Validation studies in breast cancer (AACR 2025, SABCS 2023/2025) and gastric cancer (AACR 2025). Original CRC validation: 98 patients, Stage II-III, median 36.3 months follow-up.",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT05534087 | https://www.nature.com/articles/s41416-023-02300-3",totalParticipants:98,totalParticipantsNotes:"98 patients in primary CRC validation study. Phase III trial (NCT05534087) enrolling ~1,200 CRC patients.",numPublications:2,numPublicationsNotes:"British Journal of Cancer 2023 (clinical validation), PLOS One 2025 (analytical validation). Multiple conference abstracts at AACR 2025, SABCS 2023/2025.",numPublicationsCitations:"https://www.nature.com/articles/s41416-023-02300-3 | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",clinicalSettings:["Post-Surgery","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Validated for postoperative MRD assessment at 3 weeks (61.9% sens for recurrence) and after adjuvant therapy. MRD clearance post-adjuvant associated with better outcomes. Phase III interventional trial (NCT05534087) for MRD-guided treatment.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"Commercially available in South Korea with Innovative Medical Technology designation. Previously known as AlphaLiquidDetect.",technologyDifferentiator:"Large-scale mutation tracking (up to 300 variants vs typical 16-50) combined with tumor-agnostic hotspot panel. Korean-developed with strong regulatory pathway. Ultra-sensitive detection (0.001% LOD) through expanded variant coverage rather than deeper sequencing alone. Hybrid approach enables detection of both original tumor mutations and de novo resistance mutations."},{id:"mrd-23",sampleCategory:"Blood/Plasma",name:"LymphoVista",vendor:"LIQOMICS",approach:"Tumor-informed (ctDNA sequencing)",method:"Targeted ctDNA sequencing using duplex barcodes and disease-specific gene panels optimized for lymphomas. Incorporates non-coding regions with highly frequent genetic alterations. Two variants: LymphoVista (B-cell lymphomas, 83 kbp panel) and LymphoVista HL (Hodgkin lymphoma, modified panel). Two-step workflow: initial genotyping identifies patient-specific mutations, followed by serial MRD monitoring.",methodCitations:"https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://liqomics.com/en/lymphovista/",cancerTypes:["Diffuse large B-cell lymphoma (DLBCL)","Follicular lymphoma","Mantle cell lymphoma","Marginal zone lymphoma","Burkitt lymphoma","CNS lymphomas","Hodgkin lymphoma (via LymphoVista HL)"],cancerTypesNotes:"LymphoVista covers all B-cell lymphomas. LymphoVista HL uses a slightly modified gene panel specifically optimized for Hodgkin lymphoma genomics.",cancerTypesCitations:"https://liqomics.com/en/lymphovista/",targetPopulation:"Patients with B-cell lymphomas or Hodgkin lymphoma requiring MRD assessment during treatment (e.g., after 2 cycles), post-treatment surveillance, or monitoring after CAR-T cell therapy or salvage chemotherapy.",indicationsNotes:"Designed for both interim response assessment during active treatment AND post-treatment MRD monitoring. Validated in relapsed/refractory DLBCL patients post-CAR-T/chemo and in advanced-stage Hodgkin lymphoma (HD21 trial). Addresses lymphoma-specific MRD needs distinct from solid tumor ctDNA assays.",sensitivity:100,sensitivityNotes:"At MRD level of 7.010: 100% sensitivity, 93% specificity, 94% accuracy (LymphoVista). For variant detection (genotyping) at 0.5% mAF: 93.86% sensitivity / 99.999% specificity (LymphoVista) and 91.27% sensitivity / 99.99% specificity (LymphoVista HL).",sensitivityCitations:"https://liqomics.com/en/lymphovista/ | Mattlener et al. ASH 2024",specificity:93,specificityNotes:"93% specificity at MRD level of 7.010. For variant detection (genotyping): 99.999% specificity (LymphoVista) and 99.99% specificity (LymphoVista HL).",specificityCitations:"https://liqomics.com/en/lymphovista/ | Mattlener et al. ASH 2024",ppv:92.1,ppvNotes:"92.1% PPV determined in relapsed/refractory DLBCL patients treated with various therapies including CAR-T cells and high-dose chemotherapy (Schleifenbaum et al. EHA 2024).",ppvCitations:"https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",lod:"6.69  10",lodNotes:"Limit of detection 6.69  10 (LymphoVista) and 6.54  10 (LymphoVista HL). 100% accuracy for MRD values >3.04  10 (LymphoVista) and >1.76  10 (LymphoVista HL). Duplex sequencing enables ultrasensitive detection.",lodCitations:"https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://liqomics.com/en/lymphovista/",leadTimeVsImaging:null,leadTimeVsImagingNotes:"MRD positivity after 2 cycles of treatment (MRD-2) strongly predictive of outcomes. In HD21 trial, MRD-2-positive patients had 72.2% vs 95.3% 4-year PFS (HR 6.9, p<0.0001). MRD status prognostic even in PET-2-negative patients, suggesting molecular assessment adds value beyond imaging.",leadTimeVsImagingCitations:"Mattlener et al. ASH 2024",requiresTumorTissue:"No",requiresTumorTissueNotes:"Blood-based assay. Initial genotyping can use blood sample (ctDNA) or tissue if available. Does not require solid tumor biopsy.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Genotyping identifies lymphoma-specific mutations from ctDNA without requiring matched normal sequencing.",initialTat:"10 days",initialTatNotes:"Initial genotyping test to identify patient-specific mutations: 10 days.",followUpTat:"10 days",followUpTatNotes:"Serial MRD monitoring of known mutations: 10 days from sample receipt.",bloodVolume:"20 mL",bloodVolumeNotes:"20 mL blood in cfDNA tubes required for testing.",sampleRequirements:"20 mL blood in cfDNA preservation tubes",sampleRequirementsCitations:"https://liqomics.com/en/lymphovista/",fdaStatus:"Not FDA-approved (EU/International LDT)",fdaStatusNotes:"Laboratory-developed test offered from LIQOMICS laboratory in Cologne, Germany. CE marking status not specified. Primarily serves European market.",nccnRecommended:!1,nccnGuidelinesNotes:"ctDNA testing for MRD in DLBCL recently added to NCCN Guidelines (December 2024) following Foresight CLARITY inclusion. LymphoVista not specifically named but methodology aligns with emerging guideline recommendations for ctDNA-based MRD in lymphoma.",reimbursement:"Not established (EU)",reimbursementNote:"Pricing: 2,965 for initial genotyping, 1,985 per MRD monitoring sample. Reimbursement varies by EU country and healthcare system. Not available in US market.",reimbursementCitations:"https://liqomics.com/en/lymphovista/",listPrice:2965,listPriceNotes:"2,965 for initial genotyping test; 1,985 per subsequent MRD monitoring sample. Pricing in EUR.",listPriceCitations:"https://liqomics.com/en/lymphovista/",clinicalAvailability:"Commercially available in Europe via LIQOMICS laboratory (Cologne, Germany). Single-site assay.",clinicalAvailabilityNotes:"Academic spin-off from University of Cologne, founded 2021. Strong ties to German Hodgkin Study Group (GHSG). Available for clinical use and research collaborations.",clinicalAvailabilityCitations:"https://liqomics.com/en/about/",availableRegions:["EU","Germany"],availableRegionsNotes:"Primary market is Europe. Based in Cologne, Germany. International availability via direct ordering.",clinicalTrials:"HD21 Phase III trial (Hodgkin lymphoma, BrECADD vs eBEACOPP, 72 patients in MRD validation subset); EHA 2024 DLBCL validation (88 patients, 326 samples, r/r setting including CAR-T); ISHL13 2024 presentations",clinicalTrialsCitations:"https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",totalParticipants:160,totalParticipantsNotes:"72 patients in HD21 Hodgkin lymphoma validation (ASH 2024); 88 patients in DLBCL validation (EHA 2024, 326 samples).",numPublications:2,numPublicationsPlus:!0,numPublicationsNotes:"Key conference presentations: Mattlener et al. ASH 2024 (LymphoVista HL validation in Hodgkin lymphoma); Schleifenbaum et al. EHA 2024 (LymphoVista validation in DLBCL). Peer-reviewed manuscripts under review/in submission as of December 2025.",numPublicationsCitations:"https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping",clinicalSettings:["Neoadjuvant","Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Validated for interim response assessment (after 2 treatment cycles), post-treatment MRD assessment, and long-term surveillance. HD21 trial showed MRD-2 positivity prognostic even in PET-negative patients (HR 6.9 for PFS).",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"European LDT offered from CLIA-equivalent laboratory in Germany. Strong academic validation via GHSG HD21 trial data. Not FDA-approved; no current US market presence.",technologyDifferentiator:"Lymphoma-specific ctDNA MRD test addressing an underserved niche - most competitors focus on solid tumors or use immunosequencing (clonoSEQ) for heme malignancies. Uses duplex sequencing with disease-optimized gene panels for lymphoma genomics. Founded by Sven Borchmann MD/PhD, a leading Hodgkin lymphoma researcher at University of Cologne/GHSG. Dual utility: both interim assessment during treatment and post-treatment MRD surveillance. Positioned as ctDNA alternative to PET for molecular response assessment in lymphoma."},{id:"mrd-kit-1",sampleCategory:"Bone Marrow/Blood",name:"clonoSEQ Assay",vendor:"Adaptive Biotechnologies",productType:"Laboratory IVD Kit",platformRequired:"Illumina MiSeqDx",approach:"Tumor-informed",method:"NGS-based immunosequencing of IgH/IgK/TCR rearrangements; tracks patient-specific clonotype from diagnosis sample",cancerTypes:["Multiple Myeloma","B-ALL","CLL","Mantle Cell Lymphoma"],indicationsNotes:"First and only FDA-cleared IVD for MRD detection. Indicated for hematologic malignancies only. CE-IVDR certified in EU.",distributionNotes:"US: Primarily central lab service (send-out to Adaptive). EU: IVDR-certified reagent kit available for tech transfer to qualified laboratories.",sensitivity:95,sensitivityNotes:"Detects MRD at 10^-6 sensitivity in bone marrow samples. FDA-cleared analytical sensitivity.",specificity:99,lod:"1 cell in 1 million",lod95:"10^-6",lodNotes:"Ultra-sensitive detection using immunosequencing of clonal rearrangements; depth limited by cell input.",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires diagnostic sample to identify patient-specific clonotype for tracking",requiresMatchedNormal:"No",initialTat:7,followUpTat:7,bloodVolume:null,bloodVolumeNotes:"Primarily bone marrow; peripheral blood accepted for CLL",fdaStatus:"FDA-cleared IVD (2018); CE-IVDR (2024)",reimbursement:"Medicare LCD (MolDX); expanded coverage for MM, B-ALL, CLL, MCL",cptCodes:"0364U",clinicalAvailability:"FDA-cleared IVD kit; also available as central lab service",totalParticipants:5e4,numPublications:200,numPublicationsPlus:!0,clinicalSettings:["Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Primarily used for post-treatment response assessment and ongoing surveillance in hematologic malignancies. Supported by NCCN guidelines for MM, ALL.",technologyDifferentiator:"Only FDA-cleared MRD IVD kit. Unique immunosequencing approach tracks clonal Ig/TCR rearrangements rather than somatic mutations. Available as distributed IVD kit for labs with MiSeqDx, enabling in-house testing."},{id:"mrd-kit-2",sampleCategory:"Bone Marrow/Blood",name:"LymphoTrack Dx IGH Assay",vendor:"Invivoscribe",productType:"Laboratory IVD Kit",platformRequired:"Illumina MiSeq",approach:"Tumor-informed",method:"NGS-based B-cell clonality and MRD tracking via IGH gene rearrangements",cancerTypes:["B-cell lymphomas","CLL","B-ALL"],indicationsNotes:"CE-IVDR marked for B-cell clonality assessment and MRD tracking in B-cell malignancies. Part of LymphoTrack portfolio including IGK and TRG assays.",sensitivity:98,sensitivityNotes:"98% detection rate for clonal IGH rearrangements vs PCR GeneScan/Sanger sequencing; MRD sensitivity up to 10^-6 with sufficient DNA input",specificity:99,specificityNotes:">99% specificity for clonality detection per NGS validation studies",lod:"10^-4 to 10^-6",lodNotes:"Sensitivity depends on DNA input and sequencing depth; can achieve 1 in 1 million with optimized protocols",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires diagnostic sample to identify clonal IGH rearrangement",requiresMatchedNormal:"No",initialTat:5,followUpTat:3,fdaStatus:"CE-IVDR; FDA clearance pending",reimbursement:"Coverage varies; often reimbursed as clonality assay",clinicalAvailability:"CE-IVD kit; RUO in US",totalParticipants:5e3,numPublications:30,clinicalSettings:["Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Used for both initial clonality assessment and longitudinal MRD monitoring in B-cell malignancies.",technologyDifferentiator:"CE-IVDR distributed kit enabling in-house NGS-based MRD. Works with MiSeq platform already common in molecular labs. Includes MyInformatics software for MRD trending."},{id:"mrd-kit-3",sampleCategory:"Bone Marrow",name:"BD OneFlow B-ALL MRD Kit",vendor:"BD Biosciences",productType:"Laboratory IVD Kit",platformRequired:"BD FACSLyric Flow Cytometer",approach:"Tumor-nave",method:"Multiparameter flow cytometry (Next Generation Flow); 8-color standardized panel for B-ALL MRD",cancerTypes:["B-ALL"],indicationsNotes:"CE-IVDR marked standardized flow cytometry MRD kit for B-cell ALL. Part of EuroFlow consortium standardization.",sensitivity:96,sensitivityNotes:"96% sensitivity for MRD detection at 10^-4 threshold (EuroFlow standardized protocols); sensitivity of 10^-4 to 10^-5 depending on cell events acquired",specificity:95,specificityNotes:"95% specificity vs final clinical diagnosis in validation studies",lod:"10^-4 to 10^-5",lodNotes:"Flow cytometry sensitivity depends on number of events; typically 10^-4 with 1 million cells",requiresTumorTissue:"No",requiresTumorTissueNotes:"Tumor-nave approach - no prior sample needed",requiresMatchedNormal:"No",initialTat:1,followUpTat:1,fdaStatus:"CE-IVDR; not FDA-cleared",reimbursement:"Coverage as flow cytometry MRD",clinicalAvailability:"CE-IVD kit",totalParticipants:1e4,numPublications:100,numPublicationsPlus:!0,clinicalSettings:["Post-Adjuvant","Surveillance"],clinicalSettingsNotes:"Same-day results enable rapid treatment decisions. Standard of care for MRD monitoring in many European centers.",technologyDifferentiator:"Flow cytometry provides same-day results vs. 5-7 days for NGS. Standardized EuroFlow panels ensure reproducibility across labs. No prior sample needed (tumor-nave). Different modality than NGS - may be complementary."}],Y=[{id:"ecd-1",sampleCategory:"Blood/Plasma",name:"Shield",vendor:"Guardant Health",testScope:"Single-cancer (CRC)",approach:"Blood-based cfDNA screening (plasma)",method:"NGS detecting cfDNA methylation patterns + fragmentomics + somatic mutations (~1Mb genome coverage)",cancerTypes:["Colorectal cancer (colon and rectal)"],targetPopulation:"Average-risk adults 45-84 years without prior CRC; adenomas; IBD; or hereditary CRC syndromes",indicationGroup:"CRC",sensitivity:83.1,sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",advancedAdenomaSensitivity:13.2,advancedAdenomaSensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477985/",advancedAdenomaSensitivityNotes:"Limited sensitivity for precancerous advanced adenomas (13.2%); blood-based tests generally less effective at detecting polyps than stool-based tests.",stageISensitivity:54.5,stageIISensitivity:100,stageIIISensitivity:96,stageIVSensitivity:87.5,specificity:89.6,specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",ppv:3.1,ppvCitations:"https://pubmed.ncbi.nlm.nih.gov/38477985/",ppvDefinition:"PPV for colorectal cancer (CRC) in average-risk ECLIPSE screening population",npv:99.92,npvCitations:"https://pubmed.ncbi.nlm.nih.gov/38477985/",npvDefinition:"NPV for absence of CRC in average-risk ECLIPSE screening population",performanceCitations:"https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",performanceNotes:"In ECLIPSE cfDNA blood test showed 83% sensitivity for CRC with 90% specificity. Stage I sensitivity 55-65%; limited detection of advanced adenomas (13.2%).",leadTimeNotes:"No formal lead-time vs colonoscopy; positioned as guideline-accepted primary screening option every 3 years in average-risk adults",fdaStatus:"FDA-approved PMA (P230009) July 26 2024 - First blood test for primary CRC screening; NCCN-recommended",reimbursement:"Medicare",reimbursementNote:"Medicare coverage per NCD 210.3; commercial coverage expanding",commercialPayers:[],commercialPayersCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Healths-Shield-Blood-Test-Now-Covered-for-VA-Community-Care-Beneficiaries/default.aspx",commercialPayersNotes:"No commercial payer coverage yet. Government programs: VA Community Care Network covers Shield with no copay for average-risk individuals 45+; TRICARE also covers. Commercial insurance coverage pending USPSTF guideline inclusion and ACS recommendations. Once included in guidelines, expected to be covered under ACA preventive services.",availableRegions:["US"],clinicalAvailability:"Commercially available in US since August 2024",tat:"~14 days",sampleType:"Whole blood in Guardant cfDNA BCT tubes",sampleVolume:"4 tubes (minimum 2 mL plasma)",sampleStability:"7 days at ambient temperature",cptCode:"0537U",codeType:"PLA",medicareRate:1495,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,listPrice:895,screeningInterval:"Every 3 years",clinicalTrials:"NCT04136002 ECLIPSE CRC screening study (22877); NCT05716477 OSU Guardant Shield CRC Screening Project (300)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT04136002 | https://clinicaltrials.gov/study/NCT05716477",totalParticipants:23177,numPublications:5,numPublicationsPlus:!0},{id:"ecd-2",sampleCategory:"Blood/Plasma",name:"Galleri",vendor:"GRAIL",testScope:"Multi-cancer (MCED)",approach:"Blood-based cfDNA methylation MCED (plasma)",method:"Tumor-nave cfDNA methylation profiling with targeted NGS + machine-learning classifier; predicts cancer signal and tissue of origin (CSO)",cancerTypes:["50+ cancer types including colorectal, lung, pancreas, ovary, liver, head & neck, lymphoma, esophagus, stomach, bile duct, etc."],targetPopulation:"Asymptomatic adults 50 years as adjunct to standard single-cancer screening",indicationGroup:"MCED",sensitivity:51.5,sensitivityCitations:"https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/",stageISensitivity:16.8,stageIISensitivity:40.4,stageIIISensitivity:77,stageIVSensitivity:90.1,specificity:99.5,specificityCitations:"https://www.galleri.com/hcp/galleri-test-performance | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/",ppv:61.6,ppvCitations:"https://www.galleri.com/hcp/galleri-test-performance",ppvDefinition:"PPV for any cancer among participants with Cancer Signal Detected",npv:99.1,npvCitations:"https://www.galleri.com/hcp/galleri-test-performance",npvDefinition:"NPV for remaining cancer-free after No Cancer Signal Detected (12-month follow-up)",tumorOriginAccuracy:93,tumorOriginAccuracyNotes:"Cancer Signal Origin (CSO) prediction accuracy: 93% top-1 prediction, 97% top-2 predictions in CCGA validation studies",performanceCitations:"https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/ | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/",performanceNotes:"Overall cancer signal sensitivity ~51.5% with stage-specific sensitivity rising from ~17% at stage I to ~90% at stage IV; specificity ~99.5-99.6%.",leadTimeNotes:"PATHFINDER and PATHFINDER 2 show ~7-fold increase in cancers detected when added to USPSTF A/B screening; median diagnostic resolution ~1.5 months",fdaStatus:"LDT performed in CLIA-certified CAP-accredited lab; not FDA-approved; Breakthrough Device designation; PMA submission expected H1 2026",reimbursement:"Coverage Varies",reimbursementNote:"Generally self-pay; most insurers and Medicare do not cover MCED as of 2025; TRICARE covers for 50 with elevated risk",commercialPayers:["Curative Insurance","Fountain Health","Alignment Health Plan"],commercialPayersCitations:"https://grail.com/press-releases/curative-insurance-company-adds-grails-galleri-test-to-member-benefits-for-multi-cancer-early-detection/",commercialPayersNotes:"Limited commercial coverage. Curative Insurance and Fountain Health offer $0 copay coverage. Alignment Health Plan (Medicare Advantage) covers in select CA/NC plans. Government programs: TRICARE covers with prior authorization for eligible beneficiaries 50. Most major commercial insurers consider investigational.",availableRegions:["US","UK"],clinicalAvailability:"Commercially available in US and some international markets as CLIA test since June 2021",tat:"10-14 business days (up to 4 weeks during high volume)",sampleType:"Whole blood in Streck cfDNA BCT tubes",sampleVolume:"2 tubes",sampleStability:"7 days at ambient temperature (1-40C); do not refrigerate/freeze",cptCode:"Proprietary",listPrice:949,screeningInterval:"Annual recommended",clinicalTrials:"NCT05611632 NHS-Galleri randomized screening trial (~140000); NCT05155605 PATHFINDER 2 safety/performance study (~35500); NCT03934866 SUMMIT high-risk lung cohort (13035)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT05611632 | https://clinicaltrials.gov/study/NCT05155605 | https://clinicaltrials.gov/study/NCT03934866",totalParticipants:188535,numPublications:20,numPublicationsPlus:!0},{id:"ecd-3",sampleCategory:"Stool",name:"Cologuard Plus",vendor:"Exact Sciences",testScope:"Single-cancer (CRC)",approach:"Stool-based multitarget DNA test",method:"Multitarget stool DNA assay with 5 novel methylation markers + hemoglobin immunoassay; streamlined from original 11 markers",cancerTypes:["Colorectal cancer; Advanced precancerous lesions (APL); High-grade dysplasia"],targetPopulation:"Average-risk adults 45-75 years for CRC screening at home",indicationGroup:"CRC",sensitivity:93.9,sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",advancedAdenomaSensitivity:43.4,advancedAdenomaSensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992/",advancedAdenomaSensitivityNotes:"43% sensitivity for advanced precancerous lesions (APL) including advanced adenomas and sessile serrated lesions 1cm; significantly outperforms FIT (23% for APL).",stageISensitivity:87,stageISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992/",stageIISensitivity:94,stageIISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992/",stageIIISensitivity:97,stageIIISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992/",stageIVSensitivity:100,stageIVSensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992/",specificity:91,specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",ppv:3.2,ppvCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992/",ppvDefinition:"PPV for colorectal cancer (CRC) in BLUE-C average-risk screening population",npv:99.98,npvCitations:"https://pubmed.ncbi.nlm.nih.gov/38477992/",npvDefinition:"NPV for absence of CRC in BLUE-C average-risk screening population",performanceCitations:"BLUE-C pivotal trial NEJM 2024 (n=20000+); DeeP-C studies",performanceNotes:"Pivotal data show 94% sensitivity for CRC and 43% for APL; significantly outperforms FIT (94% vs 67% for CRC; 43% vs 23% for APL).",leadTimeNotes:"Non-invasive alternative to colonoscopy; 30% lower false positive rate vs original Cologuard; significantly improved adherence vs colonoscopy",fdaStatus:"FDA-approved PMA October 4 2024",reimbursement:"Medicare",reimbursementNote:"Medicare coverage; $0 out-of-pocket for eligible; broad commercial payer coverage",commercialPayers:["Humana"],commercialPayersCitations:"https://www.cologuard.com/insurance",commercialPayersNotes:"Cologuard Plus confirmed coverage: Medicare Part B and Humana Medicare Advantage. Government programs: TRICARE expected based on legacy Cologuard coverage. Other major commercial payers (UnitedHealthcare, Aetna, Cigna, Anthem BCBS) anticipated to extend legacy Cologuard coverage to Plus but should be validated per plan.",clinicalAvailability:"Commercially launched late March 2025 via ExactNexus (350+ health systems)",tat:"3-5 days from receipt",sampleType:"At-home stool collection with enhanced preservatives",sampleVolume:"Stool sample",sampleStability:"Extended return window vs original",cptCode:"0464U",listPrice:790,screeningInterval:"Every 3 years",clinicalTrials:"NCT04144738 BLUE-C pivotal Cologuard Plus CRC screening trial (26758)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT04144738",totalParticipants:26758,numPublications:2,numPublicationsPlus:!0},{id:"ecd-4",sampleCategory:"Stool",name:"ColoSense",vendor:"Geneoscopy",testScope:"Single-cancer (CRC)",approach:"Stool-based multitarget RNA test",method:"8 stool-derived eukaryotic RNA (seRNA) transcripts via ddPCR + FIT - first FDA-approved RNA-based cancer screening test",cancerTypes:["Colorectal cancer; Advanced adenomas; Sessile serrated lesions"],targetPopulation:"Average-risk adults 45+ years for CRC screening",indicationGroup:"CRC",sensitivity:93,sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",stageISensitivity:100,stageISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/37930717/",stageIISensitivity:71.4,stageIISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/37930717/",stageIIISensitivity:100,stageIIISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/37930717/",specificity:88,specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",ppv:1.9,ppvCitations:"https://pubmed.ncbi.nlm.nih.gov/37930717/",ppvDefinition:"PPV for colorectal cancer (CRC) in PMA primary effectiveness cohort",npv:94.4,npvCitations:"https://pubmed.ncbi.nlm.nih.gov/37930717/",npvDefinition:"NPV for no advanced colorectal neoplasia (NAPL or negative colonoscopy)",performanceCitations:"CRC-PREVENT JAMA 2023 (n=14263)",performanceNotes:"CRC sensitivity 93-94% with 100% Stage I detection; advanced adenoma 45-46%; specificity 88%; outperforms FIT (94% vs 78% CRC; 46% vs 29% AA).",leadTimeNotes:"Non-invasive RNA-based alternative; 100% Stage I sensitivity notable",fdaStatus:"FDA-approved PMA May 3 2024; Breakthrough Device Designation January 2020",reimbursement:"Coverage Varies",reimbursementNote:"Medicare coverage pending - NCD reconsideration requested; NCCN Guidelines included",commercialPayers:[],commercialPayersCitations:"",commercialPayersNotes:"Emerging commercial and Medicaid coverage; no stable payer list yet. Medicare coverage pending NCD reconsideration.",clinicalAvailability:"Launched via Labcorp partnership late 2024/early 2025",tat:"Not publicly specified",sampleType:"At-home stool collection (simplified kit FDA-approved 2025)",sampleVolume:"Stool sample",sampleStability:"Not specified",cptCode:"0421U",listPrice:508.87,screeningInterval:"Every 3 years (USPSTF)",clinicalTrials:"NCT04739722 CRC-PREVENT pivotal ColoSense stool RNA CRC screening trial (14263)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT04739722",totalParticipants:8920,numPublications:3,numPublicationsPlus:!0},{id:"ecd-5",sampleCategory:"Blood/Plasma",name:"Cancerguard",vendor:"Exact Sciences",testScope:"Multi-cancer (MCED)",approach:"Blood-based multi-biomarker MCED (plasma)",method:"cfDNA methylation + tumor-associated proteins + DNA mutation reflex testing - first multi-biomarker class MCED",cancerTypes:["50+ cancer types (excludes breast and prostate); 6 deadliest cancers: pancreatic, lung, liver, esophageal, stomach, ovarian"],targetPopulation:"Adults 50-84 years with no cancer diagnosis in past 3 years",indicationGroup:"MCED",sensitivity:64,sensitivityCitations:"https://www.exactsciences.com/cancer-testing/cancerguard-mced-providers/resources",specificity:97.4,specificityCitations:"https://www.exactsciences.com/cancer-testing/cancerguard-mced-providers/resources",ppv:19.4,ppvDefinition:"PPV for any cancer in DETECT-A CancerSEEK interventional study",npv:99.3,npvDefinition:"NPV for absence of any cancer in DETECT-A CancerSEEK interventional study",tumorOriginAccuracy:null,tumorOriginAccuracyNotes:"Does not predict tissue of origin; uses imaging-guided diagnostic resolution pathway instead (up to $6,000 covered imaging workup)",performanceCitations:"DETECT-A (n=10006); ASCEND-2 (n=6354); FALCON Registry (n=25000 ongoing)",performanceNotes:"64% sensitivity for 17 cancer types excluding breast/prostate; 68% for 6 deadliest cancers; >33% early-stage (I-II) detected; 97.4% specificity.",leadTimeNotes:"First-of-its-kind multi-biomarker approach; imaging-guided resolution (no tissue of origin prediction)",fdaStatus:"LDT; not FDA-approved; Breakthrough Device Designation (via CancerSEEK)",reimbursement:"Coverage Varies",reimbursementNote:"Not covered by Medicare or commercial payers; not billed to insurance; FSA/HSA eligible",clinicalAvailability:"Launched September 2025 via Quest Diagnostics (7000+ sites)",availableRegions:["US"],tat:"Not publicly specified",sampleType:"Whole blood in LBgard tubes",sampleVolume:"4 tubes  8.5 mL = 34 mL total",sampleStability:"72 hours at room temperature (15-25C)",cptCode:"Proprietary",listPrice:689,screeningInterval:"Annual recommended",clinicalTrials:"DETECT-A prospective interventional MCED (10006); ASCEND-2 classifier development (6354); NCT06589310 FALCON Registry (25000 target)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT06589310",totalParticipants:16360,numPublications:2,numPublicationsPlus:!0},{id:"ecd-6",sampleCategory:"Blood/Plasma",name:"Freenome CRC Blood Test",vendor:"Freenome",testScope:"Single-cancer (CRC)",approach:"Blood-based cfDNA multiomics (plasma)",method:"AI/ML analyzing genomic + epigenomic (single-base methylation) + proteomic biomarkers",cancerTypes:["Colorectal cancer; Advanced adenomas"],targetPopulation:"Average-risk adults for CRC screening",indicationGroup:"CRC",sensitivity:79.2,sensitivityCitations:"https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",stageISensitivity:57.1,stageISensitivityCitations:"https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",stageIISensitivity:100,stageIISensitivityCitations:"https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",stageIIISensitivity:82.4,stageIIISensitivityCitations:"https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",stageIVSensitivity:100,stageIVSensitivityCitations:"https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",specificity:91.5,specificityCitations:"https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",ppvDefinition:"PPV for advanced colorectal neoplasia in PREEMPT CRC (not yet populated)",npvDefinition:"NPV for advanced colorectal neoplasia in PREEMPT CRC (not yet populated)",performanceCitations:"PREEMPT CRC JAMA June 2025 (n=48995 enrolled; 27010 analyzed)",performanceNotes:"79.2% CRC sensitivity with 57.1% Stage I; 12.5% advanced adenoma (29% for high-grade dysplasia); 91.5% specificity.",leadTimeNotes:"Largest blood-based CRC screening study (PREEMPT CRC n=48995); multiomics approach combines multiple biomarker classes",fdaStatus:"PMA application submitted (final module August 2025); Exact Sciences exclusive US licensing agreement announced August 2025",reimbursement:"Coverage Varies",reimbursementNote:"Not yet established",clinicalAvailability:"Not yet commercially available - pending FDA approval",tat:"Not applicable - not yet available",sampleType:"Blood",sampleVolume:"Not specified",sampleStability:"Not specified",cptCode:"UNKNOWN",screeningInterval:"Expected every 3 years",clinicalTrials:"NCT04369053 PREEMPT CRC registrational Freenome blood-based CRC screening study (48995 enrolled; 27010 analyzed)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT04369053",totalParticipants:48995,numPublications:2,numPublicationsPlus:!0},{id:"ecd-7",sampleCategory:"Blood/Plasma",name:"FirstLook Lung",vendor:"DELFI Diagnostics",testScope:"Single-cancer (Lung)",approach:"Blood-based cfDNA fragmentomics",method:"Low-pass whole genome sequencing analyzing cfDNA fragment length patterns + ML classifier - detects chaotic DNA packaging from cancer cells",cancerTypes:["Lung cancer (screening enhancement - pre-LDCT risk stratification)"],targetPopulation:"USPSTF-eligible: Adults 50-80 years; 20 pack-years smoking history; current smokers or quit within 15 years",indicationGroup:"Lung",sensitivity:80,sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38829053/",stageISensitivity:71,stageISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38829053/",stageIISensitivity:89,stageIISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38829053/",stageIIISensitivity:88,stageIIISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38829053/",stageIVSensitivity:98,stageIVSensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38829053/",specificity:58,specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/38829053/",ppvDefinition:"PPV for lung cancer among Elevated results in high-risk USPSTF screening population",npv:99.7,npvCitations:"https://pubmed.ncbi.nlm.nih.gov/38829053/",npvDefinition:"NPV for being lung-cancer free among Not Elevated results in high-risk USPSTF screening population",performanceCitations:"DELFI-L101 Cancer Discovery 2024 (n=958); CASCADE-LUNG/L201 (NCT05306288); FIRSTLung/L301 (NCT06145750)",performanceNotes:"80% overall sensitivity (71% Stage I; 98% Stage IV); 58% specificity; 99.7% NPV; fragmentomics approach novel mechanism.",leadTimeNotes:"Pre-LDCT risk stratification; 5.5 higher cancer likelihood with Elevated result; designed to increase LDCT uptake (currently only 6% eligible adults screened)",fdaStatus:"LDT; FDA IVD submission planned",reimbursement:"Coverage Varies",reimbursementNote:"Not established; not covered by Medicare",clinicalAvailability:"Early Experience Program at select health systems (OSF HealthCare; City of Hope; Indigenous Pact)",tat:"10-14 business days",sampleType:"Standard blood draw",sampleVolume:"<1 mL plasma required",sampleStability:"Standard",cptCode:"UNKNOWN",listPrice:300,screeningInterval:"Annual (complement to LDCT)",clinicalTrials:"NCT05306288 CASCADE-LUNG prospective validation (15000 target); NCT04825834 DELFI-L101 case-control development (958); NCT06145750 FIRSTLung cluster RCT (ongoing)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT05306288 | https://clinicaltrials.gov/study/NCT04825834 | https://clinicaltrials.gov/study/NCT06145750",totalParticipants:15958,numPublications:3,numPublicationsPlus:!0},{id:"ecd-8",sampleCategory:"Blood/Plasma",name:"HelioLiver",vendor:"Helio Genomics",testScope:"Single-cancer (HCC/Liver)",approach:"Blood-based cfDNA methylation + protein biomarkers",method:"AI algorithm analyzing cfDNA methylation patterns + AFP + AFP-L3 + DCP + demographics",cancerTypes:["Hepatocellular carcinoma (HCC)"],targetPopulation:"Adults with cirrhosis; chronic HBV carriers; high-risk for HCC",indicationGroup:"Liver",sensitivity:85,sensitivityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",stageISensitivity:76,stageISensitivityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",specificity:91,specificityCitations:"https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",ppvDefinition:"PPV for hepatocellular carcinoma (HCC) in high-risk surveillance population (cirrhosis / chronic HBV)",npvDefinition:"NPV for absence of HCC in high-risk surveillance population (cirrhosis / chronic HBV)",performanceCitations:"ENCORE Hepatology Communications 2022 (n=247); CLiMB EASL 2024 (n=1968); VICTORY (n=1100)",performanceNotes:"85% overall sensitivity with 76% early-stage; 91% specificity; AUC 0.944 vs AFP 0.851 and GALAD 0.899.",leadTimeNotes:"Significantly outperforms ultrasound for early-stage HCC detection (44.4% vs 11.1% for T1 tumors); designed as surveillance tool",fdaStatus:"PMA submitted Q2 2024 (Class III); currently LDT",reimbursement:"Coverage Varies",reimbursementNote:"Expected upon FDA approval; CPT code 0333U assigned",clinicalAvailability:"Commercially available as LDT",tat:"Not publicly specified",sampleType:"Blood (serum for proteins; plasma for cfDNA)",sampleVolume:"Standard blood draw",sampleStability:"Standard",cptCode:"0333U",screeningInterval:"Every 6 months (per AASLD)",clinicalTrials:"NCT05059665 ENCORE validation (247); NCT03694600 CLiMB prospective HCC surveillance (1968); VICTORY study (1100)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT05059665 | https://clinicaltrials.gov/study/NCT03694600",totalParticipants:3315,numPublications:2,numPublicationsPlus:!0},{id:"ecd-9",sampleCategory:"Blood/Plasma",name:"Oncoguard Liver",vendor:"Exact Sciences",testScope:"Single-cancer (HCC/Liver)",approach:"Blood-based methylated DNA markers + protein",method:"3 methylated DNA markers (HOXA1; EMX1; TSPYL5) + AFP + biological sex; LQAS PCR technology; developed with Mayo Clinic",cancerTypes:["Hepatocellular carcinoma (HCC)"],targetPopulation:"Adults with cirrhosis; chronic HBV; high-risk for HCC requiring surveillance",indicationGroup:"Liver",sensitivity:88,sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/34419598/",stageISensitivity:82,stageISensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/34419598/",specificity:87,specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/34419598/",ppvDefinition:"PPV for HCC in high-risk surveillance population (ALTUS / validation cohorts)",npvDefinition:"NPV for absence of HCC in high-risk surveillance population (ALTUS / validation cohorts)",performanceCitations:"Phase II validation CGH 2021; ALTUS NCT05064553 (n>3000) November 2025",performanceNotes:"88% overall sensitivity; 82% early-stage (BCLC 0/A); 87% specificity; AUC 0.91 vs AFP 0.84 and GALAD 0.88.",leadTimeNotes:"ALTUS study shows 77% early-stage vs 36% for ultrasound; 64% very early-stage vs 9% for ultrasound (6-7 improvement)",fdaStatus:"LDT; Breakthrough Device Designation October 2019",reimbursement:"Coverage Varies",reimbursementNote:"NOT covered by Medicare; financial assistance available (1-844-870-8870)",clinicalAvailability:"Commercially available",tat:"~1 week",sampleType:"Blood (Exact Sciences collection kit)",sampleVolume:"Standard blood draw",sampleStability:"Standard",cptCode:"81599",screeningInterval:"Every 3-6 months",clinicalTrials:"NCT05064553 ALTUS prospective HCC surveillance (3000+); Phase II validation CGH 2021",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT05064553",totalParticipants:3e3,numPublications:3,numPublicationsPlus:!0},{id:"ecd-10",sampleCategory:"Blood/Plasma",name:"Shield MCD",vendor:"Guardant Health",testScope:"Multi-cancer (MCED)",approach:"Blood-based cfDNA methylation MCED (plasma)",method:"Methylation-based NGS cfDNA platform detecting 10 cancer types; same Shield platform as CRC test with expanded analysis; requires physician opt-in and patient authorization for EMR data release",cancerTypes:["Bladder; Colorectal; Esophageal; Gastric; Liver; Lung; Ovarian; Pancreas; Breast; Prostate (10 tumor types)"],targetPopulation:"Average-risk adults 45+ years; ordered as add-on when physician requests Shield CRC test",indicationGroup:"MCED",tumorOriginAccuracy:null,tumorOriginAccuracyNotes:"Cancer signal of origin prediction included; specific accuracy not yet publicly disclosed; performance data presented at AACR/ASCO 2025",sensitivity:60,sensitivityCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",sensitivityNotes:"Overall episode-based sensitivity ~60% across all 10 cancer types; ~74% sensitivity for subset of deadliest/aggressive cancers. Data from interim MCED performance presented at AACR/ASCO 2025.",sensitivityType:"episode-based interim",specificity:98.5,specificityCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",specificityNotes:"~98.5% specificity from interim Shield MCED data. High specificity critical for screening use to minimize false positives.",ppvDefinition:"PPV for any of 10 target cancers among positive Shield MCD results (not yet reported)",npvDefinition:"NPV for remaining cancer-free among negative Shield MCD results (not yet reported)",performanceCitations:"AACR 2025 oral presentation; ASCO 2025; NCI Vanguard Study (NCT pending; n=24000); Guardant Health Investor Relations 2025",performanceNotes:"Overall sensitivity ~60% across all cancers; ~74% sensitivity for subset of deadliest cancers; ~98.5% specificity. Performance data from interim MCED analysis supported NCI selection for Vanguard Study.",leadTimeNotes:"Available as add-on to Shield CRC screening; physician must opt-in and patient must authorize release of medical records to Guardant in exchange for MCD results",fdaStatus:"LDT; FDA Breakthrough Device Designation (June 2025); selected for NCI Vanguard Study (24000 participants); Shield MCD reviewed by FDA as part of NCI investigational device exemption (IDE)",reimbursement:"Coverage Varies",reimbursementNote:"Not covered by Medicare or commercial payers; no additional cost when ordered with Shield CRC (data exchange model)",clinicalAvailability:"Launched nationally October 2025; available when ordering Shield CRC test with physician opt-in",availableRegions:["US"],tat:"~14 days (same blood draw as Shield CRC)",sampleType:"Whole blood in Guardant cfDNA BCT tubes (same sample as Shield CRC)",sampleVolume:"4 tubes (no additional blood draw required)",sampleStability:"7 days at ambient temperature",cptCode:"UNKNOWN",screeningInterval:"Annual recommended (with Shield CRC every 3 years)",clinicalTrials:"NCI Vanguard Study multi-cancer detection feasibility (24000 target); AACR 2025 presentations; ASCO 2025 presentations",totalParticipants:24e3,numPublications:0},{id:"ecd-11",sampleCategory:"Blood/Plasma",name:"EPISEEK",vendor:"Precision Epigenomics",testScope:"Multi-cancer (MCED)",approach:"Blood-based cfDNA methylation MCED (plasma)",method:"Methylation-specific PCR detecting hypermethylated cfDNA loci across 60+ cancer types including all 20 most fatal cancers; does not use NGS; analyzes 10 cancer biomarkers",cancerTypes:["60+ cancer types including all 20 most fatal cancers: lung, liver, pancreas, esophageal, bladder, stomach, head & neck SCC, uterine, low-grade glioma, high-grade glioma (brain cancer detection believed unique among blood-based MCED tests)"],targetPopulation:"Adults 45+ years with elevated cancer risk; can be considered from age 21 with risk factors (smoking, family history)",indicationGroup:"MCED",tumorOriginAccuracy:null,tumorOriginAccuracyNotes:"Does not predict tissue of origin (no CSO/TOO); requires standard diagnostic workup to localize cancer source",sensitivity:54,sensitivityCitations:"https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",sensitivityNotes:"Overall incidence-adjusted sensitivity (IAS) across all stages. IAS is more conservative than observed sensitivity as it weights by cancer incidence.",stageISensitivity:45,stageISensitivityCitations:"https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",stageIISensitivity:45,stageIISensitivityCitations:"https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",stageISensitivityNotes:"Combined Stage I/II IAS = 45%. For aggressive unscreened cancers (bladder, esophagus, liver, H&N, lung, pancreas, stomach, uterine) Stage I/II sensitivity is 57%.",stageIIISensitivity:73,stageIIISensitivityCitations:"https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",stageIVSensitivity:74,stageIVSensitivityCitations:"https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",specificity:99.5,specificityCitations:"https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",ppv:64.9,ppvDefinition:"PPV in validation cohort (n=482). Modeled PPV of 40% in screening population age 50+.",npv:99.5,npvDefinition:"NPV for absence of cancer in validation cohort",performanceCitations:"Pham TH et al. J Clin Oncol 2025;43(16_suppl):3144. ASCO 2025 Annual Meeting.",performanceNotes:"Validation included 281 cancer-positive plasma samples across all stages and 201 healthy controls age 40+. Analytical LOD <0.1 ng cfDNA for 8/10 biomarkers. Uses incidence-adjusted sensitivity (more conservative than observed sensitivity).",leadTimeNotes:"No lead time vs imaging data reported; designed for asymptomatic screening",fdaStatus:"CLIA LDT  NOT FDA approved",reimbursement:"Self-Pay",reimbursementNote:"No Medicare or commercial insurance coverage. Positioned as affordable/accessible alternative to NGS-based MCED tests.",commercialPayers:[],clinicalAvailability:"Commercially available in US via CLIA-certified lab in Tucson, AZ. Physician-ordered (not direct-to-consumer).",availableRegions:["US"],tat:"5 days",tatNotes:"Collection to report turnaround time (includes shipping and processing). Lab processing time is 2-3 days.",sampleType:"Two 10-mL Streck cfDNA BCT tubes",sampleVolume:"20 mL whole blood (two 10-mL tubes)",cptCode:"UNKNOWN",listPrice:699,screeningInterval:"Not specified",clinicalTrials:"ASCO 2025 validation study (n=482); simulated 100,000-patient SEER-based screening cohort modeling",totalParticipants:482,numPublications:1,numPublicationsPlus:!1,technologyDifferentiator:"PCR-based (not NGS) - enables faster TAT, lower cost, and global scalability vs sequencing-based MCED tests"},{id:"ecd-12",sampleCategory:"Blood/Plasma",name:"ProVue Lung",vendor:"PrognomiQ",testScope:"Single-cancer (Lung)",approach:"Blood-based proteomics",method:"Proteomics-based analysis using proprietary multi-omics platform to detect unique molecular protein signatures of lung cancer; does not analyze ctDNA or methylation",cancerTypes:["Lung cancer (all types)"],targetPopulation:"High-risk adults aged 50+ with 20+ pack-year smoking history; consistent with USPSTF, ACS, and NCCN lung cancer screening guidelines",indicationGroup:"Lung",tumorOriginAccuracy:null,tumorOriginAccuracyNotes:"Single-cancer test; lung-specific",sensitivity:85,sensitivityCitations:"https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",sensitivityNotes:"Overall sensitivity for all stages of lung cancer",stageISensitivity:81,stageISensitivityCitations:"https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html",stageISensitivityNotes:"Stage I sensitivity when treatment is most effective",specificity:55,specificityCitations:"https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",specificityNotes:"Lower specificity results in higher false positive rate; designed as adjunct to LDCT screening",npv:99.8,npvNotes:"NPV >99.8% indicates strong rule-out capability",ppvDefinition:"Not publicly reported",npvDefinition:"NPV for absence of lung cancer in high-risk screening population",performanceCitations:"Unpublished data on file; manuscript under preparation. PrognomiQ website and press release Nov 2025.",performanceNotes:"Validated in multiple prospective case-control studies. Binary result (ELEVATED or NOT ELEVATED). 85% sensitivity all-stage, 81% Stage I, 55% specificity, >99.8% NPV.",leadTimeNotes:"Designed as adjunct to low-dose CT (LDCT); aims to improve screening compliance (currently <16% of eligible patients undergo annual LDCT)",fdaStatus:"CLIA LDT  NOT FDA approved",fdaStatusNotes:"Laboratory is CLIA-certified and CAP-accredited. Not cleared or approved by FDA.",reimbursement:"Self-Pay",reimbursementNote:"No Medicare or commercial insurance coverage established. Available through Early Experience Program.",commercialPayers:[],clinicalAvailability:"Limited availability - Early Experience Program at select Pennsylvania health systems (Allegheny Health Network, Penn Highlands Healthcare Lung Innovations Network). Launched November 18, 2025.",clinicalAvailabilityNotes:"Initial commercial launch through Early Experience Program to evaluate clinical workflow integration. Broader availability expected as program expands.",tat:"Not publicly specified",sampleType:"Blood (simple blood draw)",sampleVolume:"Standard blood draw",cptCode:"UNKNOWN",listPrice:null,listPriceNotes:"Pricing not publicly disclosed",screeningInterval:"Not specified; designed to complement annual LDCT screening",clinicalTrials:"Multiple prospective case-control validation studies (unpublished); Early Experience Program at Allegheny Health Network and Penn Highlands Healthcare",totalParticipants:null,totalParticipantsNotes:"Validation study size not publicly disclosed; manuscript under preparation",numPublications:0,numPublicationsPlus:!1,numPublicationsNotes:"Manuscript under preparation; data presented on company website",technologyDifferentiator:"Proteomics-based (not ctDNA/methylation) - first protein-based liquid biopsy for lung cancer detection; measures protein biomarkers rather than genetic or epigenetic signals; simple blood draw with no specialized collection tubes"},{id:"ecd-13",sampleCategory:"Blood/Plasma",name:"Signal-C",vendor:"Universal DX",testScope:"Single-cancer (Colorectal)",approach:"cfDNA methylation + fragmentation",method:"Next-generation sequencing (NGS) analyzing cell-free DNA methylation patterns and fragmentation characteristics; multi-omics approach combining methylomics, fragmentomics, and machine learning algorithms to detect colorectal cancer and advanced adenomas from a single blood draw",cancerTypes:["Colorectal cancer (CRC)","Advanced adenomas (pre-cancerous)"],targetPopulation:"Average-risk adults aged 45+ eligible for colorectal cancer screening per USPSTF guidelines",indicationGroup:"CRC",tumorOriginAccuracy:null,tumorOriginAccuracyNotes:"Single-cancer test; colorectal-specific",sensitivity:93,sensitivityCitations:"https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics|https://www.universaldx.com/science",sensitivityNotes:"93% sensitivity for CRC detection in 1,000-patient multi-cohort study presented at DDW 2023. Company website reports 92% sensitivity with 94% specificity in some materials - slight variations across presentations.",stageISensitivity:85,stageISensitivityNotes:"Estimated from early-stage (I-II) combined sensitivity of 91%; Stage I likely ~85% based on typical stage distribution patterns. Exact Stage I data not separately reported.",stageIISensitivity:94,stageIISensitivityNotes:"Estimated; early-stage (I-II) combined reported as 91%",stageIIISensitivity:97,stageIIISensitivityNotes:"Later stages typically show higher sensitivity; estimated based on overall 93% and early-stage 91%",stageIVSensitivity:97,stageIVSensitivityNotes:"Later stages typically show higher sensitivity; estimated based on overall 93% and early-stage 91%",advancedAdenomaSensitivity:54,advancedAdenomaSensitivityCitations:"https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics",advancedAdenomaSensitivityNotes:"54% sensitivity for advanced adenomas at 92% specificity. This pre-cancer detection capability is a key differentiator - may help prevent CRC, not just detect it.",specificity:92,specificityCitations:"https://www.businesswire.com/news/home/20230509005536/en | https://www.universaldx.com/science",specificityNotes:"92% specificity in DDW 2023 study. Some company materials report 94% specificity - may reflect different cohorts or thresholds.",ppv:null,ppvNotes:"Not publicly reported from validation studies",npv:null,npvNotes:"Not publicly reported from validation studies",performanceCitations:"DDW 2023 presentation; ASCO GI 2023 presentation; https://www.universaldx.com/science",performanceNotes:"Large 1,000-patient international multi-cohort case-control study with prospectively collected samples from US and Europe. Performance validated across multiple presentations at ASCO GI 2023 and DDW 2023.",leadTimeNotes:"Blood-based alternative to colonoscopy and stool-based tests; aims to increase screening compliance among the ~40% of eligible adults not up-to-date on CRC screening",fdaStatus:"Investigational  FDA pivotal trial ongoing",fdaStatusCitations:"https://clinicaltrials.gov/study/NCT06059963 | https://www.businesswire.com/news/home/20240807274324/en/Universal-DX-Initiates-Clinical-Trial-for-FDA-Approval-of-Signal-C-Colorectal-Cancer-Screening-Blood-Test",fdaStatusNotes:"FDA premarket approval (PMA) pivotal trial initiated January 2024. Targeting enrollment of 15,000+ patients across 100 investigator sites. Quest Diagnostics oncology center in Lewisville, TX serves as single testing site for trial.",reimbursement:"Not yet established",reimbursementNote:"Pending FDA approval; not currently available for clinical use in US",commercialPayers:[],clinicalAvailability:"Not yet commercially available  FDA pivotal trial in progress",clinicalAvailabilityNotes:"Quest Diagnostics has exclusive US commercialization rights pending FDA approval (collaboration announced November 2023). Commercial launch expected following PMA approval.",tat:"Not specified",tatNotes:"Turnaround time not publicly disclosed; will be determined for commercial launch",sampleType:"Blood (single draw)",sampleVolume:"Not specified",cptCode:"TBD",cptCodesNotes:"CPT code to be established upon FDA approval and commercial launch",listPrice:null,listPriceNotes:"Pricing not yet established; pending FDA approval",screeningInterval:"Not specified; likely aligned with standard CRC screening intervals (every 3 years typical for blood-based tests)",clinicalTrials:"FDA pivotal trial (NCT06059963) - 15,000+ patient enrollment target across 100 sites; prior 1,000-patient validation study",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT06059963",totalParticipants:1e3,totalParticipantsNotes:"1,000 patients in published validation study (DDW 2023); 15,000+ targeted for ongoing FDA pivotal trial",numPublications:3,numPublicationsPlus:!0,numPublicationsNotes:"Multiple conference presentations at DDW 2023, ASCO GI 2023, AACR 2022; peer-reviewed publications in preparation",technologyDifferentiator:"Multi-omics approach combining methylation + fragmentation analysis with machine learning. Company claims to have identified specific cfDNA sequence regions that capture cancer's earliest signals. Spain-based biotech (Universal DX) with US office in Cambridge, MA. Platform technology (Signal-X) being extended to other GI cancers including pancreatic, liver, and gastric."},{id:"ecd-kit-1",sampleCategory:"Stool",name:"Cologuard",vendor:"Exact Sciences",productType:"Self-Collection",testScope:"Single-cancer (CRC)",approach:"Stool DNA + FIT",method:"Multi-target stool DNA test combining methylated BMP3/NDRG4, mutant KRAS, and fecal immunochemical test (FIT) for hemoglobin",cancerTypes:["Colorectal cancer"],targetPopulation:"Average-risk adults 45+ for CRC screening",indicationsNotes:"FDA PMA-approved for CRC screening. At-home self-collection cancer screening test. Patient receives kit by mail, collects stool sample at home, ships to Exact Sciences lab.",sensitivity:92,sensitivityNotes:"92% sensitivity for CRC; 42% for advanced adenomas in pivotal study",stageISensitivity:93,stageIISensitivity:94,stageIIISensitivity:93,stageIVSensitivity:92,specificity:87,specificityNotes:"87% specificity; ~13% false positive rate",ppv:3.7,ppvNotes:"PPV for CRC in average-risk screening population",npv:99.9,fdaStatus:"FDA PMA-approved (2014)",guidelinesNotes:"Included in USPSTF Grade A recommendation for CRC screening (stool DNA-FIT modality). NCCN, ACS, and ACG guidelines include mt-sDNA as screening option.",reimbursement:"Medicare covered; most commercial payers",reimbursementNote:"Covered by Medicare and most commercial insurers for average-risk CRC screening ages 45-85",commercialPayers:["UnitedHealthcare","Aetna","Cigna","BCBS","Humana"],listPrice:649,listPriceNotes:"List price $649; typically covered by insurance with no out-of-pocket",clinicalAvailability:"Self-collection kit shipped to patient home",tat:"1-2 weeks",screeningInterval:"Every 3 years",totalParticipants:1e4,numPublications:100,numPublicationsPlus:!0,technologyDifferentiator:"At-home self-collection cancer screening - patient collects sample at home with no clinic visit required. Combines DNA biomarkers with FIT in single test. Included in USPSTF Grade A recommendation for CRC screening."},{id:"ecd-kit-2",sampleCategory:"Blood/Plasma",name:"Epi proColon",vendor:"Epigenomics",productType:"Laboratory IVD Kit",platformRequired:"Real-time PCR system",testScope:"Single-cancer (CRC)",approach:"Blood-based cfDNA methylation",method:"Detects methylated SEPT9 gene in plasma cfDNA via real-time PCR",cancerTypes:["Colorectal cancer"],targetPopulation:"Average-risk adults who decline colonoscopy or stool-based testing",indicationsNotes:"FDA-approved blood-based CRC screening test. Intended for patients unwilling to undergo other screening methods.",sensitivity:68,sensitivityNotes:"68% sensitivity for CRC (all stages); lower than stool-based tests",stageISensitivity:57,stageIISensitivity:72,stageIIISensitivity:85,stageIVSensitivity:78,specificity:80,specificityNotes:"80% specificity in screening population",fdaStatus:"FDA-approved (2016)",reimbursement:"Coverage variable/limited",reimbursementNote:"Medicare coverage has faced challenges; commercial coverage limited. Verify current coverage before ordering.",commercialPayers:[],listPrice:192,clinicalAvailability:"FDA-approved IVD kit for laboratory use",tat:"3-5 days",screeningInterval:"Annual",totalParticipants:8e3,numPublications:50,numPublicationsPlus:!0,technologyDifferentiator:"First FDA-approved blood-based CRC screening test. Distributed IVD kit for labs with PCR capability. Positioned for patients who refuse colonoscopy and stool tests - 'better than no screening.'"}],K=[{id:"trm-1",sampleCategory:"Blood/Plasma",name:"Guardant360 Response",vendor:"Guardant Health",approach:"Tumor-agnostic",method:"Hybrid-capture NGS ctDNA panel (Guardant360) with algorithmic quantitation of variant allele fraction changes over time",cancerTypes:["Advanced solid tumors (NSCLC, bladder, breast, GI, others)"],targetPopulation:"Patients with measurable or evaluable advanced solid tumors starting systemic therapy",responseDefinition:"50% decrease in ctDNA level from baseline to first on-treatment time point; increase from baseline defines molecular non-response",leadTimeVsImaging:56,leadTimeVsImagingNotes:"Guardant Response can predict treatment response approximately 8 weeks (~56 days) earlier than standard imaging assessments.",leadTimeVsImagingCitations:"Guardant Health TRM product page; ACE-CRT clinical development brief.",lod:"~0.10.2% VAF",lodNotes:"Analytical validation demonstrates detection sensitivity down to ~0.1% MAF (mutant allele fraction) with high accuracy. Detection range 0.1%0.8% VAF depending on variant type and sample characteristics.",lodCitations:"Lanman RB et al. PLoS One 2015;10(10):e0140712; Guardant360 CDx technical specifications.",fdaStatus:"DISCONTINUED - CLIA LDT no longer available",reimbursement:"N/A - Discontinued",reimbursementNote:"Product sun-setted December 2025. Guardant has consolidated to Reveal MRD (early-stage) and Reveal TRM (advanced/metastatic) for monitoring applications.",clinicalTrials:"SERENA-6 Phase III ESR1-mutant advanced breast cancer (866); clinical validation supported by 40+ studies using Guardant360 platform for ctDNA response assessment",totalParticipants:866,numPublications:40,numPublicationsPlus:!0,isDiscontinued:!0,discontinuedDate:"December 2025",discontinuedReason:"Product consolidated into Reveal TRM for therapy response monitoring"},{id:"trm-2",sampleCategory:"Blood/Plasma",name:"Signatera (IO Monitoring)",vendor:"Natera",approach:"Tumor-informed",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Tumor-informed; needs primary tumor tissue.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Matched normal blood required.",method:"Personalized amplicon-based NGS panels targeting 16+ patient-specific variants identified from tumor/normal sequencing",cancerTypes:["Any solid tumor on ICI therapy"],targetPopulation:"Patients with advanced or metastatic solid tumors starting ICI monotherapy or ICI-based combinations",responseDefinition:"Change in personalized ctDNA level from baseline to beginning of cycle 3 (~6 weeks); increase vs decrease vs clearance",lod:"~0.01% VAF",lodNotes:"Analytical validation demonstrates LoD ~0.01% VAF (2 mutant haploid genomes among 20,000 normals), with 95% sensitivity and ~9999.7% specificity at this level. Detection rule requires 2 of 16 tracked variants to call positive.",lodCitations:"Natera Signatera FAQ; Signatera analytical validation white papers; Chen et al. 2021 MRD review.",fdaStatus:"LDT in CLIA/CAP lab; covered by Medicare for ICI treatment response monitoring",reimbursement:"Medicare",reimbursementNote:"Medicare-covered under LCD L38779 for colorectal, breast, bladder, ovarian, and lung cancers, including ovarian cancer in adjuvant/surveillance settings, neoadjuvant and adjuvant breast cancer, and stage IIII NSCLC surveillance, as well as pan-cancer immunotherapy response monitoring. As of June 2025, the genome-based Signatera Genome assay has matching Medicare coverage for these indications.",commercialPayers:["UnitedHealthcare","Cigna","Anthem BCBS","BCBS Louisiana","Blue Shield of California"],commercialPayersCitations:"https://www.natera.com/oncology/billing/",commercialPayersNotes:"Natera is in-network with most major health plans including Cigna, UnitedHealthcare, and Blue Shield of California. BCBS Louisiana provides explicit coverage. Note: Aetna lists Signatera codes as in-network but current policies show non-covered; verify with plan.",clinicalTrials:"NCT04660344 IMvigor011 Phase III bladder cancer (760); NCT05987241 MODERN (Alliance A032103) Phase 2/3 bladder cancer (~400 target); BESPOKE IO prospective observational study (multi-center)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT04660344 | https://clinicaltrials.gov/study/NCT05987241",totalParticipants:1160,numPublications:125,numPublicationsPlus:!0},{id:"trm-3",sampleCategory:"Blood/Plasma",name:"NeXT Personal",vendor:"Personalis",approach:"Tumor-informed",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires WGS of tumor tissue to design personalized panel.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Matched normal blood required for germline filtering.",method:"Whole-genome sequencing of tumor and matched normal with design of personalized panels targeting up to ~1,800 variants; deep sequencing of plasma cfDNA",cancerTypes:["Multiple solid tumors (breast, colorectal, NSCLC, melanoma, renal, others)"],targetPopulation:"Patients with solid tumors after curative-intent therapy (MRD) and those on systemic therapy",responseDefinition:"Quantitative change in ctDNA signal (PPM) over time; molecular response often defined as deep decrease or clearance below limit of detection",lod:"~3.45 ppm (0.000345% VAF)",lodNotes:"3.45 ppm is the LoD95 (limit of detection at 95% confidence). Detection threshold is ~1.67 ppm. WGS-based tumor-informed tracking with up to 1,800 variants provides high sensitivity for low-burden disease.",lodCitations:"Northcott et al. Oncotarget 2024; Personalis NeXT Personal Dx analytical validation brochure.",fdaStatus:"High-complexity LDT in CLIA/CAP lab; not FDA-approved",reimbursement:"Medicare coverage for select solid tumor indications including stage II-III breast cancer surveillance",reimbursementNote:"Co-commercialized with Tempus AI as xM (NeXT Personal Dx), with Tempus serving as the exclusive commercial diagnostic partner for tumor-informed MRD in breast, lung, colorectal cancers and solid-tumor immunotherapy monitoring. Clinically launched within Tempus MRD portfolio and covered by Medicare for select solid tumor indications (for example, stage IIIII breast cancer surveillance).",clinicalTrials:"NCT06230185 B-STRONGER I TNBC MRD/monitoring study (422); VICTORI resectable colorectal cancer MRD study (~71, interim cohort)",clinicalTrialsCitations:"https://clinicaltrials.gov/study/NCT06230185",totalParticipants:493,numPublications:5,numPublicationsPlus:!0},{id:"trm-4",sampleCategory:"Blood/Plasma",name:"Tempus xM for TRM",vendor:"Tempus",approach:"Tumor-nave",method:"Algorithmic estimation of ctDNA tumor fraction from Tempus xF/xF+ liquid biopsy data using diverse genomic events and germline-informed modeling",cancerTypes:["Advanced solid tumors on ICI"],targetPopulation:"Patients with advanced cancers receiving ICI-based therapy",responseDefinition:"50% reduction in ctDNA tumor fraction from baseline to early on-treatment time point (e.g., post-cycle 1)",lod:"~0.1% VAF",lodNotes:"LoD inferred from Tempus xF/xF+ platform specifications and general hybrid-capture ctDNA literature. Not explicitly validated for the TRM-specific application; most published data are for MRD (GALAXY/CIRCULATE-Japan analyses).",lodCitations:"Tempus xM technical documentation; general ctDNA review literature describing ~0.1% as typical NGS LoD.",fdaStatus:"Research-use-only biomarker and clinical-development tool",reimbursement:"Coverage Varies",reimbursementNote:"Currently available for research use only, with clinical availability expected later in 2025 per Tempus June 2025 xM for TRM announcement; used mainly in research and biopharma collaborations and not yet a standard reimbursed clinical assay.",numPublications:3,numPublicationsPlus:!0},{id:"trm-5",sampleCategory:"Blood/Plasma",name:"RaDaR",vendor:"NeoGenomics",approach:"Tumor-informed",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Tumor-informed (WES of tumor); personalized panel designed from tumor variants.",requiresMatchedNormal:"Yes",requiresMatchedNormalNotes:"Buffy coat matched normal used for germline filtering.",method:"Personalized amplicon-based NGS panels (up to ~48 variants) designed from WES of tumor and matched normal; deep ctDNA sequencing",cancerTypes:["Multiple solid tumors (breast, melanoma, colorectal, head & neck, lung, others)"],targetPopulation:"High-risk early-stage and advanced solid-tumor patients followed longitudinally after treatment or on systemic therapy",responseDefinition:"Track ctDNA levels over serial time points; response often defined as rapid fall or clearance vs persistent or rising ctDNA",lod:"0.001% VAF",lodNotes:"Analytical LoD ~0.001% VAF (~10 ppm), consistent with RaDaR ST MRD assay specifications. Earlier claims of 1010 were not supported by peer-reviewed validation data.",lodCitations:"PMC commercial MRD assay review; NeoGenomics RaDaR product specifications.",fdaStatus:"LDT in NeoGenomics CLIA/CAP lab; not FDA-approved",reimbursement:"Coverage Varies",reimbursementNote:"Used in clinical research and select clinical programs; payer coverage still emerging. NeoGenomics has also introduced a WES-based RaDaR ST assay, currently positioned for biopharma partners and interventional trials.",commercialPayers:["Blue Shield of California"],commercialPayersCitations:"https://www.decibio.com/",commercialPayersNotes:"Blue Shield of California covers RaDaR. Coverage is still emerging for TRM applications.",clinicalTrials:"ISLB 2025 bridging study (166; 15 solid tumor types; 97% concordance RaDaR ST vs RaDaR 1.0); c-TRAK TN TNBC study (161); TRACER breast cancer MRD study (~100); CHiRP breast cancer study (~100); NABUCCO bladder cancer study (54); LUCID NSCLC study (88); CLEAR-Me melanoma study (66)",totalParticipants:735,numPublications:15,numPublicationsPlus:!0},{id:"trm-6",sampleCategory:"Blood/Plasma",name:"FoundationOne Tracker (TRM)",vendor:"Foundation Medicine / Natera",approach:"Tumor-informed",requiresTumorTissue:"Yes",requiresTumorTissueNotes:"Requires prior or concurrent tumor CGP by FoundationOne CDx to identify patient-specific somatic variants for personalized panel design.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Germline and CHIP filtering performed computationally without mandatory matched-normal sequencing.",method:"Personalized ctDNA assay derived from FoundationOne CDx tumor sequencing; multiplex PCRbased plasma assay quantifies mean tumor molecules per mL (MTM/mL) over time to track treatment response in patients with advanced solid tumors.",cancerTypes:["Advanced solid tumors (all solid tumors)"],targetPopulation:"Patients with advanced solid tumors receiving systemic therapy, particularly immune checkpoint inhibitor (ICI) therapy. Medicare coverage specifically for ICI response monitoring.",responseDefinition:"Continuous change in ctDNA level (MTM/mL) from baseline to early on-treatment timepoints; molecular response (ctDNA decline or clearance) correlates with improved PFS and OS.",leadTimeVsImaging:null,leadTimeVsImagingNotes:"Studies in NSCLC (IMpower131) showed ctDNA clearance preceded imaging response; in OMICO-MoST study, ctDNA clearance preceded scan response with median lead time of 11.5 months in complete responders.",lod:"5 mean tumor molecules/mL",fdaStatus:"CLIA clinical LDT for treatment response monitoring  NOT separately FDA cleared/approved",fdaStatusCitations:"Foundation Medicine press release October 2023.",reimbursement:"Medicare",reimbursementNote:"Medicare coverage via Palmetto GBA MolDX, effective June 17, 2023, for monitoring response to immune checkpoint inhibitor (ICI) therapy in all solid tumors. Also approved through New York CLEP. Commercial payer coverage varies.",reimbursementCitations:"Foundation Medicine/Natera press release October 10, 2023.",cptCodesNotes:"Billing via MolDX program; specific PLA code TBD.",availableRegions:["US","EU","International"],availableRegionsNotes:"US: Medicare covered for ICI monitoring. International: Available via Roche global network.",clinicalAvailability:"Broadly available to all U.S. physicians since October 2023 for treatment response monitoring; available internationally via Roche affiliates.",clinicalTrials:"IMpower131 (NSCLC, Kasi et al. Clin Cancer Res 2023); OMICO-MoST (pan-cancer immunotherapy); multiple interventional studies.",clinicalTrialsCitations:"Kasi PM et al. Clin Cancer Res 2023; OMICO-MoST (Mol Oncol 2023).",totalParticipants:null,numPublications:4,numPublicationsPlus:!0,isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"Clinical LDT with Medicare coverage for TRM of ICI therapy. Broad clinical launch October 2023. MolDX coverage effective June 17, 2023. Uses the same personalized ctDNA technology as the MRD application but is commercially available for TRM while MRD remains investigational."},{id:"trm-7",sampleCategory:"Blood/Plasma",name:"FoundationOne Monitor",vendor:"Foundation Medicine",approach:"Tumor-nave",method:"324-gene hybrid-capture ctDNA NGS assay built on the FoundationOne Liquid CDx platform; reports ctDNA tumor fraction (%) and percent change over time while detecting SNVs, indels, CNAs, rearrangements, and complex biomarkers (bTMB, MSI).",cancerTypes:["Advanced solid tumors"],targetPopulation:"Patients with advanced or metastatic solid tumors enrolled in clinical trials where longitudinal ctDNA tumor fraction and emerging resistance mutations are monitored.",responseDefinition:"Percentage change in ctDNA tumor fraction between baseline and early on-treatment timepoints; incorporates multi-omic information (aneuploidy, VAFs, CNVs, fragment length) with CHIP filtering.",leadTimeVsImaging:null,leadTimeVsImagingNotes:"In mCRPC study (IMbassador250), ctDNA tumor fraction detected treatment response earlier than radiographic progression.",lod:"5 mean tumor molecules/mL (MTM/mL)",lodNotes:"5 MTM/mL is the validated LoD threshold. This is sample-level mean tumor molecules, not VAF. Analytical sensitivity varies by sample input, tumor characteristics, and variant type.",lodCitations:"Woodhouse R et al. PLoS One 2020;15:e0237802; Foundation Medicine Monitoring Portfolio technical documentation.",fdaStatus:"Clinical LDT  built on FDA-approved FoundationOne Liquid CDx platform; not separately FDA approved",fdaStatusCitations:"Foundation Medicine press release June 2023; Foundation Medicine monitoring portfolio.",reimbursement:"No specific coverage",reimbursementNote:"Clinical LDT without dedicated reimbursement pathway; coverage may depend on institution and context.",cptCodesNotes:"No specific CPT codes; may be billed under general CGP codes.",availableRegions:["US","EU","International"],availableRegionsNotes:"Available via Foundation Medicine and Roche global network.",clinicalAvailability:"Available as clinical LDT in US and internationally via Roche. Initially launched June 2023 for biopharma partners; now available for clinical use.",clinicalTrials:"IMbassador250 (mCRPC, enzalutamide  atezolizumab); multiple biopharma-sponsored early-phase and response-adaptive studies.",clinicalTrialsCitations:"Sweeney CJ et al. Clin Cancer Res 2024;30:4115-4122.",totalParticipants:null,numPublications:3,numPublicationsPlus:!0,isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"Tissue-nave ctDNA tumor-fraction assay for TRM and resistance detection. Available as clinical LDT built on FDA-approved FoundationOne Liquid CDx platform. No dedicated payer coverage pathway yet. Positioned as option when tumor tissue is not available."},{id:"trm-8",sampleCategory:"Blood/Plasma",name:"Northstar Response",vendor:"BillionToOne",approach:"Tumor-nave",method:"Single-molecule NGS (smNGS) with patented Quantitative Counting Templates (QCT) technology; measures >2200 cancer-specific methylated genomic loci (v2, expanded from >500 in v1); provides absolute quantification of methylated ctDNA molecules with WBC noise filtering via buffy coat sequencing.",cancerTypes:["Pan-cancer: all advanced solid tumors (validated in lung, colorectal, pancreatic, GI cancers, and others)"],targetPopulation:"Patients with Stage III-IV solid tumors on any systemic treatment regimen (chemotherapy, immunotherapy, targeted therapy)",responseDefinition:"Tumor Methylation Score (TMS) - total methylated tumor molecules per 1000 assayed genomic equivalents; serial quantification tracks response, progression, or stable disease over time",leadTimeVsImaging:null,leadTimeVsImagingNotes:"In NSCLC study, detected treatment response and progression earlier than CT scans. Can provide actionable signals weeks in advance of imaging.",lod:"0.01% tumor fraction",lodNotes:"Can accurately discriminate tumor fraction changes as small as 0.25%. Single-molecule precision enables detection of subtle shifts in tumor burden.",lodCitations:"Ye PP et al. Sci Rep 2025;15:5869; Hsiao A et al. Clin Lung Cancer 2025;26(1):72-77.",fdaStatus:"CLIA LDT  NOT FDA approved",reimbursement:"Self-Pay",reimbursementNote:"No Medicare or commercial coverage established. Available as CLIA-certified laboratory test.",tat:"10 days",tatNotes:"Turnaround time typically within 10 days from sample receipt to results.",clinicalAvailability:"Commercially available in US via CLIA-certified laboratory in Menlo Park, CA. Physician-ordered.",clinicalTrials:"Prospective observational study at University of Florida (advanced GI cancers, n=73+); UCSD NSCLC collaboration; multiple ongoing clinical validity studies",clinicalTrialsCitations:"Sahin I et al. JCO 2024;42(3_suppl):756; Sahin I et al. JCO 2025;43(4_suppl):839.",totalParticipants:100,totalParticipantsNotes:"Initial validation cohort of 100 advanced GI cancer patients; additional cohorts in lung and other solid tumors.",numPublications:5,numPublicationsPlus:!0,numPublicationsCitations:"Ye PP et al. Sci Rep 2025;15:5869; Hsiao A et al. Clin Lung Cancer 2025;26(1):72-77; JCO 2024 and 2025 abstracts.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,technologyDifferentiator:"Methylation-based (not mutation/VAF-based) - measures epigenetic signal across >2200 loci rather than tracking somatic variants. Tissue-free with no tumor biopsy required. QCT technology enables single-molecule counting precision for absolute quantification. Version 2 (2025) expanded panel from >500 to >2200 loci for increased sensitivity.",regulatoryStatusNotes:"CLIA-certified laboratory test. Methylation-based approach differentiates from SNV/VAF-based response monitoring assays. Measures 10x more informative loci (average 90 vs 9) compared to SNV-based ctDNA monitoring. Part of BillionToOne's Northstar oncology portfolio alongside Northstar Select (therapy selection)."},{id:"trm-11",sampleCategory:"Blood/Plasma",name:"Caris Assure",vendor:"Caris Life Sciences",approach:"Blood-based TRM (cfDNA + cfRNA + WBC)",method:"AI-enabled whole exome and whole transcriptome sequencing (WES/WTS) from plasma cfDNA/cfRNA and buffy coat WBC DNA/RNA; 22,000 genes; circulating Nucleic Acid Sequencing (cNAS) with CHIP subtraction",methodCitations:"https://www.carislifesciences.com/physicians/physician-tests/caris-assure/ | https://www.nature.com/articles/s41598-025-08986-0",indicationsNotes:"Multi-functional liquid biopsy for therapy selection, treatment response monitoring, and MRD detection. Distinguishes somatic tumor variants from clonal hematopoiesis (CH) and germline variants by sequencing both plasma and buffy coat.",sensitivity:93.8,sensitivityNotes:"93.8% positive percent agreement (PPA) with matched tissue collected within 30 days using 5ng input material and CHIP subtraction.",sensitivityCitations:"https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/physicians/physician-tests/caris-assure/",specificity:99.99,specificityNotes:">99.99% specificity for variant detection; 96.8% positive predictive value (PPV) for therapy selection.",specificityCitations:"https://www.nature.com/articles/s41598-025-08986-0",lod:"0.5% VAF",lodNotes:">95% sensitivity for variant allele frequencies 0.5%.",lodCitations:"https://www.prnewswire.com/news-releases/caris-life-sciences-introduces-the-caris-assure-liquid-biopsy-assay-at-asco-2022-301560767.html",performanceNotes:"AI-enabled platform (ABCDai) couples WES/WTS with machine learning. For monitoring, disease-free survival of patients predicted to have an event was significantly shorter (HR=4.39, p=0.008). Detects CH mutations in ~40% of samples, critical for avoiding false positives in therapy selection.",performanceCitations:"https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-showcases-data-demonstrating-the-clinical-value-of-clonal-hematopoiesis-identification-and-subtraction-in-liquid-biopsy-to-improve-the-accuracy-of-treatment-recommendations/",fdaStatus:"CLIA LDT",fdaStatusNotes:"CLIA-certified laboratory developed test. Not FDA cleared/approved.",reimbursement:"Coverage Varies",reimbursementNote:"Coverage expanding; contact Caris for current payer coverage.",clinicalAvailability:"Commercially available in US since late 2022",availableRegions:["US"],tat:"10-14 days",tatNotes:"Turnaround time typically 10-14 business days.",sampleType:"Whole blood",sampleTypeNotes:"Blood collection in approved tubes; plasma and buffy coat analyzed separately.",bloodVolume:20,bloodVolumeNotes:"Approximately 20mL whole blood required for plasma and buffy coat extraction.",numPublications:5,numPublicationsPlus:!0,numPublicationsCitations:"https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/research/publications/",clinicalTrials:"Validation studies with 1,910 therapy selection samples; 3,439 MRD/monitoring training samples; 86 MRD validation; 101 monitoring validation",totalParticipants:5536,variantsTracked:"22,000 genes (WES/WTS)",variantsTrackedNotes:"Whole exome (DNA) and whole transcriptome (RNA) sequencing across 22,000 genes. Reports SNVs, indels, CNAs, fusions, MSI, bTMB, and HLA genotype.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,technologyDifferentiator:"Only commercially available liquid biopsy that sequences both plasma and buffy coat (WBC) to distinguish somatic tumor variants from clonal hematopoiesis (CH) and germline variants. CHIP subtraction prevents ~40% of samples from receiving potentially incorrect therapy recommendations based on non-tumor mutations."},{id:"trm-12",sampleCategory:"Blood/Plasma",name:"Reveal TRM",vendor:"Guardant Health",approach:"Tumor-nave (methylation-based)",method:"Epigenetic tumor fraction (epiTF) quantification on Guardant Infinity platform. Analyzes over 19,000 differentially methylated loci to calculate mutation-agnostic tumor fractionnot dependent on known oncogenic mutations. Provides high sensitivity and precision not confounded by copy number alterations (CNAs) or clonal hematopoiesis (CHIP).",methodCitations:"AACR 2025 Tumor Fraction Update presentation; Nakamura Y et al. Clin Cancer Res 2024; Liang et al. 2025 Cancer Res Commun.",cancerTypes:["Pan-cancer: any solid tumor on systemic therapy"],targetPopulation:"Patients with advanced/metastatic solid tumors receiving systemic therapy who need treatment response monitoring",responseDefinition:"Molecular responders defined by significant decrease in epigenetic tumor fraction (epiTF) from baseline. epiTF changes correlate with radiological tumor volume changes and predict clinical outcomes.",indicationsNotes:"Therapy response monitoring for advanced cancer with visible disease. Early prediction of therapy response and outcomes. Patients with significant decrease in ctDNA tumor fraction have better clinical response than molecular non-responders.",sensitivity:null,sensitivityNotes:"Not applicable for response monitoring - measures relative epiTF changes over time rather than absolute detection.",specificity:null,specificityNotes:"High specificity for tumor-derived signal due to methylation approach that excludes non-tumor biological noise without requiring additional specimen types.",lod:"0.01% TF",lodNotes:"Epigenetic tumor fraction (epiTF) quantification validated with precision down to ~0.01% TF. Analyzes over 19,000 differentially methylated locimutation-agnostic approach not dependent on known oncogenic mutations. Not impacted by CNAs like genomic VAF approaches.",lodCitations:"AACR 2025 Tumor Fraction Update; cohort of >50,000 cfDNA samples from >20 cancer types.",leadTimeVsImaging:null,leadTimeVsImagingNotes:"epiTF changes mirror radiological tumor volume changes (Harvey-Jones et al. Annals of Oncology 2024). Molecular response detectable earlier than imaging in many cases.",leadTimeVsImagingCitations:"Harvey-Jones et al. Annals of Oncology 2024; AACR 2025 presentations.",fdaStatus:"CLIA LDT",fdaStatusNotes:"Laboratory Developed Test performed at Guardant Health Clinical Laboratory (Redwood City, CA). Part of Guardant's consolidated monitoring portfolio using Infinity platform.",reimbursement:"Coverage emerging",reimbursementNote:"New product launched as successor to Guardant360 Response. Reimbursement pathways developing.",clinicalAvailability:"Clinical LDT  commercially available December 2025",clinicalAvailabilityNotes:"Launched December 2025 as part of Guardant portfolio consolidation. Replaces Guardant360 Response for therapy response monitoring in advanced cancer. Part of Reveal product family alongside Reveal MRD for early-stage cancer.",availableRegions:["US"],tat:"7 days",tatNotes:"Vendor-reported 7-day median TAT, same as Reveal MRD.",sampleType:"Whole blood in Guardant cfDNA BCT tubes",bloodVolume:20,bloodVolumeNotes:"Two 10mL Streck cfDNA tubes (approximately 20mL).",clinicalTrials:"Validated in >31,000 patients in LDT/CLIA setting; >50,000 cfDNA samples across >20 cancer types used for algorithm development",clinicalTrialsCitations:"AACR 2025 Tumor Fraction Update presentation.",totalParticipants:31e3,totalParticipantsNotes:"Pan-cancer landscape of tumor fraction in >31,000 patients across most frequent solid tumors from CLIA ordering.",numPublications:80,numPublicationsPlus:!0,numPublicationsCitations:"Guardant Health claims >80 publications showing clinical feasibility or validity of genomic MR and/or monitoring.",requiresTumorTissue:"No",requiresTumorTissueNotes:"Tumor-nave approach - no tumor tissue required for panel design or analysis.",requiresMatchedNormal:"No",requiresMatchedNormalNotes:"Methylation-based approach provides improved exclusion of biological noise without additional sequencing of matched normal specimen.",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,technologyDifferentiator:"Methylation-based tumor fraction quantification offers advantages over genomic VAF methods: (1) Tracks thousands of methylation loci vs handful of coding loci for higher sensitivity; (2) Not confounded by CNAs that affect genomic max-MAF estimates; (3) Excludes non-tumor noise (including CHIP) without requiring matched normal sequencing; (4) Validated precision down to 0.01% TF. Uses same Guardant Infinity platform as Reveal MRD, Shield, and Shield MCD.",regulatoryStatusNotes:"CLIA-certified LDT. Represents Guardant's consolidated approach to therapy response monitoring, replacing genomic VAF-based Guardant360 Response with epigenetic tumor fraction (epiTF) quantification."}],X=[{id:"tds-1",name:"FoundationOne CDx",vendor:"Foundation Medicine",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Hybrid-capture NGS of FFPE tumor tissue; detects SNVs, indels, CNAs, and select rearrangements in 324 genes; reports MSI, TMB, and HRD signature.",methodCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",genesAnalyzed:324,genesAnalyzedCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",geneListUrl:"https://www.foundationmedicine.com/test/foundationone-cdx",biomarkersReported:["SNVs","Indels","CNAs","Rearrangements","TMB","MSI","HRD"],biomarkersReportedCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",targetPopulation:"Patients with advanced solid malignant neoplasms requiring genomic profiling to guide treatment decisions",targetPopulationCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",fdaStatus:"FDA-approved PMA (P170019) - First FDA-approved broad companion diagnostic for solid tumors",fdaStatusCitations:"https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-f1cdx-p170019s048",fdaApprovalDate:"2017-11-30",fdaApprovalDateCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",fdaCompanionDxCount:57,fdaCompanionDxCountNotes:"57 FDA-approved CDx indications in US as of Dec 2025 (100 total CDx indications including Japan). Includes pan-tumor indications for TMB-H, MSI-H, NTRK fusions, RET fusions, and tumor-specific indications across NSCLC, melanoma, breast, colorectal, ovarian, prostate, cholangiocarcinoma, and pediatric brain tumors.",fdaCompanionDxCountCitations:"https://www.businesswire.com/news/home/20251204680697/en/Foundation-Medicine-Achieves-Historic-Milestone-of-100-Approved-and-Active-Companion-Diagnostic-Indications-Solidifying-Leadership-in-Precision-Medicine",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer","Ovarian Cancer","Melanoma","Gastric Cancer","Cholangiocarcinoma"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers and 'broad molecular profiling' but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.foundationmedicine.com/test/foundationone-cdx",tat:"8 days",tatNotes:"Typically 8 days or less from receipt of specimen.",tatCitations:"https://www.foundationmedicine.com/info/detail/order-a-test",sampleRequirements:"FFPE tissue; minimum 25% tumor content; 10 unstained slides or tissue block",sampleRequirementsNotes:"Foundation Medicine contacts pathology lab for specimen procurement. Can reflex to FoundationOne Liquid CDx if tissue insufficient.",sampleRequirementsCitations:"https://www.foundationmedicine.com/info/detail/order-a-test",reimbursement:"Medicare",reimbursementNote:"National Medicare coverage for advanced cancer (CAG-00450R). 87% of patients pay $0 out-of-pocket. 80+ commercial health plans cover Foundation Medicine tests.",reimbursementCitations:"https://www.foundationmedicine.com/resource/billing-and-financial-assistance | https://www.foundationmedicine.com/test/foundationone-cdx",listPrice:3500,listPriceCitations:"https://www.foundationmedicine.com/faq/patient-faqs",cptCodes:"0037U",cptCodesCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",codeType:"PLA",medicareRate:3500,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,availableRegions:["US","EU","UK","Japan","Canada","Australia","International"],availableRegionsNotes:"Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany). Regulatory: FDA approved (US), MHLW approved (Japan, Dec 2018), CE marked (EU).",availableRegionsCitations:"https://www.roche.com/media/releases/med-cor-2021-10-25 | https://www.foundationmedicine.com/press-releases/aa55275f-b849-4e31-a770-152c8e7cad8f",clinicalAvailability:"Commercially available in US since 2017; available in 100+ countries via Roche affiliates",clinicalAvailabilityCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",numPublications:1e3,numPublicationsPlus:!0,numPublicationsSource:"vendor-estimate",numPublicationsNotes:"Foundation Medicine tests cited in >1,000 peer-reviewed publications (vendor estimate).",numPublicationsCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",publicationsExampleCitations:["https://doi.org/10.1038/nm.4333","https://doi.org/10.1200/JCO.2017.75.3780"]},{id:"tds-2",name:"FoundationOne Liquid CDx",vendor:"Foundation Medicine",sampleCategory:"Blood/Plasma",approach:"Liquid CGP",method:"Hybrid-capture NGS of cfDNA from plasma; analyzes 324 genes; reports short variants in 311 genes, rearrangements in 8 genes, CNAs in 3 genes, plus bTMB and MSI.",methodCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",genesAnalyzed:324,genesAnalyzedCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",genesReported:311,genesReportedCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",geneListUrl:"https://www.foundationmedicine.com/test/foundationone-liquid-cdx",biomarkersReported:["SNVs","Indels","Select CNAs","Select Rearrangements","bTMB","MSI"],biomarkersReportedCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",cancerTypes:["Advanced solid tumors"],cancerTypesCitations:"https://www.foundationmedicine.com/test/foundationone-liquid-cdx",targetPopulation:"Patients with advanced solid tumors when tissue biopsy is not feasible or as complement to tissue testing",targetPopulationCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",fdaStatus:"FDA-approved PMA (P200006) August 2020",fdaStatusCitations:"https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",fdaApprovalDate:"2020-08-26",fdaApprovalDateCitations:"https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",fdaCompanionDxCount:10,fdaCompanionDxCountNotes:"Multiple CDx indications in NSCLC (osimertinib, sotorasib, capmatinib), breast cancer (PIK3CA), prostate cancer (BRCA1/2, ATM), cholangiocarcinoma (FGFR2), pan-tumor (NTRK).",fdaCompanionDxCountCitations:"https://www.foundationmedicine.com/press-release/fda-approves-foundationonercdx-and-foundationonerliquid-cdx-companion-diagnostics",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Prostate Cancer","Cholangiocarcinoma"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",tat:"7-10 days",tatNotes:"Results typically available within 7-10 business days.",tatCitations:"https://www.foundationmedicine.com/info/detail/order-a-test",sampleRequirements:"2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL per tube",sampleRequirementsNotes:"7-day sample stability at ambient temperature. Can reflex to tissue testing if liquid negative for CDx mutations.",sampleRequirementsCitations:"https://www.foundationmedicine.com/info/detail/order-a-test",reimbursement:"Medicare",reimbursementNote:"National Medicare coverage for advanced cancer. Broad commercial payer coverage.",reimbursementCitations:"https://www.foundationmedicine.com/resource/billing-and-financial-assistance",listPrice:3500,listPriceCitations:"https://www.foundationmedicine.com/faq/patient-faqs",cptCodes:"0239U",cptCodesCitations:"https://www.foundationmedicine.com/test/foundationone-cdx",codeType:"PLA",medicareRate:3500,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,availableRegions:["US","EU","UK","Japan","Canada","Australia","International"],availableRegionsNotes:"Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany).",availableRegionsCitations:"https://www.roche.com/media/releases/med-cor-2021-10-25",clinicalAvailability:"Commercially available in US since 2020; available in 100+ countries via Roche affiliates",clinicalAvailabilityCitations:"https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic"},{id:"tds-3",name:"FoundationOne Heme",vendor:"Foundation Medicine",sampleCategory:"Tissue/Blood/Bone Marrow",approach:"Tissue + Liquid CGP",method:"Hybrid-capture DNA sequencing of 406 genes plus RNA sequencing of 265 genes for fusion detection; covers hematologic malignancies and sarcomas.",methodCitations:"https://www.foundationmedicine.com/test/foundationone-heme",genesAnalyzed:406,genesAnalyzedCitations:"https://www.foundationmedicine.com/test/foundationone-heme",rnaGenesAnalyzed:265,rnaGenesAnalyzedCitations:"https://www.foundationmedicine.com/test/foundationone-heme",geneListUrl:"https://www.foundationmedicine.com/test/foundationone-heme",biomarkersReported:["SNVs","Indels","CNAs","Rearrangements/Fusions","TMB","MSI"],biomarkersReportedCitations:"https://www.foundationmedicine.com/test/foundationone-heme",cancerTypes:["Hematologic malignancies","Sarcomas"],cancerTypesNotes:"Leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and sarcomas.",cancerTypesCitations:"https://www.foundationmedicine.com/test/foundationone-heme",targetPopulation:"Patients with hematologic malignancies or sarcomas requiring comprehensive genomic profiling",targetPopulationCitations:"https://www.foundationmedicine.com/test/foundationone-heme",fdaStatus:"CLIA LDT - not FDA approved",fdaStatusCitations:"https://www.foundationmedicine.com/test/foundationone-heme",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["Acute Myeloid Leukemia","Chronic Myeloid Leukemia","B-Cell Lymphomas","Myelodysplastic Syndromes","Soft Tissue Sarcoma"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines for hematologic malignancies and sarcomas. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.foundationmedicine.com/test/foundationone-heme",tat:"10-14 days",tatCitations:"https://www.foundationmedicine.com/test/foundationone-heme",sampleRequirements:"FFPE tissue, bone marrow aspirate, or peripheral blood depending on disease type",sampleRequirementsCitations:"https://www.foundationmedicine.com/test/foundationone-heme",reimbursement:"Medicare",reimbursementNote:"Medicare coverage for qualifying patients. Commercial coverage varies.",reimbursementCitations:"https://www.foundationmedicine.com/resource/billing-and-financial-assistance",listPrice:3500,listPriceCitations:"https://www.foundationmedicine.com/faq/patient-faqs",availableRegions:["US","EU","UK","Japan","Canada","Australia","International"],availableRegionsNotes:"Available in 100+ countries via Roche global network.",availableRegionsCitations:"https://www.roche.com/media/releases/med-cor-2021-10-25",clinicalAvailability:"Commercially available in US; available internationally via Roche affiliates",clinicalAvailabilityCitations:"https://www.foundationmedicine.com/test/foundationone-heme"},{id:"tds-4",name:"Guardant360 CDx",vendor:"Guardant Health",sampleCategory:"Blood/Plasma",approach:"Liquid CGP",method:"Digital sequencing of cfDNA; targets 74 genes; reports SNVs, indels, CNAs (6 genes), and fusions (4 genes) with high sensitivity at low allele frequencies.",methodCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",genesAnalyzed:74,genesAnalyzedCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",genesReported:55,genesReportedNotes:"74 genes targeted, 55 genes with reportable short variants.",genesReportedCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",geneListUrl:"https://www.guardantcomplete.com/hcp/solutions/guardant360-cdx",biomarkersReported:["SNVs","Indels","Select CNAs","Select Fusions"],biomarkersReportedCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",targetPopulation:"Patients with advanced solid tumors; first liquid biopsy with FDA-approved CGP indication for all solid tumors",targetPopulationCitations:"https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",fdaStatus:"FDA-approved PMA (P200010) August 2020 - First FDA-approved liquid biopsy NGS CDx",fdaStatusCitations:"https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008 | https://www.targetedonc.com/view/fda-approves-guardant360-cdx-for-tumor-mutation-profiling-of-all-solid-cancers",fdaApprovalDate:"2020-08-07",fdaApprovalDateCitations:"https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008",fdaCompanionDxCount:6,fdaCompanionDxCountNotes:"6 CDx indications: NSCLC (osimertinib/EGFR, amivantamab/EGFR exon 20, trastuzumab deruxtecan/ERBB2, sotorasib/KRAS G12C); Breast cancer (elacestrant/ESR1, imlunestrant/ESR1).",fdaCompanionDxCountCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx | https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer"],nccnGuidelinesNotes:"Covers all genes recommended by NCCN for NSCLC and relevant biomarkers for breast cancer treatment. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.guardanthealth.com/",tat:"5-7 days",tatNotes:"Actionable results typically within 7 days; as fast as 5 days.",tatCitations:"https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",sampleRequirements:"2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL",sampleRequirementsCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S008C.pdf",reimbursement:"Medicare",reimbursementNote:"Broadly covered by Medicare and commercial insurers representing >300 million lives.",reimbursementCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx",cptCodes:"0242U",codeType:"PLA",medicareRate:5e3,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,clinicalAvailability:"Commercially available in US since 2020",clinicalAvailabilityCitations:"https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",numPublications:150,numPublicationsPlus:!0,numPublicationsSource:"vendor-estimate",numPublicationsNotes:"Guardant360 cited in >150 peer-reviewed publications (vendor estimate).",numPublicationsCitations:"https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",publicationsExampleCitations:["https://pubmed.ncbi.nlm.nih.gov/33619370/","https://pubmed.ncbi.nlm.nih.gov/37256839/"]},{id:"tds-17",name:"Guardant360 Liquid",vendor:"Guardant Health",sampleCategory:"Blood/Plasma",approach:"Liquid CGP",method:"Digital sequencing of cfDNA on Guardant Infinity platform; targets 744 genes; reports SNVs, indels, CNAs, CNLs, fusions/rearrangements, MSI, TMB, tumor fraction, and promoter methylation (epigenomic features). CHIP filtering via proprietary algorithm. Virus detection (EBV, HPV).",methodCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",genesAnalyzed:744,genesAnalyzedCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",genesReported:744,genesReportedNotes:"Full 744-gene panel reported. 10x more genes than previous Guardant360 version and 10x higher sensitivity for tumor fraction quantification.",genesReportedCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",geneListUrl:"https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",biomarkersReported:["SNVs","Indels","CNAs","CNLs","Fusions/Rearrangements","MSI","TMB","Tumor Fraction","Promoter Methylation"],biomarkersReportedNotes:"First and only liquid biopsy to deliver genomic and epigenomic insights (promoter methylation) from a single input. CHIP variants flagged via proprietary algorithm.",biomarkersReportedCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",targetPopulation:"Patients with advanced solid tumors; comprehensive genomic and epigenomic profiling for treatment selection",targetPopulationCitations:"https://guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/",fdaStatus:"CLIA LDT; not FDA-cleared/approved",fdaStatusNotes:"Developed as a Laboratory Developed Test (LDT) by Guardant Health Clinical Laboratory (CLIA-certified). Distinct from Guardant360 CDx which is FDA-approved but covers only 74 genes.",fdaStatusCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",fdaCompanionDxCount:0,fdaCompanionDxCountNotes:"LDT version - no FDA companion diagnostic claims. For FDA-approved CDx, see Guardant360 CDx.",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer","Ovarian Cancer","Melanoma"],nccnGuidelinesNotes:"Covers all guideline-recommended genomic biomarkers across advanced solid tumors plus emerging biomarkers. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",tat:"7 days",tatNotes:"Median 7 days from sample receipt to results.",tatCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",sampleRequirements:"Two 10 mL tubes of whole blood; ship same or next day at room temperature (do not freeze/refrigerate)",sampleRequirementsCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",lod:"SNVs: 0.20% VAF; Indels: 0.26%; CNAs: 2.46 copies; Fusions: 0.05%; MSI: 0.05%; Tumor Fraction: 1.6%",lodNotes:"LoD defined as allele fraction/copy number at 95% probability of detection for oncogenic variants. TMB evaluable at 0.3% sample allele fraction.",lodCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",specificity:"99.9% for SNVs, Indels, CNAs, CNLs, Fusions, MSI, Promoter Methylation",specificityCitations:"https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",reimbursement:"Medicare",reimbursementNote:"Covered by Medicare and major private payers for comprehensive genomic profiling of all advanced solid tumors.",reimbursementCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",availableRegions:["US"],availableRegionsNotes:"US availability via Guardant Health. International availability via regional spec sheets (AMEA region).",availableRegionsCitations:"https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",clinicalAvailability:"Commercially available in US; 2024 major upgrade launched",clinicalAvailabilityCitations:"https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx"},{id:"tds-5",name:"Tempus xT CDx",vendor:"Tempus AI",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Tumor-normal matched NGS of FFPE tissue and matched normal blood/saliva; detects SNVs, MNVs, indels in 648 genes plus MSI status; tumor-normal matching improves somatic variant accuracy.",methodCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf | https://www.tempus.com/oncology/genomic-profiling/xt-xr/",genesAnalyzed:648,genesAnalyzedCitations:"https://www.tempus.com/oncology/genomic-profiling/xt-xr/ | https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",geneListUrl:"https://www.tempus.com/oncology/genomic-profiling/xt-xr/",biomarkersReported:["SNVs","MNVs","Indels","CNVs","Rearrangements","TMB","MSI"],biomarkersReportedNotes:"HRD and HLA genotyping available as add-ons via professional services report.",biomarkersReportedCitations:"https://www.tempus.com/oncology/genomic-profiling/xt-xr/",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",targetPopulation:"Patients with previously diagnosed solid malignant neoplasms",targetPopulationCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",fdaStatus:"FDA-approved IVD (P210011) - National launch January 2025",fdaStatusCitations:"https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test | https://investors.tempus.com/news-releases/news-release-details/tempus-announces-national-launch-fda-approved-xt-cdx-test",fdaApprovalDate:"2024-06-01",fdaApprovalDateCitations:"https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",fdaCompanionDxCount:2,fdaCompanionDxCountNotes:"CDx claims for colorectal cancer (KRAS, NRAS, BRAF); positioned as one of the largest FDA-approved gene panels.",fdaCompanionDxCountCitations:"https://www.tempus.com/oncology/genomic-profiling/xt-xr/",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Colorectal Cancer","Breast Cancer","Melanoma","Prostate Cancer","Ovarian Cancer"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.tempus.com/oncology/genomic-profiling/xt-xr/",tat:"14 days",tatNotes:"Results typically within 14 days.",tatCitations:"https://www.tempus.com/oncology/genomic-profiling/xt-xr/",sampleRequirements:"FFPE tissue plus matched normal (blood or saliva)",sampleRequirementsNotes:"Tumor-normal matched approach differentiates somatic from germline variants.",sampleRequirementsCitations:"https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",reimbursement:"Medicare",reimbursementNote:"CMS Advanced Diagnostic Laboratory Test (ADLT) designation; Medicare rate $4,500.",reimbursementCitations:"https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",listPrice:4500,listPriceCitations:"https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",cptCodes:"0473U",cptCodesCitations:"https://www.discoveriesinhealthpolicy.com/2024/09/cms-releases-preliminary-crosswalk-for.html",codeType:"PLA",medicareRate:4500,medicareStatus:"Priced",medicareEffective:"2025-Q4",adltStatus:!0,clinicalAvailability:"Commercially available nationwide since January 2025",clinicalAvailabilityCitations:"https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",complementaryTests:"Can add xR RNA sequencing, xF/xF+ liquid biopsy, HER2 IHC, PD-L1 IHC, HRD, Immune Profile Score",complementaryTestsCitations:"https://www.tempus.com/oncology/genomic-profiling/xt-xr/"},{id:"tds-6",name:"Tempus xF",vendor:"Tempus AI",sampleCategory:"Blood/Plasma",approach:"Liquid CGP",method:"ctDNA NGS panel targeting 105 genes; detects SNVs, indels, CNGs (6 genes), CNLs (BRCA1/2), and rearrangements (6 genes) plus MSI-H.",methodCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/ | https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",analyticalValidation:"Validated performance metrics from Finkle et al. 2021 analytical validation study.",analyticalValidationCitations:"https://www.tempus.com/wp-content/uploads/2021/09/xF-Validation-Summary.pdf",genesAnalyzed:105,genesAnalyzedCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",geneListUrl:"https://www.tempus.com/oncology/genomic-profiling/xf/",biomarkersReported:["SNVs","Indels","Select CNAs","Select Rearrangements","MSI"],biomarkersReportedCitations:"https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",cancerTypes:["Advanced solid tumors"],cancerTypesCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",targetPopulation:"Patients with advanced solid tumors; not intended for hematologic malignancies, early-stage cancers, or primary CNS malignancies",targetPopulationCitations:"https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",fdaStatus:"CLIA LDT - not FDA approved",fdaStatusCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer"],nccnGuidelinesNotes:"Covers key biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.tempus.com/oncology/genomic-profiling/xf/",tat:"5-7 days",tatCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",sampleRequirements:"Blood in Streck cfDNA BCT tubes",sampleRequirementsCitations:"https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",reimbursement:"Coverage Varies",reimbursementNote:"Commercial and Medicare coverage varies by indication.",reimbursementCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",clinicalAvailability:"Commercially available in US",clinicalAvailabilityCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",sensitivity:">99% for SNVs/CNGs at 0.5% VAF; >98% for indels; >97% for rearrangements",sensitivityCitations:"https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",specificity:">99.9% for SNVs, indels, rearrangements; >96% for CNGs",specificityCitations:"https://www.ncbi.nlm.nih.gov/gtr/tests/569040/"},{id:"tds-7",name:"Tempus xF+",vendor:"Tempus AI",sampleCategory:"Blood/Plasma",approach:"Liquid CGP",method:"Expanded ctDNA NGS panel targeting 523 genes; detects SNVs, indels, CNGs, and rearrangements; includes clonal hematopoiesis (CH) variant identification.",methodCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",analyticalValidation:"Validated per Boulos et al. 2025 analytical validation study.",analyticalValidationCitations:"https://pubmed.ncbi.nlm.nih.gov/39820598/",genesAnalyzed:523,genesAnalyzedCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",geneListUrl:"https://www.tempus.com/oncology/genomic-profiling/xf/",biomarkersReported:["SNVs","Indels","CNAs","Rearrangements","CH variants"],biomarkersReportedCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",cancerTypes:["Advanced solid tumors"],cancerTypesCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",targetPopulation:"Patients requiring expanded liquid biopsy coverage",targetPopulationCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",fdaStatus:"CLIA LDT - not FDA approved",fdaStatusCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer","Ovarian Cancer"],nccnGuidelinesNotes:"Expanded 523-gene panel covers all biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.tempus.com/oncology/genomic-profiling/xf/",tat:"7-10 days",tatCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",sampleRequirements:"Blood in Streck cfDNA BCT tubes",sampleRequirementsCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",reimbursement:"Coverage Varies",reimbursementCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/",clinicalAvailability:"Commercially available in US",clinicalAvailabilityCitations:"https://www.tempus.com/oncology/genomic-profiling/xf/"},{id:"tds-8",name:"MSK-IMPACT",vendor:"Memorial Sloan Kettering",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Hybrid-capture NGS of matched tumor/normal FFPE tissue; targets 468 cancer-associated genes covering ~1.5Mb of the genome; detects SNVs, indels, CNAs, select rearrangements, and MSI.",methodCitations:"https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://www.mskcc.org/msk-impact",genesAnalyzed:468,genesAnalyzedNotes:"468 genes in original FDA-authorized configuration (2017); panel has since expanded to ~505 genes per current MSK documentation.",genesAnalyzedCitations:"https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://ascopost.com/News/58263 | https://www.mskcc.org/msk-impact",geneListUrl:"https://www.mskcc.org/msk-impact",biomarkersReported:["SNVs","Indels","CNAs","Select Rearrangements","MSI"],biomarkersReportedCitations:"https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.mskcc.org/msk-impact",targetPopulation:"Patients with advanced cancer treated at Memorial Sloan Kettering Cancer Center",targetPopulationCitations:"https://www.mskcc.org/msk-impact",fdaStatus:"FDA authorized (de novo, DEN170058) November 2017 - First tumor-profiling LDT to receive FDA authorization",fdaStatusCitations:"https://ascopost.com/News/58263 | https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors",fdaAuthorizationDate:"2017-11-15",fdaAuthorizationDateCitations:"https://ascopost.com/News/58263",fdaStatusNotes:"Not FDA-approved as CDx; authorized for tumor mutation profiling. Also approved by NYSDOH.",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer","Melanoma","Ovarian Cancer","Gastric Cancer"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.mskcc.org/msk-impact",tat:"2-3 weeks",tatCitations:"https://www.mskcc.org/msk-impact",sampleRequirements:"FFPE tumor tissue plus matched normal sample",sampleRequirementsNotes:"Tumor-normal matching allows accurate distinction of somatic vs germline variants.",sampleRequirementsCitations:"https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",reimbursement:"Coverage Varies",reimbursementNote:"Coverage depends on payer; available primarily to MSK patients.",reimbursementCitations:"https://www.mskcc.org/msk-impact",clinicalAvailability:"Available only at Memorial Sloan Kettering Cancer Center",clinicalAvailabilityNotes:"Single-site assay; >20,000 patients sequenced since 2014. Results accessible via cBioPortal and annotated using OncoKB.",clinicalAvailabilityCitations:"https://www.mskcc.org/msk-impact | https://www.mskcc.org/news-releases/msk-impact-first-tumor-profiling-multiplex-panel-authorized-fda-setting-new-pathway-market-future-oncopanels",numPublications:1e3,numPublicationsPlus:!0,numPublicationsSource:"vendor-estimate",numPublicationsNotes:">1,000 peer-reviewed publications featuring MSK-IMPACT data as of end of 2024 (vendor estimate).",numPublicationsCitations:"https://www.mskcc.org/msk-impact",publicationsExampleCitations:["https://doi.org/10.1038/nm.4333","https://doi.org/10.1056/NEJMoa1610624"],keyFindings:"37% of profiled patients have at least one actionable mutation; 11% enrolled in matched clinical trials.",keyFindingsCitations:"https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors | https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer"},{id:"tds-9",name:"MI Cancer Seek",vendor:"Caris Life Sciences",sampleCategory:"Tissue",approach:"Tissue CGP (WES + WTS)",method:"Combined whole exome sequencing (WES) and whole transcriptome sequencing (WTS) from single FFPE tissue extraction; detects SNVs, indels in 228 genes, MSI, TMB, and ERBB2 amplification.",methodCitations:"https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12581394/",genesAnalyzed:228,genesAnalyzedNotes:"228 genes with reportable SNVs/indels in CDx subset; WES/WTS technically interrogates ~20,000 genes for research findings and signatures. This prevents confusion between '228 genes' and 'whole-exome' claims.",genesAnalyzedCitations:"https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",geneListUrl:"https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",biomarkersReported:["SNVs","Indels","MSI","TMB","ERBB2 CNA"],biomarkersReportedCitations:"https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",targetPopulation:"Adults and pediatric patients (ages 1-22) with previously diagnosed solid malignant neoplasms",targetPopulationNotes:"First and only FDA-approved CGP with CDx indications for both adult and pediatric patients.",targetPopulationCitations:"https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",fdaStatus:"FDA-approved IVD (P240010) November 2024 - First WES+WTS combined assay with CDx indications",fdaStatusCitations:"https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/ | https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",fdaApprovalDate:"2024-11-06",fdaApprovalDateCitations:"https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",fdaCompanionDxCount:8,fdaCompanionDxCountNotes:"8 CDx claims: 1 pan-cancer indication plus 5 tumor-specific indications (breast, colorectal, melanoma, NSCLC, endometrial). Includes PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H.",fdaCompanionDxCountCitations:"https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html | https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Melanoma","Endometrial Cancer"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines including PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",tat:"14 days",tatNotes:"Results within 14 days.",tatCitations:"https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",sampleRequirements:"FFPE tissue; minimum 20% tumor content",sampleRequirementsNotes:"Simultaneous DNA and RNA extraction from single sample minimizes tissue requirements compared to separate assays.",sampleRequirementsCitations:"https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://www.mlo-online.com/diagnostics/assays/news/55241478/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",reimbursement:"Coverage Varies",reimbursementNote:"Coverage expanding; contact Caris for current payer coverage.",reimbursementCitations:"https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",clinicalAvailability:"Commercially available in US since November 2024",clinicalAvailabilityCitations:"https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",analyticalValidation:"97-100% positive and negative percent agreement compared to other FDA-approved assays",analyticalValidationCitations:"https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html"},{id:"tds-11",name:"OncoExTra",vendor:"Exact Sciences",sampleCategory:"Tissue",approach:"Tissue CGP (WES + WTS)",method:"Whole exome sequencing (WES) of ~20,000 genes combined with whole transcriptome sequencing (WTS) from FFPE tissue; reports SNVs, indels, CNAs, fusions, MSI, TMB, and HRD status.",methodCitations:"https://www.exactsciences.com/test/oncoextra | https://www.oncotarget.com/article/28285/text/",genesAnalyzed:2e4,genesAnalyzedNotes:"WES/WTS comprehensively interrogates ~20,000 genes; reportable subset varies by biomarker type.",genesAnalyzedCitations:"https://www.exactsciences.com/test/oncoextra",geneListUrl:"https://www.exactsciences.com/test/oncoextra",biomarkersReported:["SNVs","Indels","CNAs","Fusions","TMB","MSI","HRD"],biomarkersReportedCitations:"https://www.exactsciences.com/test/oncoextra",cancerTypes:["Advanced solid tumors"],cancerTypesCitations:"https://www.exactsciences.com/test/oncoextra",targetPopulation:"Patients with advanced solid tumors requiring comprehensive genomic and transcriptomic profiling",targetPopulationCitations:"https://www.exactsciences.com/test/oncoextra",fdaStatus:"CLIA LDT - not FDA approved",fdaStatusCitations:"https://www.exactsciences.com/test/oncoextra",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer","Ovarian Cancer","Melanoma"],nccnGuidelinesNotes:"WES/WTS approach covers all biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.exactsciences.com/test/oncoextra",tat:"10-14 days",tatCitations:"https://www.exactsciences.com/test/oncoextra",sampleRequirements:"FFPE tissue; 10 unstained slides or tissue block",sampleRequirementsCitations:"https://www.exactsciences.com/test/oncoextra",reimbursement:"Medicare",reimbursementNote:"Medicare coverage; commercial coverage varies by payer.",reimbursementCitations:"https://www.exactsciences.com/test/oncoextra",clinicalAvailability:"Commercially available in US",clinicalAvailabilityCitations:"https://www.exactsciences.com/test/oncoextra",clinicalUtility:"Studies demonstrate increased matched therapy rates compared to single-gene testing.",clinicalUtilityCitations:"https://www.oncotarget.com/article/28285/text/ | https://pubmed.ncbi.nlm.nih.gov/37256839/"},{id:"tds-12",name:"OmniSeq INSIGHT",vendor:"Labcorp Oncology (OmniSeq)",sampleCategory:"Tissue",approach:"Tissue CGP + Immune Profiling",method:"NGS panel covering full coding regions of 523 genes plus immune profiling including PD-L1 expression and immune signatures; detects SNVs, indels, CNAs, fusions, TMB, and MSI.",methodCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight | https://pmc.ncbi.nlm.nih.gov/articles/PMC8796288/",genesAnalyzed:523,genesAnalyzedCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",geneListUrl:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",biomarkersReported:["SNVs","Indels","CNAs","Fusions","TMB","MSI","PD-L1","Immune Signatures"],biomarkersReportedNotes:"Combined genomic and immune profiling in single test.",biomarkersReportedCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",targetPopulation:"Patients with solid tumors requiring comprehensive genomic and immune profiling",targetPopulationCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",fdaStatus:"CLIA LDT - not FDA approved",fdaStatusCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Melanoma","Prostate Cancer"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines plus immune profiling. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",tat:"10-14 days",tatCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",sampleRequirements:"FFPE tissue",sampleRequirementsCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",reimbursement:"Medicare",reimbursementNote:"Medicare and commercial coverage; widely available via Labcorp network.",reimbursementCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",clinicalAvailability:"Commercially available in US via Labcorp network",clinicalAvailabilityCitations:"https://oncology.labcorp.com/providers/order-a-test/omniseq-insight"},{id:"tds-13",name:"StrataNGS",vendor:"Strata Oncology",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Multiplex PCR/semiconductor sequencing panel targeting 429 genes; detects SNVs, indels, CNAs, select fusions, TMB, and MSI.",methodCitations:"https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/",genesAnalyzed:429,genesAnalyzedCitations:"https://ascopubs.org/doi/10.1200/PO.21.00088",geneListUrl:"https://www.strataoncology.com/stratangs",biomarkersReported:["SNVs","Indels","CNAs","Select Fusions","TMB","MSI"],biomarkersReportedCitations:"https://ascopubs.org/doi/10.1200/PO.21.00088",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.strataoncology.com/stratangs",targetPopulation:"Patients with advanced solid tumors requiring genomic profiling",targetPopulationCitations:"https://www.strataoncology.com/stratangs",fdaStatus:"CLIA LDT - not FDA approved",fdaStatusCitations:"https://www.strataoncology.com/stratangs",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer","Ovarian Cancer"],nccnGuidelinesNotes:"Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.strataoncology.com/stratangs",tat:"7-10 days",tatCitations:"https://www.strataoncology.com/stratangs",sampleRequirements:"FFPE tissue",sampleRequirementsCitations:"https://www.strataoncology.com/stratangs",reimbursement:"Medicare",reimbursementNote:"Medicare-covered CGP; specific footprint in health-system networks.",reimbursementCitations:"https://www.strataoncology.com/stratangs",clinicalAvailability:"Commercially available in US",clinicalAvailabilityCitations:"https://www.strataoncology.com/stratangs",clinicalUtility:"Published data on access and outcomes in real-world settings.",clinicalUtilityCitations:"https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/"},{id:"tds-14",name:"MI Profile",vendor:"Caris Life Sciences",sampleCategory:"Tissue",approach:"Tissue Multi-omic Profiling",method:"Comprehensive multi-omic profiling combining WES, WTS, and protein analysis (IHC/FISH) from FFPE tissue; reports DNA variants, RNA fusions, and protein expression.",methodCitations:"https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/molecular-intelligence-platform/",genesAnalyzed:22e3,genesAnalyzedNotes:"WES/WTS interrogates ~22,000 genes; protein analysis adds expression-level biomarkers.",genesAnalyzedCitations:"https://www.carislifesciences.com/physicians/profiling/",geneListUrl:"https://www.carislifesciences.com/physicians/profiling/",biomarkersReported:["SNVs","Indels","CNAs","Fusions","TMB","MSI","Protein Expression"],biomarkersReportedNotes:"Multi-omic approach combines genomic, transcriptomic, and proteomic data.",biomarkersReportedCitations:"https://www.carislifesciences.com/physicians/profiling/",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.carislifesciences.com/physicians/profiling/",targetPopulation:"Patients requiring comprehensive multi-omic tumor profiling",targetPopulationCitations:"https://www.carislifesciences.com/physicians/profiling/",fdaStatus:"CLIA LDT - MI Cancer Seek component FDA approved; full MI Profile is LDT",fdaStatusNotes:"MI Cancer Seek (WES+WTS component) received FDA approval Nov 2024; MI Profile as comprehensive service remains CLIA LDT.",fdaStatusCitations:"https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Melanoma","Prostate Cancer","Ovarian Cancer","Gastric Cancer"],nccnGuidelinesNotes:"Multi-omic approach covers biomarkers recommended by NCCN guidelines at DNA, RNA, and protein levels. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1 | https://www.carislifesciences.com/physicians/profiling/",tat:"10-14 days",tatCitations:"https://www.carislifesciences.com/physicians/profiling/",sampleRequirements:"FFPE tissue",sampleRequirementsCitations:"https://www.carislifesciences.com/physicians/profiling/",reimbursement:"Coverage Varies",reimbursementNote:"Coverage varies by payer and specific tests ordered.",reimbursementCitations:"https://www.carislifesciences.com/physicians/profiling/",clinicalAvailability:"Commercially available in US",clinicalAvailabilityCitations:"https://www.carislifesciences.com/physicians/profiling/"},{id:"tds-15",name:"NEO PanTracer Tissue",previousName:"Neo Comprehensive",vendor:"NeoGenomics",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Comprehensive genomic profiling using DNA and RNA NGS; detects SNVs, indels, CNVs, fusions, splice variants, MSI, and TMB across 517 genes from FFPE tissue samples.",methodCitations:"https://ir.neogenomics.com/news-events/press-releases/detail/235/neogenomics-expands-ngs-portfolio-with-launch-of-neo | https://www.neogenomics.com/test-menu",genesAnalyzed:517,genesAnalyzedNotes:"517 genes analyzed via both DNA and RNA NGS methods.",genesAnalyzedCitations:"NeoGenomics press release March 2023; NeoGenomics test menu.",geneListUrl:"https://www.neogenomics.com/test-menu",biomarkersReported:["SNVs","Indels","CNVs","Fusions","Splice variants","TMB","MSI"],biomarkersReportedNotes:"Comprehensive biomarker detection including both DNA alterations and RNA fusions/splice variants.",biomarkersReportedCitations:"NeoGenomics press release March 2023.",cancerTypes:["All solid tumors"],cancerTypesCitations:"https://www.neogenomics.com/test-menu",targetPopulation:"Patients with solid tumors requiring comprehensive genomic profiling for diagnosis, therapy selection, prognosis, and clinical trial eligibility",targetPopulationCitations:"NeoGenomics test menu; press releases.",fdaStatus:"CLIA LDT - NOT FDA approved",fdaStatusNotes:"CLIA-certified and CAP-accredited laboratory-developed test. New York State approved (Jan 2024).",fdaStatusCitations:"https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Melanoma","Prostate Cancer","Ovarian Cancer"],nccnGuidelinesNotes:"Pan-cancer CGP aligns with NCCN guidelines for solid tumor biomarker testing. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1",tat:"7-10 days",tatNotes:"Improved turnaround time compared to previous NeoGenomics panels. Streamlined workflow.",tatCitations:"NeoGenomics press release March 2023.",sampleRequirements:"FFPE tissue (decreased specimen requirements vs previous panels)",sampleRequirementsCitations:"NeoGenomics press release March 2023.",reimbursement:"Coverage Varies",reimbursementNote:"Coverage varies by payer. Medicare coverage for CGP in advanced solid tumors. Commercial coverage varies.",reimbursementCitations:"NeoGenomics website.",clinicalAvailability:"Commercially available in US (including NY State)",clinicalAvailabilityCitations:"https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",numPublications:null,numPublicationsNotes:"Platform launched March 2023; publication record building.",regulatoryStatusNotes:"CAP-accredited and CLIA-certified laboratories in Fort Myers and Tampa, FL; Aliso Viejo and San Diego, CA; Research Triangle Park, NC; and Houston, TX. New York State approved January 2024."},{id:"tds-16",name:"Northstar Select",vendor:"BillionToOne",sampleCategory:"Blood/Plasma",approach:"Liquid CGP",method:"Single-molecule NGS (smNGS) with QCT (Quantitative Counting Templates) for cfDNA analysis. 84-gene panel optimized for sensitivity over breadth. Detects SNVs, indels, CNAs (amplifications and losses), fusions, and MSI-H. Unique ability to differentiate focal copy number changes from aneuploidies using insights from >1 million cfDNA tests for fetal aneuploidy.",methodCitations:"https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action | Bower X et al. J Liq Biopsy 2025;9:1003222",genesAnalyzed:84,genesAnalyzedNotes:"84-gene panel: 82 genes for SNV/indels, 19 genes for CNA amplification, 5 genes for CNA loss, 9 genes for fusions. Panel designed for actionability over breadth.",genesAnalyzedCitations:"https://www.northstaronc.com/",geneListUrl:"https://cdn.prod.website-files.com/676903c0e34284138d6e0066/68e3c65e20bf5b7173202a4f_NS-SEL-FL-001-2509%20-%20Spec%20Sheet%20-%20DIGITAL.pdf",biomarkersReported:["SNVs","Indels","CNAs (amplification)","CNAs (loss)","Fusions","MSI-H"],biomarkersReportedNotes:"Reports guideline-recommended alterations with focus on actionability. Unique capability to detect CNA losses and differentiate focal driver amplifications from broad chromosomal aneuploidies.",biomarkersReportedCitations:"https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",cancerTypes:["Advanced solid tumors (17+ types)","CNS cancers","Low-shedding tumors"],cancerTypesCitations:"https://www.prnewswire.com/news-releases/billiontoones-northstar-select-demonstrates-superior-sensitivity-in-prospective-head-to-head-validation-study-publication-302539192.html",targetPopulation:"Patients with stage III or IV solid tumors requiring comprehensive genomic profiling, particularly when tissue is not feasible or for low-shedding tumors",targetPopulationCitations:"https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",sensitivity:null,sensitivityNotes:"In prospective head-to-head validation (n=182), detected 51% more pathogenic SNV/Indels and 109% more CNVs than comparator assays. 87% detection rate in CNS cancers vs 27-55% reported for other liquid biopsies. 91% of additional clinically actionable variants found below 0.5% VAF.",sensitivityCitations:"Bower X et al. J Liq Biopsy 2025;9:1003222 | https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",specificity:99.9,specificityNotes:">99.9% analytical specificity across all variant classes. 98% concordance with ddPCR orthogonal validation. CHIP rate equivalent to comparators (19.0% vs 17.2%), confirming additional detections are true positives.",specificityCitations:"Bower X et al. J Liq Biopsy 2025;9:1003222",lod:"0.15% VAF",lodNotes:"LOD95 of 0.15% VAF for SNVs - among the lowest in commercially available liquid biopsy CGP. 2-5x lower LOD than comparator assays.",lodCitations:"https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",fdaStatus:"CLIA LDT - NOT FDA approved",fdaStatusNotes:"CLIA-certified laboratory-developed test. CAP-accredited.",fdaStatusCitations:"https://www.northstaronc.com/",nccnRecommended:!0,nccnAlignmentType:"biomarker-coverage",nccnGuidelinesAligned:["NSCLC","Breast Cancer","Colorectal Cancer","Prostate Cancer"],nccnGuidelinesNotes:"84-gene panel covers guideline-recommended biomarkers. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",nccnGuidelinesCitations:"https://www.nccn.org/guidelines/category_1",tat:"5-8 days",tatNotes:"Typical turnaround time 5-8 days from specimen receipt.",tatCitations:"https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action",sampleRequirements:"Blood draw (plasma cfDNA)",sampleRequirementsCitations:"https://www.northstaronc.com/",reimbursement:"Medicare",reimbursementNote:"Medicare coverage via MolDx (Palmetto GBA LCD L38043) effective February 14, 2025 for eligible beneficiaries with advanced solid tumors.",reimbursementCitations:"https://www.billiontoone.com/news-media/billiontoone-announces-medicare-coverage-for-northstar-select",clinicalAvailability:"Commercially available in US since January 2023",clinicalAvailabilityCitations:"https://www.delveinsight.com/asco-conference/article/billiontoone-northstar-select",numPublications:2,numPublicationsNotes:"Peer-reviewed validation study published September 2025 in Journal of Liquid Biopsy. ASCO 2024 abstract.",numPublicationsCitations:"Bower X et al. J Liq Biopsy 2025;9:1003222 | JCO 2024;42:16_suppl,3072",publicationsExampleCitations:["https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00038-4/fulltext","https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072"],technologyDifferentiator:"Only liquid biopsy with prospective head-to-head peer-reviewed publication showing superior sensitivity vs multiple commercially available comparators. smNGS with QCT technology enables single-molecule precision. Unique ability to detect CNA losses and differentiate focal amplifications from aneuploidies.",independentValidation:"Prospective head-to-head validation against 6 commercially available assays from 4 CLIA/CAP labs (n=182 patients, 17+ tumor types, 6 community clinics + 1 hospital). Orthogonal ddPCR validation showed 98% concordance.",independentValidationCitations:"Bower X et al. J Liq Biopsy 2025;9:1003222",vendorDataSource:"Rob Manor (BillionToOne) submission Dec 2025"},{id:"tds-18",name:"IsoPSA",vendor:"Cleveland Diagnostics",sampleCategory:"Blood/Serum",approach:"Protein Structure Analysis",method:"IsoClear platform analyzes structural differences in PSA protein isoforms to distinguish cancer-derived PSA from benign elevations. Measures prostate cancer-specific structural variants of the PSA protein rather than total PSA concentration. Runs on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad deployment from large centers to community practices.",methodCitations:"Klein EA et al. Eur Urol 2017 | Stovsky M et al. J Urol 2019",cancerTypes:["Prostate cancer (high-grade)"],cancerTypesNotes:"Specifically designed to detect high-grade (clinically significant) prostate cancer, helping avoid unnecessary biopsies for low-grade or benign conditions.",targetPopulation:"Men 50 years of age with elevated PSA levels who are candidates for prostate biopsy decision-making",targetPopulationCitations:"FDA PMA approval December 2025",indicationsNotes:"Aid in the decision for prostate biopsy. Can be used prior to initial biopsy or in patients with prior negative biopsy who remain at elevated risk. Helps clinicians and patients make more informed biopsy decisions.",sensitivity:90.2,sensitivityNotes:"90.2% sensitivity (95% CI: 86.4%-93.0%) for high-grade prostate cancer in prospective multicenter validation study (n=888).",sensitivityCitations:"FDA PMA clinical data; Klein EA et al. Eur Urol 2017",specificity:45.5,specificityNotes:"45.5% specificity (95% CI: 41.4%-49.6%) for high-grade prostate cancer. Specificity is 2-3x higher than traditional PSA tests, potentially avoiding up to 46% of unnecessary biopsies.",specificityCitations:"FDA PMA clinical data; Klein EA et al. Eur Urol 2017",ppv:47.7,ppvNotes:"47.7% PPV (95% CI: 45.7%-49.8%) for high-grade prostate cancer.",ppvCitations:"FDA PMA clinical data",npv:89.3,npvNotes:"89.3% NPV (95% CI: 85.6%-92.2%) for high-grade prostate cancer, providing high confidence in negative results.",npvCitations:"FDA PMA clinical data",auc:.783,aucNotes:"AUC of 0.783 (95% CI: 0.752-0.814) for high-grade prostate cancer, outperforming total PSA and % free PSA.",aucCitations:"FDA PMA clinical data",fdaStatus:"FDA PMA Approved (December 2025)",fdaStatusNotes:"FDA Premarket Approval (PMA) granted December 1, 2025. Previously offered as CLIA LDT since 2020. Breakthrough Device Designation granted October 2019.",fdaStatusCitations:"https://www.businesswire.com/news/home/20251201324198/en/FDA-Approves-IsoPSA----Cleveland-Diagnostics-Novel-Blood-Based-Prostate-Cancer-Test",nccnRecommended:!0,nccnGuidelinesAligned:["Prostate Cancer Early Detection"],nccnGuidelinesNotes:"Included in NCCN Prostate Cancer Early Detection Guidelines (2025) for use prior to biopsy and in patients with prior negative biopsy at higher risk for clinically significant prostate cancer. Also in AUA/SUO Early Detection of Prostate Cancer Guideline (2023).",nccnGuidelinesCitations:"NCCN Guidelines Prostate Cancer Early Detection v1.2026",reimbursement:"Medicare",reimbursementNote:"Medicare coverage established. Commercial payer coverage for 140 million covered lives. More IsoPSAs ordered in first full year as LDT than Guardant360 tests in first 3 years.",reimbursementCitations:"Cleveland Diagnostics; Sameer Rohatgi communication Dec 2025",commercialPayers:["Multiple commercial payers (140M covered lives)"],tat:"3-5 days",tatNotes:"Results typically available in 3-5 days from sample receipt.",tatCitations:"https://www.isopsa.com/for-patients/",sampleRequirements:"Blood draw in Streck tube",sampleRequirementsNotes:"Simple blood draw collected in Streck tube. No DRE required prior to collection.",sampleRequirementsCitations:"https://www.clevelanddx.com/isopsa-testing",clinicalAvailability:"Commercially available in US (LDT since 2020, FDA PMA December 2025)",clinicalAvailabilityNotes:"Available through Cleveland Diagnostics CLIA lab and Quest Diagnostics. IVD kit format enables deployment on standard clinical analyzers (Roche COBAS, Siemens, Abbott) at any laboratory.",clinicalAvailabilityCitations:"https://www.clevelanddx.com",availableRegions:["US"],clinicalTrials:"Prospective multicenter validation study (n=888 patients scheduled for prostate biopsy)",clinicalTrialsCitations:"FDA PMA clinical data; Klein EA et al. Eur Urol 2017",totalParticipants:888,totalParticipantsNotes:"888 patients in prospective multicenter validation study. Additional longitudinal outcome data published in Urology 2025.",numPublications:10,numPublicationsPlus:!0,numPublicationsNotes:"Extensive publication portfolio including Klein EA et al. Eur Urol 2017 (initial validation), Stovsky M et al. J Urol 2019, decision analysis in Urol Pract 2022, and longitudinal outcomes in Urology 2025.",numPublicationsCitations:"https://www.clevelanddx.com/news-archive",publicationsExampleCitations:["Klein EA et al. Eur Urol 2017","Stovsky M et al. J Urol 2019","Abdallah et al. Urology 2025"],technologyDifferentiator:"Only FDA-approved protein structure-based cancer diagnostic. IsoClear platform measures structural differences in proteins rather than concentration. Deployable on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad access from academic centers to community urology practices - not limited to centralized specialty labs.",regulatoryStatusNotes:"FDA PMA approved December 2025. Breakthrough Device Designation 2019. In NCCN and AUA/SUO guidelines. First protein structure-based cancer blood test to receive FDA approval.",vendorDataSource:"Sameer Rohatgi (Cleveland Diagnostics) communication Dec 2025"},{id:"tds-kit-1",name:"TruSight Oncology Comprehensive (TSO Comp)",vendor:"Illumina",productType:"Laboratory IVD Kit",platformRequired:"NextSeq 550Dx",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Hybrid-capture NGS covering 517 genes; detects SNVs, indels, CNAs, fusions/rearrangements; reports TMB, MSI status",genesAnalyzed:517,cancerTypes:["Pan-solid tumor"],indicationsNotes:"First FDA-approved distributable CGP IVD kit. Enables hospitals to bring comprehensive genomic profiling in-house. CE-IVD since March 2022.",fdaStatus:"FDA-approved (Aug 2024); CE-IVD",fdaCompanionDxCount:2,fdaCompanionDxNotes:"FDA approval includes CDx claims for NTRK fusions (pan-tumor) and RET fusions (NSCLC). TMB and MSI reported as biomarkers but not CDx-labeled. Additional CDx claims may expand post-approval.",tmb:"Yes",tmbNotes:"TMB calculated and reported; supports pembrolizumab TMB-H indication",msi:"Yes",msiNotes:"MSI status determined from NGS data",reimbursement:"Medicare LCD (MolDX)",commercialPayers:["UnitedHealthcare","Aetna","Cigna"],clinicalAvailability:"FDA-approved IVD kit",tat:"10-14 days",totalParticipants:1e4,numPublications:50,numPublicationsPlus:!0,technologyDifferentiator:"First FDA-approved pan-cancer CGP IVD kit. Enables decentralized in-house CGP testing at hospitals with NextSeq 550Dx. Complete workflow solution with TruSight Oncology Analysis software."},{id:"tds-kit-2",name:"GeneseeqPrime",vendor:"Geneseeq Technology",productType:"Laboratory IVD Kit",platformRequired:"Illumina NextSeq/NovaSeq",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Hybrid-capture NGS panel covering 425 cancer-related genes; detects SNVs, indels, CNAs, fusions; reports TMB and MSI",genesAnalyzed:425,cancerTypes:["Pan-solid tumor"],indicationsNotes:"FDA 510(k) cleared August 2025 (K-number pending publication). Also CE-IVDR and NMPA (China) approved. First Chinese CGP to receive FDA clearance.",fdaStatus:"FDA 510(k) cleared (Aug 2025); CE-IVDR; NMPA",tmb:"Yes",msi:"Yes",reimbursement:"Emerging - new FDA clearance",clinicalAvailability:"FDA-cleared IVD kit",tat:"7-10 days",totalParticipants:5e4,numPublications:100,numPublicationsPlus:!0,technologyDifferentiator:"Global regulatory approvals (FDA, CE-IVDR, NMPA). Fresh FDA clearance (Sep 2025). Established in Asia market with US expansion. Competitive pricing expected."},{id:"tds-kit-3",name:"PGDx elio tissue complete",vendor:"Labcorp (Personal Genome Diagnostics)",productType:"Laboratory IVD Kit",platformRequired:"Illumina NextSeq 550Dx",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Hybrid-capture NGS covering ~500 genes; comprehensive solid tumor profiling including SNVs, indels, CNAs, MSI, TMB",genesAnalyzed:505,cancerTypes:["Pan-solid tumor"],indicationsNotes:"FDA-cleared and CE-IVDR (July 2025). First and only test CE-marked for comprehensive solid tumor profiling under new EU IVDR regulation.",fdaStatus:"FDA-cleared; CE-IVDR (Jul 2025)",tmb:"Yes",msi:"Yes",reimbursement:"Medicare LCD coverage",commercialPayers:["UnitedHealthcare","Aetna"],clinicalAvailability:"FDA-cleared IVD kit",tat:"10-14 days",totalParticipants:5e3,numPublications:30,technologyDifferentiator:"First CE-IVDR comprehensive CGP kit. Part of elio platform family including plasma focus Dx for liquid biopsy. PGDx analytics platform included."},{id:"tds-kit-4",name:"Oncomine Comprehensive Assay Plus",vendor:"Thermo Fisher Scientific",productType:"Laboratory IVD Kit",platformRequired:"Ion GeneStudio S5",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Amplicon-based NGS covering 500+ genes from DNA and RNA; detects SNVs, indels, CNAs, and fusions including novel fusions via RNA",genesAnalyzed:500,cancerTypes:["Pan-solid tumor"],indicationsNotes:"Primarily positioned for oncology research. DNA+RNA workflow captures both mutation and fusion biomarkers. Popular choice for labs with Ion Torrent infrastructure. CE-IVD/IVDR status requires verification.",fdaStatus:"RUO in US; CE-IVD status pending verification",tmb:"Yes",msi:"Yes",reimbursement:"Coverage varies",clinicalAvailability:"CE-IVD kit",tat:"5-7 days",totalParticipants:2e4,numPublications:80,numPublicationsPlus:!0,technologyDifferentiator:"Ion Torrent amplicon-based sequencing - lower DNA input requirements than hybrid-capture. DNA+RNA workflow in single assay. Strong in APAC market. Automated Genexus workflow option available."},{id:"tds-kit-5",name:"TSO 500",vendor:"Illumina",productType:"Laboratory IVD Kit",platformRequired:"NextSeq 500/550/550Dx",sampleCategory:"Tissue",approach:"Tissue CGP",method:"Hybrid-capture NGS covering 523 genes from DNA and RNA; comprehensive detection of SNVs, indels, CNAs, fusions, TMB, MSI",genesAnalyzed:523,cancerTypes:["Pan-solid tumor"],indicationsNotes:"RUO (Research Use Only) in US. CE-IVD marked in EU - widely deployed in European laboratories. Predecessor to TSO Comprehensive (FDA-approved IVD). For clinical use in US, use TSO Comprehensive.",fdaStatus:"RUO in US; CE-IVD in EU",tmb:"Yes",msi:"Yes",reimbursement:"Coverage varies",clinicalAvailability:"CE-IVD kit; RUO in US",tat:"7-10 days",totalParticipants:5e4,numPublications:200,numPublicationsPlus:!0,technologyDifferentiator:"Established CE-IVD CGP panel with extensive real-world deployment. DNA+RNA enrichment in single workflow. Foundation for TSO Comprehensive."},{id:"tds-kit-6",sampleCategory:"Blood/Plasma",name:"cobas EGFR Mutation Test v2",vendor:"Roche",productType:"Laboratory IVD Kit",platformRequired:"cobas 4800/6800/8800 System",approach:"Tumor-agnostic",method:"Real-time PCR detection of 42 EGFR mutations including exon 19 deletions, L858R, T790M resistance mutation, and exon 20 insertions",cancerTypes:["NSCLC"],targetPopulation:"NSCLC patients for EGFR TKI therapy selection",indicationsNotes:"FDA-approved companion diagnostic for multiple EGFR TKIs. First liquid biopsy test FDA-approved (June 2016). Detects T790M resistance mutation for osimertinib eligibility.",sensitivity:85,sensitivityNotes:"~85% concordance with tissue for EGFR mutations in plasma",specificity:98,lod:"0.1% MAF",lodNotes:"Limit of detection varies by mutation; generally 0.1-1% mutant allele frequency",requiresTumorTissue:"No",requiresTumorTissueNotes:"Liquid biopsy - plasma cfDNA; also validated for tissue",requiresMatchedNormal:"No",tat:"1-2 days",leadTimeVsImaging:null,fdaStatus:"FDA-approved CDx (tissue 2013, plasma 2016)",reimbursement:"Medicare covered as CDx",clinicalAvailability:"FDA-approved IVD kit",totalParticipants:5e4,numPublications:200,numPublicationsPlus:!0,technologyDifferentiator:"Gold standard EGFR liquid biopsy kit. First FDA-approved liquid biopsy CDx. Distributed IVD kit for labs with cobas system. Rapid TAT (1-2 days) vs. NGS-based tests."},{id:"tds-kit-7",sampleCategory:"Blood/Plasma",name:"cobas KRAS Mutation Test",vendor:"Roche",productType:"Laboratory IVD Kit",platformRequired:"cobas 4800 System",approach:"Tumor-agnostic",method:"Real-time PCR detection of KRAS mutations in codons 12, 13, and 61",cancerTypes:["Colorectal cancer"],targetPopulation:"mCRC patients for anti-EGFR therapy selection",indicationsNotes:"FDA-approved companion diagnostic for cetuximab and panitumumab. KRAS wild-type required for anti-EGFR therapy eligibility.",sensitivity:95,sensitivityNotes:"High concordance with tissue testing",specificity:99,lod:"1% MAF",requiresTumorTissue:"No",requiresMatchedNormal:"No",tat:"1-2 days",fdaStatus:"FDA-approved CDx",reimbursement:"Medicare covered as CDx",clinicalAvailability:"FDA-approved IVD kit",totalParticipants:2e4,numPublications:100,numPublicationsPlus:!0,technologyDifferentiator:"Rapid PCR-based KRAS testing for CRC. Distributed IVD kit enables in-house testing. Essential for anti-EGFR therapy decisions."},{id:"tds-kit-8",sampleCategory:"Blood/Plasma",name:"therascreen EGFR RGQ PCR Kit",vendor:"QIAGEN",productType:"Laboratory IVD Kit",platformRequired:"Rotor-Gene Q MDx",approach:"Tumor-agnostic",method:"Scorpions ARMS real-time PCR for EGFR exon 19 deletions, L858R, T790M, and other sensitizing mutations",cancerTypes:["NSCLC"],targetPopulation:"NSCLC patients for EGFR TKI therapy selection",indicationsNotes:"CE-IVD marked. Widely used in EU and Asia. FDA-approved for tissue; CE-IVD for plasma.",sensitivity:80,sensitivityNotes:"~80% sensitivity for major EGFR mutations in plasma",specificity:98,lod:"1% MAF",requiresTumorTissue:"No",requiresMatchedNormal:"No",tat:"1 day",fdaStatus:"FDA-approved (tissue); CE-IVD (plasma)",reimbursement:"Coverage varies by region",clinicalAvailability:"CE-IVD kit; FDA-approved for tissue",totalParticipants:3e4,numPublications:150,numPublicationsPlus:!0,technologyDifferentiator:"Rotor-Gene Q platform common in many molecular labs. Rapid same-day results. Lower capital equipment cost than cobas system."},{id:"tds-kit-9",sampleCategory:"Blood/Plasma",name:"OncoBEAM RAS CRC Kit",vendor:"Sysmex Inostics",productType:"Laboratory IVD Kit",platformRequired:"OncoBEAM System",approach:"Tumor-agnostic",method:"BEAMing (Beads, Emulsion, Amplification, Magnetics) digital PCR for extended RAS panel including KRAS exons 2-4 and NRAS exons 2-4",cancerTypes:["Colorectal cancer"],targetPopulation:"mCRC patients for anti-EGFR therapy selection",indicationsNotes:"CE-IVD marked for RAS testing in mCRC. Extended RAS panel covers all clinically relevant mutations. Ultra-sensitive digital PCR platform.",sensitivity:95,sensitivityNotes:"BEAMing digital PCR provides high sensitivity for low-frequency mutations",specificity:99,lod:"0.02% MAF",lodNotes:"Digital PCR achieves 0.02% MAF sensitivity - among the most sensitive RAS tests",requiresTumorTissue:"No",requiresMatchedNormal:"No",tat:"3-5 days",fdaStatus:"CE-IVD",reimbursement:"Coverage varies; reimbursed in EU",clinicalAvailability:"CE-IVD kit",totalParticipants:1e4,numPublications:50,numPublicationsPlus:!0,technologyDifferentiator:"Ultra-sensitive digital PCR (BEAMing) achieves 0.02% MAF - one of the most sensitive RAS liquid biopsy tests. Extended RAS panel for comprehensive therapy selection."},{id:"tds-kit-10",sampleCategory:"Blood/Plasma",name:"PGDx elio plasma focus Dx",vendor:"Labcorp (Personal Genome Diagnostics)",productType:"Laboratory IVD Kit",platformRequired:"Illumina NextSeq 550Dx",approach:"Tumor-agnostic",method:"NGS-based ~70-gene ctDNA panel; detects SNVs, indels, CNAs, and select fusions across pan-solid tumor biomarkers",cancerTypes:["Pan-solid tumor"],targetPopulation:"Advanced solid tumor patients for therapy selection",indicationsNotes:"FDA De Novo authorized - first FDA-authorized pan-tumor liquid biopsy IVD kit. Enables decentralized NGS liquid biopsy testing.",sensitivity:90,sensitivityNotes:"90% analytical sensitivity across variant types at LoD; multi-gene panel sensitivity varies by biomarker and VAF",specificity:95,specificityNotes:"95% analytical specificity in validation studies; >99.9% NPV across variant types",lod:"0.5% MAF",lodNotes:"Analytical sensitivity ~0.5% VAF for most variants",requiresTumorTissue:"No",requiresMatchedNormal:"No",tat:"5-7 days",fdaStatus:"FDA De Novo authorized",reimbursement:"Medicare LCD coverage",clinicalAvailability:"FDA-authorized IVD kit",totalParticipants:5e3,numPublications:30,technologyDifferentiator:"First FDA-authorized pan-tumor liquid biopsy IVD kit. Enables hospitals to bring NGS liquid biopsy in-house. Part of elio platform including tissue CGP (elio tissue complete)."},{id:"tds-kit-11",sampleCategory:"Bone Marrow/Blood",name:"LeukoStrat CDx FLT3 Mutation Assay",vendor:"Invivoscribe",productType:"Laboratory IVD Kit",platformRequired:"ABI 3500 Genetic Analyzer",approach:"Targeted CDx",method:"PCR-based detection of FLT3-ITD and TKD mutations; FDA-approved companion diagnostic",cancerTypes:["AML"],targetPopulation:"AML patients for FLT3-targeted therapy selection",indicationsNotes:"FDA-approved companion diagnostic for VANFLYTA (quizartinib), RYDAPT (midostaurin), and XOSPATA (gilteritinib). Primary use is therapy selection at diagnosis.",sensitivity:null,sensitivityNotes:"Designed for mutation detection at diagnosis; sensitivity depends on allelic ratio",lod:"5% ITD ratio",lodNotes:"Clinical cutoff for FLT3-ITD positivity",requiresTumorTissue:"No",requiresTumorTissueNotes:"Uses bone marrow or peripheral blood directly",requiresMatchedNormal:"No",tat:"3 days",fdaStatus:"FDA-approved CDx; CE-IVDR",reimbursement:"Medicare covered as CDx",clinicalAvailability:"FDA-approved IVD kit",totalParticipants:1e4,numPublications:50,numPublicationsPlus:!0,technologyDifferentiator:"FDA-approved companion diagnostic for FLT3-targeted AML therapies. Distributed IVD kit enables in-house testing on ABI genetic analyzers. Essential for quizartinib, midostaurin, and gilteritinib eligibility."}],kt=[{id:"alz-1",sampleCategory:"Blood/Plasma",name:"PrecivityAD2",vendor:"C2N Diagnostics",approach:"Mass spectrometry",method:"LC-MS/MS quantification of plasma pTau217 and Abeta42/40 ratio. Combines two biomarkers into the Amyloid Probability Score 2 (APS2) for improved accuracy in detecting brain amyloid and tau pathology.",methodCitations:"https://precivityad.com/precivityad2",biomarkers:["pTau217","Abeta42/40"],primaryBiomarker:"pTau217 + Abeta42/40",targetPopulation:"Adults 55+ with mild cognitive impairment (MCI) or mild dementia being evaluated for Alzheimer's disease",indicationsNotes:"Intended to aid in the evaluation of patients with MCI or mild dementia who are being assessed for Alzheimer's disease. Reports Amyloid Probability Score 2 (APS2) indicating likelihood of amyloid PET positivity. Medicare covered with LCD.",sensitivity:88,sensitivityNotes:"88% sensitivity for detecting amyloid PET positivity in the intended use population (MCI/mild dementia)",sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/37768938/",specificity:87,specificityNotes:"87% specificity vs amyloid PET in intended use population",specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/37768938/",ppv:null,ppvNotes:"PPV depends on pre-test probability; highest in MCI population with ~50% amyloid prevalence",npv:null,npvNotes:"NPV depends on pre-test probability",concordanceWithPET:88,concordanceWithPETNotes:"88% overall agreement with amyloid PET",concordanceWithCSF:90,concordanceWithCSFNotes:"~90% concordance with CSF biomarkers",tat:"7-10 business days",tatNotes:"Results typically available within 7-10 business days from sample receipt",sampleRequirements:"K2-EDTA plasma, 6 mL blood draw, shipped frozen",sampleRequirementsCitations:"https://precivityad.com/healthcare-professionals",fdaStatus:"CLIA LDT",fdaStatusNotes:"Laboratory-developed test performed at C2N Diagnostics CLIA-certified laboratory. Not FDA cleared/approved. Breakthrough Device designation granted.",nccnRecommended:!1,guidelinesAligned:["Alzheimer's Association appropriate use recommendations"],guidelinesNotes:"Aligns with 2024 Alzheimer's Association blood biomarker appropriate use recommendations for patients being evaluated for MCI or dementia",guidelinesCitations:"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13856",reimbursement:"Medicare LCD",reimbursementNote:"Medicare coverage via Palmetto GBA MolDX LCD (L39291) effective January 2024. First Alzheimer's blood test with Medicare coverage. ~$1,250 list price.",reimbursementCitations:"https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39291",cptCodes:"0352U",listPrice:1250,listPriceNotes:"Approximately $1,250; financial assistance available",clinicalAvailability:"Commercially available in US via C2N Diagnostics laboratory (St. Louis, MO)",clinicalAvailabilityCitations:"https://precivityad.com/",availableRegions:["US"],availableRegionsNotes:"Currently US only. International expansion planned.",clinicalTrials:"Validated in multiple cohorts including TRAILBLAZER-ALZ, A4, AHEAD, BioFINDER-2. Over 8,000 samples analyzed in clinical validation.",clinicalTrialsCitations:"https://pubmed.ncbi.nlm.nih.gov/37768938/",totalParticipants:8e3,totalParticipantsNotes:"Clinical validation across multiple cohorts totaling ~8,000 samples",numPublications:25,numPublicationsPlus:!0,numPublicationsNotes:"Extensive peer-reviewed evidence including Alzheimer's & Dementia, JAMA Neurology, Nature Medicine publications",isRUO:!1,isInvestigational:!1,isClinicalLDT:!0,regulatoryStatusNotes:"FDA Breakthrough Device designation. CLIA-certified LDT. First blood test with Medicare coverage for Alzheimer's evaluation.",technologyDifferentiator:"First Alzheimer's blood test with Medicare coverage. Combines pTau217 and Abeta42/40 via mass spectrometry for improved accuracy. APS2 score provides actionable probability of amyloid pathology. Validated against amyloid PET and CSF biomarkers."},{id:"alz-2",sampleCategory:"Blood/Plasma",name:"AD-Detect",vendor:"Quest Diagnostics",approach:"Mass spectrometry",method:"LC-MS/MS quantification of plasma Abeta42/40 ratio. Single biomarker approach measuring amyloid-beta peptide ratio as indicator of brain amyloid deposition.",methodCitations:"https://www.questdiagnostics.com/healthcare-professionals/about-our-tests/brain-health/ad-detect",biomarkers:["Abeta42/40"],primaryBiomarker:"Abeta42/40 ratio",targetPopulation:"Adults 55+ with cognitive symptoms being evaluated for causes of cognitive decline",indicationsNotes:"Intended to help determine if brain amyloid pathology may be contributing to cognitive symptoms. Low Abeta42/40 ratio indicates higher likelihood of amyloid PET positivity.",sensitivity:83,sensitivityNotes:"~83% sensitivity for detecting amyloid PET positivity",sensitivityCitations:"Quest Diagnostics clinical validation data",specificity:85,specificityNotes:"~85% specificity vs amyloid PET",specificityCitations:"Quest Diagnostics clinical validation data",concordanceWithPET:84,concordanceWithPETNotes:"~84% overall agreement with amyloid PET imaging",tat:"5-7 business days",tatNotes:"Results typically within 5-7 business days",sampleRequirements:"EDTA plasma, standard blood draw, shipped frozen",fdaStatus:"CLIA LDT",fdaStatusNotes:"Laboratory-developed test performed at Quest Diagnostics CLIA-certified laboratories",reimbursement:"Coverage varies",reimbursementNote:"Not yet Medicare covered. Out-of-pocket ~$500. Some commercial coverage available.",cptCodes:"0323U",listPrice:500,listPriceNotes:"Approximately $500 list price",clinicalAvailability:"Commercially available nationwide via Quest Diagnostics laboratory network",clinicalAvailabilityCitations:"https://www.questdiagnostics.com/",availableRegions:["US"],availableRegionsNotes:"Available throughout US via Quest laboratory network",totalParticipants:2e3,totalParticipantsNotes:"Clinical validation in ~2,000 patients",numPublications:5,numPublicationsNotes:"Published validation data; leverages extensive amyloid ratio literature",isRUO:!1,isClinicalLDT:!0,technologyDifferentiator:"Single biomarker (Abeta42/40) approach offering accessibility through Quest's nationwide laboratory network. More affordable option for initial amyloid assessment. Simple interpretation: low ratio suggests amyloid pathology."},{id:"alz-3",sampleCategory:"Blood/Plasma",name:"Lumipulse pTau217",vendor:"Fujirebio",approach:"Immunoassay (CLEIA)",method:"Chemiluminescent enzyme immunoassay (CLEIA) on Lumipulse G automated platform. Quantifies plasma pTau217, the most AD-specific phosphorylated tau epitope.",methodCitations:"https://www.fujirebio.com/en/products-solutions/lumipulse",biomarkers:["pTau217"],primaryBiomarker:"pTau217",targetPopulation:"Adults being evaluated for Alzheimer's disease pathology",indicationsNotes:"CE-IVD marked in Europe for aid in diagnosis of Alzheimer's disease. Detects pTau217, which shows earliest changes in AD continuum.",sensitivity:91,sensitivityNotes:"91% sensitivity for amyloid PET positivity in BioFINDER-2 cohort",sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38382644/",specificity:92,specificityNotes:"92% specificity vs amyloid PET in BioFINDER-2",specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/38382644/",concordanceWithPET:91,concordanceWithPETNotes:"91% overall agreement with amyloid PET (AUC 0.96)",concordanceWithCSF:93,concordanceWithCSFNotes:"93% concordance with CSF pTau217",tat:"Same day",tatNotes:"Rapid automated immunoassay; same-day results possible with on-site Lumipulse system",sampleRequirements:"EDTA plasma, 200 uL minimum, standard blood draw",fdaStatus:"CE-IVD (EU); pending FDA",fdaStatusNotes:"CE-IVD marked in Europe. FDA submission anticipated. Available as LDT in select US laboratories.",guidelinesAligned:["Swedish BioFINDER recommendations","EU diagnostic workup pathways"],reimbursement:"Coverage varies by country",reimbursementNote:"EU: Coverage varies by country. US: Not yet broadly covered pending FDA clearance.",listPrice:null,listPriceNotes:"Pricing varies by laboratory; automated platform enables cost-effective testing",clinicalAvailability:"CE-IVD available in Europe. Available as LDT at select US laboratories.",availableRegions:["EU","US (limited)"],availableRegionsNotes:"Broadly available in EU; limited US availability as LDT",clinicalTrials:"Validated in BioFINDER-2, ADNI, and multiple European cohorts. Head-to-head comparisons show among highest accuracy of plasma biomarkers.",clinicalTrialsCitations:"https://pubmed.ncbi.nlm.nih.gov/38382644/",totalParticipants:5e3,totalParticipantsNotes:"Validated across >5,000 subjects in multiple cohorts",numPublications:30,numPublicationsPlus:!0,numPublicationsNotes:"Extensive BioFINDER-2 publications; considered reference standard for plasma pTau217",isRUO:!1,isClinicalLDT:!0,technologyDifferentiator:"Fully automated immunoassay platform enabling high-throughput, standardized testing. CE-IVD marked providing regulatory pathway for clinical use. pTau217 shows highest diagnostic accuracy among plasma biomarkers. Random access system allows integration into clinical laboratory workflow."},{id:"alz-4",sampleCategory:"Blood/Plasma",name:"Elecsys pTau217",vendor:"Roche Diagnostics",approach:"Immunoassay (ECLIA)",method:"Electrochemiluminescence immunoassay (ECLIA) on cobas platform. Quantifies plasma pTau217 using Roche's established automated immunoassay infrastructure.",methodCitations:"https://diagnostics.roche.com/",biomarkers:["pTau217"],primaryBiomarker:"pTau217",targetPopulation:"Adults being evaluated for Alzheimer's disease",indicationsNotes:"Under development for clinical use. Leverages Roche's global cobas platform installed base for potential broad accessibility.",sensitivity:90,sensitivityNotes:"~90% sensitivity reported in validation studies",specificity:90,specificityNotes:"~90% specificity vs amyloid PET",concordanceWithPET:90,concordanceWithPETNotes:"~90% agreement with amyloid PET in clinical studies",tat:"Same day",tatNotes:"Automated platform enables same-day results",sampleRequirements:"EDTA plasma, standard cobas requirements",fdaStatus:"In development",fdaStatusNotes:"Under development; regulatory submission timeline TBD. Builds on Roche's extensive IVD experience.",reimbursement:"Not yet available",reimbursementNote:"Pending regulatory clearance and commercial launch",clinicalAvailability:"Not yet commercially available; in late-stage development",availableRegions:[],availableRegionsNotes:"Expected global availability via Roche's cobas network upon launch",clinicalTrials:"Clinical validation ongoing; leverages TRAILBLAZER-ALZ and other trial data",totalParticipants:null,numPublications:5,numPublicationsNotes:"Early validation publications; full data expected with regulatory submission",isRUO:!0,isInvestigational:!0,isClinicalLDT:!1,technologyDifferentiator:"Potential for massive scalability via Roche's global cobas installed base (>40,000 systems). Standardized ECLIA technology with established quality systems. Upon launch, could enable routine pTau217 testing in any laboratory with cobas system."},{id:"alz-5",sampleCategory:"Blood/Plasma",name:"ALZpath pTau217",vendor:"ALZpath",approach:"Immunoassay (Simoa)",method:"Single molecule array (Simoa) immunoassay using proprietary pTau217 antibody. Ultra-sensitive digital immunoassay technology enables detection at very low concentrations.",methodCitations:"https://alzpath.com/",biomarkers:["pTau217"],primaryBiomarker:"pTau217",targetPopulation:"Adults being evaluated for Alzheimer's disease or at risk for AD",indicationsNotes:"Research use and clinical laboratory-developed testing. ALZpath's proprietary antibody licensed to multiple platforms and laboratories.",sensitivity:93,sensitivityNotes:"93% sensitivity for detecting amyloid PET positivity in validation cohorts",sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/38048578/",specificity:91,specificityNotes:"91% specificity vs amyloid PET",specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/38048578/",concordanceWithPET:92,concordanceWithPETNotes:"92% agreement with amyloid PET (AUC 0.97)",tat:"Variable",tatNotes:"TAT depends on testing laboratory; Simoa requires specialized equipment",sampleRequirements:"EDTA plasma, low volume required due to Simoa sensitivity",fdaStatus:"RUO / LDT",fdaStatusNotes:"Antibody available for research use. Clinical testing available as LDT at select laboratories.",reimbursement:"Coverage varies",reimbursementNote:"Not broadly covered; out-of-pocket costs vary by laboratory",listPrice:null,listPriceNotes:"Pricing varies by testing laboratory",clinicalAvailability:"Available through research collaborations and select clinical laboratories",clinicalAvailabilityCitations:"https://alzpath.com/",availableRegions:["US","EU","International"],availableRegionsNotes:"Antibody licensed globally; clinical testing availability varies",clinicalTrials:"Validated in ADNI, BioFINDER, and multiple academic cohorts. Considered among most accurate pTau217 assays.",clinicalTrialsCitations:"https://pubmed.ncbi.nlm.nih.gov/38048578/",totalParticipants:3e3,totalParticipantsNotes:"Validated across >3,000 subjects in published studies",numPublications:40,numPublicationsPlus:!0,numPublicationsNotes:"Extensively validated in academic literature; high-profile Nature Medicine and JAMA publications",isRUO:!0,isClinicalLDT:!0,technologyDifferentiator:"Ultra-sensitive Simoa technology enables detection at lowest concentrations. Proprietary antibody showing among highest accuracy for plasma pTau217. Widely used in research enabling extensive validation data. Antibody licensed to multiple platforms."},{id:"alz-6",sampleCategory:"Blood/Plasma",name:"Simoa pTau181",vendor:"Quanterix",approach:"Immunoassay (Simoa)",method:"Single molecule array (Simoa) digital immunoassay for plasma pTau181. Ultra-sensitive bead-based technology counts individual protein molecules.",methodCitations:"https://www.quanterix.com/simoa-technology/",biomarkers:["pTau181"],primaryBiomarker:"pTau181",targetPopulation:"Adults being evaluated for Alzheimer's disease or neurodegeneration",indicationsNotes:"Research use and LDT. pTau181 was first plasma tau biomarker validated for AD; now considered less specific than pTau217 but still clinically useful.",sensitivity:85,sensitivityNotes:"~85% sensitivity for amyloid PET positivity; lower than pTau217 assays",sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/32333900/",specificity:83,specificityNotes:"~83% specificity vs amyloid PET",specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/32333900/",concordanceWithPET:84,concordanceWithPETNotes:"84% agreement with amyloid PET (lower than pTau217 assays)",tat:"Variable",tatNotes:"TAT depends on laboratory; requires Simoa HD-X platform",sampleRequirements:"EDTA plasma, low volume (50-100 uL)",fdaStatus:"RUO",fdaStatusNotes:"Research use only. Available as LDT at select CLIA laboratories.",reimbursement:"Not covered",reimbursementNote:"Generally not covered by insurance; used primarily in research",listPrice:null,listPriceNotes:"Research pricing; varies by volume and laboratory",clinicalAvailability:"Available via Quanterix and licensed laboratories for research; limited clinical LDT availability",availableRegions:["US","EU","International"],availableRegionsNotes:"Simoa platform installed globally; primarily research use",clinicalTrials:"Foundational plasma tau biomarker with validation in ADNI, BLSA, and dozens of cohorts",clinicalTrialsCitations:"https://pubmed.ncbi.nlm.nih.gov/32333900/",totalParticipants:1e4,totalParticipantsPlus:!0,totalParticipantsNotes:"Most extensively validated plasma tau biomarker; >10,000 subjects across published studies",numPublications:100,numPublicationsPlus:!0,numPublicationsNotes:"Extensive literature; first plasma tau biomarker with clinical validation",isRUO:!0,isClinicalLDT:!1,technologyDifferentiator:"First plasma tau biomarker validated for AD detection. Extensive research validation and literature. Lower accuracy than pTau217 but established technology with broad data. Simoa platform enables ultra-sensitive detection."},{id:"alz-7",sampleCategory:"Blood/Plasma",name:"PrecivityAD",vendor:"C2N Diagnostics",approach:"Mass spectrometry",method:"LC-MS/MS quantification of plasma Abeta42/40 ratio. First-generation test from C2N measuring amyloid-beta peptide ratio.",methodCitations:"https://precivityad.com/",biomarkers:["Abeta42/40"],primaryBiomarker:"Abeta42/40 ratio",targetPopulation:"Adults 60+ with cognitive symptoms being evaluated for Alzheimer's disease",indicationsNotes:"First-generation C2N test. Now largely superseded by PrecivityAD2 which adds pTau217 for improved accuracy. Still available for Abeta-only assessment.",sensitivity:81,sensitivityNotes:"81% sensitivity for amyloid PET positivity (lower than PrecivityAD2)",sensitivityCitations:"https://pubmed.ncbi.nlm.nih.gov/32333829/",specificity:83,specificityNotes:"83% specificity vs amyloid PET",specificityCitations:"https://pubmed.ncbi.nlm.nih.gov/32333829/",concordanceWithPET:82,concordanceWithPETNotes:"82% agreement with amyloid PET",tat:"7-10 business days",tatNotes:"Same TAT as PrecivityAD2",sampleRequirements:"K2-EDTA plasma, 6 mL blood draw, shipped frozen",fdaStatus:"CLIA LDT",fdaStatusNotes:"Laboratory-developed test. Breakthrough Device designation.",reimbursement:"Medicare LCD",reimbursementNote:"Covered under same Medicare LCD as PrecivityAD2; ~$1,000 list price",cptCodes:"0350U",listPrice:1e3,listPriceNotes:"Approximately $1,000; lower than PrecivityAD2",clinicalAvailability:"Commercially available via C2N Diagnostics",availableRegions:["US"],totalParticipants:5e3,numPublications:20,numPublicationsNotes:"Foundational plasma Abeta publications from C2N",isRUO:!1,isClinicalLDT:!0,technologyDifferentiator:"First mass spectrometry plasma Abeta test with Medicare coverage. Single biomarker approach may be appropriate when pTau217 not needed. Established track record since 2020 launch."},{id:"alz-8",sampleCategory:"Blood/Plasma",name:"Lumipulse Amyloid Ratio",vendor:"Fujirebio",approach:"Immunoassay (CLEIA)",method:"Chemiluminescent enzyme immunoassay (CLEIA) for plasma Abeta42/40 ratio on Lumipulse G platform. Automated immunoassay approach to amyloid measurement.",methodCitations:"https://www.fujirebio.com/",biomarkers:["Abeta42/40"],primaryBiomarker:"Abeta42/40 ratio",targetPopulation:"Adults being evaluated for Alzheimer's disease amyloid pathology",indicationsNotes:"CE-IVD for amyloid ratio measurement. Can be combined with Lumipulse pTau217 for comprehensive blood biomarker assessment.",sensitivity:82,sensitivityNotes:"~82% sensitivity for amyloid PET positivity",specificity:84,specificityNotes:"~84% specificity vs amyloid PET",concordanceWithPET:83,concordanceWithPETNotes:"83% agreement with amyloid PET",tat:"Same day",tatNotes:"Automated platform enables same-day results",sampleRequirements:"EDTA plasma, automated platform requirements",fdaStatus:"CE-IVD (EU)",fdaStatusNotes:"CE-IVD marked in Europe. US availability as LDT.",reimbursement:"Coverage varies",reimbursementNote:"EU coverage varies by country; limited US coverage",clinicalAvailability:"Available in Europe; limited US availability",availableRegions:["EU","US (limited)"],totalParticipants:3e3,numPublications:15,numPublicationsNotes:"Validation publications including BioFINDER-2 cohort data",isRUO:!1,isClinicalLDT:!0,technologyDifferentiator:"Automated immunoassay for plasma Abeta ratio enabling integration with Lumipulse pTau217. CE-IVD marked providing clear regulatory pathway. Part of comprehensive Fujirebio AD blood biomarker menu."},{id:"alz-9",sampleCategory:"Blood/Plasma",name:"ADNEX Blood Test",vendor:"Cogstate (with Eisai)",approach:"Multi-biomarker panel",method:"Combines blood biomarkers with digital cognitive assessment for comprehensive AD risk evaluation. Integrates pTau217, Abeta42/40, and Cogstate Brief Battery cognitive scores.",methodCitations:"https://cogstate.com/",biomarkers:["pTau217","Abeta42/40","Cognitive assessment"],primaryBiomarker:"Multi-modal (blood + cognitive)",targetPopulation:"Adults with subjective cognitive decline or early MCI being screened for AD clinical trials or clinical evaluation",indicationsNotes:"Integrated solution combining blood biomarkers with validated digital cognitive testing. Designed to improve efficiency of AD screening and clinical trial enrollment.",sensitivity:null,sensitivityNotes:"Performance data emerging from validation studies",specificity:null,specificityNotes:"Performance data emerging from validation studies",tat:"Variable",tatNotes:"Depends on biomarker testing laboratory and cognitive assessment scheduling",sampleRequirements:"Blood sample for biomarkers + digital cognitive assessment",fdaStatus:"Research/clinical development",fdaStatusNotes:"Integration platform in development. Individual components have varying regulatory status.",reimbursement:"Not established",reimbursementNote:"Reimbursement pathway in development",clinicalAvailability:"Available through research partnerships and select clinical programs",availableRegions:["US","International"],availableRegionsNotes:"Global availability through Cogstate network",clinicalTrials:"Used in AHEAD, TRAILBLAZER, and other AD prevention trials for screening",totalParticipants:null,numPublications:5,numPublicationsNotes:"Emerging publications on integrated approach",isRUO:!0,isInvestigational:!0,isClinicalLDT:!1,technologyDifferentiator:"Unique multi-modal approach combining blood biomarkers with digital cognitive assessment. Designed for efficient screening and staging. Partnership with Eisai provides integration with AD therapeutic development. Addresses need for comprehensive, accessible AD evaluation."}],is={ONCO:"onco",ALZ:"alz"},Du=()=>is.ALZ,Cf=()=>({domain:is.ALZ,name:"OpenAlz",tagline:"Alzheimer's Diagnostics Database",description:"Compare blood-based Alzheimer's biomarker tests",logoText:"OpenAlz",themeColor:"#6366f1",categories:["ALZ-BLOOD"]}),bt={ONCO:"onco",ALZ:"alz"},Pu=[{id:"ECD",name:"Early Cancer Detection",acronym:"ECD",phase:"Healthy / Screening",color:"emerald",icon:"",gridPosition:0,arrowDirection:"right",domain:bt.ONCO},{id:"TDS",name:"Treatment Decision Support",acronym:"TDS",phase:"Newly Diagnosed",color:"violet",icon:"",gridPosition:1,arrowDirection:"down",domain:bt.ONCO},{id:"TRM",name:"Treatment Response Monitoring",acronym:"TRM",phase:"Active Treatment",color:"sky",icon:"",gridPosition:3,arrowDirection:"left",domain:bt.ONCO},{id:"MRD",name:"Minimal Residual Disease",acronym:"MRD",phase:"Surveillance",color:"orange",icon:"",gridPosition:2,arrowDirection:"up",domain:bt.ONCO},{id:"ALZ-BLOOD",name:"Blood Biomarkers",acronym:"ALZ-BLOOD",phase:"Screening / Diagnosis",color:"indigo",icon:"",gridPosition:0,arrowDirection:"right",domain:bt.ALZ}];[...Pu].sort((e,t)=>e.gridPosition-t.gridPosition);const wf=e=>Pu.filter(t=>t.domain===e),Ho={emerald:{bg:"bg-emerald-500",bgLight:"bg-emerald-50",bgMedium:"bg-emerald-100",border:"border-emerald-200",borderActive:"border-emerald-500",text:"text-emerald-600",textLight:"text-emerald-400",textDark:"text-emerald-700"},violet:{bg:"bg-violet-500",bgLight:"bg-violet-50",bgMedium:"bg-violet-100",border:"border-violet-200",borderActive:"border-violet-500",text:"text-violet-600",textLight:"text-violet-400",textDark:"text-violet-700"},sky:{bg:"bg-sky-500",bgLight:"bg-sky-50",bgMedium:"bg-sky-100",border:"border-sky-200",borderActive:"border-sky-500",text:"text-sky-600",textLight:"text-sky-400",textDark:"text-sky-700"},orange:{bg:"bg-orange-500",bgLight:"bg-orange-50",bgMedium:"bg-orange-100",border:"border-orange-200",borderActive:"border-orange-500",text:"text-orange-600",textLight:"text-orange-400",textDark:"text-orange-700"},indigo:{bg:"bg-indigo-500",bgLight:"bg-indigo-50",bgMedium:"bg-indigo-100",border:"border-indigo-200",borderActive:"border-indigo-500",text:"text-indigo-600",textLight:"text-indigo-400",textDark:"text-indigo-700"}},Xs={SELF_COLLECTION:{id:"Self-Collection",label:"Self-Collection",icon:"",description:"Patient collects sample at home",bgColor:"bg-teal-50",textColor:"text-teal-700",borderColor:"border-teal-200"},LAB_KIT:{id:"Laboratory IVD Kit",label:"Lab Kit",icon:"",description:"IVD kit run at CLIA-certified lab",bgColor:"bg-indigo-50",textColor:"text-indigo-700",borderColor:"border-indigo-200"},CENTRAL_LAB:{id:"Central Lab Service",label:"Service",icon:"",description:"Sample shipped to central laboratory",bgColor:"bg-slate-50",textColor:"text-slate-600",borderColor:"border-slate-200"}},ku=e=>e&&Object.values(Xs).find(t=>t.id===e)||Xs.CENTRAL_LAB,Nf=(e={})=>({MRD:{title:"Molecular Residual Disease",shortTitle:"MRD Testing",description:"Molecular Residual Disease (MRD) testing detects tiny amounts of cancer that remain in the body after treatment, often before any symptoms or imaging findings appear. These tests analyze circulating tumor DNA (ctDNA) from a blood sample to identify whether cancer cells persist at the molecular level. MRD results help oncologists make critical decisions about whether additional treatment is needed, assess the effectiveness of therapy, and monitor for early signs of recurrence during surveillance.",patientTitle:"Tests After Treatment",patientDescription:"These blood tests check if any cancer cells remain after surgery or treatment. Finding leftover cancer early can help your doctor decide if you need more treatment.",color:"orange",tests:z,sourceUrl:e.MRD||"",domain:bt.ONCO},ECD:{title:"Early Cancer Detection",shortTitle:"Early Detection",description:"Early Cancer Detection (ECD) tests screen for cancer in people who have no symptoms, with the goal of catching the disease at its earliest and most treatable stages. These tests look for cancer signals in blood samples using various biomarkers including ctDNA methylation patterns, tumor-derived proteins, and genetic mutations. Some tests screen for a single cancer type (like colorectal), while multi-cancer early detection (MCED) tests can screen for dozens of cancer types simultaneously.",patientTitle:"Cancer Screening Tests",patientDescription:"These blood tests look for signs of cancer before you have any symptoms. Finding cancer early, when it's easiest to treat, can save lives.",color:"green",tests:Y,sourceUrl:e.ECD||"",domain:bt.ONCO},TRM:{title:"Treatment Response Monitoring",shortTitle:"Response Monitoring",description:"Treatment Response Monitoring (TRM) tests track how well a cancer treatment is working by measuring changes in circulating tumor DNA (ctDNA) levels over time. A decrease in ctDNA often indicates the treatment is effective, while stable or rising levels may signal resistance or progressionsometimes weeks before changes appear on imaging scans. This sensitive molecular monitoring helps oncologists optimize therapy for most favorable outcomes, potentially switching ineffective treatments earlier and sparing patients unnecessary toxicity.",patientTitle:"Is My Treatment Working?",patientDescription:"These blood tests track whether your cancer treatment is working. They can show results weeks before a scan, helping your doctor adjust treatment if needed.",color:"red",tests:K,sourceUrl:e.TRM||"",domain:bt.ONCO},TDS:{title:"Treatment Decision Support",shortTitle:"Treatment Decisions",description:"Treatment Decision Support (TDS) tests help guide clinical decisions about cancer treatment. This includes Comprehensive Genomic Profiling (CGP) tests that analyze tumor DNA/RNA to identify targetable mutations and match patients to therapies, as well as risk stratification tests that help determine whether interventions like biopsies are needed. These tests support personalized treatment decisions based on molecular and protein biomarker analysis.",patientTitle:"Find My Best Treatment",patientDescription:"These tests help your doctor decide the best treatment approach for you. They can analyze your tumor's characteristics to find specific treatments that may work best, or help determine if procedures like biopsies are necessary.",color:"violet",tests:X,sourceUrl:e.TDS||"",domain:bt.ONCO},"ALZ-BLOOD":{title:"Blood Biomarkers",shortTitle:"Blood Tests",description:"Blood-based biomarker tests for Alzheimer's disease detection and risk assessment. These tests measure proteins like phosphorylated tau (pTau217, pTau181) and amyloid-beta ratios (Abeta42/40) that indicate Alzheimer's pathology in the brain. Blood biomarkers offer a less invasive alternative to PET scans and lumbar punctures for detecting amyloid plaques and tau tangles.",patientTitle:"Alzheimer's Blood Tests",patientDescription:"These blood tests can help detect signs of Alzheimer's disease by measuring specific proteins. They're less invasive than brain scans or spinal taps and can help your doctor understand if Alzheimer's might be causing memory problems.",color:"indigo",tests:kt,sourceUrl:e["ALZ-BLOOD"]||"",domain:bt.ALZ}}),Af={MRD:{productTypes:["Central Lab Service","Laboratory IVD Kit"],cancerTypes:[...new Set(z.flatMap(e=>e.cancerTypes||[]))].sort(),sampleCategories:[...new Set(z.map(e=>e.sampleCategory||"Blood/Plasma"))].sort(),fdaStatuses:["FDA Approved","FDA Breakthrough","LDT"],reimbursements:["Medicare","Commercial"],approaches:["Tumor-informed","Tumor-nave"],regions:["US","EU","UK","International","RUO"],clinicalSettings:["Neoadjuvant","Post-Surgery","Post-Adjuvant","Surveillance"]},ECD:{productTypes:["Self-Collection","Central Lab Service","Laboratory IVD Kit"],testScopes:["Single-cancer (CRC)","Multi-cancer (MCED)"],sampleCategories:["Blood/Plasma","Stool"],fdaStatuses:["FDA Approved","FDA Breakthrough","LDT","Investigational"],reimbursements:["Medicare","Commercial"],approaches:["Blood-based cfDNA screening (plasma)","Blood-based cfDNA methylation MCED (plasma)","Stool DNA + FIT"],regions:["US","EU","UK","International","RUO"]},TRM:{productTypes:["Central Lab Service","Laboratory IVD Kit"],cancerTypes:[...new Set(K.flatMap(e=>e.cancerTypes||[]))].sort(),sampleCategories:["Blood/Plasma"],fdaStatuses:["FDA Approved","FDA Breakthrough","LDT"],approaches:["Tumor-informed","Tumor-nave","Tumor-agnostic"],reimbursements:["Medicare","Commercial"],regions:["US","EU","UK","International","RUO"]},TDS:{productTypes:["Central Lab Service","Laboratory IVD Kit"],cancerTypes:[...new Set(X.flatMap(e=>e.cancerTypes||[]))].sort(),sampleCategories:[...new Set(X.map(e=>e.sampleCategory||"Unknown"))].sort(),approaches:[...new Set(X.map(e=>e.approach||"Unknown"))].sort(),fdaStatuses:["FDA Approved","FDA Breakthrough","LDT"],reimbursements:["Medicare","Commercial"]},"ALZ-BLOOD":{biomarkers:[...new Set(kt.flatMap(e=>e.biomarkers||[]))].sort(),approaches:[...new Set(kt.map(e=>e.approach||"Unknown"))].sort(),fdaStatuses:["FDA Approved","CE-IVD","CLIA LDT","RUO","In development"],reimbursements:["Medicare LCD","Coverage varies","Not covered"],regions:[...new Set(kt.flatMap(e=>e.availableRegions||[]))].sort()}},sc={MRD:[{key:"productType",label:"Product Type"},{key:"platformRequired",label:"Platform Required"},{key:"approach",label:"Approach"},{key:"method",label:"Method"},{key:"sampleCategory",label:"Sample Type"},{key:"cancerTypesStr",label:"Cancer Types"},{key:"clinicalSettingsStr",label:"Clinical Settings"},{key:"sensitivity",label:"Reported Sensitivity (%)"},{key:"sensitivityStagesReported",label:"Stages in Headline"},{key:"stageIISensitivity",label:"Stage II Sensitivity (%)"},{key:"stageIIISensitivity",label:"Stage III Sensitivity (%)"},{key:"landmarkSensitivity",label:"Post-Surgery Sensitivity (%)"},{key:"longitudinalSensitivity",label:"Surveillance Sensitivity (%)"},{key:"specificity",label:"Reported Specificity (%)"},{key:"analyticalSpecificity",label:"Analytical Specificity (%)"},{key:"clinicalSpecificity",label:"Clinical Specificity (%)"},{key:"lod",label:"LOD (detection)"},{key:"lod95",label:"LOD95 (95% conf)"},{key:"variantsTracked",label:"Variants Tracked"},{key:"bloodVolume",label:"Blood Volume (mL)"},{key:"cfdnaInput",label:"cfDNA Input (ng)"},{key:"initialTat",label:"Initial TAT (days)"},{key:"followUpTat",label:"Follow-up TAT (days)"},{key:"totalParticipants",label:"Trial Participants"},{key:"numPublications",label:"Publications"},{key:"fdaStatus",label:"Regulatory"},{key:"reimbursement",label:"Medicare"},{key:"commercialPayersStr",label:"Private Insurance"},{key:"availableRegionsStr",label:"Availability"}],ECD:[{key:"productType",label:"Product Type"},{key:"platformRequired",label:"Platform Required"},{key:"testScope",label:"Scope"},{key:"approach",label:"Approach"},{key:"method",label:"Method"},{key:"sampleCategory",label:"Sample Type"},{key:"cancerTypesStr",label:"Target Cancers"},{key:"targetPopulation",label:"Population"},{key:"sensitivity",label:"Reported Sensitivity (%)"},{key:"stageISensitivity",label:"Stage I Sens (%)"},{key:"stageIISensitivity",label:"Stage II Sens (%)"},{key:"stageIIISensitivity",label:"Stage III Sens (%)"},{key:"stageIVSensitivity",label:"Stage IV Sens (%)"},{key:"specificity",label:"Reported Specificity (%)"},{key:"ppv",label:"PPV (%)"},{key:"npv",label:"NPV (%)"},{key:"tumorOriginAccuracy",label:"Origin Prediction (%)"},{key:"leadTimeNotes",label:"Lead Time vs Screening"},{key:"totalParticipants",label:"Trial Participants"},{key:"numPublications",label:"Publications"},{key:"fdaStatus",label:"Regulatory"},{key:"reimbursement",label:"Medicare"},{key:"commercialPayersStr",label:"Private Insurance"},{key:"availableRegionsStr",label:"Availability"},{key:"clinicalAvailability",label:"Clinical Availability"},{key:"tat",label:"Turnaround Time"},{key:"sampleType",label:"Sample Details"},{key:"listPrice",label:"List Price (USD)"},{key:"screeningInterval",label:"Screening Interval"},{key:"cptCode",label:"CPT Code"},{key:"performanceCitations",label:"Citations"},{key:"performanceNotes",label:"Performance Notes"}],TRM:[{key:"productType",label:"Product Type"},{key:"platformRequired",label:"Platform Required"},{key:"approach",label:"Approach"},{key:"method",label:"Method"},{key:"sampleCategory",label:"Sample Type"},{key:"cancerTypesStr",label:"Target Cancers"},{key:"targetPopulation",label:"Population"},{key:"responseDefinition",label:"Response Definition"},{key:"leadTimeVsImaging",label:"Lead Time (days)"},{key:"lod",label:"LOD (detection)"},{key:"lod95",label:"LOD95 (95% conf)"},{key:"sensitivity",label:"Reported Sensitivity (%)"},{key:"specificity",label:"Reported Specificity (%)"},{key:"totalParticipants",label:"Trial Participants"},{key:"numPublications",label:"Publications"},{key:"fdaStatus",label:"Regulatory"},{key:"reimbursement",label:"Medicare"},{key:"commercialPayersStr",label:"Private Insurance"},{key:"availableRegionsStr",label:"Availability"}],TDS:[{key:"productType",label:"Product Type"},{key:"platformRequired",label:"Platform Required"},{key:"approach",label:"Approach"},{key:"method",label:"Method"},{key:"sampleCategory",label:"Sample Type"},{key:"genesAnalyzed",label:"Genes Analyzed"},{key:"biomarkersReportedStr",label:"Biomarkers Reported"},{key:"cancerTypesStr",label:"Target Cancers"},{key:"targetPopulation",label:"Population"},{key:"fdaCompanionDxCount",label:"FDA CDx Indications"},{key:"nccnRecommended",label:"NCCN Recommended"},{key:"tat",label:"Turnaround Time"},{key:"sampleRequirements",label:"Sample Requirements"},{key:"numPublications",label:"Publications"},{key:"fdaStatus",label:"Regulatory"},{key:"reimbursement",label:"Medicare"},{key:"listPrice",label:"List Price (USD)"}],"ALZ-BLOOD":[{key:"approach",label:"Technology"},{key:"primaryBiomarker",label:"Primary Biomarker"},{key:"biomarkersStr",label:"Biomarkers Measured"},{key:"method",label:"Method"},{key:"targetPopulation",label:"Target Population"},{key:"sensitivity",label:"Sensitivity (%)"},{key:"specificity",label:"Specificity (%)"},{key:"concordanceWithPET",label:"PET Concordance (%)"},{key:"concordanceWithCSF",label:"CSF Concordance (%)"},{key:"tat",label:"Turnaround Time"},{key:"sampleRequirements",label:"Sample Requirements"},{key:"fdaStatus",label:"Regulatory Status"},{key:"reimbursement",label:"Coverage"},{key:"listPrice",label:"List Price (USD)"},{key:"availableRegionsStr",label:"Availability"},{key:"totalParticipants",label:"Validation Participants"},{key:"numPublications",label:"Publications"}]},Js={"Exact Sciences":[{id:"openness-leader",icon:"",label:"Openness Leader",tooltip:"Top 3 in OpenOnco Data Openness Ranking"}]},Zi=[{id:"claude-haiku-4-5-20251001",name:"More speed",description:"Fast responses"},{id:"claude-sonnet-4-5-20250929",name:"More thinking",description:"Deeper analysis"}],Sf=e=>{if(!e)return[];if(Js[e])return Js[e];for(const[t,a]of Object.entries(Js))if(e.includes(t)||t.includes(e))return a;return[]},_a=({vendor:e,size:t="sm"})=>{const a=Sf(e);if(a.length===0)return null;const n={xs:"text-xs",sm:"text-sm",md:"text-base",lg:"text-lg"};return i.jsx(i.Fragment,{children:a.map(s=>i.jsx("span",{className:`${n[t]} cursor-help ml-1 inline-flex items-center`,title:s.tooltip,children:i.jsx("span",{className:"hover:scale-110 transition-transform",children:s.icon})},s.id))})},Tf=({productType:e,size:t="sm"})=>{const a=ku(e),n={xs:"text-[10px] px-1.5 py-0.5",sm:"text-xs px-2 py-0.5",md:"text-sm px-2.5 py-1"};return i.jsxs("span",{className:`inline-flex items-center gap-1 ${n[t]} ${a.bgColor} ${a.textColor} border ${a.borderColor} rounded-full font-medium`,title:a.description,children:[i.jsx("span",{children:a.icon}),i.jsx("span",{children:a.label})]})},zo=({children:e,className:t=""})=>{if(!e)return null;const a=s=>{try{const r=new URL(s,window.location.origin);return["http:","https:"].includes(r.protocol)?s:null}catch{return null}},n=s=>{const r=s.split(`
`),o=[];let l=[],d=null,u=0;const g=()=>{l.length>0&&(d==="ul"?o.push(i.jsx("ul",{className:"list-disc list-inside my-2 space-y-1",children:l},u++)):o.push(i.jsx("ol",{className:"list-decimal list-inside my-2 space-y-1",children:l},u++)),l=[],d=null)},p=j=>{const m=[];let c=j,h=0;for(;c.length>0;){let C=c.match(/^(\*\*|__)(.+?)\1/);if(C){m.push(i.jsx("strong",{className:"font-semibold",children:p(C[2])},h++)),c=c.slice(C[0].length);continue}if(C=c.match(/^(\*|_)(.+?)\1/),C){m.push(i.jsx("em",{className:"italic",children:p(C[2])},h++)),c=c.slice(C[0].length);continue}if(C=c.match(/^`([^`]+)`/),C){m.push(i.jsx("code",{className:"bg-gray-200 text-gray-800 px-1.5 py-0.5 rounded text-xs font-mono",children:C[1]},h++)),c=c.slice(C[0].length);continue}if(C=c.match(/^\[([^\]]+)\]\(([^)]+)\)/),C){const P=a(C[2]);P?m.push(i.jsx("a",{href:P,target:"_blank",rel:"noopener noreferrer",className:"text-emerald-600 underline hover:text-emerald-700",children:C[1]},h++)):m.push(i.jsx("span",{className:"text-gray-500",children:C[1]},h++)),c=c.slice(C[0].length);continue}if(C=c.match(/^[^*_`\[]+/),C){m.push(C[0]),c=c.slice(C[0].length);continue}m.push(c[0]),c=c.slice(1)}return m.length===1&&typeof m[0]=="string"?m[0]:m},y=j=>j.split("|").map(m=>m.trim()).filter((m,c,h)=>c>0&&c<h.length-1||h[0]!==""&&c===0||h[h.length-1]!==""&&c===h.length-1).filter(m=>m!==""),x=j=>/^\|?[\s\-:|]+\|?$/.test(j)&&j.includes("-"),w=j=>j.includes("|")&&!x(j);let b=0;for(;b<r.length;){const j=r[b];if(w(j)&&b+1<r.length&&x(r[b+1])){g();const C=y(j);b+=2;const P=[];for(;b<r.length&&w(r[b]);)P.push(y(r[b])),b++;o.push(i.jsx("div",{className:"overflow-x-auto my-2",children:i.jsxs("table",{className:"min-w-full text-sm border-collapse",children:[i.jsx("thead",{children:i.jsx("tr",{className:"bg-gray-100",children:C.map((R,v)=>i.jsx("th",{className:"border border-gray-300 px-3 py-1.5 text-left font-semibold text-gray-700",children:p(R)},v))})}),i.jsx("tbody",{children:P.map((R,v)=>i.jsx("tr",{className:v%2===0?"bg-white":"bg-gray-50",children:R.map((N,F)=>i.jsx("td",{className:"border border-gray-300 px-3 py-1.5 text-gray-600",children:p(N)},F))},v))})]})},u++));continue}const m=j.match(/^(#{1,6})\s+(.+)$/);if(m){g();const C=m[1].length,P=p(m[2]),R={1:"text-lg font-bold mt-3 mb-2",2:"text-base font-bold mt-3 mb-1.5",3:"text-sm font-semibold mt-2 mb-1",4:"text-sm font-semibold mt-2 mb-1",5:"text-sm font-medium mt-1 mb-1",6:"text-sm font-medium mt-1 mb-1"},v=`h${C}`;o.push(i.jsx(v,{className:R[C],children:P},u++)),b++;continue}const c=j.match(/^[\s]*[-*]\s+(.+)$/);if(c){d!=="ul"&&g(),d="ul",l.push(i.jsx("li",{children:p(c[1])},u++)),b++;continue}const h=j.match(/^[\s]*\d+\.\s+(.+)$/);if(h){d!=="ol"&&g(),d="ol",l.push(i.jsx("li",{children:p(h[1])},u++)),b++;continue}if(j.trim()===""){g(),b++;continue}g(),o.push(i.jsx("p",{className:"my-1",children:p(j)},u++)),b++}return g(),o};return i.jsx("div",{className:t,children:n(e)})},Ja=()=>{try{return localStorage.getItem("openonco-persona")}catch{return null}},Df=e=>{switch(e){case"ECD":return["Galleri","Shield","Cancerguard","Freenome CRC","GRAIL NHS","Cologuard Plus"];case"TDS":return["FoundationOne CDx","Guardant360 CDx","Tempus xT CDx","MSK-IMPACT","MI Cancer Seek","OncoExTra"];case"TRM":return["Reveal TRM","Signatera (IO Monitoring)","NeXT Personal","RaDaR","Oncodetect"];case"MRD":return["Signatera","Reveal MRD","RaDaR","Oncodetect","Invitae Personalis","FoundationOne Tracker"];default:return[]}},Pf=({direction:e,isPulsing:t,color:a})=>{const n=Ho[a],s={right:"right-0 top-1/2 translate-x-1/2 -translate-y-1/2",down:"bottom-0 left-1/2 -translate-x-1/2 translate-y-1/2",left:"left-0 top-1/2 -translate-x-1/2 -translate-y-1/2",up:"top-0 left-1/2 -translate-x-1/2 -translate-y-1/2"},r={right:"rotate-0",down:"rotate-90",left:"rotate-180",up:"-rotate-90"};return i.jsx("div",{className:`absolute z-20 ${s[e]}`,children:i.jsx("div",{className:`
        w-7 h-7 rounded-full flex items-center justify-center transition-all duration-500
        ${t?`${n.bg} shadow-lg scale-110`:`bg-white shadow-md border ${n.border}`}
        ${r[e]}
      `,children:i.jsx("svg",{className:`w-3.5 h-3.5 transition-colors duration-500 ${t?"text-white":n.textLight}`,fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2.5,d:"M9 5l7 7-7 7"})})})})},kf=({tests:e,isHighlighted:t,color:a})=>{const n=Ho[a],s=e.join("    "),r=`${s}    ${s}    `;return i.jsx("div",{className:`mt-3 pt-2 border-t transition-colors duration-500 overflow-hidden ${t?n.borderActive:n.border}`,children:i.jsx("div",{className:"relative",children:i.jsx("div",{className:`flex whitespace-nowrap text-xs transition-colors duration-500 ${t?"text-gray-600":"text-gray-400"}`,style:{animation:"lifecycleScroll 15s linear infinite"},children:i.jsx("span",{className:"pr-4",children:r})})})})},jf=({stage:e,isHighlighted:t,onClick:a,onMouseEnter:n,testCount:s})=>{const r=Ho[e.color],o=Df(e.id);return i.jsxs("button",{onClick:a,onMouseEnter:n,className:`
        relative p-5 rounded-xl text-left transition-all duration-500 h-full
        ${t?`${r.bgMedium} border-2 ${r.borderActive} shadow-lg`:`${r.bgLight} border ${r.border}`}
      `,children:[i.jsxs("div",{className:"flex items-center gap-4",children:[i.jsx("div",{className:`
          w-12 h-12 rounded-lg flex items-center justify-center flex-shrink-0 transition-all duration-500
          ${t?`${r.bg} text-white shadow-md`:`${r.bgMedium} ${r.text}`}
        `,children:i.jsx("span",{className:"text-2xl",children:e.icon})}),i.jsxs("div",{className:"flex-1 min-w-0",children:[i.jsxs("h3",{className:`text-base font-bold leading-tight transition-colors duration-500 ${t?r.textDark:r.text}`,children:[e.phase,": ",e.acronym]}),i.jsx("p",{className:`text-sm font-semibold mt-1 transition-colors duration-500 ${t?r.textDark:r.text}`,children:e.name}),i.jsx("p",{className:`text-sm font-semibold mt-1 transition-colors duration-500 ${t?r.text:r.textLight}`,children:`Click to explore ${s} tests `})]})]}),i.jsx(kf,{tests:o,isHighlighted:t,color:e.color}),i.jsx(Pf,{direction:e.arrowDirection,isPulsing:t,color:e.color})]})},ju=({onNavigate:e})=>{var y,x;const[t,a]=A.useState(0),[n,s]=A.useState(null),[r,o]=A.useState(!1),l=Du(),d=A.useMemo(()=>wf(l).sort((w,b)=>w.gridPosition-b.gridPosition),[l]),u={ECD:typeof Y<"u"?Y.length:13,TDS:typeof X<"u"?X.length:10,TRM:typeof K<"u"?K.length:9,MRD:typeof z<"u"?z.length:15,"ALZ-BLOOD":typeof kt<"u"?kt.length:9},g=r&&n?n:((y=d[t%d.length])==null?void 0:y.id)||((x=d[0])==null?void 0:x.id);A.useEffect(()=>{if(r)return;const w=setInterval(()=>{a(b=>(b+1)%d.length)},2250);return()=>clearInterval(w)},[r,d.length]);const p=w=>{e(w)};return i.jsxs("div",{className:"relative",onMouseEnter:()=>o(!0),onMouseLeave:()=>{o(!1),s(null)},children:[i.jsx("style",{children:`
        @keyframes lifecycleScroll {
          0% { transform: translateX(0); }
          100% { transform: translateX(-50%); }
        }
      `}),i.jsx("div",{className:`grid ${d.length===1?"grid-cols-1 max-w-md mx-auto":"grid-cols-2"} gap-6`,children:d.map(w=>i.jsx(jf,{stage:w,isHighlighted:g===w.id,onClick:()=>p(w.id),onMouseEnter:()=>s(w.id),testCount:u[w.id]},w.id))})]})},ea={date:new Date("2025-12-15T04:11:16.901Z").toLocaleString("en-US",{year:"numeric",month:"short",day:"numeric",hour:"2-digit",minute:"2-digit",timeZoneName:"short"}),sources:{MRD:"https://docs.google.com/spreadsheets/d/16F_QRjpiqlrCK1f5fPSHQsODdE5QVPrrdx-0rfKAa5U/edit",ECD:"https://docs.google.com/spreadsheets/d/1eFZg2EtdnR4Ly_lrXoZxzI4Z2bH23LDkCAVCXrewwnI/edit",TRM:"https://docs.google.com/spreadsheets/d/1ZgvK8AgZzZ4XuZEija_m1FSffnnhvIgmVCkQvP1AIXE/edit",TDS:"https://docs.google.com/spreadsheets/d/1HxYNQ9s4qJKHxFMkYjW1uXBq3Zg3nVkFp3mQZQvZF0s/edit"}},bs=Nf(ea.sources),xn=e=>{const t={id:"id",name:"nm",vendor:"vn",approach:"ap",method:"mt",sampleCategory:"samp",productType:"pType",platformRequired:"platform",cancerTypes:"ca",indicationsNotes:"ind",sensitivity:"sens",specificity:"spec",analyticalSpecificity:"aSpec",clinicalSpecificity:"cSpec",ppv:"ppv",npv:"npv",lod:"lod",lod95:"lod95",lodNotes:"lodN",requiresTumorTissue:"tumorReq",requiresMatchedNormal:"normReq",variantsTracked:"vars",initialTat:"tat1",followUpTat:"tat2",leadTimeVsImaging:"lead",bloodVolume:"bvol",cfdnaInput:"cfIn",fdaStatus:"fda",reimbursement:"reimb",reimbursementNote:"reimbN",commercialPayers:"privIns",availableRegions:"regions",clinicalAvailability:"avail",cptCodes:"cpt",cptCode:"cpt",totalParticipants:"trial",numPublications:"pubs",numPublicationsPlus:"pubsPlus",exampleTestReport:"rpt",clinicalTrials:"trials",testScope:"scope",targetPopulation:"pop",indicationGroup:"indGrp",stageISensitivity:"s1",stageIISensitivity:"s2",stageIIISensitivity:"s3",stageIVSensitivity:"s4",tumorOriginAccuracy:"origAcc",tumorOriginAccuracyNotes:"origN",performanceNotes:"perfN",leadTimeNotes:"leadN",tat:"tat",sampleType:"sampT",sampleVolume:"sampV",sampleStability:"sampStab",listPrice:"price",screeningInterval:"interval",landmarkSensitivity:"lmSens",landmarkSpecificity:"lmSpec",longitudinalSensitivity:"loSens",longitudinalSpecificity:"loSpec",responseDefinition:"respDef",independentValidation:"indepVal",nccnGuidelines:"nccn",technologyDifferentiator:"techDiff",sensitivityNotes:"sensN",specificityNotes:"specN",ppvDefinition:"ppvDef",npvDefinition:"npvDef",genesAnalyzed:"genes",fdaCompanionDxCount:"cdxCount",tmb:"tmb",msi:"msi"},a={};for(const[n,s]of Object.entries(e)){if(s==null||Array.isArray(s)&&s.length===0||n.toLowerCase().includes("citation"))continue;const r=t[n]||n;a[r]=s}return a},as={MRD:z.map(xn),ECD:Y.map(xn),TRM:K.map(xn),TDS:X.map(xn)},Ru="KEY: nm=name, vn=vendor, pType=product type (Self-Collection/Laboratory IVD Kit/Central Lab Service), platform=required instrument, ap=approach, mt=method, samp=sample type, ca=cancers, sens/spec=sensitivity/specificity%, aSpec=analytical specificity% (lab validation), cSpec=clinical specificity% (real-world, debatable in MRD), s1-s4=stage I-IV sensitivity, ppv/npv=predictive values, lod=detection threshold, lod95=95% confidence limit (gap between lod and lod95 means serial testing helps), tumorReq=requires tumor, vars=variants tracked, bvol=blood volume mL, cfIn=cfDNA input ng (critical for pharma - determines analytical sensitivity ceiling), tat1/tat2=initial/followup TAT days, lead=lead time vs imaging days, fda=FDA status, reimb=reimbursement, privIns=commercial payers, regions=availability (US/EU/UK/International/RUO), avail=clinical availability status, trial=participants, pubs=publications, scope=test scope, pop=target population, origAcc=tumor origin accuracy%, price=list price, respDef=response definition, nccn=NCCN guidelines, genes=genes analyzed, cdxCount=FDA CDx indications, tmb/msi=TMB/MSI reporting.",Lu=e=>{const t="LENGTH: Keep responses under 20 lines. Be concise - lead with the answer, then add essential context. Use short paragraphs. Avoid lengthy preambles.",a='REMEMBER: Only discuss tests in the database. For medical questions about diseases, genetics, screening decisions, or result interpretation, say "Please discuss with your healthcare provider."';switch(e){case"Patient":return`AUDIENCE: Patient or caregiver seeking to understand options.
STYLE: Use clear, accessible language. Avoid jargon - if you must use technical terms, briefly explain them. Be warm but careful not to give medical advice. Focus ONLY on explaining what tests exist and their basic attributes. Do NOT suggest whether someone should get tested or interpret what results might mean.
IMPORTANT: If asked about disease inheritance, genetics, or whether they should be screened, say "That's an important question for your healthcare provider - they can assess your individual situation."
${t}
${a}`;case"Clinician":return`AUDIENCE: Healthcare professional comparing tests for patients.
STYLE: Be direct and clinical. Use standard medical terminology freely. Focus on actionable metrics: sensitivity, specificity, LOD, TAT, reimbursement status, FDA clearance. When describing a test, always note its "targetPopulation" field so the clinician can assess fit.
IMPORTANT: If the described patient doesn't match a test's target population, explicitly note this discrepancy rather than recommending the test.
${t}
${a}`;case"Academic/Industry":return`AUDIENCE: Researcher or industry professional studying the landscape.
STYLE: Be technical and detailed. Include methodology details, analytical performance metrics, and validation data. Reference publications and trial data when relevant. Discuss technology differentiators and emerging approaches.
${t}
${a}`;default:return`STYLE: Be concise and helpful. Lead with key insights. Use prose not bullets.
${t}
${a}`}},Ve=({checked:e,onChange:t,label:a})=>i.jsxs("label",{className:"flex items-center gap-2 cursor-pointer py-1 group",children:[i.jsx("div",{onClick:t,className:`w-4 h-4 rounded border-2 flex items-center justify-center transition-all flex-shrink-0 ${e?"bg-emerald-500 border-emerald-500":"border-gray-300 group-hover:border-gray-400"}`,children:e&&i.jsx("svg",{className:"w-3 h-3 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:3,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M5 13l4 4L19 7"})})}),i.jsx("span",{className:"text-sm text-gray-700",children:a})]}),ai=({title:e,defaultOpen:t=!1,activeCount:a=0,children:n})=>{const[s,r]=A.useState(t);return i.jsxs("div",{className:"border-b border-gray-100 last:border-b-0",children:[i.jsxs("button",{onClick:()=>r(!s),className:"w-full flex items-center justify-between py-3 text-left hover:bg-gray-50 transition-colors -mx-2 px-2 rounded",children:[i.jsxs("div",{className:"flex items-center gap-2",children:[i.jsx("span",{className:"text-xs font-semibold text-gray-700 uppercase tracking-wide",children:e}),a>0&&i.jsx("span",{className:"bg-emerald-100 text-emerald-700 text-xs font-medium px-1.5 py-0.5 rounded-full",children:a})]}),i.jsx("svg",{className:`w-4 h-4 text-gray-400 transition-transform ${s?"rotate-180":""}`,fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M19 9l-7 7-7-7"})})]}),s&&i.jsx("div",{className:"pb-4 space-y-1",children:n})]})},lt=({children:e,variant:t="default",title:a})=>{const n={default:"bg-gray-100 text-gray-700 border-gray-200",success:"bg-emerald-50 text-emerald-700 border-emerald-200",orange:"bg-orange-50 text-orange-700 border-orange-200",green:"bg-emerald-50 text-emerald-700 border-emerald-200",red:"bg-red-100 text-red-700 border-red-300",sky:"bg-sky-100 text-sky-700 border-sky-300",blue:"bg-blue-50 text-blue-700 border-blue-200",purple:"bg-purple-50 text-purple-700 border-purple-200",amber:"bg-amber-50 text-amber-700 border-amber-200",slate:"bg-slate-100 text-slate-700 border-slate-300"};return i.jsx("span",{className:`inline-flex items-center px-2 py-0.5 rounded text-xs font-medium border ${n[t]}`,title:a,children:e})},Rf=({currentPage:e,onNavigate:t})=>{const[a,n]=A.useState(!1),s=l=>{t(l),n(!1),window.scrollTo({top:0,behavior:"smooth"})},r=["home","submissions","how-it-works","data-sources","faq","learn","about"],o=l=>({home:"Home",learn:"Learn","data-sources":"Data Download","how-it-works":"How it Works",submissions:"Submissions",faq:"FAQ",about:"About"})[l]||l;return i.jsxs("header",{className:"bg-white border-b border-gray-200 sticky top-0 z-40",children:[i.jsxs("div",{className:"max-w-7xl mx-auto px-4 sm:px-6 py-3 sm:py-4 flex items-center justify-between gap-4",children:[i.jsx("div",{className:"cursor-pointer hidden sm:flex items-center flex-shrink-0",onClick:()=>s("home"),children:i.jsx("img",{src:"data:image/jpeg;base64,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",alt:"OpenOnco",className:"h-14"})}),i.jsx("span",{className:"sm:hidden text-xl font-bold text-[#2A63A4] cursor-pointer",onClick:()=>s("home"),children:"OpenOnco"}),i.jsx("nav",{className:"hidden sm:flex items-center flex-1 justify-evenly overflow-x-auto",children:r.map(l=>i.jsx("button",{onClick:()=>s(l),className:`px-2 sm:px-4 py-2 rounded-lg text-sm sm:text-lg font-semibold transition-colors whitespace-nowrap ${e===l?"bg-gray-100 text-gray-900":"text-gray-600 hover:text-gray-900 hover:bg-gray-50"}`,children:o(l)},l))}),i.jsx("button",{className:"sm:hidden p-2 rounded-lg hover:bg-gray-100",onClick:()=>n(!a),children:i.jsx("svg",{className:"w-6 h-6",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:a?i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"}):i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 6h16M4 12h16M4 18h16"})})})]}),a&&i.jsx("div",{className:"sm:hidden border-t border-gray-200 bg-white",children:i.jsx("div",{className:"flex flex-col py-2",children:r.map(l=>i.jsx("button",{onClick:()=>s(l),className:`px-4 py-3 text-left font-medium ${e===l?"bg-gray-100 text-gray-900":"text-gray-600"}`,children:o(l)},l))})})]})},Lf=()=>{const e=Cf(),t={[is.ONCO]:"OpenOnco is provided for informational and educational purposes only. The information on this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. OpenOnco does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Nothing on this website constitutes reimbursement or coverage guidance, and should not be used to determine insurance coverage, patient financial responsibility, or billing practices. Reliance on any information provided by OpenOnco is solely at your own risk. Test performance data, pricing, and availability are subject to change and should be verified directly with test vendors.",[is.ALZ]:"OpenAlz is provided for informational and educational purposes only. The information on this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding Alzheimer's disease, cognitive symptoms, or treatment options. OpenAlz does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Nothing on this website constitutes reimbursement or coverage guidance, and should not be used to determine insurance coverage, patient financial responsibility, or billing practices. Reliance on any information provided by OpenAlz is solely at your own risk. Test performance data, pricing, and availability are subject to change and should be verified directly with test vendors."};return i.jsx("footer",{className:"border-t border-gray-200 py-8 mt-12 bg-white",children:i.jsxs("div",{className:"max-w-4xl mx-auto px-6",children:[i.jsxs("p",{className:"text-sm text-gray-500 leading-relaxed text-justify",children:[i.jsx("strong",{children:"Disclaimer:"})," ",t[e.domain]]}),i.jsxs("p",{className:"text-xs text-gray-400 mt-4 text-center",children:["Built: ",ea.date]})]})})},Mf=({onNavigate:e})=>{const[t,a]=A.useState(null),[n,s]=A.useState("vendor"),[r,o]=A.useState(""),l=Du(),[d,u]=A.useState(""),[g,p]=A.useState([]),[y,x]=A.useState(!1),[w,b]=A.useState(Zi[0].id),j=A.useRef(null),[m,c]=A.useState(Ja()||"Clinician");A.useEffect(()=>{const f=k=>c(k.detail);return window.addEventListener("personaChanged",f),()=>window.removeEventListener("personaChanged",f)},[]);const h=m==="Patient";A.useEffect(()=>{if(j.current&&g.length>0){const f=j.current;if(g[g.length-1].role==="assistant"){const D=f.querySelectorAll('[data-message-role="assistant"]'),L=D[D.length-1];L&&(f.scrollTop=L.offsetTop-8)}}},[g]),typeof Y<"u"&&Y.length,typeof X<"u"&&X.length,typeof K<"u"&&K.length,typeof z<"u"&&z.length,typeof kt<"u"&&kt.length;const C=A.useMemo(()=>kt.map(f=>({...f,category:"ALZ-BLOOD",color:"indigo"})),[l]),P=f=>{let k=0;if(f.reimbursement){const D=f.reimbursement.toLowerCase();D.includes("medicare")&&!D.includes("not yet")&&!D.includes("no established")&&(k+=1)}return f.commercialPayers&&f.commercialPayers.length>0&&(k+=f.commercialPayers.length),k},R=(f,k)=>{const D=V=>V!=null&&V!==""&&V!=="N/A";let L=0;switch(D(f.listPrice)&&(L+=30),f.numPublications!=null&&f.numPublications>0&&(L+=15),(D(f.tat)||D(f.initialTat))&&(L+=10),(D(f.bloodVolume)||D(f.sampleType)||D(f.sampleCategory))&&(L+=10),f.totalParticipants!=null&&f.totalParticipants>0&&(L+=5),f.category){case"ECD":D(f.sensitivity)&&(L+=15),D(f.specificity)&&(L+=15);break;case"MRD":(D(f.lod)||D(f.lod95))&&(L+=30);break;case"TRM":D(f.sensitivity)&&(L+=15),D(f.specificity)&&(L+=15);break;case"TDS":D(f.genesAnalyzed)&&(L+=15),(D(f.tmb)||D(f.msi))&&(L+=15);break;default:D(f.sensitivity)&&(L+=15),D(f.specificity)&&(L+=15)}return L},v=A.useMemo(()=>{const f={};return C.forEach(k=>{f[k.vendor]=(f[k.vendor]||0)+1}),f},[C]),N=A.useMemo(()=>{const f={},k={};return C.forEach(D=>{k[D.vendor]||(k[D.vendor]={total:0,count:0}),k[D.vendor].total+=R(D),k[D.vendor].count+=1}),Object.entries(k).forEach(([D,L])=>{L.count>=2?f[D]=L.total/L.count:f[D]=-1}),f},[C]),F=f=>{const k=f.tat||f.initialTat||f.followUpTat;if(k==null)return 999;const D=typeof k=="number"?k:parseInt(k);return isNaN(D)?999:D},I=A.useMemo(()=>{const f=[...C];switch(n){case"category":const k={MRD:0,ECD:1,TRM:2,TDS:3,"ALZ-BLOOD":4};return f.sort((D,L)=>(k[D.category]??99)-(k[L.category]??99)||D.vendor.localeCompare(L.vendor));case"tat":return f.sort((D,L)=>F(D)-F(L));case"reimbursement":return f.sort((D,L)=>P(L)-P(D)||D.vendor.localeCompare(L.vendor));case"vendorTests":return f.sort((D,L)=>v[L.vendor]-v[D.vendor]||D.vendor.localeCompare(L.vendor));case"openness":return f.sort((D,L)=>{const O=N[D.vendor]??-1,V=N[L.vendor]??-1;return O!==V?V-O:R(L)-R(D)||D.vendor.localeCompare(L.vendor)});case"vendor":default:return f.sort((D,L)=>D.name.localeCompare(L.name))}},[n,v,N,C]),q=A.useMemo(()=>{if(!r.trim())return I;const f=r.toLowerCase().trim().split(/\s+/).filter(k=>k.length>0);return I.filter(k=>{const D=k.productType==="Laboratory IVD Kit"?"kit ivd laboratory":k.productType==="Self-Collection"?"self-collection home":"service central lab",L=`${k.name} ${k.vendor} ${k.category} ${D}`.toLowerCase();return f.every(O=>L.includes(O))})},[I,r]),be=[...z.map(f=>({...f,category:"MRD"})),...Y.map(f=>({...f,category:"ECD"})),...K.map(f=>({...f,category:"TRM"})),...X.map(f=>({...f,category:"TDS"}))],re=f=>f==="Clinician"?"Respond in a clinical, professional tone suitable for oncologists and healthcare providers. Use medical terminology freely.":f==="Academic/Industry"?"Respond with technical depth suitable for researchers and industry professionals. Include analytical details and methodology notes where relevant.":"";A.useMemo(()=>`You are a liquid biopsy test information assistant for OpenOnco. Your ONLY role is to help users explore and compare the specific tests in the database below.

STRICT SCOPE LIMITATIONS:
- ONLY discuss tests that exist in the database below
- NEVER speculate about disease genetics, heredity, inheritance patterns, or etiology
- NEVER suggest screening strategies or make recommendations about who should be tested
- NEVER interpret what positive or negative test results mean clinically
- For ANY question outside the specific test data: respond with "That's outside my scope. Please discuss with your healthcare provider."

WHAT YOU CAN DO:
- Compare tests in the database on their documented attributes (sensitivity, specificity, TAT, cost, coverage, etc.)
- Explain what data is available or not available for specific tests
- Help users understand the differences between test approaches (tumor-informed vs tumor-nave, etc.)
- Direct users to the appropriate test category

DATABASE:
${JSON.stringify(be)}

${re(m)}

Say "not specified" for missing data. When uncertain, err on the side of saying "please consult your healthcare provider."`,[m]);const Ce=async f=>{var O,V;const k=f||d;if(!k.trim())return;u("");const D={role:"user",content:k},L=[...g,D];p(L),x(!0);try{const U=L.slice(-6),ae=await(await fetch("/api/chat",{method:"POST",headers:{"Content-Type":"application/json"},body:JSON.stringify({category:"all",persona:m,testData:JSON.stringify(be),messages:U,model:w})})).json();(V=(O=ae==null?void 0:ae.content)==null?void 0:O[0])!=null&&V.text?p(he=>[...he,{role:"assistant",content:ae.content[0].text}]):p(he=>[...he,{role:"assistant",content:"I received an unexpected response. Please try again."}])}catch{p(ee=>[...ee,{role:"assistant",content:"I'm having trouble connecting. Please try again in a moment."}])}x(!1)},Me=f=>{const k=[],D=U=>{if(U==null)return null;if(typeof U=="number")return`${U}%`;const ee=String(U);if(ee.length<=10)return ee.includes("%")?ee:`${ee}%`;const ae=ee.match(/^[>~]?\d+(?:\.\d+)?%?/);return ae?ae[0].includes("%")?ae[0]:`${ae[0]}%`:null},L=D(f.sensitivity);L&&k.push({label:"Sens",value:L,type:"clinical"});const O=D(f.specificity);O&&k.push({label:"Spec",value:O,type:"clinical"});const V=f.tat||f.initialTat;if(V!=null){const U=typeof V=="number"?V:parseInt(V);isNaN(U)||k.push({label:"TAT",value:`${U}d`,type:"operational"})}return f.numPublications!=null&&f.numPublications>0&&k.push({label:"Pubs",value:f.numPublications,type:"clinical"}),f.listPrice!=null&&k.push({label:"$",value:`${(f.listPrice/1e3).toFixed(1)}k`,type:"operational"}),k.slice(0,3)},We=f=>{var U;const k=[],D=((U=f.reimbursement)==null?void 0:U.toLowerCase())||"",L=D.includes("medicare")&&!D.includes("not yet"),O=f.commercialPayers&&f.commercialPayers.length>0;L&&O?k.push({label:"",value:"Medicare + Private",type:"good"}):L?k.push({label:"",value:"Medicare",type:"good"}):O&&k.push({label:"~",value:"Some Insurance",type:"neutral"});const V=f.tat||f.initialTat;if(V!=null){const ee=typeof V=="number"?V:parseInt(V);isNaN(ee)||k.push({label:"",value:`${ee} days`,type:"neutral"})}return(f.approach==="Tumor-nave"||f.requiresTumorTissue==="No")&&k.push({label:"",value:"Blood only",type:"good"}),k.slice(0,3)},fe={orange:{bg:"bg-orange-50",border:"border-orange-200",badge:"bg-orange-500",text:"text-orange-600"},emerald:{bg:"bg-emerald-50",border:"border-emerald-200",badge:"bg-emerald-500",text:"text-emerald-600"},red:{bg:"bg-sky-100",border:"border-sky-300",badge:"bg-sky-500",text:"text-sky-600"},sky:{bg:"bg-sky-50",border:"border-sky-200",badge:"bg-sky-500",text:"text-sky-600"},violet:{bg:"bg-violet-50",border:"border-violet-200",badge:"bg-violet-500",text:"text-violet-600"}};return h?i.jsxs("div",{className:"bg-white rounded-2xl border border-slate-200 p-4 shadow-sm",children:[i.jsxs("div",{className:"mb-4 p-3 bg-amber-50 border border-amber-300 rounded-lg flex items-center gap-3",children:[i.jsx("span",{className:"text-2xl",children:""}),i.jsxs("div",{children:[i.jsx("p",{className:"font-semibold text-amber-800",children:"Patient View Under Construction"}),i.jsx("p",{className:"text-sm text-amber-700",children:"We're actively improving this experience. Some features may be incomplete."})]})]}),i.jsxs("div",{className:"flex items-center justify-between mb-2",children:[i.jsx("h3",{className:"text-lg font-bold text-slate-800",children:r?`Search Results (${q.length})`:`The ${I.length} Tests We Track`}),i.jsxs("div",{className:"flex items-center gap-2",children:[i.jsx("span",{className:"text-xs text-slate-500",children:"Sort Order"}),i.jsxs("select",{value:n,onChange:f=>s(f.target.value),className:"text-xs bg-slate-50 border border-slate-200 rounded px-2 py-1 text-slate-600 cursor-pointer hover:bg-slate-100",children:[i.jsx("option",{value:"vendor",children:"Alphabetical"}),i.jsx("option",{value:"category",children:"By Category"}),i.jsx("option",{value:"tat",children:"By TAT (fastest)"}),i.jsx("option",{value:"reimbursement",children:"By Coverage"})]})]})]}),i.jsxs("div",{className:"relative mb-3",children:[i.jsx("input",{type:"text",value:r,onChange:f=>o(f.target.value),placeholder:"Search tests or vendors...",className:"w-full px-3 py-2 pl-8 text-sm bg-slate-50 border border-slate-200 rounded-lg focus:outline-none focus:ring-2 focus:ring-blue-300 focus:border-blue-300"}),i.jsx("svg",{className:"absolute left-2.5 top-1/2 -translate-y-1/2 w-4 h-4 text-slate-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})}),r&&i.jsx("button",{onClick:()=>o(""),className:"absolute right-2.5 top-1/2 -translate-y-1/2 text-slate-400 hover:text-slate-600",children:i.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]}),i.jsx("p",{className:"text-xs text-slate-500 text-center mb-3",children:"Showing coverage, pricing & wait times"}),i.jsxs("div",{className:"grid grid-cols-2 lg:grid-cols-3 gap-2",children:[q.length===0&&r&&i.jsx("div",{className:"col-span-full text-center py-8 text-slate-500",children:"No test or vendor match found."}),q.map(f=>{const k=We(f),D=fe[f.color],L=f.isDiscontinued===!0;return i.jsxs("div",{onClick:()=>e(f.category,f.id),className:`relative ${D.bg} ${D.border} border rounded-lg p-2 cursor-pointer hover:shadow-md transition-all overflow-hidden`,children:[L&&i.jsx("div",{className:"absolute inset-0 flex items-center justify-center pointer-events-none",children:i.jsx("span",{className:"text-gray-400/40 font-bold text-lg tracking-wider transform -rotate-12",children:"DISCONTINUED"})}),i.jsxs("div",{className:"flex items-start justify-between mb-1",children:[i.jsxs("div",{className:"flex-1 min-w-0",children:[i.jsx("p",{className:`text-xs font-semibold truncate ${L?"text-gray-400":"text-slate-800"}`,children:f.name}),i.jsxs("p",{className:"text-[10px] text-slate-500 truncate",children:[f.vendor,i.jsx(_a,{vendor:f.vendor,size:"xs"})]})]}),L?i.jsx("span",{className:"bg-gray-200 text-gray-600 text-[9px] px-1 py-0.5 rounded font-medium ml-1 flex-shrink-0",children:"DISC"}):i.jsxs("div",{className:"flex items-center gap-0.5 flex-shrink-0 ml-1",children:[f.productType==="Laboratory IVD Kit"?i.jsx("span",{className:"bg-indigo-100 text-indigo-700 text-[9px] px-1 py-0.5 rounded font-medium",title:"Laboratory IVD Kit",children:"Kit"}):f.productType==="Self-Collection"?i.jsx("span",{className:"bg-teal-100 text-teal-700 text-[9px] px-1 py-0.5 rounded font-medium",title:"Self-Collection",children:"Home"}):null,i.jsx("span",{className:`${D.badge} text-white text-[9px] px-1 py-0.5 rounded font-medium`,children:f.category})]})]}),i.jsxs("div",{className:"flex flex-wrap gap-1 mt-1",children:[k.map((O,V)=>i.jsxs("span",{className:`text-[10px] px-1.5 py-0.5 rounded ${O.type==="good"?"bg-emerald-100 text-emerald-700":"bg-slate-100 text-slate-600"}`,children:[O.label," ",O.value]},V)),k.length===0&&i.jsx("span",{className:"text-[10px] text-slate-400",children:"No data"})]})]},f.id)})]}),i.jsxs("div",{className:"flex flex-wrap items-center justify-center gap-2 mt-3 pt-2 border-t border-slate-200 text-[10px]",children:[i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"bg-indigo-100 text-indigo-700 px-1 rounded",children:"Kit"}),i.jsx("span",{className:"text-slate-500",children:"IVD Kit"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"bg-teal-100 text-teal-700 px-1 rounded",children:"Home"}),i.jsx("span",{className:"text-slate-500",children:"Self-Collect"})]}),i.jsx("span",{className:"text-slate-300",children:"|"}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-orange-500"}),i.jsx("span",{className:"text-slate-500",children:"After Treatment"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-emerald-500"}),i.jsx("span",{className:"text-slate-500",children:"Screening"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-sky-500"}),i.jsx("span",{className:"text-slate-500",children:"During Treatment"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-violet-500"}),i.jsx("span",{className:"text-slate-500",children:"Diagnosis"})]})]}),t&&i.jsx("div",{className:"fixed inset-0 bg-black/60 backdrop-blur-sm z-50 flex items-center justify-center p-4",onClick:()=>a(null),children:i.jsx("div",{className:"bg-white rounded-2xl shadow-2xl max-w-4xl w-full overflow-hidden",onClick:f=>f.stopPropagation(),style:{maxHeight:"90vh",display:"flex",flexDirection:"column"},children:(()=>{var V,U;const f=t.category,k={MRD:{headerBg:"bg-gradient-to-r from-orange-500 to-amber-500"},ECD:{headerBg:"bg-gradient-to-r from-emerald-500 to-teal-500"},TRM:{headerBg:"bg-gradient-to-r from-sky-500 to-blue-500"},TDS:{headerBg:"bg-gradient-to-r from-violet-500 to-purple-500"}},D=k[f]||k.MRD,L=((V=t.reimbursement)==null?void 0:V.toLowerCase().includes("medicare"))&&!((U=t.reimbursement)!=null&&U.toLowerCase().includes("not yet")),O=t.commercialPayers&&t.commercialPayers.length>0;return i.jsxs(i.Fragment,{children:[i.jsxs("div",{className:`flex justify-between items-start p-5 ${D.headerBg}`,style:{flexShrink:0},children:[i.jsxs("div",{className:"flex-1 mr-4",children:[i.jsxs("div",{className:"flex flex-wrap gap-2 mb-2",children:[L&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:"Medicare"}),O&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:"Private Insurance"})]}),i.jsx("h2",{className:"text-2xl font-bold text-white",children:t.name}),i.jsx("p",{className:"text-white/80",children:t.vendor})]}),i.jsx("button",{onClick:()=>a(null),className:"p-2 hover:bg-white/20 rounded-xl transition-colors flex-shrink-0",children:i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M6 18L18 6M6 6l12 12"})})})]}),i.jsxs("div",{className:"p-5 overflow-y-auto",style:{flex:1},children:[i.jsxs("p",{className:"text-gray-700 mb-4",children:[f==="MRD"&&"This test looks for tiny amounts of cancer DNA in your blood after treatment to help your doctor know if treatment worked.",f==="ECD"&&"This test screens your blood for signs of cancer before you have symptoms.",f==="TRM"&&"This test tracks whether your cancer treatment is working by measuring cancer DNA in your blood.",f==="TDS"&&"This test helps your doctor decide the best treatment approach for your specific cancer."]}),i.jsxs("div",{className:"grid grid-cols-2 gap-2",children:[i.jsxs("div",{className:`flex items-center gap-2 p-2 rounded-lg ${L?"bg-emerald-50":"bg-gray-50"}`,children:[i.jsx("span",{className:`w-5 h-5 rounded-full flex items-center justify-center text-xs font-bold ${L?"bg-emerald-100 text-emerald-700":"bg-gray-200 text-gray-500"}`,children:L?"":""}),i.jsx("span",{className:"text-sm",children:"Medicare coverage"})]}),i.jsxs("div",{className:`flex items-center gap-2 p-2 rounded-lg ${O?"bg-emerald-50":"bg-gray-50"}`,children:[i.jsx("span",{className:`w-5 h-5 rounded-full flex items-center justify-center text-xs font-bold ${O?"bg-emerald-100 text-emerald-700":"bg-gray-200 text-gray-500"}`,children:O?"":""}),i.jsx("span",{className:"text-sm",children:"Private insurance"})]})]})]}),i.jsxs("div",{className:"border-t border-gray-200 px-5 py-4 flex justify-between items-center bg-gray-50",style:{flexShrink:0},children:[i.jsx("p",{className:"text-sm text-gray-500",children:"View full details in the navigator"}),i.jsx("button",{onClick:()=>{a(null),e(t.category,t.id)},className:"px-4 py-2 text-white rounded-lg font-medium hover:opacity-90",style:{backgroundColor:"#2A63A4"},children:"See All Options"})]})]})})()})})]}):i.jsxs("div",{className:"bg-white rounded-2xl border border-slate-200 shadow-sm overflow-hidden",children:[i.jsxs("div",{className:"p-4 flex flex-col lg:flex-row gap-4",children:[i.jsxs("div",{className:"hidden md:block lg:w-[55%] flex-shrink-0",children:[i.jsx("h3",{className:"text-lg font-bold text-slate-800 mb-3 text-center",children:"Explore Tests by Category"}),i.jsx(ju,{onNavigate:e})]}),i.jsxs("div",{className:"w-full lg:w-[45%] flex flex-col gap-3",children:[i.jsx("h3",{className:"text-lg font-bold text-slate-800 text-center",children:"Explore Tests by AI"}),i.jsxs("div",{className:"bg-gradient-to-br from-slate-100 to-slate-200 rounded-xl p-4 border-2 border-slate-300 flex-[2] flex flex-col shadow-sm hover:border-slate-400 hover:shadow-md transition-all cursor-pointer",children:[i.jsxs("form",{onSubmit:f=>{f.preventDefault(),Ce()},className:"flex flex-col gap-2",children:[i.jsxs("div",{className:"relative",children:[i.jsx("input",{type:"text",value:d,onChange:f=>u(f.target.value),placeholder:"Ask Claude about tests...",className:"w-full px-3 py-2 pl-9 text-sm bg-white border border-slate-200 rounded-lg focus:outline-none focus:ring-2 focus:ring-blue-300 focus:border-blue-300",disabled:y}),i.jsx("svg",{className:"absolute left-2.5 top-1/2 -translate-y-1/2 w-4 h-4 text-slate-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 10h.01M12 10h.01M16 10h.01M9 16H5a2 2 0 01-2-2V6a2 2 0 012-2h14a2 2 0 012 2v8a2 2 0 01-2 2h-5l-5 5v-5z"})})]}),i.jsxs("div",{className:"flex gap-2 justify-end",children:[i.jsx("select",{value:w,onChange:f=>b(f.target.value),className:"px-2 py-1 bg-white border border-slate-200 rounded-lg text-xs focus:outline-none cursor-pointer",title:"Select AI model",children:Zi.map(f=>i.jsx("option",{value:f.id,children:f.name},f.id))}),i.jsx("button",{type:"submit",disabled:y||!d.trim(),className:"text-white px-4 py-1.5 rounded-lg text-sm font-medium disabled:opacity-50 disabled:cursor-not-allowed transition-all hover:opacity-90",style:{background:"linear-gradient(to right, #2A63A4, #1E4A7A)"},children:"Ask"})]})]}),g.length===0&&i.jsx("div",{className:"flex-1 flex flex-col mt-2",children:i.jsxs("div",{className:"flex flex-col gap-1.5",children:[i.jsx("span",{className:"text-[10px] text-slate-500 font-medium",children:"Try asking:"}),i.jsx("button",{onClick:()=>Ce("Compare Signatera and Reveal MRD for MRD monitoring"),className:"text-[11px] text-left bg-white border border-slate-200 rounded-lg px-2.5 py-1.5 text-slate-600 hover:bg-[#EAF1F8] hover:border-[#6AA1C8] hover:text-[#1E4A7A] transition-colors",children:"Compare Signatera and Reveal MRD for MRD monitoring"}),i.jsx("button",{onClick:()=>Ce("Which TDS tests have the fastest turnaround time?"),className:"text-[11px] text-left bg-white border border-slate-200 rounded-lg px-2.5 py-1.5 text-slate-600 hover:bg-[#EAF1F8] hover:border-[#6AA1C8] hover:text-[#1E4A7A] transition-colors",children:"Which TDS tests have the fastest turnaround time?"}),i.jsx("button",{onClick:()=>Ce("I am a patient, please use straightforward language"),className:"text-[11px] text-left bg-white border border-slate-200 rounded-lg px-2.5 py-1.5 text-slate-600 hover:bg-[#EAF1F8] hover:border-[#6AA1C8] hover:text-[#1E4A7A] transition-colors",children:" I am a patient, please use straightforward language"}),i.jsx("button",{onClick:()=>Ce("I am a physician, please use clinical language"),className:"text-[11px] text-left bg-white border border-slate-200 rounded-lg px-2.5 py-1.5 text-slate-600 hover:bg-[#EAF1F8] hover:border-[#6AA1C8] hover:text-[#1E4A7A] transition-colors",children:" I am a physician, please use clinical language"})]})}),g.length>0&&i.jsxs("div",{ref:j,className:"flex-1 overflow-y-auto mt-2 p-2 space-y-2 bg-white rounded-lg border border-slate-200",children:[g.map((f,k)=>i.jsx("div",{"data-message-role":f.role,className:`flex ${f.role==="user"?"justify-end":"justify-start"}`,children:i.jsx("div",{className:`max-w-[85%] rounded-xl px-3 py-1.5 ${f.role==="user"?"text-white rounded-br-sm":"bg-slate-50 border border-slate-200 text-slate-800 rounded-bl-sm"}`,style:f.role==="user"?{backgroundColor:"#2A63A4"}:{},children:f.role==="user"?i.jsx("p",{className:"text-xs whitespace-pre-wrap",children:f.content}):i.jsx(zo,{className:"text-xs",children:f.content})})},k)),y&&i.jsx("div",{className:"flex justify-start",children:i.jsx("div",{className:"bg-slate-50 border border-slate-200 rounded-xl rounded-bl-sm px-3 py-1.5",children:i.jsx("p",{className:"text-xs text-slate-500",children:"Thinking..."})})})]})]}),i.jsxs("div",{className:"bg-gradient-to-br from-red-100 to-red-200 rounded-xl p-3 border-2 border-red-300 shadow-sm hover:border-red-400 hover:shadow-md transition-all cursor-pointer",children:[i.jsx("p",{className:"text-[10px] font-semibold text-red-700 uppercase tracking-wide mb-1.5 text-center",children:"Or: Quick Search"}),i.jsxs("div",{className:"relative",children:[i.jsx("input",{type:"text",value:r,onChange:f=>o(f.target.value),placeholder:"Filter by name, vendor, cancer...",className:"w-full px-3 py-1.5 pl-8 text-sm bg-white border border-red-200 rounded-lg focus:outline-none focus:ring-2 focus:ring-red-300 focus:border-red-300"}),i.jsx("svg",{className:"absolute left-2.5 top-1/2 -translate-y-1/2 w-3.5 h-3.5 text-red-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})}),r&&i.jsx("button",{onClick:()=>o(""),className:"absolute right-2.5 top-1/2 -translate-y-1/2 text-red-400 hover:text-red-600",children:i.jsx("svg",{className:"w-3.5 h-3.5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]})]})]})]}),i.jsxs("div",{className:"p-4 border-t border-slate-100",children:[i.jsxs("div",{className:"flex items-center justify-between mb-3",children:[i.jsx("p",{className:"text-xs font-semibold text-slate-500 uppercase tracking-wide",children:r?`Search results (${q.length})`:`All the tests we track (${I.length})`}),i.jsxs("div",{className:"flex items-center gap-2",children:[i.jsx("span",{className:"text-xs text-slate-500",children:"Sort:"}),i.jsxs("select",{value:n,onChange:f=>s(f.target.value),className:"text-xs bg-slate-50 border border-slate-200 rounded px-2 py-1 text-slate-600 cursor-pointer hover:bg-slate-100",children:[i.jsx("option",{value:"vendor",children:"Alphabetical"}),i.jsx("option",{value:"category",children:"By Category"}),i.jsx("option",{value:"tat",children:"By TAT (fastest)"}),i.jsx("option",{value:"reimbursement",children:"By Coverage"}),i.jsx("option",{value:"vendorTests",children:"By # Tests"}),i.jsx("option",{value:"openness",children:"By Openness"})]})]})]}),i.jsxs("div",{className:"grid grid-cols-2 lg:grid-cols-3 gap-2",children:[q.length===0&&r&&i.jsx("div",{className:"col-span-full text-center py-8 text-slate-500",children:"No test or vendor match found."}),q.map(f=>{const k=Me(f),D=fe[f.color],L=f.isDiscontinued===!0;return i.jsxs("div",{onClick:()=>e(f.category,f.id),className:`relative ${D.bg} ${D.border} border rounded-lg p-2 cursor-pointer hover:shadow-md transition-all overflow-hidden`,children:[L&&i.jsx("div",{className:"absolute inset-0 flex items-center justify-center pointer-events-none",children:i.jsx("span",{className:"text-gray-400/40 font-bold text-lg tracking-wider transform -rotate-12",children:"DISCONTINUED"})}),i.jsxs("div",{className:"flex items-start justify-between mb-1",children:[i.jsxs("div",{className:"flex-1 min-w-0",children:[i.jsx("p",{className:`text-xs font-semibold truncate ${L?"text-gray-400":"text-slate-800"}`,children:f.name}),i.jsxs("p",{className:"text-[10px] text-slate-500 truncate",children:[f.vendor,i.jsx(_a,{vendor:f.vendor,size:"xs"})]})]}),L?i.jsx("span",{className:"bg-gray-200 text-gray-600 text-[9px] px-1 py-0.5 rounded font-medium ml-1 flex-shrink-0",children:"DISC"}):i.jsxs("div",{className:"flex items-center gap-0.5 flex-shrink-0 ml-1",children:[f.productType==="Laboratory IVD Kit"?i.jsx("span",{className:"bg-indigo-100 text-indigo-700 text-[9px] px-1 py-0.5 rounded font-medium",title:"Laboratory IVD Kit",children:"Kit"}):f.productType==="Self-Collection"?i.jsx("span",{className:"bg-teal-100 text-teal-700 text-[9px] px-1 py-0.5 rounded font-medium",title:"Self-Collection",children:"Home"}):null,i.jsx("span",{className:`${D.badge} text-white text-[9px] px-1 py-0.5 rounded font-medium`,children:f.category})]})]}),i.jsxs("div",{className:"flex flex-wrap gap-1 mt-1",children:[k.map((O,V)=>i.jsxs("span",{className:`text-[10px] px-1.5 py-0.5 rounded ${O.type==="clinical"?"bg-emerald-100 text-emerald-700":"bg-slate-100 text-slate-600"}`,children:[O.label,": ",O.value]},V)),k.length===0&&i.jsx("span",{className:"text-[10px] text-slate-400",children:"No data"})]})]},f.id)})]}),i.jsxs("div",{className:"flex flex-wrap items-center justify-center gap-2 mt-3 pt-2 border-t border-slate-200 text-[10px]",children:[i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"bg-indigo-100 text-indigo-700 px-1 rounded",children:"Kit"}),i.jsx("span",{className:"text-slate-500",children:"IVD Kit"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"bg-teal-100 text-teal-700 px-1 rounded",children:"Home"}),i.jsx("span",{className:"text-slate-500",children:"Self-Collect"})]}),i.jsx("span",{className:"text-slate-300",children:"|"}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-emerald-500"}),i.jsx("span",{className:"text-slate-500",children:"ECD"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-violet-500"}),i.jsx("span",{className:"text-slate-500",children:"TDS"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-sky-500"}),i.jsx("span",{className:"text-slate-500",children:"TRM"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-1.5 h-1.5 rounded-full bg-orange-500"}),i.jsx("span",{className:"text-slate-500",children:"MRD"})]})]})]}),t&&i.jsx("div",{className:"fixed inset-0 bg-black/60 backdrop-blur-sm z-50 flex items-center justify-center p-4",onClick:()=>a(null),children:i.jsx("div",{className:"bg-white rounded-2xl shadow-2xl max-w-4xl w-full overflow-hidden",onClick:f=>f.stopPropagation(),style:{maxHeight:"90vh",display:"flex",flexDirection:"column"},children:(()=>{var V,U;const f=t.category,k={MRD:{headerBg:"bg-gradient-to-r from-orange-500 to-amber-500"},ECD:{headerBg:"bg-gradient-to-r from-emerald-500 to-teal-500"},TRM:{headerBg:"bg-gradient-to-r from-sky-500 to-blue-500"},TDS:{headerBg:"bg-gradient-to-r from-violet-500 to-purple-500"}},D=k[f]||k.MRD,L=((V=t.reimbursement)==null?void 0:V.toLowerCase().includes("medicare"))&&!((U=t.reimbursement)!=null&&U.toLowerCase().includes("not yet")),O=t.commercialPayers&&t.commercialPayers.length>0;return i.jsxs(i.Fragment,{children:[i.jsxs("div",{className:`flex justify-between items-start p-5 ${D.headerBg}`,style:{flexShrink:0},children:[i.jsxs("div",{className:"flex-1 mr-4",children:[i.jsxs("div",{className:"flex flex-wrap gap-2 mb-2",children:[L&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:"Medicare"}),O&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:"Private Insurance"}),t.fdaStatus&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:t.fdaStatus.split(" - ")[0]})]}),i.jsx("h2",{className:"text-2xl font-bold text-white",children:t.name}),i.jsx("p",{className:"text-white/80",children:t.vendor})]}),i.jsx("button",{onClick:()=>a(null),className:"p-2 hover:bg-white/20 rounded-xl transition-colors flex-shrink-0",children:i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M6 18L18 6M6 6l12 12"})})})]}),i.jsx("div",{className:"p-5 overflow-y-auto",style:{flex:1},children:i.jsxs("div",{className:"grid grid-cols-3 gap-4",children:[t.sensitivity!=null&&i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsx("p",{className:`font-bold text-emerald-600 ${String(t.sensitivity).length>10?"text-sm":"text-2xl"}`,children:String(t.sensitivity).length>20?(String(t.sensitivity).match(/^[>]?\d+\.?\d*%?/)||[t.sensitivity])[0]+(String(t.sensitivity).includes("%")?"":"%"):t.sensitivity+(String(t.sensitivity).includes("%")?"":"%")}),i.jsx("p",{className:"text-xs text-gray-500",children:"Sensitivity"})]}),t.specificity!=null&&i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsx("p",{className:`font-bold text-emerald-600 ${String(t.specificity).length>10?"text-sm":"text-2xl"}`,children:String(t.specificity).length>20?(String(t.specificity).match(/^[>]?\d+\.?\d*%?/)||[t.specificity])[0]+(String(t.specificity).includes("%")?"":"%"):t.specificity+(String(t.specificity).includes("%")?"":"%")}),i.jsx("p",{className:"text-xs text-gray-500",children:"Specificity"})]}),(t.initialTat||t.tat)&&i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsx("p",{className:"text-2xl font-bold text-slate-600",children:t.initialTat||t.tat}),i.jsx("p",{className:"text-xs text-gray-500",children:"TAT"})]})]})}),i.jsxs("div",{className:"border-t border-gray-200 px-5 py-4 flex justify-between items-center bg-gray-50",style:{flexShrink:0},children:[i.jsx("p",{className:"text-sm text-gray-500",children:"View full details in the navigator"}),i.jsxs("button",{onClick:()=>{a(null),e(t.category,t.id)},className:"px-4 py-2 text-white rounded-lg font-medium hover:opacity-90",style:{backgroundColor:"#2A63A4"},children:["Open ",f," Navigator"]})]})]})})()})})]})},rc=({onNavigate:e})=>{const[t,a]=A.useState(""),[n,s]=A.useState([]),[r,o]=A.useState(!1),[l,d]=A.useState(()=>Ja()||"Academic/Industry"),[u,g]=A.useState(Zi[0].id),p=A.useRef(null);A.useEffect(()=>{if(p.current&&n.length>0){const m=p.current;if(n[n.length-1].role==="assistant"){const h=m.querySelectorAll('[data-message-role="assistant"]'),C=h[h.length-1];C&&(m.scrollTop=C.offsetTop-8)}}},[n]);const y=z.length>0?Object.keys(z[0]).length:0,x=Y.length>0?Object.keys(Y[0]).length:0,w=K.length>0?Object.keys(K[0]).length:0;z.length*y+Y.length*x+K.length*w;const b=["Compare Signatera and Reveal MRD for colorectal cancer MRD monitoring","What ECD tests have Medicare coverage?"];A.useMemo(()=>`You are a liquid biopsy test information assistant for OpenOnco. Your ONLY role is to help users explore and compare the specific tests in the database below.

STRICT SCOPE LIMITATIONS:
- ONLY discuss tests that exist in the database below
- NEVER speculate about disease genetics, heredity, inheritance patterns, or etiology - these are complex medical topics outside your scope
- NEVER suggest screening strategies or make recommendations about who should be tested
- NEVER interpret what positive or negative test results mean clinically
- NEVER make claims about diseases, conditions, or cancer types beyond what is explicitly stated in the test data
- If a user describes a patient/situation, check the "targetPopulation" field - if they don't clearly fit, say "This test is designed for [target population]. Please discuss with a healthcare provider whether it's appropriate for this situation."
- For ANY question outside the specific test data (disease inheritance, screening recommendations, result interpretation, treatment decisions): respond with "That's outside my scope. Please discuss with your healthcare provider."

WHAT YOU CAN DO:
- Compare tests in the database on their documented attributes (sensitivity, specificity, TAT, cost, coverage, etc.)
- Explain what data is available or not available for specific tests
- Help users understand the differences between test approaches (tumor-informed vs tumor-nave, etc.)
- Direct users to the appropriate test category

DATABASE:
${JSON.stringify(as)}

${Ru}

${Lu(l)}

Say "not specified" for missing data. When uncertain, err on the side of saying "please consult your healthcare provider."`,[l]);const j=async m=>{var R,v;const c=m||t;if(!c.trim())return;const h=`persona-${l.toLowerCase().replace(/[^a-z]/g,"-")}`;Ji("home_chat_message_sent",{model:u,message_length:c.trim().length,is_suggested:m!==void 0},{flags:[h]}),a("");const C={role:"user",content:c},P=[...n,C];s(P),o(!0);try{const N=P.slice(-6),I=await(await fetch("/api/chat",{method:"POST",headers:{"Content-Type":"application/json"},body:JSON.stringify({category:"all",persona:l,testData:JSON.stringify(as),messages:N,model:u})})).json();(v=(R=I==null?void 0:I.content)==null?void 0:R[0])!=null&&v.text?s(q=>[...q,{role:"assistant",content:I.content[0].text}]):s(q=>[...q,{role:"assistant",content:"I received an unexpected response. Please try again."}])}catch{s(F=>[...F,{role:"assistant",content:"I'm having trouble connecting. Please try again in a moment."}])}o(!1)};return i.jsx("div",{children:i.jsxs("div",{className:"max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-4 sm:py-6 relative",children:[i.jsxs("div",{className:"absolute top-2 right-6 text-xs text-gray-400",children:["Build: ",ea.date]}),i.jsx("div",{className:"bg-slate-50 rounded-2xl px-6 py-4 sm:px-8 sm:py-5 lg:px-10 lg:py-6 border border-slate-200 mb-4",children:i.jsx("h1",{className:"text-xl sm:text-2xl lg:text-3xl font-bold text-slate-800 text-center",children:"Advanced Molecular Diagnostics: Collected, Curated, Explained"})}),l==="Patient"&&i.jsxs("div",{className:"rounded-2xl border-2 border-slate-300 bg-slate-50 mb-4 overflow-hidden",children:[i.jsxs("div",{className:"mx-4 mt-4 p-3 bg-amber-50 border border-amber-300 rounded-lg flex items-center gap-3",children:[i.jsx("span",{className:"text-2xl",children:""}),i.jsxs("div",{children:[i.jsx("p",{className:"font-semibold text-amber-800",children:"Patient View Under Construction"}),i.jsx("p",{className:"text-sm text-amber-700",children:"We're actively improving this experience. Some features may be incomplete."})]})]}),i.jsx("div",{className:"px-4 lg:px-6 py-3 bg-slate-100 border-b border-slate-200 mt-4",children:i.jsx("h2",{className:"text-sm lg:text-base font-semibold text-slate-600 uppercase tracking-wide",children:"Ask about liquid biopsy tests for cancer treatment"})}),i.jsxs("div",{className:"bg-white",children:[n.length>0&&i.jsxs("div",{ref:p,className:"max-h-64 overflow-y-auto p-4 space-y-3 bg-slate-50",children:[n.map((m,c)=>i.jsx("div",{"data-message-role":m.role,className:`flex ${m.role==="user"?"justify-end":"justify-start"}`,children:i.jsx("div",{className:`max-w-[80%] rounded-2xl px-4 py-2 ${m.role==="user"?"text-white rounded-br-md":"bg-white border border-slate-200 text-slate-800 rounded-bl-md"}`,style:m.role==="user"?{backgroundColor:"#2A63A4"}:{},children:m.role==="user"?i.jsx("p",{className:"text-sm whitespace-pre-wrap",children:m.content}):i.jsx(zo,{className:"text-sm",children:m.content})})},c)),r&&i.jsx("div",{className:"flex justify-start",children:i.jsx("div",{className:"bg-white border border-slate-200 rounded-2xl rounded-bl-md px-4 py-2",children:i.jsx("p",{className:"text-sm text-slate-500",children:"Thinking..."})})})]}),i.jsxs("div",{className:"p-4 lg:p-6 border-t border-slate-200 bg-white",children:[i.jsxs("form",{onSubmit:m=>{m.preventDefault(),j()},className:"flex gap-2 lg:gap-3 items-center",children:[i.jsx("select",{value:u,onChange:m=>g(m.target.value),className:"px-2 py-2 lg:py-3 bg-gray-50 border border-gray-200 rounded-lg text-xs focus:outline-none focus:ring-2 cursor-pointer",title:"Select AI model",children:Zi.map(m=>i.jsx("option",{value:m.id,children:m.name},m.id))}),i.jsx("input",{type:"text",value:t,onChange:m=>a(m.target.value),placeholder:"Type your liquid biopsy test question here...",className:"flex-1 border-2 rounded-lg px-4 py-2 lg:py-3 lg:text-lg focus:outline-none focus:ring-2",style:{borderColor:"#2A63A4","--tw-ring-color":"#2A63A4"},disabled:r}),i.jsx("button",{type:"submit",disabled:r||!t.trim(),className:"text-white px-6 lg:px-8 py-2 lg:py-3 rounded-lg font-medium lg:text-lg disabled:opacity-50 disabled:cursor-not-allowed transition-all hover:opacity-90",style:{background:"linear-gradient(to right, #2A63A4, #1E4A7A)"},children:"Ask"})]}),i.jsx("p",{className:"text-[10px] text-slate-400 mt-2 text-center",children:"Powered by Claude AI. Responses may be inaccurate and should be independently verified."})]}),n.length===0&&i.jsx("div",{className:"px-4 lg:px-6 py-3 bg-slate-50 border-t border-slate-100",children:i.jsxs("div",{className:"flex items-center gap-2 lg:gap-3 overflow-x-auto",children:[i.jsx("span",{className:"text-xs lg:text-sm text-slate-500 flex-shrink-0",children:"Try:"}),b.map((m,c)=>i.jsx("button",{onClick:()=>j(m),className:"text-sm bg-white border border-slate-200 rounded-full px-3 py-1 text-slate-600 hover:bg-[#EAF1F8] hover:border-[#6AA1C8] hover:text-[#1E4A7A] transition-colors whitespace-nowrap flex-shrink-0",children:m},c))]})})]}),i.jsx("div",{className:"mx-4 lg:mx-6 border-t border-slate-200"}),i.jsx("div",{className:"px-4 lg:px-6 py-3 bg-slate-100 border-b border-slate-200",children:i.jsx("h3",{className:"text-sm lg:text-base font-semibold text-slate-600 uppercase tracking-wide",children:"Or browse by category:"})}),i.jsx("div",{className:"p-4 lg:p-6",children:i.jsx(ju,{onNavigate:e})})]}),l!=="Patient"&&i.jsx("div",{className:"mb-4",children:i.jsx(Mf,{onNavigate:e})}),l!=="Patient"&&i.jsx("div",{className:"hidden md:block mb-4",children:i.jsx(Wo,{})})]})})},If=()=>{const e=z.length>0?Object.keys(z[0]).length:0,t=Y.length>0?Object.keys(Y[0]).length:0,a=K.length>0?Object.keys(K[0]).length:0,n=X.length>0?Object.keys(X[0]).length:0,s=z.length+Y.length+K.length+X.length,r=z.length*e+Y.length*t+K.length*a+X.length*n,o=new Set([...z.map(l=>l.vendor),...Y.map(l=>l.vendor),...K.map(l=>l.vendor),...X.map(l=>l.vendor)]);return i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("h3",{className:"text-lg font-semibold text-gray-800 mb-4",children:"Database Overview"}),i.jsxs("div",{className:"grid grid-cols-2 sm:grid-cols-4 gap-4 mb-6",children:[i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsx("p",{className:"text-2xl font-bold text-gray-800",children:s}),i.jsx("p",{className:"text-xs text-gray-500",children:"Total Tests"})]}),i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsx("p",{className:"text-2xl font-bold text-gray-800",children:o.size}),i.jsx("p",{className:"text-xs text-gray-500",children:"Vendors"})]}),i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsx("p",{className:"text-2xl font-bold text-gray-800",children:r.toLocaleString()}),i.jsx("p",{className:"text-xs text-gray-500",children:"Data Points"})]}),i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsx("p",{className:"text-2xl font-bold text-gray-800",children:"4"}),i.jsx("p",{className:"text-xs text-gray-500",children:"Categories"})]})]}),i.jsxs("div",{className:"grid grid-cols-2 sm:grid-cols-4 gap-3",children:[i.jsxs("div",{className:"flex items-center gap-2 p-2 bg-orange-50 rounded-lg border border-orange-100",children:[i.jsx("div",{className:"w-8 h-8 rounded-full bg-orange-500 flex items-center justify-center text-white text-xs font-bold",children:z.length}),i.jsxs("div",{children:[i.jsx("p",{className:"text-xs font-medium text-gray-800",children:"MRD"}),i.jsxs("p",{className:"text-[10px] text-gray-500",children:[e," fields"]})]})]}),i.jsxs("div",{className:"flex items-center gap-2 p-2 bg-emerald-50 rounded-lg border border-emerald-100",children:[i.jsx("div",{className:"w-8 h-8 rounded-full bg-emerald-500 flex items-center justify-center text-white text-xs font-bold",children:Y.length}),i.jsxs("div",{children:[i.jsx("p",{className:"text-xs font-medium text-gray-800",children:"ECD"}),i.jsxs("p",{className:"text-[10px] text-gray-500",children:[t," fields"]})]})]}),i.jsxs("div",{className:"flex items-center gap-2 p-2 bg-sky-50 rounded-lg border border-sky-100",children:[i.jsx("div",{className:"w-8 h-8 rounded-full bg-sky-500 flex items-center justify-center text-white text-xs font-bold",children:K.length}),i.jsxs("div",{children:[i.jsx("p",{className:"text-xs font-medium text-gray-800",children:"TRM"}),i.jsxs("p",{className:"text-[10px] text-gray-500",children:[a," fields"]})]})]}),i.jsxs("div",{className:"flex items-center gap-2 p-2 bg-violet-50 rounded-lg border border-violet-100",children:[i.jsx("div",{className:"w-8 h-8 rounded-full bg-violet-500 flex items-center justify-center text-white text-xs font-bold",children:X.length}),i.jsxs("div",{children:[i.jsx("p",{className:"text-xs font-medium text-gray-800",children:"TDS"}),i.jsxs("p",{className:"text-[10px] text-gray-500",children:[n," fields"]})]})]})]})]})},Wo=()=>{const[e,t]=A.useState(!1),a=z.length>0?Object.keys(z[0]).length:0,n=Y.length>0?Object.keys(Y[0]).length:0,s=K.length>0?Object.keys(K[0]).length:0,r=X.length>0?Object.keys(X[0]).length:0,o=z.length+Y.length+K.length+X.length;z.length*a+Y.length*n+K.length*s+X.length*r;const l=[...z.map(v=>({...v,category:"MRD"})),...Y.map(v=>({...v,category:"ECD"})),...K.map(v=>({...v,category:"TRM"})),...X.map(v=>({...v,category:"TDS"}))],d=new Set([...z.map(v=>v.vendor),...Y.map(v=>v.vendor),...K.map(v=>v.vendor),...X.map(v=>v.vendor)]),u=v=>v!=null&&String(v).trim()!==""&&v!=="N/A"&&v!=="Not disclosed",g=v=>{const N=(v.reimbursement||"").toLowerCase();return!N||N.includes("not applicable")||N.includes("not established")||N.includes("no established")||N.includes("no specific")||N==="self-pay"||N==="coverage varies"||N.startsWith("coverage emerging")?!1:N.includes("medicare")||N.includes("covered")||v.commercialPayers&&v.commercialPayers.length>0},p=v=>{let N=0;switch(u(v.listPrice)&&(N+=30),v.numPublications!=null&&v.numPublications>0&&(N+=15),(u(v.tat)||u(v.initialTat))&&(N+=10),(u(v.bloodVolume)||u(v.sampleType)||u(v.sampleCategory))&&(N+=10),v.totalParticipants!=null&&v.totalParticipants>0&&(N+=5),v.category){case"ECD":u(v.sensitivity)&&(N+=15),u(v.specificity)&&(N+=15);break;case"MRD":(u(v.lod)||u(v.lod95))&&(N+=30);break;case"TRM":u(v.sensitivity)&&(N+=15),u(v.specificity)&&(N+=15);break;case"TDS":u(v.genesAnalyzed)&&(N+=15),(u(v.tmb)||u(v.msi))&&(N+=15);break;default:u(v.sensitivity)&&(N+=15),u(v.specificity)&&(N+=15)}return N},y=v=>v?v.includes("Guardant")?"Guardant Health":v.includes("Foundation Medicine")?"Foundation Medicine":v:"Unknown";l.filter(g);const x={};l.forEach(v=>{const N=y(v.vendor);x[N]||(x[N]={scores:[],total:0,count:0,tests:[]});const F=p(v);x[N].scores.push(F),x[N].total+=F,x[N].count+=1,x[N].tests.push({name:v.name,score:F})});const b=Object.entries(x).filter(([v,N])=>N.count>=2).map(([v,N])=>({vendor:v,avgScore:N.total/N.count,testCount:N.count,tests:N.tests})).sort((v,N)=>N.avgScore-v.avgScore).slice(0,3),j=(v,N)=>{if(!v||v.length===0)return 0;const F=v.filter(N).length;return Math.round(F/v.length*100)},m=[{label:"List Price",rate:j(l,v=>u(v.listPrice)),color:"amber",description:"published pricing"},{label:"Sensitivity",rate:j(l,v=>u(v.sensitivity)),color:"emerald",description:"detection rate"},{label:"Specificity",rate:j(l,v=>u(v.specificity)),color:"emerald",description:"true negative rate"},{label:"TAT",rate:j(l,v=>u(v.tat)||u(v.initialTat)),color:"sky",description:"turnaround time"},{label:"Publications",rate:j(l,v=>v.numPublications!=null&&v.numPublications>0),color:"violet",description:"peer-reviewed"}],c=Object.entries(x).filter(([v,N])=>N.count>=2),h=c.length>0?Math.round(c.reduce((v,[N,F])=>v+F.total/F.count,0)/c.length):0,C=v=>({rose:"bg-rose-500",amber:"bg-amber-500",emerald:"bg-emerald-500",sky:"bg-sky-500",violet:"bg-violet-500"})[v]||"bg-slate-500",P=v=>({rose:"text-rose-600",amber:"text-amber-600",emerald:"text-emerald-600",sky:"text-sky-600",violet:"text-violet-600"})[v]||"text-slate-600",R=[{bg:"bg-gradient-to-r from-emerald-100 to-emerald-50",border:"border-emerald-500",text:"text-emerald-800"},{bg:"bg-gradient-to-r from-emerald-50 to-green-50",border:"border-emerald-400",text:"text-emerald-700"},{bg:"bg-gradient-to-r from-green-50 to-teal-50",border:"border-emerald-300",text:"text-emerald-600"}];return i.jsxs("div",{className:"bg-gradient-to-br from-slate-200 to-slate-300 rounded-2xl p-6",children:[i.jsxs("div",{className:"flex items-center justify-between mb-4",children:[i.jsx("h2",{className:"text-lg font-semibold text-slate-700",children:"Data Openness Overview"}),i.jsxs("div",{className:"text-xs text-slate-500",children:["Updated ",ea.date.split(" ").slice(0,2).join(" ")]})]}),b.length>0&&i.jsxs("div",{className:"bg-white/40 rounded-xl p-4 mb-4",children:[i.jsxs("div",{className:"flex items-center justify-between mb-3",children:[i.jsx("h3",{className:"text-sm font-semibold text-slate-700",children:"Top 3 Vendors by Data Openness"}),i.jsx("span",{className:"text-[10px] text-slate-500",children:"Min. 2 tests to qualify"})]}),i.jsx("div",{className:"grid grid-cols-3 gap-3",children:b.map((v,N)=>i.jsxs("div",{className:`flex items-center px-3 py-4 rounded-lg border ${R[N].bg} ${R[N].border}`,children:[i.jsx("div",{className:"w-16 flex-shrink-0 flex items-center justify-center",children:i.jsx("span",{className:`text-5xl font-bold ${R[N].text} opacity-40`,children:N+1})}),i.jsxs("div",{className:"flex flex-col items-center text-center flex-1 min-w-0",children:[i.jsx("p",{className:`font-semibold text-sm ${R[N].text} truncate w-full`,children:v.vendor}),i.jsxs("p",{className:"text-[10px] text-slate-500 mb-1",children:[v.testCount," tests"]}),i.jsxs("div",{className:"flex items-center gap-1.5",children:[i.jsx("span",{className:`text-2xl font-bold ${R[N].text}`,children:Math.round(v.avgScore)}),i.jsx("span",{className:"text-sm text-slate-400",children:"vs"}),i.jsx("span",{className:"text-xl font-bold text-slate-400",children:h}),i.jsx("span",{className:"text-xs text-slate-400",children:"(Avg)"})]})]})]},v.vendor))}),i.jsxs("div",{className:"mt-3 pt-3 border-t border-slate-200 flex items-center justify-between",children:[i.jsxs("div",{className:"text-xs text-slate-500 flex items-center gap-3",children:[i.jsxs("span",{children:[c.length," vendors with 2+ tests"]}),i.jsx("span",{children:""}),i.jsxs("span",{children:[Pa.length," changelog entries"]})]}),i.jsxs("button",{onClick:()=>t(!e),className:"text-xs text-slate-600 hover:text-slate-800 font-medium flex items-center gap-1",children:[e?"Hide":"Methodology",i.jsx("svg",{className:`w-3 h-3 transition-transform ${e?"rotate-180":""}`,fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]})]}),e&&i.jsx("div",{className:"mt-4 pt-4 border-t border-slate-200 text-sm text-slate-700 space-y-3",children:i.jsxs("p",{className:"text-xs text-slate-600",children:["The Openness Score measures vendor data disclosure using ",i.jsx("strong",{children:"category-normalized"})," metrics. Universal fields: ",i.jsx("strong",{children:"Price (30%)"}),", ",i.jsx("strong",{children:"Publications (15%)"}),", ",i.jsx("strong",{children:"TAT (10%)"}),",",i.jsx("strong",{children:" Sample Info (10%)"}),", ",i.jsx("strong",{children:"Trial Participants (5%)"}),". Plus 30% for category-specific metrics (e.g., Sens/Spec for ECD/TRM, LOD for MRD, Genes/CDx for TDS). Vendor scores are averaged across all their tests."]})})]}),i.jsxs("div",{className:"bg-white/40 rounded-xl p-4",children:[i.jsx("h3",{className:"text-sm font-semibold text-slate-700 mb-4",children:"Data Completeness by Field"}),i.jsx("div",{className:"space-y-3",children:m.map(({label:v,rate:N,color:F,description:I})=>i.jsxs("div",{children:[i.jsxs("div",{className:"flex justify-between items-center mb-1",children:[i.jsxs("div",{className:"flex items-center gap-2",children:[i.jsx("span",{className:"text-sm font-medium text-slate-700",children:v}),i.jsx("span",{className:"text-[10px] text-slate-400",children:I})]}),i.jsxs("span",{className:`text-sm font-bold ${P(F)}`,children:[N,"%"]})]}),i.jsx("div",{className:"h-3 bg-slate-200 rounded-full overflow-hidden",children:i.jsx("div",{className:`h-full ${C(F)} rounded-full transition-all duration-500`,style:{width:`${N}%`}})})]},v))}),i.jsxs("p",{className:"mt-4 pt-3 border-t border-slate-200 text-[10px] text-slate-500 text-center",children:["Completeness rates reflect publicly available data across ",o," tests from ",d.size," vendors."]})]})]})},Ef=()=>{const[e,t]=A.useState(!1),a=[...z.map(p=>({...p,category:"MRD"})),...Y.map(p=>({...p,category:"ECD"})),...K.map(p=>({...p,category:"TRM"})),...X.map(p=>({...p,category:"TDS"}))],n=p=>p!=null&&String(p).trim()!==""&&p!=="N/A"&&p!=="Not disclosed",s=p=>{let y=0;switch(n(p.listPrice)&&(y+=30),p.numPublications!=null&&p.numPublications>0&&(y+=15),(n(p.tat)||n(p.initialTat))&&(y+=10),(n(p.bloodVolume)||n(p.sampleType)||n(p.sampleCategory))&&(y+=10),p.totalParticipants!=null&&p.totalParticipants>0&&(y+=5),p.category){case"ECD":n(p.sensitivity)&&(y+=15),n(p.specificity)&&(y+=15);break;case"MRD":(n(p.lod)||n(p.lod95))&&(y+=30);break;case"TRM":n(p.sensitivity)&&(y+=15),n(p.specificity)&&(y+=15);break;case"TDS":n(p.genesAnalyzed)&&(y+=15),(n(p.tmb)||n(p.msi))&&(y+=15);break;default:n(p.sensitivity)&&(y+=15),n(p.specificity)&&(y+=15)}return y},r=p=>p?p.includes("Guardant")?"Guardant Health":p.includes("Foundation Medicine")?"Foundation Medicine":p:"Unknown",o={};a.forEach(p=>{const y=r(p.vendor);o[y]||(o[y]={scores:[],total:0,count:0,tests:[]});const x=s(p);o[y].scores.push(x),o[y].total+=x,o[y].count+=1,o[y].tests.push({name:p.name,score:x})});const l=Object.entries(o).filter(([p,y])=>y.count>=2).map(([p,y])=>({vendor:p,avgScore:y.total/y.count,testCount:y.count,tests:y.tests})).sort((p,y)=>y.avgScore-p.avgScore),d=l.slice(0,3),u=l.length>0?Math.round(l.reduce((p,y)=>p+y.avgScore,0)/l.length):0;if(d.length===0)return null;const g=[{bg:"bg-amber-100",border:"border-amber-300",text:"text-amber-700",badge:"bg-amber-500",icon:""},{bg:"bg-slate-100",border:"border-slate-300",text:"text-slate-600",badge:"bg-slate-400",icon:""},{bg:"bg-orange-100",border:"border-orange-300",text:"text-orange-700",badge:"bg-orange-400",icon:""}];return i.jsxs("div",{className:"bg-gradient-to-br from-slate-50 to-slate-100 border border-slate-200 rounded-xl p-4 shadow-sm",children:[i.jsxs("div",{className:"flex items-center justify-between mb-3",children:[i.jsx("h3",{className:"text-sm font-semibold text-slate-700",children:"Top 3 Vendors by Data Openness"}),i.jsx("span",{className:"text-[10px] text-slate-500",children:"Min. 2 tests to qualify"})]}),i.jsx("div",{className:"space-y-2",children:d.map((p,y)=>i.jsxs("div",{className:`flex items-center gap-3 p-2.5 rounded-lg border ${g[y].bg} ${g[y].border}`,children:[i.jsx("span",{className:"text-xl",children:g[y].icon}),i.jsxs("div",{className:"flex-1 min-w-0",children:[i.jsx("p",{className:`font-semibold text-sm ${g[y].text} truncate`,children:p.vendor}),i.jsxs("p",{className:"text-[10px] text-slate-500",children:[p.testCount," tests"]})]}),i.jsx("div",{className:`px-2.5 py-1 rounded-lg text-white text-sm font-bold ${g[y].badge}`,children:Math.round(p.avgScore)})]},p.vendor))}),i.jsxs("div",{className:"mt-3 pt-3 border-t border-slate-200 flex items-center justify-between",children:[i.jsxs("div",{className:"text-xs text-slate-500",children:["Field average: ",i.jsx("span",{className:"font-semibold text-slate-700",children:u})," across ",l.length," qualifying vendors"]}),i.jsxs("button",{onClick:()=>t(!e),className:"text-xs text-slate-600 hover:text-slate-800 font-medium flex items-center gap-1",children:[e?"Hide":"Methodology",i.jsx("svg",{className:`w-3 h-3 transition-transform ${e?"rotate-180":""}`,fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]})]}),e&&i.jsxs("div",{className:"mt-4 pt-4 border-t border-slate-200 text-sm text-slate-700 space-y-4",children:[i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-slate-800 mb-2",children:"What is the Openness Score?"}),i.jsx("p",{className:"text-xs text-slate-600",children:"The OpenOnco Openness Score measures how completely vendors disclose key information about their tests. It rewards vendors who publish pricing, performance data, and clinical evidenceinformation that helps patients and clinicians make informed decisions."})]}),i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-slate-800 mb-2",children:"How is it calculated?"}),i.jsx("p",{className:"text-xs text-slate-600 mb-2",children:"Each test is scored based on disclosure of key fields (weights sum to 100):"}),i.jsx("div",{className:"bg-white/60 rounded-lg p-3 overflow-x-auto",children:i.jsxs("table",{className:"w-full text-xs",children:[i.jsx("thead",{children:i.jsxs("tr",{className:"border-b border-slate-200",children:[i.jsx("th",{className:"text-left py-1.5 pr-4 font-semibold text-slate-700",children:"Field"}),i.jsx("th",{className:"text-center py-1.5 px-2 font-semibold text-slate-700",children:"Weight"}),i.jsx("th",{className:"text-left py-1.5 pl-4 font-semibold text-slate-700",children:"Why it matters"})]})}),i.jsxs("tbody",{className:"text-slate-600",children:[i.jsxs("tr",{className:"border-b border-slate-100",children:[i.jsx("td",{className:"py-1.5 pr-4 font-medium",children:"List Price"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-amber-600",children:"30%"}),i.jsx("td",{className:"py-1.5 pl-4",children:"Most critical for access decisions"})]}),i.jsxs("tr",{className:"border-b border-slate-100",children:[i.jsx("td",{className:"py-1.5 pr-4 font-medium",children:"Sensitivity"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-amber-600",children:"15%"}),i.jsx("td",{className:"py-1.5 pl-4",children:"Detection rate / true positive rate"})]}),i.jsxs("tr",{className:"border-b border-slate-100",children:[i.jsx("td",{className:"py-1.5 pr-4 font-medium",children:"Specificity"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-amber-600",children:"15%"}),i.jsx("td",{className:"py-1.5 pl-4",children:"Reduces unnecessary follow-ups"})]}),i.jsxs("tr",{className:"border-b border-slate-100",children:[i.jsx("td",{className:"py-1.5 pr-4 font-medium",children:"Publications"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-amber-600",children:"15%"}),i.jsx("td",{className:"py-1.5 pl-4",children:"Evidence of independent validation"})]}),i.jsxs("tr",{className:"border-b border-slate-100",children:[i.jsx("td",{className:"py-1.5 pr-4 font-medium",children:"Turnaround Time"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-amber-600",children:"10%"}),i.jsx("td",{className:"py-1.5 pl-4",children:"Practical info for clinicians"})]}),i.jsxs("tr",{className:"border-b border-slate-100",children:[i.jsx("td",{className:"py-1.5 pr-4 font-medium",children:"Sample Info"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-amber-600",children:"10%"}),i.jsx("td",{className:"py-1.5 pl-4",children:"Blood volume, sample type, or category"})]}),i.jsxs("tr",{children:[i.jsx("td",{className:"py-1.5 pr-4 font-medium",children:"Trial Participants"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-amber-600",children:"5%"}),i.jsx("td",{className:"py-1.5 pl-4",children:"Clinical evidence depth"})]})]}),i.jsx("tfoot",{children:i.jsxs("tr",{className:"border-t border-slate-200",children:[i.jsx("td",{className:"py-1.5 pr-4 font-bold text-slate-800",children:"Total"}),i.jsx("td",{className:"text-center py-1.5 px-2 font-bold text-slate-800",children:"100%"}),i.jsx("td",{className:"py-1.5 pl-4"})]})})]})})]}),i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-slate-800 mb-2",children:"Who is eligible?"}),i.jsxs("p",{className:"text-xs text-slate-600",children:["Vendors must have ",i.jsx("strong",{children:"2 or more tests"})," in the OpenOnco database to qualify for ranking. The vendor's score is the ",i.jsx("strong",{children:"average"})," across all their tests. This prevents a single well-documented test from dominating while encouraging comprehensive disclosure across product portfolios."]})]}),i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-slate-800 mb-2",children:"How can vendors improve their score?"}),i.jsx("p",{className:"text-xs text-slate-600",children:"Publish your list price, disclose sensitivity and specificity from validation studies, maintain an active publication record, and provide clear sample requirements. Vendors can submit updated information through our Submissions page."})]})]})]})},Ff=({onNavigate:e})=>{const t=[{id:"ECD",phase:"Screening",name:"Early Cancer Detection",acronym:"ECD",color:"emerald",icon:"",clinicalQuestion:"Can cancer be detected before clinical presentation?",description:"Multi-cancer early detection (MCED) tests screen asymptomatic individuals for cancer signals in blood. These assays analyze tumor-derived molecules including ctDNA methylation patterns, fragmentomic features (cfDNA fragment size distributions and end motifs), and protein biomarkers.",technology:"Most ECD tests rely on methylation profiling, as cancer-specific methylation patterns are more abundant and consistent than somatic mutations in early-stage disease. Machine learning classifiers trained on methylation arrays can detect cancer signals and predict tissue of origin. Some platforms combine methylation with fragmentomics or proteomics for improved sensitivity.",keyMetrics:["Sensitivity by cancer type and stage (typically 20-40% for stage I, 70-90% for stage IV)","Specificity (target >99% to minimize false positives in screening populations)","Positive predictive value (PPV) depends heavily on cancer prevalence","Cancer signal origin (CSO) accuracy for localization"],challenges:["Low ctDNA fraction in early-stage disease (<0.1% VAF)","Clonal hematopoiesis of indeterminate potential (CHIP) confounds mutation-based approaches","Requires large validation cohorts across diverse cancer types","Clinical utility studies (mortality reduction) still in progress"],testCount:Y.length},{id:"TDS",phase:"Diagnosis",name:"Treatment Decision Support",acronym:"TDS",color:"violet",icon:"",clinicalQuestion:"What is the best treatment approach for this patient?",description:"TDS tests help guide treatment decisions by providing molecular or biomarker information. This includes genomic profiling tests that identify actionable mutations for targeted therapy selection, as well as risk stratification tests that help determine whether interventions like biopsies are needed.",technology:"Includes multiple technologies: NGS-based comprehensive genomic profiling (CGP) from tumor tissue or liquid biopsy to identify targetable alterations; protein structure analysis for risk stratification; and other biomarker assays. Some tests are FDA-approved as companion diagnostics.",keyMetrics:["Sensitivity and specificity for intended use case","FDA approval status and guideline recommendations","Turnaround time","Coverage by Medicare and commercial payers"],challenges:["Matching test results to appropriate clinical decisions","Variants of uncertain significance (VUS) interpretation in genomic tests","Balancing sensitivity vs specificity for risk stratification","Integration into clinical workflow"],testCount:X.length},{id:"TRM",phase:"Treatment",name:"Treatment Response Monitoring",acronym:"TRM",color:"sky",icon:"",clinicalQuestion:"Is the current therapy effective, and is resistance emerging?",description:"TRM uses serial liquid biopsies to quantify ctDNA dynamics during active therapy. Decreasing ctDNA levels correlate with treatment response; rising levels may indicate progression or resistanceoften weeks before radiographic changes are detectable.",technology:"TRM approaches vary: some track specific mutations identified at baseline (tumor-informed), while others monitor a fixed panel of common cancer mutations (tumor-nave). Quantification methods include variant allele frequency (VAF), absolute ctDNA concentration (copies/mL), or composite molecular response scores. Some platforms can detect emerging resistance mutations to guide therapy switching.",keyMetrics:["Analytical sensitivity for quantification at low VAF","Coefficient of variation (CV) for serial measurements","Molecular response thresholds (fold-change or absolute cutoffs)","Correlation with clinical outcomes (PFS, OS)"],challenges:['Standardization of "molecular response" definitions across platforms',"Optimal sampling intervals during therapy","Integration with imaging-based response assessment","Cost of serial testing"],testCount:K.length},{id:"MRD",phase:"Surveillance",name:"Minimal Residual Disease",acronym:"MRD",color:"orange",icon:"",clinicalQuestion:"Does molecular evidence of disease persist after curative-intent treatment?",description:"MRD testing detects residual cancer at levels far below imaging resolution (typically 0.01-0.001% VAF). MRD-positive status after surgery correlates with higher recurrence risk; MRD-negative results support molecular complete response. Serial MRD testing during surveillance can detect recurrence months before clinical presentation.",technology:"Tumor-informed MRD assays sequence the primary tumor to identify patient-specific mutations, then design custom PCR or hybrid capture panels to track those variants in plasma with maximum sensitivity. Tumor-nave approaches use fixed panels or methylation signatures. Tumor-informed methods achieve lower LOD but require tissue and longer setup time.",keyMetrics:["Limit of detection (LOD)tumor-informed typically 0.001-0.01% VAF","Sensitivity (% of relapsing patients detected MRD+)","Specificity (% of non-relapsing patients correctly MRD-)","Lead time before clinical/radiographic recurrence"],challenges:["Requires adequate tumor tissue for tumor-informed approaches","Turnaround time for custom assay design (2-4 weeks)","Optimal surveillance testing intervals not established for all cancers","Clinical utility data (does MRD-guided therapy improve outcomes?) still maturing"],testCount:z.length}],a={emerald:{bg:"bg-emerald-50",bgMedium:"bg-emerald-100",border:"border-emerald-200",borderActive:"border-emerald-500",text:"text-emerald-600",textDark:"text-emerald-700",button:"bg-emerald-500 hover:bg-emerald-600",iconBg:"bg-emerald-100"},violet:{bg:"bg-violet-50",bgMedium:"bg-violet-100",border:"border-violet-200",borderActive:"border-violet-500",text:"text-violet-600",textDark:"text-violet-700",button:"bg-violet-500 hover:bg-violet-600",iconBg:"bg-violet-100"},sky:{bg:"bg-sky-50",bgMedium:"bg-sky-100",border:"border-sky-200",borderActive:"border-sky-500",text:"text-sky-600",textDark:"text-sky-700",button:"bg-sky-500 hover:bg-sky-600",iconBg:"bg-sky-100"},orange:{bg:"bg-orange-50",bgMedium:"bg-orange-100",border:"border-orange-200",borderActive:"border-orange-500",text:"text-orange-600",textDark:"text-orange-700",button:"bg-orange-500 hover:bg-orange-600",iconBg:"bg-orange-100"}};return i.jsxs("div",{className:"max-w-6xl mx-auto px-4 sm:px-6 py-8 sm:py-12",children:[i.jsxs("div",{className:"text-center mb-12",children:[i.jsx("h1",{className:"text-3xl sm:text-4xl font-bold text-gray-900 mb-4",children:"Advanced Molecular Diagnostics: An Overview"}),i.jsx("p",{className:"text-lg sm:text-xl text-gray-600 max-w-3xl mx-auto",children:"Modern diagnostic technologiesfrom next-generation sequencing to protein biomarker analysisenable blood-based tests across the full cancer care continuum, from early detection to post-treatment surveillance."})]}),i.jsxs("div",{className:"bg-gradient-to-br from-slate-50 to-gray-100 rounded-2xl p-6 sm:p-8 mb-12 border border-slate-200",children:[i.jsx("h2",{className:"text-xl sm:text-2xl font-bold text-gray-900 mb-4",children:"The Underlying Technologies"}),i.jsxs("p",{className:"text-gray-700 mb-4",children:["Advanced molecular diagnostics leverage multiple technologies to extract clinically actionable information from patient samples. ",i.jsx("strong",{children:"Cell-free DNA (cfDNA)"})," analysis isolates DNA fragments released by cells into the bloodstreamin cancer patients, a fraction derives from tumor cells (",i.jsx("strong",{children:"circulating tumor DNA or ctDNA"}),"), carrying the same somatic alterations present in the tumor. Beyond DNA, tests may analyze methylation patterns, protein biomarkers, or structural variants."]}),i.jsx("p",{className:"text-gray-700 mb-6",children:"These technologies answer different clinical questions depending on the patient's disease state:"}),i.jsxs("div",{className:"grid sm:grid-cols-2 gap-4",children:[i.jsxs("div",{className:"flex items-start gap-3 p-3 bg-white rounded-lg border border-gray-200",children:[i.jsx("span",{className:"text-2xl",children:""}),i.jsxs("div",{children:[i.jsx("p",{className:"font-semibold text-gray-900",children:"Early Detection"}),i.jsx("p",{className:"text-sm text-gray-600",children:"Detect cancer signals in asymptomatic individuals"})]})]}),i.jsxs("div",{className:"flex items-start gap-3 p-3 bg-white rounded-lg border border-gray-200",children:[i.jsx("span",{className:"text-2xl",children:""}),i.jsxs("div",{children:[i.jsx("p",{className:"font-semibold text-gray-900",children:"Treatment Decisions"}),i.jsx("p",{className:"text-sm text-gray-600",children:"Guide therapy selection and intervention decisions"})]})]}),i.jsxs("div",{className:"flex items-start gap-3 p-3 bg-white rounded-lg border border-gray-200",children:[i.jsx("span",{className:"text-2xl",children:""}),i.jsxs("div",{children:[i.jsx("p",{className:"font-semibold text-gray-900",children:"Response Monitoring"}),i.jsx("p",{className:"text-sm text-gray-600",children:"Track ctDNA dynamics during active treatment"})]})]}),i.jsxs("div",{className:"flex items-start gap-3 p-3 bg-white rounded-lg border border-gray-200",children:[i.jsx("span",{className:"text-2xl",children:""}),i.jsxs("div",{children:[i.jsx("p",{className:"font-semibold text-gray-900",children:"MRD Detection"}),i.jsx("p",{className:"text-sm text-gray-600",children:"Identify residual disease after curative treatment"})]})]})]}),i.jsxs("div",{className:"mt-6 p-4 bg-white rounded-xl border border-gray-200",children:[i.jsx("h3",{className:"font-semibold text-gray-900 mb-3",children:"The ctDNA Signal Challenge"}),i.jsx("p",{className:"text-sm text-gray-700 mb-3",children:"The fraction of cfDNA that derives from tumor (ctDNA fraction) varies dramatically by clinical context, which drives the sensitivity requirements for each test category:"}),i.jsx("div",{className:"overflow-x-auto",children:i.jsxs("table",{className:"w-full text-sm",children:[i.jsx("thead",{children:i.jsxs("tr",{className:"border-b border-gray-200",children:[i.jsx("th",{className:"text-left py-2 px-3 font-semibold text-gray-700",children:"Clinical Context"}),i.jsx("th",{className:"text-left py-2 px-3 font-semibold text-gray-700",children:"Typical ctDNA Fraction"}),i.jsx("th",{className:"text-left py-2 px-3 font-semibold text-gray-700",children:"Required LOD"})]})}),i.jsxs("tbody",{className:"divide-y divide-gray-100",children:[i.jsxs("tr",{children:[i.jsx("td",{className:"py-2 px-3 text-gray-700",children:"Advanced cancer (TDS)"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"110%+"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"0.55% VAF"})]}),i.jsxs("tr",{children:[i.jsx("td",{className:"py-2 px-3 text-gray-700",children:"Early-stage screening (ECD)"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"0.010.1%"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"<0.1% VAF"})]}),i.jsxs("tr",{children:[i.jsx("td",{className:"py-2 px-3 text-gray-700",children:"Post-surgery surveillance (MRD)"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"0.0010.01%"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"<0.01% VAF"})]}),i.jsxs("tr",{children:[i.jsx("td",{className:"py-2 px-3 text-gray-700",children:"Treatment monitoring (TRM)"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"Variable (dynamic)"}),i.jsx("td",{className:"py-2 px-3 text-gray-600",children:"Quantitative accuracy"})]})]})]})})]})]}),i.jsxs("div",{className:"space-y-8",children:[i.jsx("h2",{className:"text-xl sm:text-2xl font-bold text-gray-900 text-center mb-8",children:"Test Categories: Technical Deep Dive"}),t.map(n=>{const s=a[n.color];return i.jsxs("div",{className:`${s.bg} ${s.border} border-2 rounded-2xl overflow-hidden`,children:[i.jsx("div",{className:`${s.bgMedium} px-6 py-4 border-b ${s.border}`,children:i.jsxs("div",{className:"flex items-center gap-3",children:[i.jsx("span",{className:"text-3xl",children:n.icon}),i.jsxs("div",{children:[i.jsx("p",{className:`text-xs font-semibold ${s.text} uppercase tracking-wide`,children:n.phase}),i.jsxs("h3",{className:"text-xl sm:text-2xl font-bold text-gray-900",children:[n.name," (",n.acronym,")"]})]})]})}),i.jsxs("div",{className:"p-6 space-y-6",children:[i.jsxs("div",{className:"bg-white rounded-xl p-4 border border-gray-200",children:[i.jsx("p",{className:"text-sm font-semibold text-gray-500 uppercase tracking-wide mb-1",children:"Clinical Question"}),i.jsxs("p",{className:"text-lg font-medium text-gray-900 italic",children:['"',n.clinicalQuestion,'"']})]}),i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-gray-900 mb-2",children:"Overview"}),i.jsx("p",{className:"text-gray-700",children:n.description})]}),i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-gray-900 mb-2",children:"Technology & Methodology"}),i.jsx("p",{className:"text-gray-700",children:n.technology})]}),i.jsxs("div",{className:"grid sm:grid-cols-2 gap-6",children:[i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-gray-900 mb-2",children:"Key Performance Metrics"}),i.jsx("ul",{className:"space-y-2",children:n.keyMetrics.map((r,o)=>i.jsxs("li",{className:"flex items-start gap-2 text-gray-700 text-sm",children:[i.jsx("span",{className:`${s.text} mt-1`,children:""}),i.jsx("span",{children:r})]},o))})]}),i.jsxs("div",{children:[i.jsx("h4",{className:"font-semibold text-gray-900 mb-2",children:"Technical Challenges"}),i.jsx("ul",{className:"space-y-2",children:n.challenges.map((r,o)=>i.jsxs("li",{className:"flex items-start gap-2 text-gray-700 text-sm",children:[i.jsx("span",{className:`${s.text} mt-1`,children:""}),i.jsx("span",{children:r})]},o))})]})]}),i.jsx("div",{className:"pt-2",children:i.jsxs("button",{onClick:()=>e(n.id),className:`${s.button} text-white px-6 py-3 rounded-xl font-semibold transition-colors flex items-center gap-2`,children:["Explore ",n.testCount," ",n.acronym," Tests",i.jsx("svg",{className:"w-5 h-5",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M13 7l5 5m0 0l-5 5m5-5H6"})})]})})]})]},n.id)})]}),i.jsxs("div",{className:"mt-12 bg-white rounded-2xl border-2 border-gray-200 p-6 sm:p-8",children:[i.jsx("h2",{className:"text-xl font-bold text-gray-900 mb-4 text-center",children:"Quick Reference: Test Category Selection"}),i.jsx("p",{className:"text-gray-600 text-center mb-6",children:"Match clinical context to the appropriate test category:"}),i.jsx("div",{className:"overflow-x-auto",children:i.jsxs("table",{className:"w-full",children:[i.jsx("thead",{children:i.jsxs("tr",{className:"border-b border-gray-200",children:[i.jsx("th",{className:"text-left py-3 px-4 font-semibold text-gray-900",children:"Clinical Context"}),i.jsx("th",{className:"text-left py-3 px-4 font-semibold text-gray-900",children:"Test Category"}),i.jsx("th",{className:"text-left py-3 px-4 font-semibold text-gray-900",children:"Primary Output"})]})}),i.jsxs("tbody",{className:"divide-y divide-gray-100",children:[i.jsxs("tr",{className:"hover:bg-gray-50 cursor-pointer",onClick:()=>e("ECD"),children:[i.jsx("td",{className:"py-3 px-4 text-gray-700",children:"Asymptomatic screening"}),i.jsx("td",{className:"py-3 px-4",children:i.jsx("span",{className:"text-emerald-600 font-medium",children:"ECD "})}),i.jsx("td",{className:"py-3 px-4 text-gray-600 text-sm",children:"Cancer signal detected (Y/N), tissue of origin"})]}),i.jsxs("tr",{className:"hover:bg-gray-50 cursor-pointer",onClick:()=>e("TDS"),children:[i.jsx("td",{className:"py-3 px-4 text-gray-700",children:"Newly diagnosed / therapy selection"}),i.jsx("td",{className:"py-3 px-4",children:i.jsx("span",{className:"text-violet-600 font-medium",children:"TDS "})}),i.jsx("td",{className:"py-3 px-4 text-gray-600 text-sm",children:"Actionable mutations, MSI, TMB, fusions"})]}),i.jsxs("tr",{className:"hover:bg-gray-50 cursor-pointer",onClick:()=>e("TRM"),children:[i.jsx("td",{className:"py-3 px-4 text-gray-700",children:"On active systemic therapy"}),i.jsx("td",{className:"py-3 px-4",children:i.jsx("span",{className:"text-sky-600 font-medium",children:"TRM "})}),i.jsx("td",{className:"py-3 px-4 text-gray-600 text-sm",children:"ctDNA quantification, molecular response"})]}),i.jsxs("tr",{className:"hover:bg-gray-50 cursor-pointer",onClick:()=>e("MRD"),children:[i.jsx("td",{className:"py-3 px-4 text-gray-700",children:"Post-curative treatment surveillance"}),i.jsx("td",{className:"py-3 px-4",children:i.jsx("span",{className:"text-orange-600 font-medium",children:"MRD "})}),i.jsx("td",{className:"py-3 px-4 text-gray-600 text-sm",children:"MRD status (positive/negative), recurrence risk"})]})]})]})})]})]})},Of=({question:e,answer:t,isOpen:a,onClick:n})=>i.jsxs("div",{className:"border-b border-gray-200 last:border-b-0",children:[i.jsxs("button",{onClick:n,className:"w-full py-5 px-6 flex justify-between items-center text-left hover:bg-gray-50 transition-colors",children:[i.jsx("span",{className:"text-lg font-medium text-gray-900 pr-4",children:e}),i.jsx("svg",{className:`w-5 h-5 text-gray-500 transform transition-transform flex-shrink-0 ${a?"rotate-180":""}`,fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]}),a&&i.jsx("div",{className:"pb-5 px-6 pr-12",children:i.jsx("div",{className:"prose prose-lg text-gray-600",children:t})})]}),Bf=()=>{const[e,t]=A.useState(null),a=[{question:"What types of tests does OpenOnco cover?",answer:i.jsxs("p",{children:["OpenOnco focuses on advanced molecular diagnosticslaboratory-developed tests (LDTs) and services that patients and clinicians can access directly. We cover four categories: ",i.jsx("strong",{children:"Early Cancer Detection (ECD)"})," for screening, ",i.jsx("strong",{children:"Treatment Decision Support (TDS)"})," for guiding treatment decisions in newly diagnosed patients, ",i.jsx("strong",{children:"Treatment Response Monitoring (TRM)"})," for patients on active treatment, and ",i.jsx("strong",{children:"Minimal Residual Disease (MRD)"})," for surveillance after treatment. We include tests using various technologiesgenomic sequencing, methylation analysis, protein biomarkers, and moreas long as they're orderable clinical services rather than reagent kits laboratories must validate themselves."]})},{question:"Why aren't certain tests included in your database?",answer:i.jsxs("div",{className:"space-y-3",children:[i.jsx("p",{children:"We focus on tests that clinicians can order or patients can request directly. This means we exclude:"}),i.jsxs("ul",{className:"list-disc list-inside space-y-1",children:[i.jsxs("li",{children:[i.jsx("strong",{children:"IVD kits sold to laboratories"})," (e.g., Oncomine Dx Target Test, TruSight Oncology Comprehensive)these require labs to purchase, validate, and run themselves"]}),i.jsxs("li",{children:[i.jsx("strong",{children:"Research-use-only (RUO) assays"})," not available for clinical ordering"]}),i.jsx("li",{children:i.jsx("strong",{children:"Tests no longer commercially available"})})]}),i.jsx("p",{children:"If you believe we're missing a test that should be included, please use the Submissions tab to let us know."})]})},{question:"How do you decide what information to include for each test?",answer:i.jsx("p",{children:"We prioritize publicly available, verifiable information from peer-reviewed publications, FDA submissions, company websites, and clinical guidelines (like NCCN). Every data point includes citations so you can verify the source. We focus on information most relevant to test selection: performance metrics (sensitivity, specificity, LOD), regulatory status, turnaround time, sample requirements, cancer types covered, and reimbursement status."})},{question:"How often is the database updated?",answer:i.jsx("p",{children:'We update the database regularly as new tests launch, FDA approvals occur, or performance data is published. The build date shown on the Data Download page indicates when the current version was deployed. You can also check the "Recently Added" section on the home page to see the latest additions.'})},{question:"What does it mean when a test is 'NCCN Recommended'?",answer:i.jsx("p",{children:`This indicates that the test covers biomarkers recommended in NCCN (National Comprehensive Cancer Network) clinical guidelines for the relevant cancer type(s). It's important to note that NCCN recommends testing for specific biomarkers but does not endorse specific commercial assays by name. A test marked as "NCCN Recommended" means it can detect the biomarkers that NCCN guidelines say should be testednot that NCCN has specifically endorsed that particular test.`})},{question:"What's the difference between FDA-approved and LDT tests?",answer:i.jsxs("div",{className:"space-y-3",children:[i.jsxs("p",{children:[i.jsx("strong",{children:"FDA-approved/cleared tests"})," have been reviewed by the FDA and meet specific analytical and clinical validation requirements. They often have companion diagnostic (CDx) claims linking test results to specific therapies."]}),i.jsxs("p",{children:[i.jsx("strong",{children:"Laboratory-developed tests (LDTs)"})," are developed and validated by individual CLIA-certified laboratories. While they must meet CLIA quality standards, they haven't undergone FDA premarket review. Many high-quality tests are LDTsFDA approval status alone doesn't determine clinical utility."]})]})},{question:"How should I interpret sensitivity and specificity numbers?",answer:i.jsxs("div",{className:"space-y-3",children:[i.jsxs("p",{children:[i.jsx("strong",{children:"Sensitivity"})," measures how well a test detects disease when it's present (true positive rate). A 90% sensitivity means the test correctly identifies 90% of people who have the condition."]}),i.jsxs("p",{children:[i.jsx("strong",{children:"Specificity"})," measures how well a test correctly identifies people without disease (true negative rate). A 99% specificity means only 1% of healthy people will get a false positive."]}),i.jsx("p",{children:"Important: These numbers can vary significantly based on the patient population, cancer stage, and how the study was conducted. Always look at the context and study population when comparing tests."})]})},{question:"Is OpenOnco affiliated with any test vendors?",answer:i.jsx("p",{children:"No. OpenOnco is an independent resource with no financial relationships with test vendors. We don't accept advertising or sponsorship. Our goal is to provide unbiased, transparent information to help patients and clinicians make informed decisions."})},{question:"How does the AI chat feature work, and can I trust its answers?",answer:i.jsxs("div",{className:"space-y-3",children:[i.jsxs("p",{children:["Our chat feature is powered by Anthropic's Claude AI. We've designed it to ",i.jsx("strong",{children:"only reference information from our test database"}),"it cannot browse the internet or access external sources during your conversation. This means Claude's answers are grounded in the same curated, cited data you see throughout OpenOnco."]}),i.jsxs("p",{children:["However, ",i.jsx("strong",{children:"AI language models can still make mistakes"}),". They may occasionally misinterpret questions, make errors in reasoning, or present information in misleading ways. This is a limitation of current AI technology, not specific to our implementation."]}),i.jsx("p",{children:i.jsx("strong",{children:"We strongly recommend:"})}),i.jsxs("ul",{className:"list-disc list-inside space-y-1",children:[i.jsx("li",{children:"Cross-checking any important information with vendor websites and official product documentation"}),i.jsx("li",{children:"Verifying clinical claims with peer-reviewed publications (we provide citations throughout the database)"}),i.jsx("li",{children:"If you're a patient, discussing test options with your doctor or healthcare provider before making decisions"})]}),i.jsx("p",{children:"The chat is best used as a starting point for explorationnot as a definitive source for clinical decision-making."})]})},{question:"Can I download the data?",answer:i.jsx("p",{children:"Yes! Visit the Data Download tab to download the complete database in JSON format. The data is freely available for research, clinical decision support, or other non-commercial purposes."})},{question:"How can I report an error or suggest a correction?",answer:i.jsx("p",{children:'Please use the Submissions tab and select "Request Changes to Test Data." Include the specific test name, the field that needs correction, and ideally a citation for the correct information. We take data accuracy seriously and will review all submissions.'})},{question:"What's the difference between the Patient and Clinician views?",answer:i.jsx("p",{children:"The Patient view simplifies information and focuses on practical questions: What does this test do? Is it covered by insurance? What's involved in getting tested? The Clinician and Academic/Industry views show more detailed technical information including performance metrics, FDA status, methodology details, and clinical validation data."})},{question:"How do I contact OpenOnco?",answer:i.jsx("p",{children:"The best way to reach us is through the Submissions tab. Select the appropriate category for your inquirywhether it's suggesting a new test, requesting data corrections, or providing general feedback. We review all submissions and will respond if needed."})},{question:"What is the Openness Score?",answer:i.jsxs("div",{className:"space-y-4",children:[i.jsx("p",{children:"The OpenOnco Openness Score measures how completely vendors disclose key information about their tests. It rewards vendors who publish pricing, performance data, and clinical evidenceinformation that helps patients and clinicians make informed decisions. Vendors are ranked by their average score across all tests."}),i.jsx("p",{className:"font-medium text-gray-800",children:"How is it calculated?"}),i.jsx("p",{children:"Each test is scored based on disclosure of key fields (weights sum to 100):"}),i.jsx("div",{className:"overflow-x-auto",children:i.jsxs("table",{className:"w-full text-sm border-collapse",children:[i.jsx("thead",{children:i.jsxs("tr",{className:"bg-gray-100",children:[i.jsx("th",{className:"text-left py-2 px-3 font-semibold text-gray-700 border-b",children:"Field"}),i.jsx("th",{className:"text-center py-2 px-3 font-semibold text-gray-700 border-b",children:"Weight"}),i.jsx("th",{className:"text-left py-2 px-3 font-semibold text-gray-700 border-b",children:"Rationale"})]})}),i.jsxs("tbody",{className:"text-gray-600",children:[i.jsxs("tr",{className:"border-b",children:[i.jsx("td",{className:"py-2 px-3 font-medium",children:"Price"}),i.jsx("td",{className:"text-center py-2 px-3 font-bold text-amber-600",children:"30%"}),i.jsx("td",{className:"py-2 px-3",children:"Hardest to find, gold standard of openness"})]}),i.jsxs("tr",{className:"border-b bg-gray-50",children:[i.jsx("td",{className:"py-2 px-3 font-medium",children:"Publications"}),i.jsx("td",{className:"text-center py-2 px-3 font-bold text-amber-600",children:"15%"}),i.jsx("td",{className:"py-2 px-3",children:"Peer-reviewed evidence base"})]}),i.jsxs("tr",{className:"border-b",children:[i.jsx("td",{className:"py-2 px-3 font-medium",children:"Turnaround Time"}),i.jsx("td",{className:"text-center py-2 px-3 font-bold text-amber-600",children:"10%"}),i.jsx("td",{className:"py-2 px-3",children:"Practical info for clinicians"})]}),i.jsxs("tr",{className:"border-b bg-gray-50",children:[i.jsx("td",{className:"py-2 px-3 font-medium",children:"Sample Info"}),i.jsx("td",{className:"text-center py-2 px-3 font-bold text-amber-600",children:"10%"}),i.jsx("td",{className:"py-2 px-3",children:"Blood volume, sample type, or category"})]}),i.jsxs("tr",{className:"border-b",children:[i.jsx("td",{className:"py-2 px-3 font-medium",children:"Trial Participants"}),i.jsx("td",{className:"text-center py-2 px-3 font-bold text-amber-600",children:"5%"}),i.jsx("td",{className:"py-2 px-3",children:"Clinical evidence depth"})]}),i.jsx("tr",{className:"border-b bg-blue-50",children:i.jsx("td",{className:"py-2 px-3 font-medium italic",colSpan:"3",children:"+ Category-Specific Metrics (30%)"})}),i.jsxs("tr",{className:"border-b bg-gray-50",children:[i.jsx("td",{className:"py-2 px-3 pl-6 text-xs",children:"ECD (Screening)"}),i.jsx("td",{className:"text-center py-2 px-3 text-xs",children:"30%"}),i.jsx("td",{className:"py-2 px-3 text-xs",children:"Sensitivity + Specificity (cancer detection)"})]}),i.jsxs("tr",{className:"border-b",children:[i.jsx("td",{className:"py-2 px-3 pl-6 text-xs",children:"MRD"}),i.jsx("td",{className:"text-center py-2 px-3 text-xs",children:"30%"}),i.jsx("td",{className:"py-2 px-3 text-xs",children:"LOD (limit of detection)"})]}),i.jsxs("tr",{className:"border-b bg-gray-50",children:[i.jsx("td",{className:"py-2 px-3 pl-6 text-xs",children:"TRM"}),i.jsx("td",{className:"text-center py-2 px-3 text-xs",children:"30%"}),i.jsx("td",{className:"py-2 px-3 text-xs",children:"Sensitivity + Specificity (mutation detection)"})]}),i.jsxs("tr",{className:"border-b",children:[i.jsx("td",{className:"py-2 px-3 pl-6 text-xs",children:"TDS (CGP)"}),i.jsx("td",{className:"text-center py-2 px-3 text-xs",children:"30%"}),i.jsx("td",{className:"py-2 px-3 text-xs",children:"Genes Analyzed + CDx Claims"})]})]}),i.jsx("tfoot",{children:i.jsxs("tr",{className:"bg-amber-50 border-t-2 border-amber-200",children:[i.jsx("td",{className:"py-2 px-3 font-bold",children:"Total"}),i.jsx("td",{className:"text-center py-2 px-3 font-bold text-amber-700",children:"100%"}),i.jsx("td",{className:"py-2 px-3"})]})})]})}),i.jsx("p",{className:"font-medium text-gray-800 mt-4",children:"Why category-normalized scoring?"}),i.jsx("p",{children:`Different test categories have different "standard" metrics. CGP tests don't report sensitivity/specificity like screening tests do  they report panel size and companion diagnostic claims. MRD tests focus on limit of detection. By normalizing per-category, we compare apples to apples.`}),i.jsx("p",{className:"font-medium text-gray-800 mt-4",children:"Who is eligible for ranking?"}),i.jsxs("p",{children:["Vendors must have ",i.jsx("strong",{children:"2 or more tests"})," in the OpenOnco database to qualify. The vendor's score is the ",i.jsx("strong",{children:"average"})," across all their tests. This prevents a single well-documented test from dominating while encouraging comprehensive disclosure across product portfolios."]}),i.jsx("p",{className:"font-medium text-gray-800 mt-4",children:"Why these weights?"}),i.jsxs("p",{children:[i.jsx("strong",{children:"Price (30%)"})," is weighted highest because it's the most commonly withheld information and critically important for patients and healthcare systems. ",i.jsx("strong",{children:"Category-specific metrics (30%)"})," are essential for clinical decision-making but vary by test type. ",i.jsx("strong",{children:"Publications (15%)"})," demonstrate commitment to independent validation. Practical details like ",i.jsx("strong",{children:"TAT and sample requirements (15% combined)"})," help with care coordination."]}),i.jsx("p",{className:"font-medium text-gray-800 mt-4",children:"How can vendors improve their score?"}),i.jsx("p",{children:"Publish your list price, disclose the key performance metrics for your test category, maintain an active publication record, and provide clear sample requirements. Vendors can submit updated information through our Submissions page."})]})}];return i.jsxs("div",{className:"max-w-3xl mx-auto px-6 py-16",children:[i.jsx("h1",{className:"text-3xl font-bold text-gray-900 mb-4",children:"Frequently Asked Questions"}),i.jsx("p",{className:"text-gray-600 mb-8",children:"Common questions about OpenOnco, our data, and how to use the platform."}),i.jsx("div",{className:"bg-white rounded-xl shadow-sm border border-gray-200 divide-y divide-gray-200",children:a.map((n,s)=>i.jsx(Of,{question:n.question,answer:n.answer,isOpen:e===s,onClick:()=>t(e===s?null:s)},s))}),i.jsx("div",{className:"hidden md:block mt-8",children:i.jsx(Ef,{})}),i.jsx("div",{className:"hidden md:block mt-6",children:i.jsx(Wo,{})})]})},Vf=()=>i.jsxs("div",{className:"max-w-3xl mx-auto px-6 py-16",children:[i.jsx("h1",{className:"text-3xl font-bold text-gray-900 mb-8",children:"About"}),i.jsxs("div",{className:"prose prose-lg text-gray-700 space-y-6",children:[i.jsxs("p",{children:["Hi, my name is ",i.jsx("a",{href:"https://www.linkedin.com/in/alexgdickinson/",target:"_blank",rel:"noopener noreferrer",className:"text-emerald-600 hover:text-emerald-700 underline",children:"Alex Dickinson"}),". Like many of you, my friends and family have been impacted by cancer throughout my life. Most significantly for me, my sister Ingrid died from a brain tumor when she was eleven and I was sevenyou can see us together in the photo below."]}),i.jsx("p",{children:"Professionally I've had the good fortune to stumble into the amazing world of cancer diagnosticsthe people, companies, and technologies. Along the way I've become convinced that the emerging new generation of molecular cancer tests (largely enabled by next-generation sequencing) will have an extraordinary impact on cancer detection and treatment."}),i.jsx("p",{children:"Because these tests detect biomolecular events at tiny concentrationsnow approaching one in a billionthis is a very complex field, and test data and options can overwhelm doctors and patients alike. This confusion will only increase as the number of tests rapidly expands due to both advances in the technology and the decision to maintain a low level of test regulation in the US."}),i.jsx("p",{children:"OpenOnco is an effort to collect, curate, and explain to both patients and their doctors all the data on all these tests."}),i.jsx("p",{children:"OpenOnco is a non-profit that I am self-funding in memory of my sister Ingrid."})]}),i.jsx("div",{className:"mt-12 flex justify-center",children:i.jsx("img",{src:"/IngridandAlex.jpeg",alt:"Ingrid and Alex",className:"rounded-xl shadow-lg max-w-md w-full"})})]}),qf=()=>i.jsxs("div",{className:"max-w-3xl mx-auto px-6 py-16",children:[i.jsx("h1",{className:"text-3xl font-bold text-gray-900 mb-8",children:"How It Works"}),i.jsxs("div",{className:"prose prose-lg text-gray-700 space-y-6",children:[i.jsx("h2",{className:"text-2xl font-bold text-gray-900",children:"OpenOnco is Open"}),i.jsx("p",{children:"The OpenOnco database is assembled from a wide variety of public sources including vendor databases, peer reviewed publications, and clinical trial registries. Sources are cited to the best of our ability along with context and notes on possible contradictory data and its resolution. Information on the database update process can be found below in the Technical Information section."}),i.jsxs("p",{children:["The current version of the OpenOnco database is available for anyone to download in several formats - go to the ",i.jsx("strong",{children:"Data Download"})," tab. Go to the ",i.jsx("strong",{children:"Submissions"})," tab to tell us about a new test, request changes to test data, and send us bug reports and feature suggestions. You can also see our log of all data changes on the site."]}),i.jsx("h2",{className:"text-2xl font-bold text-gray-900 mt-10",children:"Technical Information"}),i.jsxs("p",{className:"mt-4",children:["OpenOnco is vibe-coded in React using Opus 4.5. The test database is hardcoded as a JSON structure inside the app. The app (and embedded database) are updated as-needed when new data or tools are added. You can find the build date of the version you are running under the ",i.jsx("strong",{children:"Data Download"})," tab. Data for each build is cross-checked by GPT Pro 5.1, Gemini 3, and Opus 4.5. Once the models have beaten each other into submission, the new code is committed to GitHub and deployed on Vercel."]})]})]}),Uf=()=>{var st,Ni;const[e,t]=A.useState(""),[a,n]=A.useState(""),[s,r]=A.useState(""),[o,l]=A.useState(""),[d,u]=A.useState(""),[g,p]=A.useState(""),[y,x]=A.useState(""),[w,b]=A.useState(!1),[j,m]=A.useState(""),[c,h]=A.useState(""),[C,P]=A.useState(""),[R,v]=A.useState(""),[N,F]=A.useState(""),[I,q]=A.useState(""),[be,re]=A.useState(""),[Ce,Me]=A.useState(""),[We,fe]=A.useState(""),[f,k]=A.useState("form"),[D,L]=A.useState(""),[O,V]=A.useState(""),[U,ee]=A.useState(!1),[ae,he]=A.useState(!1),[nt,Ae]=A.useState(""),[na,Se]=A.useState(!1),[xi,bi]=A.useState(""),ii={MRD:z.map(S=>({id:S.id,name:S.name,vendor:S.vendor})),ECD:Y.map(S=>({id:S.id,name:S.name,vendor:S.vendor})),TRM:K.map(S=>({id:S.id,name:S.name,vendor:S.vendor})),TDS:X.map(S=>({id:S.id,name:S.name,vendor:S.vendor}))},sa={MRD:[{key:"sensitivity",label:"Sensitivity (%)"},{key:"specificity",label:"Specificity (%)"},{key:"analyticalSpecificity",label:"Analytical Specificity (%)"},{key:"clinicalSpecificity",label:"Clinical Specificity (%)"},{key:"lod",label:"LOD (Detection Threshold)"},{key:"lod95",label:"LOD95 (95% Confidence)"},{key:"variantsTracked",label:"Variants Tracked"},{key:"initialTat",label:"Initial Turnaround Time (days)"},{key:"followUpTat",label:"Follow-up Turnaround Time (days)"},{key:"bloodVolume",label:"Blood Volume (mL)"},{key:"cfdnaInput",label:"cfDNA Input (ng)"},{key:"fdaStatus",label:"FDA Status"},{key:"reimbursement",label:"Reimbursement Status"},{key:"cptCodes",label:"CPT Codes"},{key:"clinicalTrials",label:"Clinical Trials"},{key:"totalParticipants",label:"Total Trial Participants"},{key:"numPublications",label:"Number of Publications"},{key:"other",label:"Other (specify in notes)"}],ECD:[{key:"sensitivity",label:"Overall Sensitivity (%)"},{key:"stageISensitivity",label:"Stage I Sensitivity (%)"},{key:"stageIISensitivity",label:"Stage II Sensitivity (%)"},{key:"stageIIISensitivity",label:"Stage III Sensitivity (%)"},{key:"specificity",label:"Specificity (%)"},{key:"ppv",label:"Positive Predictive Value (%)"},{key:"npv",label:"Negative Predictive Value (%)"},{key:"tat",label:"Turnaround Time (days)"},{key:"listPrice",label:"List Price ($)"},{key:"fdaStatus",label:"FDA Status"},{key:"reimbursement",label:"Reimbursement Status"},{key:"screeningInterval",label:"Screening Interval"},{key:"clinicalTrials",label:"Clinical Trials"},{key:"totalParticipants",label:"Total Trial Participants"},{key:"numPublications",label:"Number of Publications"},{key:"other",label:"Other (specify in notes)"}],TRM:[{key:"sensitivity",label:"Sensitivity (%)"},{key:"specificity",label:"Specificity (%)"},{key:"lod",label:"LOD (Detection Threshold)"},{key:"lod95",label:"LOD95 (95% Confidence)"},{key:"leadTimeVsImaging",label:"Lead Time vs Imaging (days)"},{key:"fdaStatus",label:"FDA Status"},{key:"reimbursement",label:"Reimbursement Status"},{key:"clinicalTrials",label:"Clinical Trials"},{key:"totalParticipants",label:"Total Trial Participants"},{key:"numPublications",label:"Number of Publications"},{key:"other",label:"Other (specify in notes)"}],TDS:[{key:"genesAnalyzed",label:"Genes Analyzed"},{key:"biomarkersReported",label:"Biomarkers Reported"},{key:"fdaCompanionDxCount",label:"FDA CDx Indications"},{key:"tat",label:"Turnaround Time"},{key:"sampleRequirements",label:"Sample Requirements"},{key:"fdaStatus",label:"FDA Status"},{key:"reimbursement",label:"Reimbursement Status"},{key:"listPrice",label:"List Price ($)"},{key:"numPublications",label:"Number of Publications"},{key:"other",label:"Other (specify in notes)"}]},Ci=()=>{if(!N||!I||!s)return"";const _=(s==="MRD"?z:s==="ECD"?Y:s==="TRM"?K:X).find(Ie=>Ie.id===N);if(!_||I==="other")return"";const Q=_[I];return Q!=null?String(Q):"Not specified"},Et=()=>{if(!N||!s)return"";const _=(s==="MRD"?z:s==="ECD"?Y:s==="TRM"?K:X).find(Q=>Q.id===N);return(_==null?void 0:_.vendor)||""},Cs=S=>/^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(S),ws=S=>{var Ie;const _=["gmail.com","yahoo.com","hotmail.com","outlook.com","aol.com","icloud.com","mail.com","protonmail.com","live.com","msn.com"],Q=(Ie=S.split("@")[1])==null?void 0:Ie.toLowerCase();return _.includes(Q)},Ns=(S,_)=>{var ht;if(!S||!_)return!1;const Q=((ht=S.split("@")[1])==null?void 0:ht.toLowerCase())||"",Ie=_.toLowerCase().replace(/[^a-z0-9]/g,"");return Q.replace(/[^a-z0-9]/g,"").includes(Ie)},ra=()=>{if(!Cs(g))return x("Please enter a valid email address"),!1;if(ws(g))return x("Please use a company/institutional email (not Gmail, Yahoo, etc.)"),!1;if(a==="vendor"&&(e==="new"||e==="correction")){const S=e==="new"?c:Et();if(!Ns(g,S))return x(`For vendor submissions, email domain must contain "${S||"vendor name"}"`),!1}return x(""),!0},Nt=async()=>{var Q,Ie;if(!ra())return;ee(!0),Ae("");let S="OpenOnco",_=e==="bug"?"Bug Report":e==="feature"?"Feature Request":"";e==="new"?(S=c,_=j):e==="correction"&&(S=Et(),_=(Ie=(Q=ii[s])==null?void 0:Q.find(rt=>rt.id===N))==null?void 0:Ie.name);try{const rt=await fetch("/api/send-verification",{method:"POST",headers:{"Content-Type":"application/json"},body:JSON.stringify({email:g,vendor:S,testName:_})}),ht=await rt.json();rt.ok?(V(ht.token),k("verify")):Ae(ht.error||"Failed to send verification code")}catch{Ae("Network error. Please try again.")}ee(!1)},wi=async()=>{if(D.length!==6){Ae("Please enter the 6-digit code");return}he(!0),Ae("");try{const S=await fetch("/api/verify-code",{method:"POST",headers:{"Content-Type":"application/json"},body:JSON.stringify({token:O,code:D})}),_=await S.json();S.ok?k("verified"):Ae(_.error||"Verification failed")}catch{Ae("Network error. Please try again.")}he(!1)},As=async S=>{var Q,Ie,rt,ht;if(S.preventDefault(),f!=="verified"){x("Please verify your email first");return}Se(!0),bi("");let _={submissionType:e,submitter:{firstName:o,lastName:d,email:g},emailVerified:!0,timestamp:new Date().toISOString()};e==="bug"||e==="feature"?_.feedback={type:e==="bug"?"Bug Report":"Feature Request",description:We}:(_.submitterType=a,_.category=s,e==="new"?_.newTest={name:j,vendor:c,performanceUrl:C,additionalNotes:R}:e==="correction"&&(_.correction={testId:N,testName:(Ie=(Q=ii[s])==null?void 0:Q.find(gt=>gt.id===N))==null?void 0:Ie.name,vendor:Et(),parameter:I,parameterLabel:(ht=(rt=sa[s])==null?void 0:rt.find(gt=>gt.key===I))==null?void 0:ht.label,currentValue:Ci(),newValue:be,citation:Ce}));try{const gt=await fetch("/api/submit-form",{method:"POST",headers:{"Content-Type":"application/json"},body:JSON.stringify({submission:_})}),en=await gt.json();gt.ok?b(!0):bi(en.error||"Failed to submit. Please try again.")}catch{bi("Network error. Please try again.")}Se(!1)},H=()=>{t(""),n(""),r(""),l(""),u(""),p(""),x(""),b(!1),m(""),h(""),P(""),v(""),F(""),q(""),re(""),Me(""),fe(""),k("form"),L(""),V(""),Ae(""),Se(!1),bi("")};if(w)return i.jsx("div",{className:"max-w-3xl mx-auto px-6 py-16 text-center",children:i.jsxs("div",{className:"bg-emerald-50 rounded-2xl p-8 border border-emerald-200",children:[i.jsx("svg",{className:"w-16 h-16 text-emerald-500 mx-auto mb-4",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"})}),i.jsx("h2",{className:"text-2xl font-bold text-emerald-800 mb-2",children:"Request Submitted!"}),i.jsx("p",{className:"text-emerald-700 mb-6",children:"Your request has been submitted successfully. We'll review it and update our database soon. Thank you for contributing!"}),i.jsx("button",{onClick:H,className:"bg-emerald-600 text-white px-6 py-2 rounded-lg hover:bg-emerald-700 transition-colors",children:"Submit Another Request"})]})});const Za=()=>!e||!o||!d||!g?!1:e==="bug"||e==="feature"?We.trim().length>0:!a||!s?!1:e==="new"?j&&c&&C:e==="correction"?N&&I&&be&&Ce:!1;return i.jsxs("div",{className:"max-w-3xl mx-auto px-4 sm:px-6 py-8 sm:py-16",children:[i.jsx("h1",{className:"text-2xl sm:text-3xl font-bold text-gray-900 mb-2",children:"Submissions"}),i.jsx("p",{className:"text-gray-600 mb-8",children:"Help us improve OpenOnco with your feedback and data contributions."}),i.jsxs("form",{onSubmit:As,className:"space-y-6",children:[i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("label",{className:"block text-sm font-semibold text-gray-700 mb-3",children:"Test Data Update"}),i.jsxs("div",{className:"grid grid-cols-2 gap-4",children:[i.jsxs("button",{type:"button",onClick:()=>{t("new"),F(""),q(""),fe("")},className:`p-4 rounded-lg border-2 text-left transition-all ${e==="new"?"border-[#2A63A4] bg-blue-50":"border-gray-200 hover:border-gray-300"}`,children:[i.jsx("div",{className:"font-semibold text-gray-800",children:"Suggest a New Test"}),i.jsx("div",{className:"text-sm text-gray-500",children:"Notify us of a test not in our database"})]}),i.jsxs("button",{type:"button",onClick:()=>{t("correction"),m(""),h(""),P(""),fe("")},className:`p-4 rounded-lg border-2 text-left transition-all ${e==="correction"?"border-[#2A63A4] bg-blue-50":"border-gray-200 hover:border-gray-300"}`,children:[i.jsx("div",{className:"font-semibold text-gray-800",children:"File a Correction"}),i.jsx("div",{className:"text-sm text-gray-500",children:"Suggest an update to existing test data"})]})]}),i.jsx("label",{className:"block text-sm font-semibold text-gray-700 mt-6 mb-3",children:"Bug Reports & Feature Requests"}),i.jsxs("div",{className:"grid grid-cols-2 gap-4",children:[i.jsxs("button",{type:"button",onClick:()=>{t("bug"),n(""),r(""),m(""),h(""),F("")},className:`p-4 rounded-lg border-2 text-left transition-all ${e==="bug"?"border-red-500 bg-red-50":"border-gray-200 hover:border-gray-300"}`,children:[i.jsx("div",{className:`font-semibold ${e==="bug"?"text-red-700":"text-gray-800"}`,children:"Report a Bug"}),i.jsx("div",{className:"text-sm text-gray-500",children:"Something isn't working correctly"})]}),i.jsxs("button",{type:"button",onClick:()=>{t("feature"),n(""),r(""),m(""),h(""),F("")},className:`p-4 rounded-lg border-2 text-left transition-all ${e==="feature"?"border-purple-500 bg-purple-50":"border-gray-200 hover:border-gray-300"}`,children:[i.jsx("div",{className:`font-semibold ${e==="feature"?"text-purple-700":"text-gray-800"}`,children:"Request a Feature"}),i.jsx("div",{className:"text-sm text-gray-500",children:"Suggest an improvement or new capability"})]})]})]}),(e==="new"||e==="correction")&&i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("label",{className:"block text-sm font-semibold text-gray-700 mb-3",children:"I am submitting as a..."}),i.jsxs("select",{value:a,onChange:S=>{n(S.target.value),x(""),k("form")},className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",children:[i.jsx("option",{value:"",children:"-- Select --"}),i.jsx("option",{value:"vendor",children:"Test Vendor Representative"}),i.jsx("option",{value:"expert",children:"Independent Expert / Researcher"})]}),a==="vendor"&&i.jsx("p",{className:"text-sm text-amber-600 mt-2",children:" We will verify that your email comes from the vendor's domain"}),a==="expert"&&i.jsx("p",{className:"text-sm text-gray-500 mt-2",children:"Expert submissions require a company or institutional email"})]}),a&&i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("label",{className:"block text-sm font-semibold text-gray-700 mb-3",children:"Test Category"}),i.jsx("div",{className:"grid grid-cols-2 sm:grid-cols-4 gap-3",children:[{key:"MRD",label:"MRD",desc:"Minimal Residual Disease",color:"orange"},{key:"ECD",label:"ECD",desc:"Early Cancer Detection",color:"emerald"},{key:"TRM",label:"TRM",desc:"Treatment Response",color:"sky"},{key:"TDS",label:"TDS",desc:"Treatment Decisions",color:"violet"}].map(S=>i.jsxs("button",{type:"button",onClick:()=>{r(S.key),F(""),q("")},className:`p-3 rounded-lg border-2 text-center transition-all ${s===S.key?`border-${S.color}-500 bg-${S.color}-50`:"border-gray-200 hover:border-gray-300"}`,children:[i.jsx("div",{className:`font-bold ${s===S.key?`text-${S.color}-700`:"text-gray-800"}`,children:S.label}),i.jsx("div",{className:"text-xs text-gray-500",children:S.desc})]},S.key))})]}),e==="new"&&s&&i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("h3",{className:"text-lg font-semibold text-gray-800 mb-4",children:"New Test Request"}),i.jsxs("div",{className:"space-y-4",children:[i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Test Name ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"text",value:j,onChange:S=>m(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",placeholder:"e.g., Signatera, Galleri, etc.",required:!0})]}),i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Vendor/Company ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"text",value:c,onChange:S=>{h(S.target.value),x(""),k("form")},className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",placeholder:"e.g., Natera, GRAIL, etc.",required:!0})]}),i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["URL with Test Performance Data ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"url",value:C,onChange:S=>P(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",placeholder:"https://...",required:!0}),i.jsx("p",{className:"text-sm text-gray-500 mt-1",children:"Link to publication, vendor page, or FDA approval with performance data"})]}),i.jsxs("div",{children:[i.jsx("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:"Additional Notes"}),i.jsx("textarea",{value:R,onChange:S=>v(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",rows:3,placeholder:"Any additional context about this test..."})]})]})]}),e==="correction"&&s&&i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("h3",{className:"text-lg font-semibold text-gray-800 mb-4",children:"Correction Request"}),i.jsxs("div",{className:"space-y-4",children:[i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Select Test ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsxs("select",{value:N,onChange:S=>{F(S.target.value),q(""),re(""),x(""),k("form")},className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",required:!0,children:[i.jsx("option",{value:"",children:"-- Select a test --"}),(st=ii[s])==null?void 0:st.map(S=>i.jsxs("option",{value:S.id,children:[S.name," (",S.vendor,")"]},S.id))]})]}),N&&i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Parameter to Correct ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsxs("select",{value:I,onChange:S=>{q(S.target.value),re("")},className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",required:!0,children:[i.jsx("option",{value:"",children:"-- Select parameter --"}),(Ni=sa[s])==null?void 0:Ni.map(S=>i.jsx("option",{value:S.key,children:S.label},S.key))]})]}),I&&i.jsxs(i.Fragment,{children:[I!=="other"&&i.jsxs("div",{className:"bg-gray-50 rounded-lg p-3",children:[i.jsx("span",{className:"text-sm text-gray-500",children:"Current value: "}),i.jsx("span",{className:"text-sm font-medium text-gray-800",children:Ci()})]}),i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:[I==="other"?"Describe the correction":"New Value"," ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"text",value:be,onChange:S=>re(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",placeholder:I==="other"?"Describe the parameter and new value...":"Enter the correct value",required:!0})]}),i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Citation/Source URL ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"url",value:Ce,onChange:S=>Me(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",placeholder:"https://...",required:!0}),i.jsx("p",{className:"text-sm text-gray-500 mt-1",children:"Link to publication or source supporting this value"})]})]})]})]}),(e==="bug"||e==="feature")&&i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("h3",{className:`text-lg font-semibold mb-4 ${e==="bug"?"text-red-700":"text-purple-700"}`,children:e==="bug"?"Bug Report":"Feature Request"}),i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:[e==="bug"?"Describe the bug":"Describe your feature idea"," ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("textarea",{value:We,onChange:S=>fe(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",rows:6,placeholder:e==="bug"?"Please describe what happened, what you expected to happen, and steps to reproduce the issue...":"Please describe the feature you would like to see and how it would help you...",required:!0})]})]}),(e==="bug"||e==="feature")&&We&&i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("h3",{className:"text-lg font-semibold text-gray-800 mb-4",children:"Your Information"}),i.jsxs("div",{className:"grid grid-cols-2 gap-4 mb-4",children:[i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["First Name ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"text",value:o,onChange:S=>l(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",required:!0})]}),i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Last Name ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"text",value:d,onChange:S=>u(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",required:!0})]})]}),f==="form"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Work Email ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsxs("div",{className:"flex gap-2",children:[i.jsx("input",{type:"email",value:g,onChange:S=>{p(S.target.value),x("")},className:`flex-1 border rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4] ${y?"border-red-500":"border-gray-300"}`,placeholder:"you@company.com"}),i.jsx("button",{type:"button",onClick:Nt,disabled:U||!g||!o||!d,className:"bg-[#2A63A4] text-white px-4 py-2 rounded-lg hover:bg-[#1E4A7A] disabled:opacity-50 disabled:cursor-not-allowed transition-colors whitespace-nowrap",children:U?"Sending...":"Send Code"})]}),y&&i.jsx("p",{className:"text-red-500 text-sm mt-1",children:y}),nt&&i.jsx("p",{className:"text-red-500 text-sm mt-1",children:nt}),i.jsx("p",{className:"text-sm text-gray-500 mt-2",children:"Company or institutional email required (not Gmail, Yahoo, etc.)"})]}),f==="verify"&&i.jsxs(i.Fragment,{children:[i.jsx("div",{className:"bg-blue-50 border border-blue-200 rounded-lg p-4 mb-4",children:i.jsxs("p",{className:"text-blue-800",children:["A verification code has been sent to ",i.jsx("strong",{children:g})]})}),i.jsx("label",{className:"block text-sm font-medium text-gray-600 mb-2",children:"Enter 6-digit code"}),i.jsxs("div",{className:"flex gap-2",children:[i.jsx("input",{type:"text",value:D,onChange:S=>L(S.target.value.replace(/\D/g,"").slice(0,6)),className:"flex-1 border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4] text-center text-2xl tracking-widest",placeholder:"     ",maxLength:6}),i.jsx("button",{type:"button",onClick:wi,disabled:ae||D.length!==6,className:"bg-emerald-600 text-white px-4 py-2 rounded-lg hover:bg-emerald-700 disabled:opacity-50 disabled:cursor-not-allowed transition-colors",children:ae?"Verifying...":"Verify"})]}),nt&&i.jsx("p",{className:"text-red-500 text-sm mt-2",children:nt}),i.jsx("button",{type:"button",onClick:()=>{k("form"),L(""),Ae(""),V("")},className:"text-[#2A63A4] text-sm mt-2 hover:underline",children:" Use a different email"}),i.jsxs("p",{className:"text-gray-500 text-xs mt-3",children:["Code not arriving? Corporate firewalls sometimes block verification emails."," ",i.jsx("a",{href:"https://www.linkedin.com/in/alexgdickinson/",target:"_blank",rel:"noopener noreferrer",className:"text-[#2A63A4] hover:underline",children:"DM Alex on LinkedIn"})," ","to submit directly."]})]}),f==="verified"&&i.jsxs("div",{className:"bg-emerald-50 border border-emerald-200 rounded-lg p-4 flex items-center gap-3",children:[i.jsx("svg",{className:"w-6 h-6 text-emerald-600 flex-shrink-0",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"})}),i.jsxs("div",{children:[i.jsx("p",{className:"text-emerald-800 font-medium",children:"Email Verified!"}),i.jsx("p",{className:"text-emerald-700 text-sm",children:g})]})]})]}),s&&(e==="new"?j&&c:N&&I)&&i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 p-6",children:[i.jsx("h3",{className:"text-lg font-semibold text-gray-800 mb-4",children:"Your Information"}),i.jsxs("div",{className:"grid grid-cols-2 gap-4 mb-4",children:[i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["First Name ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"text",value:o,onChange:S=>l(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",required:!0})]}),i.jsxs("div",{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Last Name ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsx("input",{type:"text",value:d,onChange:S=>u(S.target.value),className:"w-full border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4]",required:!0})]})]}),f==="form"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"block text-sm font-medium text-gray-600 mb-1",children:["Work Email ",i.jsx("span",{className:"text-red-500",children:"*"})]}),i.jsxs("div",{className:"flex gap-2",children:[i.jsx("input",{type:"email",value:g,onChange:S=>{p(S.target.value),x("")},className:`flex-1 border rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4] ${y?"border-red-500":"border-gray-300"}`,placeholder:a==="vendor"?`you@${(e==="new"?c:Et()).toLowerCase().replace(/[^a-z]/g,"")}...`:"you@company.com"}),i.jsx("button",{type:"button",onClick:Nt,disabled:U||!g||!o||!d,className:"bg-[#2A63A4] text-white px-4 py-2 rounded-lg hover:bg-[#1E4A7A] disabled:opacity-50 disabled:cursor-not-allowed transition-colors whitespace-nowrap",children:U?"Sending...":"Send Code"})]}),y&&i.jsx("p",{className:"text-red-500 text-sm mt-1",children:y}),nt&&i.jsx("p",{className:"text-red-500 text-sm mt-1",children:nt})]}),f==="verify"&&i.jsxs(i.Fragment,{children:[i.jsx("div",{className:"bg-blue-50 border border-blue-200 rounded-lg p-4 mb-4",children:i.jsxs("p",{className:"text-blue-800",children:["A verification code has been sent to ",i.jsx("strong",{children:g})]})}),i.jsx("label",{className:"block text-sm font-medium text-gray-600 mb-2",children:"Enter 6-digit code"}),i.jsxs("div",{className:"flex gap-2",children:[i.jsx("input",{type:"text",value:D,onChange:S=>L(S.target.value.replace(/\D/g,"").slice(0,6)),className:"flex-1 border border-gray-300 rounded-lg px-4 py-2 focus:outline-none focus:ring-2 focus:ring-[#2A63A4] text-center text-2xl tracking-widest",placeholder:"     ",maxLength:6}),i.jsx("button",{type:"button",onClick:wi,disabled:ae||D.length!==6,className:"bg-emerald-600 text-white px-4 py-2 rounded-lg hover:bg-emerald-700 disabled:opacity-50 disabled:cursor-not-allowed transition-colors",children:ae?"Verifying...":"Verify"})]}),nt&&i.jsx("p",{className:"text-red-500 text-sm mt-2",children:nt}),i.jsx("button",{type:"button",onClick:()=>{k("form"),L(""),Ae(""),V("")},className:"text-[#2A63A4] text-sm mt-2 hover:underline",children:" Use a different email"}),i.jsxs("p",{className:"text-gray-500 text-xs mt-3",children:["Code not arriving? Corporate firewalls sometimes block verification emails."," ",i.jsx("a",{href:"https://www.linkedin.com/in/alexgdickinson/",target:"_blank",rel:"noopener noreferrer",className:"text-[#2A63A4] hover:underline",children:"DM Alex on LinkedIn"})," ","to submit directly."]})]}),f==="verified"&&i.jsxs("div",{className:"bg-emerald-50 border border-emerald-200 rounded-lg p-4 flex items-center gap-3",children:[i.jsx("svg",{className:"w-6 h-6 text-emerald-600 flex-shrink-0",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"})}),i.jsxs("div",{children:[i.jsx("p",{className:"text-emerald-800 font-medium",children:"Email Verified!"}),i.jsx("p",{className:"text-emerald-700 text-sm",children:g})]})]})]}),Za()&&i.jsxs(i.Fragment,{children:[xi&&i.jsx("div",{className:"bg-red-50 border border-red-200 rounded-lg p-4 text-red-700",children:xi}),i.jsx("button",{type:"submit",disabled:f!=="verified"||na,className:"w-full text-white px-8 py-4 rounded-xl font-semibold transition-all text-lg shadow-md hover:opacity-90 disabled:opacity-50 disabled:cursor-not-allowed",style:{background:"linear-gradient(to right, #2A63A4, #1E4A7A)"},children:na?"Submitting...":f!=="verified"?"Verify Email to Submit Request":"Submit Request"})]})]}),i.jsxs("div",{className:"mt-12 pt-8 border-t border-gray-200",children:[i.jsx("h2",{className:"text-2xl sm:text-3xl font-bold text-gray-900 mb-2",children:"Database Changelog"}),i.jsx("p",{className:"text-gray-600 mb-6",children:"Recent updates to the OpenOnco test database, including community contributions."}),i.jsx("div",{className:"bg-white rounded-xl border border-gray-200 overflow-hidden",children:i.jsx("div",{className:"max-h-96 overflow-y-auto",children:Pa.map((S,_)=>i.jsxs("div",{className:`p-4 flex items-start gap-4 ${_!==Pa.length-1?"border-b border-gray-100":""}`,children:[i.jsx("div",{className:"flex-shrink-0 w-8 text-right",children:i.jsxs("span",{className:"text-sm font-mono text-gray-400",children:["#",Pa.length-_]})}),i.jsx("div",{className:`flex-shrink-0 w-8 h-8 rounded-full flex items-center justify-center text-sm font-bold ${S.type==="added"?"bg-emerald-100 text-emerald-700":S.type==="updated"?"bg-blue-100 text-blue-700":S.type==="feature"?"bg-purple-100 text-purple-700":"bg-red-100 text-red-700"}`,children:S.type==="added"?"+":S.type==="updated"?"":S.type==="feature"?"":""}),i.jsxs("div",{className:"flex-1 min-w-0",children:[i.jsxs("div",{className:"flex items-center gap-2 flex-wrap",children:[i.jsx("span",{className:"font-semibold text-gray-900",children:S.testName}),S.category&&i.jsx("span",{className:`text-xs px-2 py-0.5 rounded-full font-medium ${S.category==="MRD"?"bg-orange-100 text-orange-700":S.category==="ECD"?"bg-emerald-100 text-emerald-700":S.category==="TRM"?"bg-sky-100 text-sky-700":"bg-violet-100 text-violet-700"}`,children:S.category}),S.vendor&&i.jsx("span",{className:"text-xs text-gray-400",children:S.vendor})]}),i.jsx("p",{className:"text-sm text-gray-600 mt-1",children:S.description}),i.jsxs("div",{className:"flex items-center gap-3 mt-2 text-xs text-gray-400",children:[i.jsx("span",{children:S.date}),i.jsxs("span",{children:[" ",!S.affiliation||S.affiliation==="OpenOnco"?"OpenOnco":S.vendor?S.vendor.toLowerCase().includes(S.affiliation.toLowerCase())||S.affiliation.toLowerCase().includes(S.vendor.split(" ")[0].toLowerCase())?`Vendor update: ${S.contributor?S.contributor+" ("+S.affiliation+")":S.affiliation}`:S.contributor?`${S.contributor} (${S.affiliation})`:S.affiliation:S.contributor?`${S.contributor} (${S.affiliation})`:S.affiliation]})]})]})]},`${S.testId}-${_}`))})})]})]})},Gf=()=>{const e=(n,s,r)=>{const o=new Blob([n],{type:r}),l=URL.createObjectURL(o),d=document.createElement("a");d.href=l,d.download=s,document.body.appendChild(d),d.click(),document.body.removeChild(d),URL.revokeObjectURL(l)},t=()=>{const n={meta:{version:ea.date,generatedAt:new Date().toISOString(),source:"OpenOnco",website:"https://openonco.org"},changelog:Pa,categories:{MRD:{name:"Molecular Residual Disease",description:"Tests for detecting minimal/molecular residual disease after treatment",testCount:z.length,tests:z},ECD:{name:"Early Cancer Detection",description:"Screening and early detection tests including MCED",testCount:Y.length,tests:Y},TRM:{name:"Treatment Response Monitoring",description:"Tests for monitoring treatment response during therapy",testCount:K.length,tests:K},TDS:{name:"Treatment Decision Support",description:"Tests for guiding treatment decisions including therapy selection and intervention decisions",testCount:X.length,tests:X}},totalTests:z.length+Y.length+K.length+X.length};return JSON.stringify(n,null,2)},a=()=>{e(t(),"OpenOnco_AllTests.json","application/json;charset=utf-8;")};return i.jsxs("div",{className:"max-w-4xl mx-auto px-6 py-12",children:[i.jsxs("div",{className:"text-center mb-8",children:[i.jsx("h1",{className:"text-2xl sm:text-3xl font-bold text-gray-900 mb-2",children:"Data Download"}),i.jsx("p",{className:"text-gray-600 mb-4",children:"OpenOnco is committed to openness. All data is open and downloadable."}),i.jsxs("div",{className:"inline-flex items-center gap-2 px-4 py-2 bg-emerald-50 border border-emerald-200 rounded-full",children:[i.jsx("svg",{className:"w-4 h-4 text-emerald-600",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M12 8v4l3 3m6-3a9 9 0 11-18 0 9 9 0 0118 0z"})}),i.jsxs("span",{className:"text-sm font-medium text-emerald-700",children:["Last Updated: ",ea.date]})]})]}),i.jsx("div",{className:"mb-8",children:i.jsx(If,{})}),i.jsx("h2",{className:"text-xl font-bold text-gray-900 mb-4",children:"Download Complete Dataset"}),i.jsx("div",{className:"mb-8",children:i.jsx("div",{className:"rounded-xl border-2 border-slate-300 bg-slate-50 p-5",children:i.jsxs("div",{className:"flex items-center justify-between",children:[i.jsxs("div",{className:"flex items-center gap-4",children:[i.jsx("div",{className:"w-12 h-12 rounded-xl bg-gradient-to-br from-slate-600 to-slate-700 flex items-center justify-center",children:i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M17 14v6m-3-3h6M6 10h2a2 2 0 002-2V6a2 2 0 00-2-2H6a2 2 0 00-2 2v2a2 2 0 002 2zm10 0h2a2 2 0 002-2V6a2 2 0 00-2-2h-2a2 2 0 00-2 2v2a2 2 0 002 2zM6 20h2a2 2 0 002-2v-2a2 2 0 00-2-2H6a2 2 0 00-2 2v2a2 2 0 002 2z"})})}),i.jsxs("div",{children:[i.jsx("h3",{className:"font-bold text-gray-900",children:"Complete Dataset (All Categories)"}),i.jsxs("p",{className:"text-sm text-gray-500",children:[z.length+Y.length+K.length+X.length," tests  MRD + ECD + TRM + TDS combined  JSON format"]})]})]}),i.jsxs("button",{onClick:a,className:"flex items-center gap-2 px-5 py-2.5 bg-slate-700 border border-slate-600 rounded-lg hover:bg-slate-800 transition-colors text-sm font-medium text-white shadow-sm",children:[i.jsx("svg",{className:"w-4 h-4",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M4 16v1a3 3 0 003 3h10a3 3 0 003-3v-1m-4-4l-4 4m0 0l-4-4m4 4V4"})}),"Download JSON"]})]})})}),i.jsxs("div",{className:"p-6 bg-gray-50 rounded-xl border border-gray-200",children:[i.jsx("h3",{className:"font-semibold text-gray-900 mb-3",children:"Data Sources & Attribution"}),i.jsx("p",{className:"text-sm text-gray-600 mb-4",children:"OpenOnco compiles publicly available information from multiple authoritative sources:"}),i.jsxs("ul",{className:"text-sm text-gray-600 space-y-1 mb-4",children:[i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-emerald-500 mt-1",children:""}),i.jsx("span",{children:"Vendor websites, product documentation, and healthcare professional resources"})]}),i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-emerald-500 mt-1",children:""}),i.jsx("span",{children:"FDA approval documents, PMA summaries, and 510(k) clearances"})]}),i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-emerald-500 mt-1",children:""}),i.jsx("span",{children:"Peer-reviewed publications and clinical trial results"})]}),i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-emerald-500 mt-1",children:""}),i.jsx("span",{children:"CMS coverage determinations and reimbursement policies"})]})]}),i.jsx("p",{className:"text-xs text-gray-500",children:"This data is provided for informational purposes only. Always verify with official sources for clinical decision-making."})]}),i.jsx("div",{className:"hidden md:block mt-6",children:i.jsx(Wo,{})})]})},Hf=({category:e})=>{const t=bs[e],[a,n]=A.useState([{role:"assistant",content:`Hi! I can help you understand ${t.title} tests. Ask me about specific tests, comparisons, or clinical applications.`}]),[s,r]=A.useState(""),[o,l]=A.useState(!1),[d,u]=A.useState(()=>Ja()||"Clinician"),[g,p]=A.useState(Zi[0].id),y=A.useRef(null);A.useEffect(()=>{if(y.current&&a.length>0){const b=y.current;if(a[a.length-1].role==="assistant"){const m=b.querySelectorAll('[data-message-role="assistant"]'),c=m[m.length-1];c&&(b.scrollTop=c.offsetTop-8)}}},[a]),A.useEffect(()=>{const b=j=>{u(j.detail),n([{role:"assistant",content:`Hi! I can help you understand ${t.title} tests. Ask me about specific tests, comparisons, or clinical applications.`}])};return window.addEventListener("personaChanged",b),()=>window.removeEventListener("personaChanged",b)},[t.title]),A.useMemo(()=>`You are a liquid biopsy test information assistant for OpenOnco, focused on ${t.title} testing. Your ONLY role is to help users explore and compare the specific tests in the database below.

STRICT SCOPE LIMITATIONS:
- ONLY discuss ${e} tests that exist in the database below
- NEVER speculate about disease genetics, heredity, inheritance patterns, or etiology - these are complex medical topics outside your scope
- NEVER suggest screening strategies or make recommendations about who should be tested
- NEVER interpret what positive or negative test results mean clinically
- NEVER make claims about diseases, conditions, or cancer types beyond what is explicitly stated in the test data
- If a user describes a patient/situation, check the "targetPopulation" field - if they don't clearly fit, say "This test is designed for [target population]. Please discuss with a healthcare provider whether it's appropriate for this situation."
- For ANY question outside the specific test data (disease inheritance, screening recommendations, result interpretation, treatment decisions): respond with "That's outside my scope. Please discuss with your healthcare provider."

WHAT YOU CAN DO:
- Compare ${e} tests on their documented attributes (sensitivity, specificity, TAT, cost, coverage, etc.)
- Explain what data is available or not available for specific tests
- Help users understand the differences between test approaches
- Note when a test's target population may not match the user's described situation

${e} DATABASE:
${JSON.stringify(as[e])}

${Ru}

${Lu(d)}

Say "not specified" for missing data. When uncertain, err on the side of saying "please consult your healthcare provider."`,[e,t,d]);const x=b=>{b.key==="Enter"&&!b.shiftKey&&(b.preventDefault(),w())},w=async()=>{if(!s.trim()||o)return;const b=s.trim(),j=`persona-${d.toLowerCase().replace(/[^a-z]/g,"-")}`;Ji("chat_message_sent",{category:e,model:g,message_length:b.length},{flags:[j,`category-${e.toLowerCase()}`]}),r("");const m={role:"user",content:b},c=[...a,m];n(c),l(!0);try{const h=c.slice(1).slice(-6),P=await(await fetch("/api/chat",{method:"POST",headers:{"Content-Type":"application/json"},body:JSON.stringify({category:e,persona:d,testData:JSON.stringify(as[e]),messages:h,model:g})})).json();P&&P.content&&P.content[0]&&P.content[0].text?n(R=>[...R,{role:"assistant",content:P.content[0].text}]):n(R=>[...R,{role:"assistant",content:"I received an unexpected response. Please try again."}])}catch{n(C=>[...C,{role:"assistant",content:"Connection error. Please try again."}])}l(!1)};return i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 overflow-hidden",children:[i.jsxs("div",{ref:y,className:"h-56 overflow-y-auto p-4 space-y-3",children:[a.map((b,j)=>i.jsx("div",{"data-message-role":b.role,className:`flex ${b.role==="user"?"justify-end":"justify-start"}`,children:i.jsx("div",{className:`max-w-[80%] rounded-2xl px-4 py-2 ${b.role==="user"?"bg-emerald-500 text-white rounded-br-md":"bg-gray-100 text-gray-800 rounded-bl-md"}`,children:b.role==="user"?i.jsx("p",{className:"text-sm whitespace-pre-wrap",children:b.content}):i.jsx(zo,{className:"text-sm",children:b.content})})},j)),o&&i.jsx("div",{className:"flex justify-start",children:i.jsxs("div",{className:"bg-gray-100 rounded-2xl rounded-bl-md px-4 py-3 flex space-x-1",children:[i.jsx("div",{className:"w-2 h-2 bg-gray-400 rounded-full animate-bounce",style:{animationDelay:"0ms"}}),i.jsx("div",{className:"w-2 h-2 bg-gray-400 rounded-full animate-bounce",style:{animationDelay:"150ms"}}),i.jsx("div",{className:"w-2 h-2 bg-gray-400 rounded-full animate-bounce",style:{animationDelay:"300ms"}})]})})]}),i.jsxs("div",{className:"border-t border-gray-200 p-3",children:[i.jsxs("div",{className:"flex gap-2 items-center",children:[i.jsx("select",{value:g,onChange:b=>p(b.target.value),className:"px-2 py-2 bg-gray-50 border border-gray-200 rounded-lg text-xs focus:outline-none focus:ring-2 focus:ring-emerald-500 cursor-pointer",title:"Select AI model",children:Zi.map(b=>i.jsx("option",{value:b.id,children:b.name},b.id))}),i.jsx("input",{type:"text",value:s,onChange:b=>r(b.target.value),onKeyDown:x,placeholder:`Ask about ${t.shortTitle}...`,className:"flex-1 px-4 py-2 bg-gray-50 border border-gray-200 rounded-lg text-sm focus:outline-none focus:ring-2 focus:ring-emerald-500"}),i.jsx("button",{onClick:w,disabled:o,className:"bg-emerald-500 hover:bg-emerald-600 disabled:bg-emerald-300 text-white px-4 py-2 rounded-lg text-sm font-medium",children:"Send"})]}),i.jsx("p",{className:"text-[10px] text-gray-400 mt-2 text-center",children:"Powered by Claude AI. Responses may be inaccurate and should be independently verified."})]})]})},zf=e=>e==null?null:String(e),Wf={"Reported Sensitivity":"The proportion of true positive cases correctly identified by the test. May be analytical (lab conditions) or clinical (real-world), and may be landmark (single timepoint) or longitudinal (across multiple draws).","Overall Sensitivity":"The proportion of true positive cases correctly identified by the test across all stages combined.","Reported Specificity":"The proportion of true negative cases correctly identified by the test. High specificity means fewer false positives.","Analytical Specificity":"Specificity measured under controlled laboratory conditions, typically higher than clinical specificity.","Clinical Specificity":"Specificity measured in real-world clinical settings with actual patient samples.",PPV:"Positive Predictive Value. The probability that a positive test result indicates true disease presence. Depends heavily on disease prevalence.",NPV:"Negative Predictive Value. The probability that a negative test result indicates true absence of disease.",LOD:"Limit of Detection. The lowest concentration of target analyte that can be reliably detected. Reported in various units (ppm, VAF%, MTM/mL).","LOD (Detection Threshold)":"Limit of Detection. The lowest concentration of target analyte that can be reliably detected. Reported in various units (ppm, VAF%, MTM/mL).",LOD95:"The concentration at which the test achieves 95% detection probability. More conservative than LOD and often more clinically relevant.","LOD95 (95% Confidence)":"The concentration at which the test achieves 95% detection probability. More conservative than LOD and often more clinically relevant.","Stage I Sensitivity":"Detection rate for Stage I cancers, typically the most challenging due to lower tumor burden.","Stage II Sensitivity":"Detection rate for Stage II cancers. Critical for adjuvant therapy decisions in MRD testing.","Stage III Sensitivity":"Detection rate for Stage III cancers. Generally higher than earlier stages due to greater tumor burden.","Stage IV Sensitivity":"Detection rate for Stage IV/metastatic cancers. Usually highest due to significant tumor burden.","Stage-specific Sensitivity":"Sensitivity broken down by cancer stage. Earlier stages typically have lower detection rates.","Landmark Sensitivity":"Detection rate at a single post-treatment timepoint (e.g., 4 weeks post-surgery).","Landmark Specificity":"Specificity measured at a single post-treatment timepoint.","Longitudinal Sensitivity":"Detection rate across multiple serial blood draws over time. Typically higher than landmark.","Longitudinal Specificity":"Specificity measured across multiple serial timepoints.","Sample Type":"The biological sample category required for testing (e.g., Blood, Tissue).","Sample Category":"The biological sample category required for testing (e.g., Blood, Tissue).","Initial TAT":"Turnaround time for the first test, which may include assay design for tumor-informed tests.","Follow-up TAT":"Turnaround time for subsequent monitoring tests, typically faster than initial.",TAT:"Turnaround Time. Days from sample receipt to result delivery.","Lead Time vs Imaging":"How many days/months earlier the test can detect recurrence compared to standard imaging (CT/PET).","Blood Volume":"Amount of blood required for the test, typically in milliliters (mL).","cfDNA Input":"Amount of cell-free DNA required for analysis, in nanograms (ng).","Variants Tracked":"Number of genetic variants monitored by the test. More variants may improve sensitivity but isn't always better.","Sample Volume":"Volume of sample required for the test.","Sample Stability":"How long the sample remains viable after collection.","Sample Details":"Additional specifications about sample requirements.",Approach:"Whether the test is tumor-informed (requires prior tissue) or tumor-nave (blood only).","Requires Tumor Tissue":"Whether a tumor sample is needed to design a personalized assay.","Requires Matched Normal":"Whether a normal tissue sample is needed to filter germline variants.",Method:"The laboratory technique used (e.g., PCR, NGS, methylation analysis).","Target Population":"The intended patient population for the test.","Indication Group":"The clinical indication category (e.g., screening, monitoring).","Response Definition":"How the test defines treatment response.","Screening Interval":"Recommended time between screening tests.","FDA Status":"Current FDA regulatory status (Approved, Breakthrough Designation, LDT, etc.).",Medicare:"Medicare coverage and reimbursement status.","Private Insurance":"Commercial insurance payers known to cover the test.","CPT Codes":"Current Procedural Terminology codes used for billing.","CPT Code":"Current Procedural Terminology code used for billing.","Clinical Availability":"Current commercial availability status.","Available Regions":"Geographic regions where the test is available.","Independent Validation":"Whether the test has been validated by independent third parties.","List Price":"Published list price before insurance, if available.","Total Trial Participants":"Total number of patients enrolled across key clinical trials.","Peer-Reviewed Publications":"Number of peer-reviewed scientific publications about the test.","Key Trials":"Major clinical trials evaluating the test.","Tumor Origin Prediction":"Accuracy of predicting the tissue of origin for detected cancers (multi-cancer tests).","Lead Time Notes":"Additional context about detection lead time compared to standard methods."},_f={},oc=({label:e,citations:t,notes:a,expertTopic:n,useGroupHover:s=!1})=>{var b;const[r,o]=A.useState(!1),[l,d]=A.useState({}),u=A.useRef(null),g=A.useRef(null),p=Wf[e],y=_f[e]||[],x=n?Mu[n]:null,w=p||a||t||y.length>0||x;return A.useEffect(()=>{if(r&&u.current){const j=u.current.getBoundingClientRect(),m=380,c=400;let h=j.left;h+m>window.innerWidth-20&&(h=Math.max(20,window.innerWidth-m-20)),h<20&&(h=20);let C=j.bottom+8;C+c>window.innerHeight-20&&(C=Math.max(20,j.top-c-8)),d({left:`${h}px`,top:`${C}px`})}},[r]),A.useEffect(()=>{if(!r)return;const j=m=>{u.current&&!u.current.contains(m.target)&&g.current&&!g.current.contains(m.target)&&o(!1)};return document.addEventListener("mousedown",j),()=>document.removeEventListener("mousedown",j)},[r]),A.useEffect(()=>{if(!r)return;const j=m=>{g.current&&g.current.contains(m.target)||o(!1)};return window.addEventListener("scroll",j,!0),()=>window.removeEventListener("scroll",j,!0)},[r]),w?i.jsxs(i.Fragment,{children:[i.jsx("button",{ref:u,onClick:j=>{j.stopPropagation(),o(!r)},className:`text-sm text-gray-600 underline-offset-2 cursor-pointer text-left leading-normal decoration-dotted ${s?"group-hover:text-[#2A63A4] group-hover:underline":"hover:text-[#2A63A4] hover:underline"}`,children:e}),r&&wu.createPortal(i.jsxs("div",{ref:g,className:"fixed z-[9999] w-96 bg-white border border-slate-200 rounded-xl shadow-2xl overflow-hidden",style:l,onClick:j=>j.stopPropagation(),children:[i.jsxs("div",{className:"bg-gradient-to-r from-slate-700 to-slate-800 px-4 py-3 flex items-center justify-between",children:[i.jsx("h4",{className:"font-semibold text-white text-sm",children:e}),i.jsx("button",{onClick:j=>{j.stopPropagation(),o(!1)},className:"w-6 h-6 rounded-full hover:bg-white/20 flex items-center justify-center text-white/70 hover:text-white transition-colors",children:i.jsx("svg",{className:"w-4 h-4",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M6 18L18 6M6 6l12 12"})})})]}),i.jsxs("div",{className:"max-h-80 overflow-y-auto",children:[p&&i.jsxs("div",{className:"px-4 py-3 border-b border-slate-100",children:[i.jsx("p",{className:"text-xs font-semibold text-slate-500 uppercase tracking-wide mb-1",children:"Definition"}),i.jsx("p",{className:"text-sm text-slate-700",children:p})]}),x&&i.jsxs("div",{className:"px-4 py-3 border-b border-slate-100 bg-amber-50/50",children:[i.jsxs("div",{className:"flex items-center gap-2 mb-1",children:[i.jsx("div",{className:"w-4 h-4 rounded-full bg-amber-400 text-white text-[9px] font-bold flex items-center justify-center",children:"E"}),i.jsx("p",{className:"text-xs font-semibold text-amber-700 uppercase tracking-wide",children:"Expert Insight"})]}),i.jsx("p",{className:"text-xs text-slate-600 whitespace-pre-line",children:x.content}),i.jsxs("p",{className:"text-[10px] text-slate-400 mt-2",children:["Expert",(b=x.experts)!=null&&b.includes(",")?"s":"",": ",x.experts||"Advisory Panel"]})]}),a&&i.jsxs("div",{className:"px-4 py-3 border-b border-slate-100",children:[i.jsx("p",{className:"text-xs font-semibold text-slate-500 uppercase tracking-wide mb-1",children:"Notes for This Test"}),i.jsx("p",{className:"text-sm text-slate-700",children:a})]}),t&&i.jsxs("div",{className:"px-4 py-3 border-b border-slate-100",children:[i.jsx("p",{className:"text-xs font-semibold text-slate-500 uppercase tracking-wide mb-1",children:"Sources"}),i.jsx("div",{className:"space-y-1",children:t.split("|").map((j,m)=>{const c=j.trim(),h=c.startsWith("http");return i.jsxs("a",{href:h?c:"#",target:h?"_blank":void 0,rel:h?"noopener noreferrer":void 0,className:`block text-xs ${h?"text-[#2A63A4] hover:underline":"text-slate-600"}`,children:[" ",c.length>70?c.slice(0,70)+"...":c]},m)})})]}),y.length>0&&i.jsxs("div",{className:"px-4 py-3 bg-slate-50",children:[i.jsx("p",{className:"text-xs font-semibold text-slate-500 uppercase tracking-wide mb-2",children:"Change Log"}),i.jsx("div",{className:"space-y-2",children:y.map((j,m)=>i.jsxs("div",{className:"text-xs",children:[i.jsx("span",{className:"text-slate-400 font-mono",children:j.date}),i.jsx("p",{className:"text-slate-600",children:j.change})]},m))})]}),y.length===0&&i.jsxs("div",{className:"px-4 py-3 bg-slate-50",children:[i.jsx("p",{className:"text-xs font-semibold text-slate-500 uppercase tracking-wide mb-1",children:"Change Log"}),i.jsx("p",{className:"text-xs text-slate-400 italic",children:"No changes recorded for this parameter."})]})]})]}),document.body)]}):i.jsx("span",{className:"text-sm text-gray-600",children:e})},Mu={sensitivity:{title:"Understanding Sensitivity Claims",experts:"MR",content:`"Sensitivity" alone can be ambiguous. Here are helpful distinctions:

Clinical sensitivity refers to the percentage of patients who recurred that were correctly identified as MRD-positive. This is often what clinicians assume, but not always what's reported.

Analytical sensitivity refers to detection rate in lab validation conditions, which may differ from real-world clinical performance.

Landmark vs Longitudinal: Landmark measures detection at a single post-surgery timepoint. Longitudinal measures detection at any timepoint across multiple draws, which typically yields higher numbers.

Helpful questions to ask: What type of sensitivity? At what timeframe? For which stages? What was the sample size?`},stageSpecific:{title:"Why Stage-Specific Sensitivity Matters",experts:"MR",content:`When sensitivity is reported for combined stages (II, III, IV together), it can be helpful to understand the breakdown.

Stage II presents the greatest detection challenge due to lower tumor burden and less circulating tumor DNA. Yet Stage II is often where MRD-guided therapy decisions have the most impact.

Stage III/IV cases typically have more ctDNA and higher detection rates, which can lift overall sensitivity figures when stages are combined.

For a Stage II patient considering adjuvant therapy, stage-specific sensitivity datawhen availablemay be more directly relevant than blended numbers.

What to look for: Tests that report stage-specific data separately provide more granular information for decision-making.

Stage-specific reporting helps clinicians and patients make more informed comparisons, and we encourage vendors to provide this breakdown where feasible.`},stageMissing:{title:"Why Stage-Specific Data Matters",experts:"MR",content:`Stage-specific sensitivity data helps clinicians and patients make more informed decisions.

Why it's important: Stage II patients considering adjuvant therapy benefit from understanding how the test performs specifically for their situation, as detection rates typically vary by stage.

What you can do: Consider asking the vendor about stage-specific performance datathey may have additional information available.

We encourage vendors to provide stage-specific breakdowns where feasible, as this openness helps the entire field.`},specificity:{title:"Understanding Specificity Claims",experts:"MR, SW",content:`For MRD testing, specificity may be particularly importantespecially in low-recurrence populations where most patients are already cured.

Analytical vs Clinical Specificity:
Analytical specificity measures how often the test correctly identifies negative samples as negative in the lab. This is important for repeat monitoring scenarios.

Clinical specificity measures how often MRD-negative results correspond with no eventual recurrence. Interpretation can be complex in studies where MRD-positive patients receive treatment.

Reporting considerations:
Per-timepoint vs per-patient reporting can yield different numbers. With serial testing, it's worth understanding how false positive probability may compound.

Analytical specificity becomes especially relevant with repeat testing, where even small false positive rates can accumulate over serial draws.`},analyticalVsClinicalSpecificity:{title:"Analytical vs Clinical Specificity",experts:"MR, SW",content:`These metrics answer different questions and are worth understanding separately:

Analytical Specificity
What it measures: How often does the test correctly identify truly negative samples as negative in laboratory conditions?
Why it matters: Important for repeat monitoringeven 99% specificity means approximately 5% cumulative false positive probability over 5 annual tests.
How it's measured: Typically using contrived samples or healthy donor plasma.

Clinical Specificity
What it measures: How often does an MRD-negative result correspond with no eventual recurrence?
Interpretation note: In interventional trials where MRD-positive patients receive treatment, the "true" recurrence rate without treatment isn't directly observable.
Context: This metric is sometimes better understood as negative predictive value (NPV) in context.

Why both matter:
Analytical specificity reflects the test's inherent performance characteristics.
Clinical specificity is influenced by both test performance and treatment effects.

When vendors report "specificity" without specifying type, it's reasonable to ask which measurement is being referenced.`},lod:{title:"Understanding LOD Comparisons",experts:"MR, SW",content:`LOD (Limit of Detection) values can be difficult to compare directly across different MRD test architectures. We display values exactly as reported by each vendor without conversion.

LOD vs LOD95  an important distinction:
LOD (detection threshold): The level where signal can be detected, though not necessarily reliably.
LOD95: The level where detection occurs 95% of the time.

Why this matters for monitoring:
When LOD is significantly lower than LOD95, the test may detect lower levels occasionally. Serial testing provides additional opportunities for detection.
When LOD and LOD95 are similar, detection below the threshold is unlikely even with repeat testing.

Other comparison considerations:
Different units (ppm, VAF%, molecules/mL) don't convert directly.
Pre-analytical factors like extraction efficiency can affect results.

The gap between LOD and LOD95 can be particularly relevant for surveillance protocols where serial testing is planned.`},lodVsLod95:{title:"LOD vs LOD95: Why Both Matter",experts:"MR, SW",content:`Understanding both LOD and LOD95 provides helpful context for test performance:

The key distinction:
LOD (detection threshold): Signal can be detected, but not reliably at this level.
LOD95: Detection occurs 95% of the time at this level.

Why the gap between them matters:
If a test has LOD of 0.5 ppm but LOD95 of 5 ppm, this can actually be favorable for monitoringthere's a chance of detecting variants below 5 ppm with repeat testing, and serial samples provide multiple detection opportunities.

If LOD  LOD95 (very close together), detection below LOD95 is unlikely even with multiple samples.

Practical implication:
Tests where LOD is notably lower than LOD95 may offer additional surveillance potential through serial testing. This gap is one factor worth considering when evaluating tests for monitoring protocols.`},bloodVolume:{title:"Blood Volume Context",experts:"MR",content:`Higher blood volume and more variants tracked don't automatically indicate better performance.

Error suppression and assay design can matter significantlya smaller panel with excellent noise control may perform comparably to or better than a larger panel.

Different test architectures work in different ways, so direct comparisons based on volume or variant count alone may not reflect overall test quality.

Blood volume is primarily relevant for practical considerations (ease of blood draw) rather than as a direct quality indicator.`},cfdnaInput:{title:"cfDNA Input vs Blood Volume",experts:"SW",content:`For research applications, cfDNA input (measured in ng) can be as relevant as blood volume (mL).

Why this distinction matters:
Different extraction methods yield different cfDNA amounts from the same blood volume.
The amount of cfDNA that enters the assay affects the analytical sensitivity ceiling.
Genome equivalents analyzed (approximately 3.3 pg per haploid genome) represents the true denominator.

What to consider:
Blood volume (mL): How much blood is drawn
cfDNA yield: How much cfDNA is extracted
Input to assay (ng): How much cfDNA enters the test

A test using more blood but less cfDNA input may have different performance characteristics than one using less blood with more cfDNA input. Input amounts aren't always disclosed but can significantly impact sensitivity.`},tumorInformed:{title:"Tumor-Informed vs Tumor-Nave",experts:"MR",content:`Both approaches have legitimate clinical applications:

Tumor-informed testing requires tumor tissue to identify patient-specific mutations, then tracks those in blood. Generally offers higher sensitivity but requires tissue availability.

Tumor-nave (tumor-agnostic) testing works without tumor tissue, using common cancer signals such as mutations or methylation patterns. More convenient when tissue isn't available but may miss patient-specific variants.

Neither approach is universally superiorthe best choice depends on clinical context, tissue availability, cancer type, and intended use.`},clinicalTrials:{title:"Interpreting Clinical Trial Data",experts:"MR",content:`Clinical sensitivity from interventional trials requires careful interpretation.

Treatment effects on outcomes: In trials where MRD-positive patients receive additional therapy, some may be cured by that treatment. This makes it difficult to determine how many would have recurred without intervention.

Stage composition: When results combine multiple stages (II, III, IV), it's helpful to understand the breakdown when available, as detection rates typically vary by stage.

These factors don't diminish the value of clinical trial datathey simply provide context for interpretation.`},mrdUseCases:{title:"MRD vs Treatment Response vs Surveillance",experts:"MR",content:`MRD tests can support three distinct clinical decisions:

Landmark MRD: A single post-surgery timepoint to help decide on adjuvant therapy. This is often the most clinically actionable use case.

Treatment Response Monitoring: Serial tests during therapy to assess whether treatment is working, based on ctDNA kinetics.

Surveillance: Periodic testing off-therapy to detect recurrence earlier than imaging.

Many assays span more than one use-case, but trial design, endpoints, and performance claims often target just one. Sensitivity figures from a surveillance study may not apply to landmark detection, and vice versa.

When comparing tests, consider which use-case the reported performance data reflects.`}},ci=({topic:e})=>{const[t,a]=A.useState(!1),[n,s]=A.useState({}),r=A.useRef(null),o=A.useRef(null),l=Mu[e];if(A.useEffect(()=>{if(t&&r.current){const u=r.current.getBoundingClientRect(),g=320,p=300;let y=u.left;y+g>window.innerWidth-20&&(y=u.right-g),y<20&&(y=20);let x=u.bottom+8;x+p>window.innerHeight-20&&(x=u.top-p-8),s({left:`${y}px`,top:`${x}px`})}},[t]),A.useEffect(()=>{if(!t)return;const u=g=>{r.current&&!r.current.contains(g.target)&&o.current&&!o.current.contains(g.target)&&a(!1)};return document.addEventListener("mousedown",u),()=>document.removeEventListener("mousedown",u)},[t]),A.useEffect(()=>{if(!t)return;const u=g=>{o.current&&o.current.contains(g.target)||a(!1)};return window.addEventListener("scroll",u,!0),()=>window.removeEventListener("scroll",u,!0)},[t]),!l)return null;const d=u=>{if(!u)return"Expert Advisors";const g=u.split(", ").map(p=>p==="MR"?"MR":p==="SW"?"SW":p);return`Expert${g.length>1?"s":""}: ${g.join(", ")}`};return i.jsxs("span",{className:"inline-flex items-center ml-1 align-middle",children:[i.jsx("button",{ref:r,onClick:u=>{u.stopPropagation(),a(!t)},className:"w-4 h-4 rounded-full bg-amber-100 border border-amber-300 text-amber-700 text-[10px] font-bold inline-flex items-center justify-center hover:bg-amber-200 hover:border-amber-400 transition-colors cursor-pointer",title:"Expert insight available - click to view",children:"E"}),t&&wu.createPortal(i.jsxs("div",{ref:o,className:"fixed z-[9999] w-80 bg-white border border-slate-200 rounded-xl shadow-xl overflow-hidden",style:n,onClick:u=>u.stopPropagation(),children:[i.jsx("div",{className:"bg-gradient-to-r from-amber-50 to-orange-50 px-4 py-2 border-b border-amber-100",children:i.jsxs("div",{className:"flex items-center justify-between",children:[i.jsxs("div",{className:"flex items-center gap-2",children:[i.jsx("div",{className:"w-5 h-5 rounded-full bg-amber-400 text-white text-[10px] font-bold flex items-center justify-center",children:"E"}),i.jsx("h4",{className:"font-semibold text-slate-800 text-sm",children:l.title})]}),i.jsx("button",{onClick:u=>{u.stopPropagation(),a(!1)},className:"w-6 h-6 rounded-full hover:bg-slate-200 flex items-center justify-center text-slate-400 hover:text-slate-600 transition-colors",title:"Close",children:i.jsx("svg",{className:"w-4 h-4",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M6 18L18 6M6 6l12 12"})})})]})}),i.jsx("div",{className:"px-4 py-3 text-xs text-slate-600 leading-relaxed whitespace-pre-line max-h-64 overflow-y-auto",children:l.content}),i.jsx("div",{className:"px-4 py-2 bg-slate-50 border-t border-slate-100",children:i.jsx("p",{className:"text-[10px] text-slate-500",children:i.jsx("span",{className:"font-medium text-slate-600",children:d(l.experts)})})})]}),document.body)]})},B=({label:e,value:t,unit:a,citations:n,notes:s,expertTopic:r})=>{if(t==null)return null;const o=`${t}${a||""}`;return typeof o=="string"&&o.length>60?i.jsxs("div",{className:"py-2 border-b border-gray-100 last:border-0 group cursor-pointer",children:[i.jsxs("div",{className:"mb-1 flex items-center gap-1",children:[i.jsx(oc,{label:e,citations:n,notes:s,expertTopic:r,useGroupHover:!0}),r&&i.jsx(ci,{topic:r})]}),i.jsx("span",{className:"text-sm font-medium text-gray-900",children:o})]}):i.jsxs("div",{className:"flex items-center justify-between py-1.5 border-b border-gray-100 last:border-0 gap-4 group cursor-pointer",children:[i.jsxs("span",{className:"flex-shrink-0 flex items-center gap-1",children:[i.jsx(oc,{label:e,citations:n,notes:s,expertTopic:r,useGroupHover:!0}),r&&i.jsx(ci,{topic:r})]}),i.jsx("span",{className:"text-sm font-medium text-gray-900 text-right",children:o})]})},$f=({test:e,isSelected:t,onSelect:a,category:n,onShowDetail:s})=>{var l,d,u;const r=((l=bs[n])==null?void 0:l.color)||"amber",o=e.isDiscontinued===!0;return i.jsxs("div",{id:`test-card-${e.id}`,"data-testid":"test-card",className:`relative h-full flex flex-col bg-white rounded-xl border-2 p-4 transition-all overflow-hidden ${t?"border-emerald-500 shadow-md shadow-emerald-100":"border-gray-200 hover:border-gray-300"}`,children:[o&&i.jsx("div",{className:"absolute inset-0 flex items-center justify-center pointer-events-none",children:i.jsx("span",{className:"text-gray-400/30 font-bold text-4xl tracking-wider transform -rotate-12",children:"DISCONTINUED"})}),i.jsxs("div",{className:"cursor-pointer flex-1","data-testid":"test-card-clickable",onClick:()=>s&&s(e),children:[i.jsxs("div",{className:"flex justify-between items-start mb-3",children:[i.jsxs("div",{className:"flex-1",children:[i.jsxs("div",{className:"flex items-center gap-2 mb-1 flex-wrap",children:[o&&i.jsx(lt,{variant:"slate",children:"DISCONTINUED"}),!o&&e.productType&&i.jsx(Tf,{productType:e.productType,size:"xs"}),!o&&((d=e.reimbursement)!=null&&d.toLowerCase().includes("medicare"))&&e.commercialPayers&&e.commercialPayers.length>0?i.jsx(lt,{variant:"success",children:"Medicare+Private"}):!o&&((u=e.reimbursement)!=null&&u.toLowerCase().includes("medicare"))?i.jsx(lt,{variant:"success",children:"Medicare"}):!o&&e.commercialPayers&&e.commercialPayers.length>0?i.jsx(lt,{variant:"blue",children:"Private"}):null,e.adltStatus&&i.jsx(lt,{variant:"amber",title:"CMS Advanced Diagnostic Laboratory Test - annual rate updates based on private payer data",children:"ADLT"}),e.codeType==="PLA"&&i.jsx(lt,{variant:"slate",title:"Proprietary Laboratory Analyses code - specific to this laboratory's test",children:"PLA"}),n==="ECD"&&e.listPrice&&i.jsxs(lt,{variant:"amber",children:["$",e.listPrice]}),e.totalParticipants&&i.jsxs(lt,{variant:"blue",children:[e.totalParticipants.toLocaleString()," trial participants"]}),e.numPublications&&i.jsxs(lt,{variant:"purple",children:[e.numPublications,e.numPublicationsPlus?"+":""," pubs"]}),e.approach&&i.jsx(lt,{variant:r,children:e.approach}),e.testScope&&i.jsx(lt,{variant:r,children:e.testScope})]}),i.jsx("h3",{className:`font-semibold ${o?"text-gray-400":"text-gray-900"}`,children:e.name}),i.jsxs("p",{className:"text-sm text-gray-500",children:[e.vendor,i.jsx(_a,{vendor:e.vendor,size:"sm"})]}),e.platformRequired&&i.jsxs("p",{className:"text-xs text-indigo-600 mt-0.5",children:[i.jsx("span",{className:"font-medium",children:"Platform:"})," ",e.platformRequired]})]}),i.jsxs("button",{onClick:g=>{g.stopPropagation(),a(e.id)},className:`hidden md:flex items-center gap-2 px-3 py-1.5 rounded-lg border-2 transition-all flex-shrink-0 ${t?"bg-emerald-500 border-emerald-500 text-white":"bg-white border-gray-300 text-gray-500 hover:border-emerald-400 hover:text-emerald-600"}`,title:t?"Remove from comparison":"Add to comparison","data-testid":"compare-button",children:[i.jsx("div",{className:`w-5 h-5 rounded-full border-2 flex items-center justify-center ${t?"bg-white border-white":"border-current"}`,children:t&&i.jsx("svg",{className:"w-3 h-3 text-emerald-500",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:3,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M5 13l4 4L19 7"})})}),i.jsx("span",{className:"text-xs font-medium hidden sm:inline",children:t?"Selected":"Compare"})]})]}),i.jsxs("div",{className:"grid grid-cols-4 gap-2 mb-3",children:[n!=="TDS"&&e.sensitivity!=null&&i.jsxs("div",{children:[i.jsxs("p",{className:"text-lg font-bold text-emerald-600",children:[e.sensitivity,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Reported Sens."})]}),n!=="TDS"&&e.specificity!=null&&i.jsxs("div",{children:[i.jsxs("p",{className:"text-lg font-bold text-emerald-600",children:[e.specificity,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Specificity"})]}),n!=="TDS"&&(e.lod!=null||e.lod95!=null)&&i.jsx("div",{children:e.lod!=null&&e.lod95!=null?i.jsxs(i.Fragment,{children:[i.jsx("p",{className:"text-sm font-bold text-violet-600",children:e.lod}),i.jsx("p",{className:"text-xs text-violet-400",children:e.lod95}),i.jsx("p",{className:"text-xs text-gray-500",children:"LOD / LOD95"}),i.jsxs("span",{className:"inline-flex items-center gap-0.5 text-[9px] text-violet-500 font-medium mt-0.5",title:"Both LOD and LOD95 are reported; see expert notes on how to interpret the gap.",children:[i.jsx("svg",{className:"w-2.5 h-2.5",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})}),"LOD+95"]})]}):e.lod!=null?i.jsxs(i.Fragment,{children:[i.jsx("p",{className:"text-lg font-bold text-violet-600",children:e.lod}),i.jsx("p",{className:"text-xs text-gray-500",children:"LOD"})]}):i.jsxs(i.Fragment,{children:[i.jsx("p",{className:"text-lg font-bold text-violet-600",children:e.lod95}),i.jsx("p",{className:"text-xs text-gray-500",children:"LOD95"})]})}),n==="MRD"&&e.followUpTat&&i.jsxs("div",{children:[i.jsxs("p",{className:"text-lg font-bold text-slate-600",children:[e.followUpTat,"d"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"TAT"})]}),n==="TRM"&&e.leadTimeVsImaging&&i.jsxs("div",{children:[i.jsxs("p",{className:"text-lg font-bold text-emerald-600",children:[e.leadTimeVsImaging,"d"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Lead Time"})]}),n==="ECD"&&e.stageISensitivity&&i.jsxs("div",{children:[i.jsxs("p",{className:"text-lg font-bold text-emerald-600",children:[e.stageISensitivity,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Stage I"})]}),n==="ECD"&&e.ppv!=null&&i.jsxs("div",{children:[i.jsxs("p",{className:"text-lg font-bold text-emerald-600",children:[e.ppv,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"PPV"})]}),n==="TDS"&&e.genesAnalyzed&&i.jsxs("div",{children:[i.jsx("p",{className:"text-lg font-bold text-violet-600",children:e.genesAnalyzed}),i.jsx("p",{className:"text-xs text-gray-500",children:"Genes"})]}),n==="TDS"&&e.fdaCompanionDxCount&&i.jsxs("div",{children:[i.jsx("p",{className:"text-lg font-bold text-emerald-600",children:e.fdaCompanionDxCount}),i.jsx("p",{className:"text-xs text-gray-500",children:"CDx"})]}),n==="TDS"&&e.tat&&i.jsxs("div",{children:[i.jsx("p",{className:"text-lg font-bold text-slate-600",children:e.tat}),i.jsx("p",{className:"text-xs text-gray-500",children:"TAT"})]})]}),i.jsxs("div",{className:"flex flex-wrap gap-1 mb-2",children:[e.cancerTypes&&e.cancerTypes.slice(0,3).map((g,p)=>i.jsx("span",{className:"px-2 py-0.5 bg-gray-100 text-gray-600 rounded text-xs",children:g.length>20?g.slice(0,20)+"...":g},p)),e.cancerTypes&&e.cancerTypes.length>3&&i.jsxs("span",{className:"px-2 py-0.5 bg-gray-100 text-gray-500 rounded text-xs",children:["+",e.cancerTypes.length-3]})]}),n==="MRD"&&e.clinicalSettings&&e.clinicalSettings.length>0&&i.jsx("div",{className:"flex flex-wrap gap-1 mb-2",children:e.clinicalSettings.slice(0,4).map((g,p)=>i.jsx("span",{className:"px-1.5 py-0.5 bg-orange-50 text-orange-600 border border-orange-200 rounded text-[10px] font-medium",children:g==="Post-Surgery"?"Post-Surg":g==="Surveillance"?"Surveil":g==="Neoadjuvant"?"Neoadj":g==="Post-Adjuvant"?"Post-Adj":g},p))})]}),i.jsx("div",{className:"border-t border-gray-100 pt-2 mt-auto",children:i.jsxs("button",{onClick:()=>s&&s(e),className:"text-xs text-emerald-600 hover:text-emerald-700 font-medium flex items-center gap-1",children:["Show detail",i.jsx("svg",{className:"w-3 h-3",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M9 5l7 7-7 7"})})]})})]})},Kf=({test:e,category:t,onShowDetail:a})=>{var p,y,x;const n=e.isDiscontinued===!0,s=((p=e.reimbursement)==null?void 0:p.toLowerCase().includes("medicare"))&&!((y=e.reimbursement)!=null&&y.toLowerCase().includes("not yet"))&&!((x=e.reimbursement)!=null&&x.toLowerCase().includes("no established")),r=e.commercialPayers&&e.commercialPayers.length>0,o=e.approach==="Tumor-informed"||e.requiresTumorTissue==="Yes",l=e.initialTat||e.tat||null,u=(()=>{if(!l)return null;if(typeof l=="number")return{value:`~${l}`,suffix:"days"};if(String(l).toLowerCase().includes("not "))return{value:"TBD",suffix:"days",note:"Not specified"};const b=String(l).match(/(\d+(?:-\d+)?)/);return b?{value:`~${b[1]}`,suffix:"days"}:{value:"?",suffix:"days",note:"See details"}})(),g=({yes:w,label:b})=>i.jsxs("div",{className:"flex items-center gap-2 py-1.5",children:[i.jsx("span",{className:`w-6 h-6 rounded-full flex items-center justify-center text-xs font-bold flex-shrink-0 ${w?"bg-emerald-100 text-emerald-700":"bg-gray-100 text-gray-500"}`,children:w?"":""}),i.jsx("span",{className:"text-sm text-gray-700",children:b})]});return i.jsxs("div",{"data-testid":"test-card",className:"relative h-full flex flex-col bg-white rounded-xl border-2 border-gray-200 p-4 hover:border-gray-300 transition-all overflow-hidden",children:[n&&i.jsx("div",{className:"absolute inset-0 flex items-center justify-center pointer-events-none",children:i.jsx("span",{className:"text-gray-400/30 font-bold text-4xl tracking-wider transform -rotate-12",children:"DISCONTINUED"})}),i.jsxs("div",{className:"cursor-pointer flex-1 flex flex-col","data-testid":"test-card-clickable",onClick:()=>a&&a(e),children:[i.jsxs("div",{className:"flex justify-between items-start mb-3",children:[i.jsxs("div",{children:[i.jsx("h3",{className:`font-semibold text-lg ${n?"text-gray-400":"text-gray-900"}`,children:e.name}),i.jsxs("p",{className:"text-sm text-gray-500",children:["by ",e.vendor,i.jsx(_a,{vendor:e.vendor,size:"sm"})]})]}),i.jsx("div",{className:`px-3 py-1 rounded-full text-xs font-medium flex-shrink-0 ${n?"bg-gray-200 text-gray-600":s&&r?"bg-emerald-100 text-emerald-700":s||r?"bg-blue-100 text-blue-700":"bg-gray-100 text-gray-500"}`,children:n?"DISCONTINUED":s&&r?"Insurance Covered":s?"Medicare Covered":r?"Some Insurance":"Check Coverage"})]}),i.jsxs("div",{className:"grid grid-cols-2 gap-x-4 gap-y-1 mb-3",children:[i.jsx(g,{yes:s,label:"Medicare coverage"}),i.jsx(g,{yes:r,label:"Private insurance"}),i.jsx(g,{yes:!o,label:"Blood-only (no tissue)"}),u&&i.jsxs("div",{className:"flex items-center gap-2 py-1.5",children:[i.jsx("span",{className:`min-w-6 h-6 px-1.5 rounded-full flex items-center justify-center text-xs font-bold flex-shrink-0 ${u.note?"bg-gray-100 text-gray-500":"bg-blue-100 text-blue-700"}`,children:u.value}),i.jsx("span",{className:"text-sm text-gray-700",children:u.suffix})]})]}),e.cancerTypes&&i.jsxs("div",{className:"mb-2",children:[i.jsx("p",{className:"text-xs text-gray-500 mb-1",children:"Works for:"}),i.jsxs("div",{className:"flex flex-wrap gap-1",children:[e.cancerTypes.slice(0,4).map((w,b)=>i.jsx("span",{className:"px-2 py-0.5 bg-gray-100 text-gray-600 rounded text-xs",children:w.length>20?w.slice(0,20)+"...":w},b)),e.cancerTypes.length>4&&i.jsxs("span",{className:"px-2 py-0.5 bg-gray-100 text-gray-500 rounded text-xs",children:["+",e.cancerTypes.length-4," more"]})]})]}),i.jsxs("button",{className:"text-xs text-emerald-600 hover:text-emerald-700 font-medium flex items-center gap-1 mt-auto pt-2",children:["Learn more",i.jsx("svg",{className:"w-3 h-3",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M9 5l7 7-7 7"})})]})]})]})},Qf=({test:e,category:t,onClose:a,isPatientView:n=!1})=>{var j,m,c,h,C;const[s,r]=A.useState(!1);if(!e)return null;const o=P=>{P.stopPropagation();const R=`${window.location.origin}?category=${t}&test=${e.id}`;navigator.clipboard.writeText(R).then(()=>{r(!0),setTimeout(()=>r(!1),2e3)})},l=`
    @media print {
      /* Hide everything except the print area */
      body * {
        visibility: hidden;
      }
      .test-detail-print-area,
      .test-detail-print-area * {
        visibility: visible;
      }
      
      /* Reset modal positioning for print */
      .test-detail-modal-root {
        position: fixed !important;
        left: 0 !important;
        top: 0 !important;
        width: 100% !important;
        height: auto !important;
        background: white !important;
        padding: 0 !important;
        margin: 0 !important;
        display: block !important;
      }
      .test-detail-print-area { 
        position: absolute !important;
        left: 0 !important;
        top: 0 !important;
        width: 100% !important;
        max-height: none !important;
        height: auto !important;
        overflow: visible !important;
        box-shadow: none !important;
        border-radius: 0 !important;
        max-width: 100% !important;
      }
      
      /* Allow content to flow across pages */
      .test-detail-print-area,
      .test-detail-print-area > div {
        max-height: none !important;
        overflow: visible !important;
        height: auto !important;
      }
      
      /* Hide interactive elements */
      .print\\:hidden { display: none !important; }
      
      @page { margin: 0.5in; }
    }
  `,d={MRD:{headerBg:"bg-gradient-to-r from-orange-500 to-amber-500",sectionBg:"bg-orange-50",sectionBorder:"border-orange-200",sectionTitle:"text-orange-800"},ECD:{headerBg:"bg-gradient-to-r from-emerald-500 to-teal-500",sectionBg:"bg-emerald-50",sectionBorder:"border-emerald-200",sectionTitle:"text-emerald-800"},TRM:{headerBg:"bg-gradient-to-r from-rose-500 to-pink-500",sectionBg:"bg-rose-50",sectionBorder:"border-rose-200",sectionTitle:"text-rose-800"},TDS:{headerBg:"bg-gradient-to-r from-violet-500 to-purple-500",sectionBg:"bg-violet-50",sectionBorder:"border-violet-200",sectionTitle:"text-violet-800"}},u=d[t]||d.MRD,g=((j=e.reimbursement)==null?void 0:j.toLowerCase().includes("medicare"))&&!((m=e.reimbursement)!=null&&m.toLowerCase().includes("not yet"))&&!((c=e.reimbursement)!=null&&c.toLowerCase().includes("no established")),p=e.commercialPayers&&e.commercialPayers.length>0,y=e.approach==="Tumor-informed"||e.requiresTumorTissue==="Yes"||e.sampleCategory==="Tissue",x=e.isDiscontinued===!0,w=({title:P,children:R,expertTopic:v})=>i.jsxs("div",{className:`rounded-xl border ${u.sectionBorder} overflow-hidden`,children:[i.jsxs("div",{className:`${u.sectionBg} px-4 py-2 border-b ${u.sectionBorder} flex items-center gap-2`,children:[i.jsx("h3",{className:`font-semibold text-sm uppercase tracking-wide ${u.sectionTitle} leading-none`,children:P}),v&&i.jsx(ci,{topic:v})]}),i.jsx("div",{className:"bg-white p-4",children:R})]}),b=({yes:P,label:R})=>i.jsxs("div",{className:"flex items-center gap-2 py-1",children:[i.jsx("span",{className:`w-5 h-5 rounded-full flex items-center justify-center text-xs font-bold ${P?"bg-emerald-100 text-emerald-700":"bg-gray-100 text-gray-500"}`,children:P?"":""}),i.jsx("span",{className:"text-sm text-gray-700",children:R})]});return i.jsxs(i.Fragment,{children:[i.jsx("style",{children:l}),i.jsx("div",{className:"test-detail-modal-root fixed inset-0 bg-black/60 backdrop-blur-sm z-50 flex items-center justify-center p-4 print:bg-white","data-testid":"test-detail-modal",onClick:a,children:i.jsxs("div",{className:"test-detail-print-area bg-white rounded-2xl shadow-2xl max-w-4xl w-full overflow-hidden",onClick:P=>P.stopPropagation(),style:{maxHeight:"90vh",display:"flex",flexDirection:"column"},children:[x&&i.jsxs("div",{className:"bg-red-600 text-white px-5 py-3 flex items-center gap-3",style:{flexShrink:0},children:[i.jsx("svg",{className:"w-6 h-6 flex-shrink-0",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"})}),i.jsxs("div",{children:[i.jsx("p",{className:"font-bold",children:"THIS TEST HAS BEEN DISCONTINUED"}),i.jsx("p",{className:"text-sm text-red-100",children:e.discontinuedReason||"This product is no longer commercially available."})]})]}),i.jsxs("div",{className:`flex justify-between items-start p-5 ${u.headerBg}`,style:{flexShrink:0},children:[i.jsxs("div",{className:"flex-1 mr-4",children:[i.jsxs("div",{className:"flex flex-wrap gap-2 mb-2",children:[g&&p&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:"Medicare+Private"}),g&&!p&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:"Medicare"}),!g&&p&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:"Private Insurance"}),e.fdaStatus&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:e.fdaStatus.split(" - ")[0]}),e.approach&&i.jsx("span",{className:"px-2 py-0.5 bg-white/20 text-white rounded text-xs font-medium",children:e.approach})]}),i.jsx("h2",{className:"text-2xl font-bold text-white",children:e.name}),i.jsxs("p",{className:"text-white/80",children:[e.vendor,"  OpenOnco.org"]})]}),i.jsxs("div",{className:"flex items-center gap-2 flex-shrink-0",children:[i.jsx("button",{onClick:o,className:"p-2 hover:bg-white/20 rounded-xl transition-colors print:hidden relative",title:"Copy link to this test","data-testid":"share-link-button",children:s?i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M5 13l4 4L19 7"})}):i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M13.828 10.172a4 4 0 00-5.656 0l-4 4a4 4 0 105.656 5.656l1.102-1.101m-.758-4.899a4 4 0 005.656 0l4-4a4 4 0 00-5.656-5.656l-1.1 1.1"})})}),i.jsx("button",{onClick:P=>{P.stopPropagation(),window.print()},className:"p-2 hover:bg-white/20 rounded-xl transition-colors print:hidden",title:"Print or save as PDF","data-testid":"print-button",children:i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M17 17h2a2 2 0 002-2v-4a2 2 0 00-2-2H5a2 2 0 00-2 2v4a2 2 0 002 2h2m2 4h6a2 2 0 002-2v-4a2 2 0 00-2-2H9a2 2 0 00-2 2v4a2 2 0 002 2zm8-12V5a2 2 0 00-2-2H9a2 2 0 00-2 2v4h10z"})})}),i.jsx("button",{onClick:a,className:"p-2 hover:bg-white/20 rounded-xl transition-colors print:hidden",children:i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M6 18L18 6M6 6l12 12"})})})]})]}),i.jsx("div",{className:"overflow-y-auto p-5 space-y-4",style:{flex:1},children:n?i.jsxs(i.Fragment,{children:[i.jsx(w,{title:"Quick Facts",children:i.jsxs("div",{className:"grid grid-cols-2 gap-4",children:[i.jsxs("div",{children:[i.jsx(b,{yes:g,label:"Medicare coverage (age 65+)"}),i.jsx(b,{yes:p,label:"Private insurance options"}),i.jsx(b,{yes:!y,label:"Blood draw only (no surgery needed)"}),t==="TDS"&&e.fdaCompanionDxCount&&i.jsxs("div",{className:"flex items-center gap-2 py-1",children:[i.jsx("span",{className:"w-5 h-5 rounded-full bg-emerald-100 text-emerald-700 flex items-center justify-center text-xs font-bold",children:""}),i.jsxs("span",{className:"text-sm text-gray-700",children:["FDA-approved for ",e.fdaCompanionDxCount," drug matches"]})]})]}),i.jsxs("div",{children:[t!=="TDS"&&(e.initialTat||e.tat)&&i.jsxs("div",{className:"flex items-center gap-2 py-1",children:[i.jsx("span",{className:"w-5 h-5 rounded-full bg-blue-100 text-blue-700 flex items-center justify-center text-xs font-bold",children:e.initialTat||e.tat}),i.jsx("span",{className:"text-sm text-gray-700",children:"days for results"})]}),t==="TDS"&&e.tat&&i.jsxs("div",{className:"flex items-center gap-2 py-1",children:[i.jsx("span",{className:"w-5 h-5 rounded-full bg-blue-100 text-blue-700 flex items-center justify-center text-xs font-bold",children:""}),i.jsxs("span",{className:"text-sm text-gray-700",children:["Results in ",e.tat]})]}),t==="TDS"&&e.genesAnalyzed&&i.jsxs("div",{className:"flex items-center gap-2 py-1",children:[i.jsx("span",{className:"w-5 h-5 rounded-full bg-violet-100 text-violet-700 flex items-center justify-center text-xs font-bold",children:""}),i.jsxs("span",{className:"text-sm text-gray-700",children:["Tests ",e.genesAnalyzed," genes"]})]}),e.cancerTypes&&i.jsxs("p",{className:"text-sm text-gray-600 py-1",children:["Tests for: ",e.cancerTypes.slice(0,3).join(", "),e.cancerTypes.length>3?` +${e.cancerTypes.length-3} more`:""]})]})]})}),i.jsx(w,{title:"What This Test Does",children:i.jsxs("p",{className:"text-gray-700",children:[t==="MRD"&&"This test looks for tiny amounts of cancer DNA in your blood after treatment. It can help your doctor know if treatment worked and watch for cancer coming back earlier than traditional scans.",t==="ECD"&&"This test screens your blood for signs of cancer before you have symptoms. Finding cancer early often means better treatment options and outcomes.",t==="TRM"&&"This test tracks whether your cancer treatment is working by measuring cancer DNA in your blood over time, potentially detecting changes before imaging can.",t==="TDS"&&"This test analyzes hundreds of genes in your tumor to find specific mutations that can be targeted with specialized treatments. It helps your doctor match you with the most effective therapies and clinical trials for your cancer."]})}),i.jsxs(w,{title:"How It Works",children:[i.jsx("p",{className:"text-gray-700",children:t==="TDS"?e.sampleCategory==="Tissue"?"Your doctor will send a sample of your tumor (from surgery or biopsy) to the lab. The test analyzes hundreds of genes to find specific mutations that can be matched to targeted treatments.":"A simple blood draw is used to capture tumor DNA circulating in your bloodstream. The test analyzes this DNA to identify mutations that can guide treatment decisions.":y?"Your doctor will need a sample of your tumor (from surgery or biopsy) plus a blood draw. The test creates a personalized profile based on your specific cancer's DNA mutations.":"Just a simple blood draw at your doctor's office or lab - no tumor sample needed. The test looks for general cancer signals in your blood."}),e.bloodVolume&&i.jsxs("p",{className:"text-sm text-gray-500 mt-2",children:["Blood sample: ",e.bloodVolume," mL (about ",Math.round(e.bloodVolume/5)," teaspoons)"]}),t==="TDS"&&e.tat&&i.jsxs("p",{className:"text-sm text-gray-500 mt-2",children:["Results typically available in: ",e.tat]})]}),i.jsx(w,{title:"Insurance & Cost",children:i.jsxs("div",{className:"space-y-2",children:[e.reimbursement&&i.jsxs("p",{className:"text-sm",children:[i.jsx("span",{className:"font-medium",children:"Medicare:"})," ",e.reimbursement]}),p&&i.jsxs("p",{className:"text-sm",children:[i.jsx("span",{className:"font-medium",children:"Private insurers:"})," ",e.commercialPayers.join(", ")]}),e.commercialPayersNotes&&i.jsx("p",{className:"text-xs text-gray-500 mt-1",children:e.commercialPayersNotes}),(t==="ECD"||t==="TDS")&&e.listPrice&&i.jsxs("p",{className:"text-sm mt-2",children:[i.jsx("span",{className:"font-medium",children:"List price (without insurance):"})," $",e.listPrice.toLocaleString()]})]})}),i.jsx(w,{title:"Questions to Ask Your Doctor",children:i.jsxs("ul",{className:"space-y-1 text-gray-700",children:[i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-blue-500",children:""})," Is this test right for my type and stage of cancer?"]}),i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-blue-500",children:""})," Will my insurance cover this test?"]}),i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-blue-500",children:""})," How will the results change my treatment plan?"]}),t==="MRD"&&i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-blue-500",children:""})," How often should I be retested?"]}),t==="ECD"&&i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-blue-500",children:""})," What happens if the test finds something?"]}),t==="TDS"&&i.jsxs("li",{className:"flex items-start gap-2",children:[i.jsx("span",{className:"text-blue-500",children:""})," Are there targeted therapies or clinical trials that match my results?"]})]})})]}):i.jsxs(i.Fragment,{children:[t==="TDS"&&i.jsxs(i.Fragment,{children:[i.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[i.jsx(w,{title:"Genomic Coverage",children:i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"Genes Analyzed",value:e.genesAnalyzed,citations:e.genesAnalyzedCitations,notes:e.genesAnalyzedNotes}),e.geneListUrl&&i.jsxs("div",{className:"py-1.5 flex justify-between items-center",children:[i.jsx("span",{className:"text-xs text-gray-500",children:"Gene List"}),i.jsx("a",{href:e.geneListUrl,target:"_blank",rel:"noopener noreferrer",className:"text-sm font-medium hover:underline",style:{color:"#2A63A4"},children:"View Full List "})]}),i.jsx(B,{label:"Biomarkers",value:(h=e.biomarkersReported)==null?void 0:h.join(", "),citations:e.biomarkersReportedCitations}),i.jsx(B,{label:"Method",value:e.method,citations:e.methodCitations})]})}),i.jsx(w,{title:"Sample & Turnaround",children:i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"Sample Type",value:e.sampleCategory}),i.jsx(B,{label:"Sample Requirements",value:e.sampleRequirements,citations:e.sampleRequirementsCitations,notes:e.sampleRequirementsNotes}),i.jsx(B,{label:"Turnaround Time",value:e.tat,citations:e.tatCitations,notes:e.tatNotes})]})})]}),i.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[i.jsx(w,{title:"FDA Companion Diagnostics",children:i.jsxs("div",{className:"space-y-1",children:[e.fdaCompanionDxCount&&i.jsxs("div",{className:"py-1.5 flex justify-between items-center",children:[i.jsx("span",{className:"text-xs text-gray-500",children:"FDA CDx Indications"}),i.jsx("span",{className:"text-lg font-bold text-emerald-600",children:e.fdaCompanionDxCount})]}),e.fdaCompanionDxCountNotes&&i.jsx("p",{className:"text-xs text-gray-500 mt-1",children:e.fdaCompanionDxCountNotes}),i.jsx(B,{label:"FDA Status",value:e.fdaStatus,citations:e.fdaStatusCitations}),e.fdaApprovalDate&&i.jsx(B,{label:"FDA Approval Date",value:e.fdaApprovalDate,citations:e.fdaApprovalDateCitations})]})}),i.jsx(w,{title:"Guidelines & Coverage",children:i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"NCCN Recommended",value:e.nccnRecommended?"Yes":"No"}),e.nccnGuidelinesAligned&&i.jsx(B,{label:"NCCN Guidelines",value:e.nccnGuidelinesAligned.join(", "),notes:e.nccnGuidelinesNotes,citations:e.nccnGuidelinesCitations}),i.jsx(B,{label:"Medicare",value:e.reimbursement,notes:e.reimbursementNote,citations:e.reimbursementCitations}),e.medicareRate&&i.jsxs("div",{className:"py-1.5 flex justify-between items-center",children:[i.jsxs("span",{className:"text-xs text-gray-500 flex items-center gap-1",children:["Medicare CLFS Rate",e.adltStatus&&i.jsx("span",{className:"px-1.5 py-0.5 bg-amber-100 text-amber-700 rounded text-[10px] font-medium",title:"Advanced Diagnostic Laboratory Test - receives annual rate updates based on weighted median of private payer rates",children:"ADLT"})]}),i.jsxs("span",{className:"text-sm font-semibold text-emerald-600",children:["$",e.medicareRate.toLocaleString()]})]}),e.listPrice&&i.jsx(B,{label:"List Price",value:`$${e.listPrice.toLocaleString()}`,citations:e.listPriceCitations}),i.jsx(B,{label:e.codeType==="PLA"?"PLA Code":"CPT Codes",value:e.cptCodes,citations:e.cptCodesCitations,notes:e.codeType==="PLA"?"Proprietary Laboratory Analyses - specific to this laboratory":null})]})})]}),i.jsx(w,{title:"Clinical Evidence",children:i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"Target Population",value:e.targetPopulation,citations:e.targetPopulationCitations}),i.jsx(B,{label:"Cancer Types",value:(C=e.cancerTypes)==null?void 0:C.join(", "),citations:e.cancerTypesCitations}),i.jsx(B,{label:"Clinical Availability",value:e.clinicalAvailability,citations:e.clinicalAvailabilityCitations,notes:e.clinicalAvailabilityNotes}),e.numPublications&&i.jsxs("div",{className:"py-1.5 flex justify-between items-center",children:[i.jsx("span",{className:"text-xs text-gray-500",children:"Publications"}),i.jsxs("span",{className:"text-sm font-semibold text-purple-600",children:[e.numPublications,e.numPublicationsPlus?"+":""]})]})]})})]}),t!=="TDS"&&i.jsxs(i.Fragment,{children:[i.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[i.jsx(w,{title:"Test Performance",expertTopic:"sensitivity",children:i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"Reported Sensitivity",value:e.sensitivity,unit:"%",citations:e.sensitivityCitations,notes:e.sensitivityNotes}),e.advancedAdenomaSensitivity&&i.jsx(B,{label:"Advanced Adenoma Sensitivity",value:e.advancedAdenomaSensitivity,unit:"%",citations:e.advancedAdenomaSensitivityCitations,notes:e.advancedAdenomaSensitivityNotes}),i.jsx(B,{label:"Reported Specificity",value:e.specificity,unit:"%",citations:e.specificityCitations,notes:e.specificityNotes}),e.analyticalSpecificity&&i.jsx(B,{label:"Analytical Specificity",value:e.analyticalSpecificity,unit:"%"}),e.clinicalSpecificity&&i.jsx(B,{label:"Clinical Specificity",value:e.clinicalSpecificity,unit:"%"}),i.jsx(B,{label:"PPV",value:e.ppv,unit:"%",citations:e.ppvCitations,notes:e.ppvNotes}),i.jsx(B,{label:"NPV",value:e.npv,unit:"%",citations:e.npvCitations,notes:e.npvNotes}),i.jsx(B,{label:"LOD",value:zf(e.lod),citations:e.lodCitations,notes:e.lodNotes,expertTopic:"lod"}),e.lod95&&i.jsx(B,{label:"LOD95",value:e.lod95,expertTopic:"lodVsLod95"})]})}),i.jsx(w,{title:"Sample & Turnaround",children:i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"Sample Type",value:e.sampleCategory}),i.jsx(B,{label:"Blood Volume",value:e.bloodVolume,unit:" mL"}),e.cfdnaInput&&i.jsx(B,{label:"cfDNA Input",value:e.cfdnaInput,unit:" ng"}),t==="MRD"&&i.jsxs(i.Fragment,{children:[i.jsx(B,{label:"Initial TAT",value:e.initialTat,unit:" days"}),i.jsx(B,{label:"Follow-up TAT",value:e.followUpTat,unit:" days"})]}),t!=="MRD"&&i.jsx(B,{label:"TAT",value:e.tat}),e.leadTimeVsImaging&&i.jsx(B,{label:"Lead Time vs Imaging",value:e.leadTimeVsImaging,unit:" days"}),e.variantsTracked&&i.jsx(B,{label:"Variants Tracked",value:e.variantsTracked})]})})]}),(e.stageISensitivity||e.stageIISensitivity||e.stageIIISensitivity||e.stageIVSensitivity||e.landmarkSensitivity||e.longitudinalSensitivity)&&i.jsxs(w,{title:"Stage & Timepoint Performance",expertTopic:"stageSpecific",children:[i.jsxs("div",{className:"grid grid-cols-2 md:grid-cols-4 gap-4",children:[e.stageISensitivity&&i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsxs("p",{className:"text-2xl font-bold text-emerald-600",children:[e.stageISensitivity,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Stage I"})]}),e.stageIISensitivity&&i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsxs("p",{className:"text-2xl font-bold text-emerald-600",children:[e.stageIISensitivity,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Stage II"})]}),e.stageIIISensitivity&&i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsxs("p",{className:"text-2xl font-bold text-emerald-600",children:[e.stageIIISensitivity,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Stage III"})]}),e.stageIVSensitivity&&i.jsxs("div",{className:"text-center p-3 bg-gray-50 rounded-lg",children:[i.jsxs("p",{className:"text-2xl font-bold text-emerald-600",children:[e.stageIVSensitivity,"%"]}),i.jsx("p",{className:"text-xs text-gray-500",children:"Stage IV"})]})]}),(e.landmarkSensitivity||e.longitudinalSensitivity)&&i.jsxs("div",{className:"grid grid-cols-2 gap-4 mt-3 pt-3 border-t border-gray-100",children:[e.landmarkSensitivity&&i.jsx(B,{label:"Landmark Sensitivity",value:e.landmarkSensitivity,unit:"%"}),e.landmarkSpecificity&&i.jsx(B,{label:"Landmark Specificity",value:e.landmarkSpecificity,unit:"%"}),e.longitudinalSensitivity&&i.jsx(B,{label:"Longitudinal Sensitivity",value:e.longitudinalSensitivity,unit:"%"}),e.longitudinalSpecificity&&i.jsx(B,{label:"Longitudinal Specificity",value:e.longitudinalSpecificity,unit:"%"})]})]}),i.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[i.jsx(w,{title:"Regulatory & Coverage",children:i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"FDA Status",value:e.fdaStatus}),i.jsx(B,{label:"Medicare",value:e.reimbursement,notes:e.reimbursementNote}),e.medicareRate&&i.jsxs("div",{className:"py-1.5 flex justify-between items-center",children:[i.jsxs("span",{className:"text-xs text-gray-500 flex items-center gap-1",children:["Medicare CLFS Rate",e.adltStatus&&i.jsx("span",{className:"px-1.5 py-0.5 bg-amber-100 text-amber-700 rounded text-[10px] font-medium",title:"Advanced Diagnostic Laboratory Test - receives annual rate updates based on weighted median of private payer rates",children:"ADLT"})]}),i.jsxs("span",{className:"text-sm font-semibold text-emerald-600",children:["$",e.medicareRate.toLocaleString()]})]}),p&&i.jsx(B,{label:"Private Insurance",value:e.commercialPayers.join(", "),notes:e.commercialPayersNotes}),i.jsx(B,{label:e.codeType==="PLA"?"PLA Code":"CPT Code",value:e.cptCodes||e.cptCode,notes:e.codeType==="PLA"?"Proprietary Laboratory Analyses - specific to this laboratory":null}),i.jsx(B,{label:"Clinical Availability",value:e.clinicalAvailability}),e.availableRegions&&e.availableRegions.length>0&&i.jsx(B,{label:"Available Regions",value:e.availableRegions.join(", ")}),t==="ECD"&&e.listPrice&&i.jsx(B,{label:"List Price",value:`$${e.listPrice}`})]})}),i.jsx(w,{title:"Clinical Evidence",expertTopic:"clinicalTrials",children:i.jsxs("div",{className:"space-y-1",children:[e.totalParticipants&&i.jsxs("div",{className:"py-1.5 flex justify-between items-center",children:[i.jsx("span",{className:"text-xs text-gray-500",children:"Trial Participants"}),i.jsx("span",{className:"text-sm font-semibold",style:{color:"#2A63A4"},children:e.totalParticipants.toLocaleString()})]}),e.numPublications&&i.jsxs("div",{className:"py-1.5 flex justify-between items-center",children:[i.jsx("span",{className:"text-xs text-gray-500",children:"Publications"}),i.jsxs("span",{className:"text-sm font-semibold text-purple-600",children:[e.numPublications,e.numPublicationsPlus?"+":""]})]}),i.jsx(B,{label:"Independent Validation",value:e.independentValidation,notes:e.independentValidationNotes}),e.clinicalTrials&&i.jsxs("div",{className:"pt-2 mt-2 border-t border-gray-100",children:[i.jsx("p",{className:"text-xs text-gray-500 mb-1",children:"Key Trials"}),i.jsx("div",{className:"text-xs text-gray-700 space-y-1",children:e.clinicalTrials.split(/[;|]/).slice(0,5).map((P,R)=>{const v=P.trim();if(!v)return null;const N=v.match(/NCT\d+/);return i.jsxs("div",{className:"flex items-start gap-1",children:[i.jsx("span",{className:"text-gray-400",children:""}),N?i.jsx("a",{href:`https://clinicaltrials.gov/study/${N[0]}`,target:"_blank",rel:"noopener noreferrer",className:"hover:underline",style:{color:"#2A63A4"},children:v.replace(/https?:\/\/[^\s]+/g,"").trim()}):i.jsx("span",{children:v})]},R)})})]})]})})]}),i.jsx(w,{title:"Test Requirements & Method",children:i.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[i.jsxs("div",{className:"space-y-1",children:[i.jsx(B,{label:"Approach",value:e.approach,expertTopic:"tumorInformed"}),i.jsx(B,{label:"Requires Tumor Tissue",value:y?"Yes":"No",notes:e.requiresTumorTissueNotes}),i.jsx(B,{label:"Requires Matched Normal",value:e.requiresMatchedNormal})]}),i.jsxs("div",{className:"space-y-1",children:[e.method&&i.jsx(B,{label:"Method",value:e.method}),e.targetPopulation&&i.jsx(B,{label:"Target Population",value:e.targetPopulation}),e.indicationGroup&&i.jsx(B,{label:"Indication Group",value:e.indicationGroup})]})]})}),e.cancerTypes&&e.cancerTypes.length>0&&i.jsx(w,{title:"Cancer Types",children:i.jsx("div",{className:"flex flex-wrap gap-1",children:e.cancerTypes.map((P,R)=>i.jsx("span",{className:"px-2 py-1 bg-gray-100 text-gray-700 rounded text-xs",children:P},R))})}),t==="MRD"&&e.clinicalSettings&&e.clinicalSettings.length>0&&i.jsxs(w,{title:"Validated Clinical Settings",children:[i.jsx("div",{className:"flex flex-wrap gap-2 mb-2",children:e.clinicalSettings.map((P,R)=>i.jsx("span",{className:"px-3 py-1.5 bg-orange-50 text-orange-700 border border-orange-200 rounded-full text-xs font-medium",children:P==="Post-Surgery"?" Post-Surgery (landmark)":P==="Surveillance"?" Surveillance (longitudinal)":P==="Neoadjuvant"?" Neoadjuvant":P==="Post-Adjuvant"?" Post-Adjuvant":P},R))}),e.clinicalSettingsNotes&&i.jsx("p",{className:"text-xs text-gray-500 mt-2",children:e.clinicalSettingsNotes})]})]}),e.exampleTestReport&&i.jsx("div",{className:"text-center pt-2",children:i.jsx("a",{href:e.exampleTestReport,target:"_blank",rel:"noopener noreferrer",className:"text-sm font-medium hover:underline",style:{color:"#2A63A4"},children:"View Example Test Report "})})]})})]})})]})},Zs=e=>{if(!e)return null;const t=String(e).toLowerCase();return t.includes("ppm")?"ppm":t.includes("vaf")||t.includes("%")?"VAF":t.includes("mtm")||t.includes("molecules")?"MTM":t.includes("copies")?"copies":"other"},Yf=e=>{const t={ppm:{bg:"bg-violet-100",text:"text-violet-700",label:"ppm"},VAF:{bg:"bg-blue-100",text:"text-blue-700",label:"VAF%"},MTM:{bg:"bg-emerald-100",text:"text-emerald-700",label:"MTM"},copies:{bg:"bg-amber-100",text:"text-amber-700",label:"copies"},other:{bg:"bg-gray-100",text:"text-gray-600",label:""}};return t[e]||t.other},Xf=({tests:e,category:t,onClose:a,onRemoveTest:n})=>{const s=sc[t]||sc.MRD,r=bs[t],[o,l]=A.useState(!1),d=()=>{const c=e.map(h=>h.id).join(",");return`${window.location.origin}?category=${t}&compare=${c}`},u=async()=>{try{await navigator.clipboard.writeText(d()),l(!0),setTimeout(()=>l(!1),2e3)}catch{const h=document.createElement("textarea");h.value=d(),document.body.appendChild(h),h.select(),document.execCommand("copy"),document.body.removeChild(h),l(!0),setTimeout(()=>l(!1),2e3)}},g=`
    @media print {
      /* Hide everything except the print area */
      body * {
        visibility: hidden;
      }
      .comparison-print-area,
      .comparison-print-area * {
        visibility: visible;
      }
      
      /* Reset modal positioning for print */
      .comparison-modal-root {
        position: fixed !important;
        left: 0 !important;
        top: 0 !important;
        width: 100% !important;
        height: auto !important;
        background: white !important;
        padding: 0 !important;
        margin: 0 !important;
        display: block !important;
      }
      .comparison-print-area { 
        position: absolute !important;
        left: 0 !important;
        top: 0 !important;
        width: 100% !important;
        max-height: none !important;
        height: auto !important;
        overflow: visible !important;
        box-shadow: none !important;
        border-radius: 0 !important;
        max-width: 100% !important;
      }
      
      /* Allow content to flow across pages */
      .comparison-print-area,
      .comparison-print-area > div {
        max-height: none !important;
        overflow: visible !important;
        height: auto !important;
      }
      
      /* Table should break across pages naturally */
      .comparison-print-area table { 
        font-size: 9px;
      }
      .comparison-print-area thead { 
        display: table-header-group;
      }
      .comparison-print-area tr { 
        page-break-inside: avoid;
      }
      .comparison-print-area th, 
      .comparison-print-area td { 
        padding: 3px 5px;
      }
      
      /* Hide interactive elements */
      .print\\:hidden { display: none !important; }
      
      @page { 
        margin: 0.4in; 
        size: landscape;
      }
    }
  `,p=e.map(c=>Zs(c.lod)).filter(Boolean),y=e.map(c=>Zs(c.lod95)).filter(Boolean),x=[...new Set(p)],w=[...new Set(y)],b=x.length>1||w.length>1,j={MRD:{headerBg:"bg-gradient-to-r from-orange-500 to-amber-500",headerText:"text-white",accent:"bg-orange-50 border-orange-200",accentText:"text-orange-700",lightBg:"bg-orange-50/50",border:"border-orange-100",closeBtnHover:"hover:bg-orange-400/20"},ECD:{headerBg:"bg-gradient-to-r from-emerald-500 to-teal-500",headerText:"text-white",accent:"bg-emerald-50 border-emerald-200",accentText:"text-emerald-700",lightBg:"bg-emerald-50/50",border:"border-emerald-100",closeBtnHover:"hover:bg-emerald-400/20"},TRM:{headerBg:"bg-gradient-to-r from-rose-500 to-pink-500",headerText:"text-white",accent:"bg-rose-50 border-rose-200",accentText:"text-rose-700",lightBg:"bg-rose-50/50",border:"border-rose-100",closeBtnHover:"hover:bg-rose-400/20"},TDS:{headerBg:"bg-gradient-to-r from-violet-500 to-purple-500",headerText:"text-white",accent:"bg-violet-50 border-violet-200",accentText:"text-violet-700",lightBg:"bg-violet-50/50",border:"border-violet-100",closeBtnHover:"hover:bg-violet-400/20"}},m=j[t]||j.MRD;return i.jsxs(i.Fragment,{children:[i.jsx("style",{children:g}),i.jsx("div",{className:"comparison-modal-root fixed inset-0 bg-black/60 backdrop-blur-sm z-50 flex items-center justify-center p-4 print:bg-white print:backdrop-blur-none","data-testid":"comparison-modal",onClick:a,children:i.jsxs("div",{className:"comparison-print-area bg-white rounded-2xl shadow-2xl max-w-5xl w-full overflow-hidden",onClick:c=>c.stopPropagation(),style:{maxHeight:"85vh",display:"flex",flexDirection:"column"},children:[i.jsxs("div",{className:`flex justify-between items-center p-5 ${m.headerBg}`,style:{flexShrink:0},children:[i.jsxs("div",{className:"flex items-center gap-3",children:[i.jsx("div",{className:"w-10 h-10 bg-white/20 rounded-xl flex items-center justify-center print:hidden",children:i.jsx("svg",{className:"w-5 h-5 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z"})})}),i.jsxs("div",{children:[i.jsxs("h2",{className:`text-xl font-bold ${m.headerText} print:text-black`,children:["Comparing ",e.length," Tests"]}),i.jsxs("p",{className:"text-white/80 text-sm print:text-gray-600",children:[(r==null?void 0:r.title)||t," Category  OpenOnco.org"]})]})]}),i.jsxs("div",{className:"flex items-center gap-2",children:[i.jsxs("button",{onClick:u,className:`p-2 ${m.closeBtnHover} rounded-xl transition-colors print:hidden flex items-center gap-1`,title:"Copy shareable link","data-testid":"share-link-button",children:[o?i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M5 13l4 4L19 7"})}):i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M13.828 10.172a4 4 0 00-5.656 0l-4 4a4 4 0 105.656 5.656l1.102-1.101m-.758-4.899a4 4 0 005.656 0l4-4a4 4 0 00-5.656-5.656l-1.1 1.1"})}),o&&i.jsx("span",{className:"text-white text-xs",children:"Copied!"})]}),i.jsx("button",{onClick:()=>window.print(),className:`p-2 ${m.closeBtnHover} rounded-xl transition-colors print:hidden`,title:"Print or save as PDF",children:i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M17 17h2a2 2 0 002-2v-4a2 2 0 00-2-2H5a2 2 0 00-2 2v4a2 2 0 002 2h2m2 4h6a2 2 0 002-2v-4a2 2 0 00-2-2H9a2 2 0 00-2 2v4a2 2 0 002 2zm8-12V5a2 2 0 00-2-2H9a2 2 0 00-2 2v4h10z"})})}),i.jsx("button",{onClick:a,className:`p-2 ${m.closeBtnHover} rounded-xl transition-colors print:hidden`,children:i.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M6 18L18 6M6 6l12 12"})})})]})]}),i.jsxs("div",{className:"px-5 py-3 bg-amber-50 border-b border-amber-200 flex items-start gap-3",style:{flexShrink:0},children:[i.jsx("div",{className:"w-6 h-6 rounded-full bg-amber-400 text-white text-xs font-bold flex items-center justify-center flex-shrink-0 mt-0.5",children:"E"}),i.jsxs("div",{className:"text-sm",children:[i.jsx("p",{className:"font-medium text-amber-800",children:"Comparison Limitations"}),i.jsxs("p",{className:"text-amber-700 text-xs mt-1",children:["Performance metrics may not be directly comparable across tests due to differences in methodology (analytical vs clinical, landmark vs longitudinal), patient populations, and reporting standards. See ",i.jsx("span",{className:"font-medium",children:"[E]"})," icons for context."]}),b&&i.jsxs("p",{className:"text-red-700 text-xs mt-2 font-medium flex items-center gap-1",children:[i.jsx("svg",{className:"w-4 h-4",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"})}),"LOD values below use different units (",x.join(", "),")  cannot be directly compared. Unit badges shown for clarity."]}),i.jsx("p",{className:"text-amber-600 text-[10px] mt-1 italic",children:" Expert Advisors: MR, SW"})]})]}),i.jsx("div",{style:{overflow:"auto",flex:"1 1 auto"},children:i.jsxs("table",{className:"w-full border-collapse",children:[i.jsx("thead",{children:i.jsxs("tr",{children:[i.jsx("th",{className:`text-left p-4 font-semibold text-gray-500 text-xs uppercase tracking-wider ${m.lightBg} min-w-[140px] sticky top-0 z-10`,children:"Parameter"}),e.map((c,h)=>i.jsx("th",{className:`text-left p-4 min-w-[200px] sticky top-0 z-10 ${m.lightBg}`,children:i.jsxs("div",{className:"flex justify-between items-start gap-2",children:[i.jsxs("div",{className:`flex-1 p-3 rounded-xl ${m.accent} border`,children:[i.jsx("p",{className:`font-bold ${m.accentText}`,children:c.name}),i.jsxs("p",{className:"text-xs text-gray-500 mt-0.5",children:[c.vendor,i.jsx(_a,{vendor:c.vendor,size:"xs"})]})]}),i.jsx("button",{onClick:()=>n(c.id),className:"p-1.5 hover:bg-gray-200 rounded-lg transition-colors flex-shrink-0 print:hidden",title:"Remove from comparison",children:i.jsx("svg",{className:"w-4 h-4 text-gray-400",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M6 18L18 6M6 6l12 12"})})})]})},c.id))]})}),i.jsx("tbody",{children:s.map((c,h)=>i.jsxs("tr",{className:`${h%2===0?"bg-white":"bg-gray-50/70"} hover:bg-gray-100/50 transition-colors`,children:[i.jsx("td",{className:`p-4 text-sm font-medium text-gray-600 ${m.border} border-b`,children:i.jsxs("span",{className:"flex items-center gap-1",children:[c.label,t!=="TDS"&&(c.key==="sensitivity"||c.key==="specificity")&&i.jsx(ci,{topic:c.key}),t!=="TDS"&&c.key==="lod"&&i.jsx(ci,{topic:"lod"}),t!=="TDS"&&c.key==="lod95"&&i.jsx(ci,{topic:"lodVsLod95"}),t!=="TDS"&&(c.key==="sensitivityStagesReported"||c.key==="stageIISensitivity"||c.key==="stageIIISensitivity")&&i.jsx(ci,{topic:"stageSpecific"})]})}),e.map(C=>{var I,q,be,re,Ce;let P=c.key==="cancerTypesStr"?(I=C.cancerTypes)==null?void 0:I.join(", "):c.key==="commercialPayersStr"?(q=C.commercialPayers)==null?void 0:q.join(", "):c.key==="availableRegionsStr"?((be=C.availableRegions)==null?void 0:be.join(", "))||"US":c.key==="biomarkersReportedStr"?(re=C.biomarkersReported)==null?void 0:re.join(", "):c.key==="clinicalSettingsStr"?(Ce=C.clinicalSettings)==null?void 0:Ce.join(", "):C[c.key];const R=P!=null&&P!=="",N=c.key==="lod"||c.key==="lod95"?Zs(P):null,F=N?Yf(N):null;return i.jsx("td",{className:`p-4 text-sm ${m.border} border-b ${R?"text-gray-900":"text-gray-300"}`,children:R?i.jsxs("span",{className:"flex items-center gap-2",children:[i.jsx("span",{children:String(P)}),F&&i.jsx("span",{className:`text-[10px] px-1.5 py-0.5 rounded font-medium ${F.bg} ${F.text}`,children:F.label})]}):""},C.id)})]},c.key))})]})}),i.jsx("div",{className:`p-4 ${m.lightBg} border-t ${m.border} flex-shrink-0 print:hidden`,children:i.jsx("p",{className:"text-xs text-gray-500 text-center",children:"Click the  next to a test name to remove it from comparison  Use print button to save as PDF"})})]})})]})},Jf=(e,t,a=6)=>{if(e.length===0)return[];const n=t.filter(g=>e.includes(g.id)),s=t.filter(g=>!e.includes(g.id)),r=new Set(n.map(g=>g.indicationGroup).filter(Boolean)),o=new Set(n.flatMap(g=>g.cancerTypes||[])),l=new Set(n.map(g=>g.approach).filter(Boolean)),d=new Set(n.map(g=>g.testScope).filter(Boolean));return s.map(g=>{let p=0,y="";g.indicationGroup&&r.has(g.indicationGroup)&&(p+=100,y=`${g.indicationGroup} tests`);const w=(g.cancerTypes||[]).filter(b=>o.has(b));return w.length>0&&(p+=30*w.length,y||(y=`${w[0].length>15?w[0].slice(0,15)+"...":w[0]}`)),g.testScope&&d.has(g.testScope)&&(p+=20,y||(y=g.testScope)),g.approach&&l.has(g.approach)&&(p+=10,y||(y=g.approach)),{test:g,score:p,matchReason:y}}).filter(g=>g.score>0).sort((g,p)=>p.score-g.score).slice(0,a)},Zf=({category:e,initialSelectedTestId:t,initialCompareIds:a,onClearInitialTest:n})=>{var gt,en,_o;const s=bs[e],r=Af[e],o=s.tests,[l,d]=A.useState(""),[u,g]=A.useState([]),[p,y]=A.useState([]),[x,w]=A.useState([]),[b,j]=A.useState([]),[m,c]=A.useState([]),[h,C]=A.useState([]),[P,R]=A.useState([]),[v,N]=A.useState([]),[F,I]=A.useState(0),[q,be]=A.useState(0),[re,Ce]=A.useState(1e3),[Me,We]=A.useState(0),[fe,f]=A.useState(0),[k,D]=A.useState(30),[L,O]=A.useState(!1),[V,U]=A.useState("any"),[ee,ae]=A.useState(0),[he,nt]=A.useState(0),[Ae,na]=A.useState([]),[Se,xi]=A.useState(()=>a&&a.length>=2?a:t?[t]:[]),[bi,ii]=A.useState(()=>a&&a.length>=2),[sa,Ci]=A.useState(null),[Et,Cs]=A.useState(!1),[ws,Ns]=A.useState(!1),ra=A.useRef(null),Nt=A.useRef(null),[wi,As]=A.useState(()=>Ja()||"Clinician");A.useEffect(()=>{const T=J=>As(J.detail);return window.addEventListener("personaChanged",T),()=>window.removeEventListener("personaChanged",T)},[]);const H=wi==="Patient",Za=T=>{const J=`persona-${wi.toLowerCase().replace(/[^a-z]/g,"-")}`;Ji("test_detail_viewed",{category:e,test_id:T.id,test_name:T.name,vendor:T.vendor},{flags:[J,`category-${e.toLowerCase()}`]}),Ci(T)},st=T=>J=>{const ye=window.scrollY;Nt.current&&clearInterval(Nt.current),T(Number(J.target.value));const $=Date.now();Nt.current=setInterval(()=>{window.scrollTo(0,ye),Date.now()-$>200&&clearInterval(Nt.current)},10)};A.useEffect(()=>{if(t){const T=o.find(J=>J.id===t);T&&Ci(T),n==null||n()}},[t,o]),A.useEffect(()=>{t||window.scrollTo(0,0)},[e]),A.useEffect(()=>{const T=()=>{const ye=ra.current;if(ye){const $=ye.scrollHeight>ye.clientHeight,me=ye.scrollHeight-ye.scrollTop-ye.clientHeight<10;Ns($&&!me)}};T();const J=ra.current;return J&&(J.addEventListener("scroll",T),window.addEventListener("resize",T)),()=>{J&&(J.removeEventListener("scroll",T),window.removeEventListener("resize",T))}},[e]),A.useEffect(()=>()=>{Nt.current&&clearInterval(Nt.current)},[]);const Ni=A.useMemo(()=>o.filter(T=>{var J,ye;if(l){const $=l.toLowerCase().split(/\s+/).filter(Ai=>Ai.length>0),me=T.productType==="Laboratory IVD Kit"?"kit ivd laboratory":T.productType==="Self-Collection"?"self-collection home":"service central lab",te=`${T.name} ${T.vendor} ${e} ${me}`.toLowerCase();if(!$.every(Ai=>te.includes(Ai)))return!1}if(u.length>0&&!u.includes(T.approach)||p.length>0&&!((J=T.cancerTypes)!=null&&J.some($=>p.includes($)))||x.length>0&&!x.some(me=>{if(me==="Commercial")return T.commercialPayers&&T.commercialPayers.length>0;if(me==="Medicare"){const te=(T.reimbursement||"").toLowerCase(),Ai=te==="medicare"||te.startsWith("medicare ")||te.includes("medicare covered")||te.includes("medicare lcd")||te.includes("broad medicare")||te.includes("medicare (moldx)")||te.includes("(moldx)")||te.includes("moldx"),Si=te.includes("not yet established")||te.includes("not routinely")||te.includes("no established")||te.includes("not applicable")||te.startsWith("coverage emerging");return Ai&&!Si}return T.reimbursement===me})||b.length>0&&!b.includes(T.testScope)||m.length>0&&!m.includes(T.sampleCategory)||F>0&&(!T.totalParticipants||T.totalParticipants<F)||q>0&&(!T.numPublications||T.numPublications<q)||e==="ECD"&&re<1e3&&T.listPrice&&T.listPrice>re)return!1;if(h.length>0){const $=T.fdaStatus||"";if(!h.some(te=>te==="FDA Approved"?$.includes("FDA Approved")||$.includes("FDA-approved"):te==="FDA Breakthrough"?$.includes("Breakthrough"):te==="LDT"?$.includes("LDT"):te==="Investigational"?$.includes("Investigational")||$.includes("Research"):!1))return!1}if(P.length>0){const $=T.availableRegions||[],me=((ye=T.clinicalAvailability)==null?void 0:ye.toLowerCase())||"",te=$.length>0?$:me.includes("shipping")||me.includes("commercially available")||me.includes("launched")||me.includes("us ")||me.includes("in us")||me.includes("quest")||me.includes("labcorp")?["US"]:[];if(!P.some(Si=>{var $o;return Si==="US"?te.includes("US")||te.includes("US-only"):Si==="International"?te.includes("International")||te.includes("Global")||te.length>1:Si==="RUO"?te.includes("RUO")||(($o=T.clinicalAvailability)==null?void 0:$o.includes("RUO")):te.includes(Si)}))return!1}if(v.length>0&&T.clinicalSettings&&!v.some(me=>T.clinicalSettings.includes(me)))return!1;if(Me>0){const $=parseFloat(T.sensitivity);if(isNaN($)||$<Me)return!1}if(fe>0){const $=parseFloat(T.specificity);if(isNaN($)||$<fe)return!1}if(k<30){const $=T.tat||T.initialTat||T.followUpTat;if($){const me=parseFloat($);if(!isNaN(me)&&me>k)return!1}}if(L&&!T.nccnRecommended||V==="yes"&&T.requiresTumorTissue!=="Yes"||V==="no"&&T.requiresTumorTissue!=="No"||ee>0&&(!T.genesAnalyzed||T.genesAnalyzed<ee)||he>0&&(!T.fdaCompanionDxCount||T.fdaCompanionDxCount<he))return!1;if(Ae.length>0){const $=T.productType||"Central Lab Service";if(!Ae.includes($))return!1}return!0}),[o,l,u,p,x,b,m,h,P,v,F,q,re,Me,fe,k,L,V,ee,he,Ae,e]),S=A.useMemo(()=>o.filter(T=>Se.includes(T.id)),[o,Se]),_=A.useMemo(()=>Jf(Se,o),[Se,o]),Q=T=>J=>T(ye=>ye.includes(J)?ye.filter($=>$!==J):[...ye,J]),Ie=()=>{d(""),g([]),y([]),w([]),j([]),c([]),C([]),R([]),N([]),I(0),be(0),Ce(1e3),We(0),f(0),D(30),O(!1),U("any"),ae(0),nt(0),na([])},rt=l||u.length||p.length||x.length||b.length||m.length||h.length||P.length||v.length||F>0||q>0||re<1e3||Me>0||fe>0||k<30||L||V!=="any"||ee>0||he>0||Ae.length,ht={orange:"from-orange-500 to-orange-600",green:"from-emerald-500 to-emerald-600",red:"from-sky-500 to-sky-600",violet:"from-violet-500 to-violet-600"};return i.jsxs(i.Fragment,{children:[i.jsx("style",{children:`
        * { overflow-anchor: none !important; }
      `}),i.jsxs("div",{className:"max-w-7xl mx-auto px-6 py-8",style:{overflowAnchor:"none"},children:[i.jsxs("div",{className:"mb-8",children:[i.jsx("div",{className:`inline-flex items-center gap-2 px-3 py-1 rounded-full bg-gradient-to-r ${ht[s.color]} text-white text-sm font-medium mb-3`,children:H?s.patientTitle:s.shortTitle}),i.jsx("h1",{className:"text-2xl sm:text-3xl font-bold text-gray-900 mb-2",children:H?s.patientTitle:s.title}),i.jsx("p",{className:"text-gray-600",children:H?s.patientDescription:s.description}),!H&&i.jsxs("div",{className:"flex items-center gap-4 mt-3 text-xs",children:[i.jsx("span",{className:"text-slate-500",children:"Data types:"}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-2 h-2 rounded-full bg-emerald-500"}),i.jsx("span",{className:"text-slate-500",children:"Clinical"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-2 h-2 rounded-full bg-violet-500"}),i.jsx("span",{className:"text-slate-500",children:"Analytical"})]}),i.jsxs("span",{className:"flex items-center gap-1",children:[i.jsx("span",{className:"w-2 h-2 rounded-full bg-slate-400"}),i.jsx("span",{className:"text-slate-500",children:"Operational"})]})]}),H&&i.jsx("div",{className:"mt-4 p-4 bg-blue-50 rounded-lg border border-blue-100",children:i.jsxs("p",{className:"text-sm text-blue-800",children:[i.jsx("strong",{children:" Tip:"})," Use the filters to find tests that match your situation. Each test card shows whether it's covered by insurance and what's involved. Always discuss testing options with your doctor."]})})]}),i.jsxs("section",{children:[i.jsxs("div",{className:"flex items-center justify-between mb-4",children:[i.jsx("h2",{className:"text-lg font-semibold text-gray-900",children:"Browse Tests"}),i.jsx("button",{className:"md:hidden px-3 py-1.5 text-sm font-medium bg-gray-100 rounded-lg",onClick:()=>Cs(!Et),children:Et?"Hide Filters":"Show Filters"})]}),i.jsxs("div",{className:"flex flex-col md:flex-row gap-6",children:[i.jsx("aside",{className:`${Et?"block":"hidden"} md:block w-full md:w-64 flex-shrink-0`,children:i.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 sticky top-24 max-h-[calc(100vh-120px)] flex flex-col overflow-hidden",children:[i.jsxs("div",{className:"p-5 pb-0 flex-shrink-0",children:[i.jsxs("div",{className:"flex justify-between items-center mb-4",children:[i.jsx("h3",{className:"font-semibold text-gray-900",children:"Filters"}),rt&&i.jsx("button",{onClick:Ie,className:"text-xs text-emerald-600 hover:text-emerald-700",children:"Clear all"})]}),i.jsxs("div",{className:"mb-5",children:[i.jsx("label",{className:"text-xs font-medium text-gray-500 uppercase tracking-wide mb-2 block",children:"Search"}),i.jsx("input",{type:"text",placeholder:"Test or vendor...",value:l,onChange:T=>d(T.target.value),className:"w-full px-3 py-2 border border-gray-300 rounded-lg text-sm focus:outline-none focus:ring-2 focus:ring-emerald-500"})]})]}),i.jsxs("div",{ref:ra,className:"flex-1 overflow-y-auto px-5 pb-5 overscroll-contain",children:[r.productTypes&&i.jsxs(ai,{title:H?"How It Works":"Product Type",defaultOpen:!0,activeCount:Ae.length,children:[i.jsx("div",{className:"space-y-1",children:r.productTypes.map(T=>{const J=ku(T);return i.jsxs("label",{className:"flex items-center gap-2 cursor-pointer group",children:[i.jsx("input",{type:"checkbox",checked:Ae.includes(T),onChange:()=>Q(na)(T),className:"w-3.5 h-3.5 rounded border-gray-300 text-emerald-600 focus:ring-emerald-500"}),i.jsxs("span",{className:"flex items-center gap-1.5 text-sm text-gray-700 group-hover:text-gray-900",children:[i.jsx("span",{children:J.icon}),i.jsx("span",{children:H?T==="Self-Collection"?"At-home collection":T==="Laboratory IVD Kit"?"Hospital lab test":"Send-away test":J.label})]})]},T)})}),!H&&i.jsxs("p",{className:"text-xs text-gray-400 mt-2 italic",children:[" Self-collection: patient collects at home",i.jsx("br",{})," Lab Kit: IVD kit run at any equipped lab",i.jsx("br",{})," Service: sample shipped to central lab"]})]}),i.jsxs(ai,{title:H?"My Cancer":"Clinical",defaultOpen:!1,activeCount:p.length+b.length+v.length,children:[e!=="ECD"&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 block",children:"Cancer Type"}),i.jsx("div",{className:"max-h-40 overflow-y-auto",children:(gt=r.cancerTypes)==null?void 0:gt.map(T=>i.jsx(Ve,{label:T.length>28?T.slice(0,28)+"...":T,checked:p.includes(T),onChange:()=>Q(y)(T)},T))})]}),e==="MRD"&&!H&&r.clinicalSettings&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 mt-3 block",children:"Clinical Setting"}),i.jsx("div",{className:"space-y-0.5",children:r.clinicalSettings.map(T=>i.jsx(Ve,{label:T==="Post-Surgery"?"Post-Surgery (landmark)":T==="Surveillance"?"Surveillance (longitudinal)":T,checked:v.includes(T),onChange:()=>Q(N)(T)},T))}),i.jsx("p",{className:"text-xs text-gray-400 mt-1 italic",children:"Filter by validated clinical context"})]}),e==="MRD"&&H&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 mt-3 block",children:"When in my treatment?"}),i.jsxs("div",{className:"space-y-0.5",children:[i.jsx(Ve,{label:"Before surgery (during chemo)",checked:v.includes("Neoadjuvant"),onChange:()=>Q(N)("Neoadjuvant")}),i.jsx(Ve,{label:"Right after surgery",checked:v.includes("Post-Surgery"),onChange:()=>Q(N)("Post-Surgery")}),i.jsx(Ve,{label:"After chemo finishes",checked:v.includes("Post-Adjuvant"),onChange:()=>Q(N)("Post-Adjuvant")}),i.jsx(Ve,{label:"Ongoing monitoring",checked:v.includes("Surveillance"),onChange:()=>Q(N)("Surveillance")})]})]}),e==="ECD"&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 block",children:H?"Type of Screening":"Scope"}),(en=r.testScopes)==null?void 0:en.map(T=>i.jsx(Ve,{label:H?T.includes("Single")?"Single cancer type":"Multiple cancer types":T,checked:b.includes(T),onChange:()=>Q(j)(T)},T))]})]}),!H&&i.jsxs(ai,{title:"Methodology",defaultOpen:!1,activeCount:u.length+m.length+(V!=="any"?1:0),children:[e!=="ECD"&&r.approaches&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 block",children:"Approach"}),r.approaches.map(T=>i.jsx(Ve,{label:T,checked:u.includes(T),onChange:()=>Q(g)(T)},T))]}),r.sampleCategories&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 mt-3 block",children:"Sample Type"}),r.sampleCategories.map(T=>i.jsx(Ve,{label:T,checked:m.includes(T),onChange:()=>Q(c)(T)},T))]}),e==="MRD"&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 mt-3 block",children:"Tumor Tissue Required"}),i.jsxs("div",{className:"space-y-1",children:[i.jsxs("label",{className:"flex items-center gap-2 cursor-pointer",children:[i.jsx("input",{type:"radio",name:"tumorTissue",checked:V==="any",onChange:()=>U("any"),className:"w-3.5 h-3.5 text-blue-600"}),i.jsx("span",{className:"text-sm text-gray-700",children:"Any"})]}),i.jsxs("label",{className:"flex items-center gap-2 cursor-pointer",children:[i.jsx("input",{type:"radio",name:"tumorTissue",checked:V==="no",onChange:()=>U("no"),className:"w-3.5 h-3.5 text-blue-600"}),i.jsx("span",{className:"text-sm text-gray-700",children:"No (tumor-nave)"})]}),i.jsxs("label",{className:"flex items-center gap-2 cursor-pointer",children:[i.jsx("input",{type:"radio",name:"tumorTissue",checked:V==="yes",onChange:()=>U("yes"),className:"w-3.5 h-3.5 text-blue-600"}),i.jsx("span",{className:"text-sm text-gray-700",children:"Yes (tumor-informed)"})]})]})]})]}),H&&e!=="ECD"&&i.jsx(ai,{title:"Test Type",defaultOpen:!1,activeCount:u.length,children:i.jsx(Ve,{label:"Blood test only (no tissue needed)",checked:u.includes("Tumor-nave"),onChange:()=>Q(g)("Tumor-nave")})}),i.jsxs(ai,{title:H?"Insurance & Access":"Regulatory & Access",defaultOpen:!1,activeCount:h.length+x.length+P.length+(L?1:0),children:[!H&&r.fdaStatuses&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 block",children:"FDA Status"}),r.fdaStatuses.map(T=>i.jsx(Ve,{label:T,checked:h.includes(T),onChange:()=>Q(C)(T)},T))]}),!H&&(e==="MRD"||e==="TRM")&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 mt-3 block",children:"Guidelines"}),i.jsx(Ve,{label:"NCCN Recommended",checked:L,onChange:()=>O(!L)})]}),i.jsx("label",{className:"text-xs text-gray-500 mb-1 mt-3 block",children:H?"My Insurance":"Coverage"}),(_o=r.reimbursements)==null?void 0:_o.map(T=>i.jsx(Ve,{label:T==="Medicare"?H?"Medicare (age 65+)":"Medicare":T==="Commercial"?"Private Insurance":T,checked:x.includes(T),onChange:()=>Q(w)(T)},T)),!H&&r.regions&&i.jsxs(i.Fragment,{children:[i.jsx("label",{className:"text-xs text-gray-500 mb-1 mt-3 block",children:"Availability"}),r.regions.map(T=>i.jsx(Ve,{label:T==="RUO"?"Research Use Only":T==="International"?"International/Global":T,checked:P.includes(T),onChange:()=>Q(R)(T)},T))]})]}),!H&&i.jsxs(ai,{title:"Performance",defaultOpen:!1,activeCount:(Me>0?1:0)+(fe>0?1:0)+(k<30?1:0)+(ee>0?1:0)+(he>0?1:0),children:[e!=="TDS"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:["Min Sensitivity: ",Me===0?"Any":`${Me}%+`]}),i.jsx("input",{type:"range",min:"0",max:"99",step:"5",value:Me,onChange:st(We),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-emerald-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1 mb-4",children:[i.jsx("span",{children:"Any"}),i.jsx("span",{children:"50%"}),i.jsx("span",{children:"99%"})]})]}),e!=="TDS"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:["Min Specificity: ",fe===0?"Any":`${fe}%+`]}),i.jsx("input",{type:"range",min:"0",max:"99",step:"5",value:fe,onChange:st(f),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-sky-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1 mb-4",children:[i.jsx("span",{children:"Any"}),i.jsx("span",{children:"50%"}),i.jsx("span",{children:"99%"})]})]}),e!=="ECD"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:["Max Turnaround: ",k>=30?"Any":`${k} days`]}),i.jsx("input",{type:"range",min:"1",max:"30",step:"1",value:k,onChange:st(D),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-orange-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1 mb-4",children:[i.jsx("span",{children:"1 day"}),i.jsx("span",{children:"14 days"}),i.jsx("span",{children:"Any"})]})]}),e==="TDS"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:["Min Genes Analyzed: ",ee===0?"Any":ee>=500?"500+":ee]}),i.jsx("input",{type:"range",min:"0",max:"500",step:"50",value:ee,onChange:st(ae),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-violet-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1 mb-4",children:[i.jsx("span",{children:"Any"}),i.jsx("span",{children:"250"}),i.jsx("span",{children:"500+"})]})]}),e==="TDS"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:["Min FDA Companion Dx: ",he===0?"Any":he]}),i.jsx("input",{type:"range",min:"0",max:"60",step:"5",value:he,onChange:st(nt),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-emerald-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1",children:[i.jsx("span",{children:"Any"}),i.jsx("span",{children:"30"}),i.jsx("span",{children:"60"})]})]})]}),i.jsxs(ai,{title:H&&e==="ECD"?"Cost":H?"More Filters":"Validation",defaultOpen:!1,activeCount:(F>0?1:0)+(q>0?1:0)+(re<1e3?1:0),children:[e==="ECD"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:[H?"Budget":"Max List Price",": ",re>=1e3?"Any":`$${re}`]}),i.jsx("input",{type:"range",min:"0",max:"1000",step:"50",value:re,onChange:st(Ce),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-emerald-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1 mb-4",children:[i.jsx("span",{children:"$0"}),i.jsx("span",{children:"$500"}),i.jsx("span",{children:"$1000+"})]})]}),!H&&e!=="TDS"&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:["Min Trial Participants: ",F===0?"Any":e==="ECD"?F>=1e5?"100,000+":F.toLocaleString():F>=1e3?"1,000+":F.toLocaleString()]}),i.jsx("input",{type:"range",min:"0",max:e==="ECD"?"100000":"1000",step:e==="ECD"?"10000":"100",value:F,onChange:st(I),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-blue-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1 mb-4",children:[i.jsx("span",{children:"0"}),i.jsx("span",{children:e==="ECD"?"50k":"500"}),i.jsx("span",{children:e==="ECD"?"100k+":"1,000+"})]})]}),!H&&i.jsxs(i.Fragment,{children:[i.jsxs("label",{className:"text-xs text-gray-500 mb-1 block",children:["Min Publications: ",q===0?"Any":e==="ECD"?q>=20?"20+":q:e==="TDS"?q>=1e3?"1,000+":q:q>=100?"100+":q]}),i.jsx("input",{type:"range",min:"0",max:e==="ECD"?"20":e==="TDS"?"1000":"100",step:e==="ECD"?"2":e==="TDS"?"50":"5",value:q,onChange:st(be),className:"w-full h-2 bg-gray-200 rounded-lg appearance-none cursor-pointer accent-purple-600"}),i.jsxs("div",{className:"flex justify-between text-xs text-gray-400 mt-1",children:[i.jsx("span",{children:"0"}),i.jsx("span",{children:e==="ECD"?"10":e==="TDS"?"500":"50"}),i.jsx("span",{children:e==="ECD"?"20+":e==="TDS"?"1,000+":"100+"})]})]})]})]}),ws&&i.jsx("div",{className:"h-8 bg-gradient-to-t from-white via-white to-transparent flex-shrink-0 -mt-8 relative z-10 pointer-events-none flex items-end justify-center pb-1",children:i.jsx("svg",{className:"w-4 h-4 text-gray-400 animate-bounce",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M19 9l-7 7-7-7"})})})]})}),i.jsxs("div",{className:"flex-1",style:{overflowAnchor:"none",contain:"layout"},children:[i.jsxs("div",{className:"flex justify-between items-center mb-4",children:[i.jsxs("p",{className:"text-sm text-gray-500",children:["Showing ",Ni.length," of ",o.length," tests"]}),!H&&Se.length===0&&i.jsx("p",{className:"hidden md:block text-sm text-gray-400 italic",children:" Select tests to compare them side-by-side"}),!H&&Se.length===1&&i.jsx("p",{className:"hidden md:block text-sm text-orange-600",children:"Select at least one more test to compare"}),!H&&Se.length>=2&&i.jsxs("button",{onClick:()=>{const T=`persona-${wi.toLowerCase().replace(/[^a-z]/g,"-")}`;Ji("tests_compared",{category:e,test_count:Se.length,test_ids:Se.join(",")},{flags:[T,`category-${e.toLowerCase()}`]}),ii(!0)},className:"hidden md:flex bg-emerald-500 hover:bg-emerald-600 text-white px-4 py-2 rounded-lg text-sm font-medium items-center gap-2","data-testid":"compare-tests-button",children:[i.jsx("svg",{className:"w-4 h-4",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z"})}),"Compare (",Se.length,")"]})]}),!H&&Se.length>=1&&_.length>0&&i.jsxs("div",{className:"hidden md:block mb-4 p-3 bg-gradient-to-r from-blue-50 to-indigo-50 border border-blue-200 rounded-xl",children:[i.jsxs("div",{className:"flex items-center gap-2 mb-2",children:[i.jsx("svg",{className:"w-4 h-4 text-blue-600",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M9.663 17h4.673M12 3v1m6.364 1.636l-.707.707M21 12h-1M4 12H3m3.343-5.657l-.707-.707m2.828 9.9a5 5 0 117.072 0l-.548.547A3.374 3.374 0 0014 18.469V19a2 2 0 11-4 0v-.531c0-.895-.356-1.754-.988-2.386l-.548-.547z"})}),i.jsx("span",{className:"text-sm font-semibold text-blue-800",children:"Suggested Comparisons"}),i.jsx("span",{className:"text-xs text-blue-600",children:"based on your selection"})]}),i.jsx("div",{className:"flex flex-wrap gap-2",children:_.map(({test:T,matchReason:J})=>i.jsxs("button",{onClick:()=>xi(ye=>[...ye,T.id]),className:"inline-flex items-center gap-1.5 px-3 py-1.5 bg-white border border-blue-200 rounded-full text-sm hover:border-blue-400 hover:bg-blue-50 transition-colors group",children:[i.jsx("span",{className:"font-medium text-gray-700 group-hover:text-blue-700",children:T.name}),J&&i.jsxs("span",{className:"text-xs text-blue-500",children:["(",J,")"]}),i.jsx("svg",{className:"w-3.5 h-3.5 text-blue-400 group-hover:text-blue-600",fill:"none",viewBox:"0 0 24 24",stroke:"currentColor",strokeWidth:2,children:i.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",d:"M12 4v16m8-8H4"})})]},T.id))})]}),i.jsx("div",{className:"grid grid-cols-1 md:grid-cols-2 xl:grid-cols-3 gap-4",style:{minHeight:"800px",overflowAnchor:"none",contain:"layout"},children:Ni.map(T=>H?i.jsx(Kf,{test:T,category:e,onShowDetail:Za},T.id):i.jsx($f,{test:T,category:e,isSelected:Se.includes(T.id),onSelect:J=>Q(xi)(J),onShowDetail:Za},T.id))}),Ni.length===0&&i.jsxs("div",{className:"text-center py-12 text-gray-500",children:[i.jsx("p",{children:"No tests match your filters."}),i.jsx("button",{onClick:Ie,className:"text-emerald-600 text-sm mt-2",children:"Clear filters"})]})]})]})]}),i.jsxs("section",{className:"mt-10",children:[i.jsx("h2",{className:"text-lg font-semibold text-gray-900 mb-3",children:"Ask a Question"}),i.jsx(Hf,{category:e})]}),!H&&bi&&S.length>=2&&i.jsx(Xf,{tests:S,category:e,onClose:()=>ii(!1),onRemoveTest:T=>{xi(J=>J.filter(ye=>ye!==T)),Se.length<=2&&ii(!1)}}),sa&&i.jsx(Qf,{test:sa,category:e,onClose:()=>Ci(null),isPatientView:H})]})]})};function eh(){const e={"/":"home","/submissions":"submissions","/how-it-works":"how-it-works","/data-sources":"data-sources","/faq":"faq","/learn":"learn","/about":"about","/mrd":"MRD","/ecd":"ECD","/trm":"TRM","/tds":"TDS"},t={home:"/",submissions:"/submissions","how-it-works":"/how-it-works","data-sources":"/data-sources",faq:"/faq",learn:"/learn",about:"/about",MRD:"/mrd",ECD:"/ecd",TRM:"/trm",TDS:"/tds"},a=()=>{const x=window.location.pathname.toLowerCase();return e[x]||"home"},[n,s]=A.useState(a),[r,o]=A.useState(null),[l,d]=A.useState(null),[u,g]=A.useState(()=>Ja()||"Clinician");A.useEffect(()=>{const x=new URLSearchParams(window.location.search),w=x.get("category"),b=x.get("test"),j=x.get("compare"),m=c=>/^[a-z]+-\d+$/.test(c);if(w&&["MRD","ECD","TRM","TDS"].includes(w)){if(s(w),b&&m(b)&&o(b),j){const c=j.split(",").map(h=>h.trim()).filter(h=>h&&m(h));c.length>=2&&d(c)}window.history.replaceState({},"",window.location.pathname)}},[]),A.useEffect(()=>{const x=w=>g(w.detail);return window.addEventListener("personaChanged",x),()=>window.removeEventListener("personaChanged",x)},[]),A.useEffect(()=>{const x=()=>{const w=window.location.pathname.toLowerCase(),b=e[w]||"home";s(b),o(null)};return window.addEventListener("popstate",x),()=>window.removeEventListener("popstate",x)},[]),A.useEffect(()=>{const x={persona:u.toLowerCase().replace(/[^a-z]/g,"-"),page:n};document.documentElement.dataset.flags=JSON.stringify(x)},[u,n]);const p=(x,w=null)=>{const b=`persona-${u.toLowerCase().replace(/[^a-z]/g,"-")}`;["MRD","ECD","TRM","TDS"].includes(x)?Ji("category_viewed",{category:x,from_test_link:w!==null},{flags:[b,`category-${x.toLowerCase()}`]}):x!==n&&Ji("page_viewed",{page:x},{flags:[b]}),s(x),o(w);const j=t[x]||"/";window.history.pushState({page:x},"",j)},y=()=>{switch(n){case"home":return i.jsx(rc,{onNavigate:p});case"learn":return i.jsx(Ff,{onNavigate:p});case"MRD":case"ECD":case"TRM":case"TDS":case"ALZ-BLOOD":return i.jsx(Zf,{category:n,initialSelectedTestId:r,initialCompareIds:l,onClearInitialTest:()=>{o(null),d(null)}},`${n}-${u}`);case"data-sources":return i.jsx(Gf,{});case"how-it-works":return i.jsx(qf,{});case"submissions":return i.jsx(Uf,{});case"faq":return i.jsx(Bf,{});case"about":return i.jsx(Vf,{});default:return i.jsx(rc,{onNavigate:p})}};return i.jsxs("div",{className:"min-h-screen bg-gray-50 flex flex-col",children:[i.jsx(Rf,{currentPage:n,onNavigate:p}),i.jsx("main",{className:"flex-1",children:y()},`main-${u}`),i.jsx(Lf,{}),i.jsx(gf,{})]})}er.createRoot(document.getElementById("root")).render(i.jsx(Qu.StrictMode,{children:i.jsx(eh,{})}));
